,source,target,value,type,source layer,target layer,normalized value
0,IGLC7,Initial triggering of complement,0.00040079407483459864,0,0,1,0.0004255159370467968
1,IGLC7,Initial triggering of complement,0.00019585201050227477,1,0,1,0.00020793259432731604
2,IGLC7,Regulation of Complement cascade,0.00040079407483459864,0,0,1,0.0004255159370467968
3,IGLC7,Regulation of Complement cascade,0.00019585201050227477,1,0,1,0.00020793259432731604
4,IGLC7,FCGR activation,0.00040079407483459864,0,0,1,0.0004255159370467968
5,IGLC7,FCGR activation,0.00019585201050227477,1,0,1,0.00020793259432731604
6,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.00040079407483459864,0,0,1,0.0004255159370467968
7,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.00019585201050227477,1,0,1,0.00020793259432731604
8,IGLC7,Role of phospholipids in phagocytosis,0.00040079407483459864,0,0,1,0.0004255159370467968
9,IGLC7,Role of phospholipids in phagocytosis,0.00019585201050227477,1,0,1,0.00020793259432731604
10,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.00040079407483459864,0,0,1,0.0004255159370467968
11,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.00019585201050227477,1,0,1,0.00020793259432731604
12,IGLC7,FCERI mediated MAPK activation,0.00040079407483459864,0,0,1,0.0004255159370467968
13,IGLC7,FCERI mediated MAPK activation,0.00019585201050227477,1,0,1,0.00020793259432731604
14,IGLC7,FCERI mediated Ca+2 mobilization,0.00040079407483459864,0,0,1,0.0004255159370467968
15,IGLC7,FCERI mediated Ca+2 mobilization,0.00019585201050227477,1,0,1,0.00020793259432731604
16,IGLC7,FCERI mediated NF-kB activation,0.00040079407483459864,0,0,1,0.0004255159370467968
17,IGLC7,FCERI mediated NF-kB activation,0.00019585201050227477,1,0,1,0.00020793259432731604
18,IGLC7,Parasite infection,0.00040079407483459864,0,0,1,0.0004255159370467968
19,IGLC7,Parasite infection,0.00019585201050227477,1,0,1,0.00020793259432731604
20,IGLC7,Leishmania parasite growth and survival,0.00040079407483459864,0,0,1,0.0004255159370467968
21,IGLC7,Leishmania parasite growth and survival,0.00019585201050227477,1,0,1,0.00020793259432731604
22,IGLC7,Potential therapeutics for SARS,0.00040079407483459864,0,0,1,0.0004255159370467968
23,IGLC7,Potential therapeutics for SARS,0.00019585201050227477,1,0,1,0.00020793259432731604
24,IGLC7,CD22 mediated BCR regulation,0.00040079407483459864,0,0,1,0.0004255159370467968
25,IGLC7,CD22 mediated BCR regulation,0.00019585201050227477,1,0,1,0.00020793259432731604
26,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00040079407483459864,0,0,1,0.0004255159370467968
27,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00019585201050227477,1,0,1,0.00020793259432731604
28,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00040079407483459864,0,0,1,0.0004255159370467968
29,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00019585201050227477,1,0,1,0.00020793259432731604
30,IGLC7,Scavenging of heme from plasma,0.00040079407483459864,0,0,1,0.0004255159370467968
31,IGLC7,Scavenging of heme from plasma,0.00019585201050227477,1,0,1,0.00020793259432731604
32,RB27B,Platelet degranulation ,6.466151787351337e-05,0,0,1,6.864998286257361e-05
33,RB27B,Platelet degranulation ,3.39427488004472e-05,1,0,1,3.6036412383907626e-05
34,RB27B,RAB GEFs exchange GTP for GDP on RABs,6.466151787351337e-05,0,0,1,6.864998286257361e-05
35,RB27B,RAB GEFs exchange GTP for GDP on RABs,3.39427488004472e-05,1,0,1,3.6036412383907626e-05
36,RB27B,RAB geranylgeranylation,6.466151787351337e-05,0,0,1,6.864998286257361e-05
37,RB27B,RAB geranylgeranylation,3.39427488004472e-05,1,0,1,3.6036412383907626e-05
38,QSOX1,Platelet degranulation ,0.00013187207935869377,0,0,1,0.000140006239966949
39,QSOX1,Platelet degranulation ,0.0002171722228998766,1,0,1,0.00023056788443270542
40,QSOX1,Neutrophil degranulation,0.00013187207935869377,0,0,1,0.000140006239966949
41,QSOX1,Neutrophil degranulation,0.0002171722228998766,1,0,1,0.00023056788443270542
42,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00013187207935869377,0,0,1,0.000140006239966949
43,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002171722228998766,1,0,1,0.00023056788443270542
44,QSOX1,Post-translational protein phosphorylation,0.00013187207935869377,0,0,1,0.000140006239966949
45,QSOX1,Post-translational protein phosphorylation,0.0002171722228998766,1,0,1,0.00023056788443270542
46,NRP1,Neurophilin interactions with VEGF and VEGFR,0.00022987855572576102,0,0,1,0.00024405797188239127
47,NRP1,Neurophilin interactions with VEGF and VEGFR,0.00040739709447388384,1,0,1,0.00043252624549586346
48,NRP1,Semaphorin interactions,0.00022987855572576102,0,0,1,0.00024405797188239127
49,NRP1,Semaphorin interactions,0.00040739709447388384,1,0,1,0.00043252624549586346
50,NRP1,L1CAM interactions,0.00022987855572576102,0,0,1,0.00024405797188239127
51,NRP1,L1CAM interactions,0.00040739709447388384,1,0,1,0.00043252624549586346
52,NRP1,Signaling by ROBO receptors,0.00022987855572576102,0,0,1,0.00024405797188239127
53,NRP1,Signaling by ROBO receptors,0.00040739709447388384,1,0,1,0.00043252624549586346
54,NRP1,SARS-CoV-2 Infection,0.00022987855572576102,0,0,1,0.00024405797188239127
55,NRP1,SARS-CoV-2 Infection,0.00040739709447388384,1,0,1,0.00043252624549586346
56,APOL1,Scavenging of heme from plasma,0.0002918681549461898,0,0,1,0.00030987122625827435
57,APOL1,Scavenging of heme from plasma,0.00048571715995209615,1,0,1,0.0005156772652939513
58,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002918681549461898,0,0,1,0.00030987122625827435
59,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00048571715995209615,1,0,1,0.0005156772652939513
60,APOL1,Post-translational protein phosphorylation,0.0002918681549461898,0,0,1,0.00030987122625827435
61,APOL1,Post-translational protein phosphorylation,0.00048571715995209615,1,0,1,0.0005156772652939513
62,ARPC3,RHO GTPase Effectors,0.00021917518470356557,0,0,1,0.0002326943933366042
63,ARPC3,RHO GTPase Effectors,0.0003921207854790769,1,0,1,0.00041630766008083644
64,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.00021917518470356557,0,0,1,0.0002326943933366042
65,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0003921207854790769,1,0,1,0.00041630766008083644
66,ARPC3,EPH-Ephrin signaling,0.00021917518470356557,0,0,1,0.0002326943933366042
67,ARPC3,EPH-Ephrin signaling,0.0003921207854790769,1,0,1,0.00041630766008083644
68,ARPC3,Parasite infection,0.00021917518470356557,0,0,1,0.0002326943933366042
69,ARPC3,Parasite infection,0.0003921207854790769,1,0,1,0.00041630766008083644
70,ACTN4,Platelet degranulation ,6.117792670615904e-05,0,0,1,6.495151611134617e-05
71,ACTN4,Platelet degranulation ,8.019979738173557e-05,1,0,1,8.514669770987966e-05
72,ACTN4,Nephrin family interactions,6.117792670615904e-05,0,0,1,6.495151611134617e-05
73,ACTN4,Nephrin family interactions,8.019979738173557e-05,1,0,1,8.514669770987966e-05
74,FLNB,Antiviral mechanism by IFN-stimulated genes,2.5785134164437706e-05,0,0,1,2.7375618091125846e-05
75,FLNB,Antiviral mechanism by IFN-stimulated genes,1.2259274958962336e-05,1,0,1,1.3015454067852586e-05
76,PGRP1,Neutrophil degranulation,0.0002830502893131576,0,0,1,0.0003005094552312428
77,PGRP1,Neutrophil degranulation,0.00023485561571294337,1,0,1,0.00024934202790307476
78,FCN3,Initial triggering of complement,0.0001189505724213918,0,0,1,0.00012628770599223445
79,FCN3,Initial triggering of complement,9.612279238647111e-05,1,0,1,0.0001020518581537501
80,IDHC,NADPH regeneration,0.0007484639877498358,0,0,1,0.0007946308967381483
81,IDHC,NADPH regeneration,0.00033018596748541333,1,0,1,0.0003505525659585679
82,IDHC,KEAP1-NFE2L2 pathway,0.0007484639877498358,0,0,1,0.0007946308967381483
83,IDHC,KEAP1-NFE2L2 pathway,0.00033018596748541333,1,0,1,0.0003505525659585679
84,IDHC,Neutrophil degranulation,0.0007484639877498358,0,0,1,0.0007946308967381483
85,IDHC,Neutrophil degranulation,0.00033018596748541333,1,0,1,0.0003505525659585679
86,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0007484639877498358,0,0,1,0.0007946308967381483
87,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00033018596748541333,1,0,1,0.0003505525659585679
88,UTS2,Class A/1 (Rhodopsin-like receptors),0.00020870691732483381,0,0,1,0.00022158042014536945
89,UTS2,Class A/1 (Rhodopsin-like receptors),0.00014951732059279065,1,0,1,0.00015873987858484046
90,UTS2,G alpha (q) signalling events,0.00020870691732483381,0,0,1,0.00022158042014536945
91,UTS2,G alpha (q) signalling events,0.00014951732059279065,1,0,1,0.00015873987858484046
92,APOM,Retinoid metabolism and transport,0.0005983259325748712,0,0,1,0.0006352319952935011
93,APOM,Retinoid metabolism and transport,0.00033396670581626074,1,0,1,0.00035456650856548693
94,VNN1,Vitamin B5 (pantothenate) metabolism,0.0004556751366070032,0,0,1,0.0004837821837118584
95,VNN1,Vitamin B5 (pantothenate) metabolism,0.00016338719171176425,1,0,1,0.0001734652739349188
96,VNN1,Neutrophil degranulation,0.0004556751366070032,0,0,1,0.0004837821837118584
97,VNN1,Neutrophil degranulation,0.00016338719171176425,1,0,1,0.0001734652739349188
98,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0004556751366070032,0,0,1,0.0004837821837118584
99,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.00016338719171176425,1,0,1,0.0001734652739349188
100,FSTL3,Antagonism of Activin by Follistatin,0.00012847204796224125,0,0,1,0.00013639648713752636
101,FSTL3,Antagonism of Activin by Follistatin,4.493870433572258e-05,1,0,1,4.771062270063585e-05
102,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00012847204796224125,0,0,1,0.00013639648713752636
103,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4.493870433572258e-05,1,0,1,4.771062270063585e-05
104,FSTL3,Post-translational protein phosphorylation,0.00012847204796224125,0,0,1,0.00013639648713752636
105,FSTL3,Post-translational protein phosphorylation,4.493870433572258e-05,1,0,1,4.771062270063585e-05
106,K2C75,Formation of the cornified envelope,7.367740724434329e-05,0,0,1,7.822199216815572e-05
107,K2C75,Formation of the cornified envelope,3.0982949564247916e-06,1,0,1,3.289404620501268e-06
108,PAK4,RHO GTPase cycle,0.0002337864339500959,0,0,1,0.0002482068966517479
109,PAK4,RHO GTPase cycle,1.424305869569728e-05,1,0,1,1.512160195934356e-05
110,PAK4,Signaling by ROBO receptors,0.0002337864339500959,0,0,1,0.0002482068966517479
111,PAK4,Signaling by ROBO receptors,1.424305869569728e-05,1,0,1,1.512160195934356e-05
112,ADH1B,Ethanol oxidation,0.00020883125937774276,0,0,1,0.00022171243189025294
113,ADH1B,Ethanol oxidation,0.00013443354187698132,1,0,1,0.00014272569914091304
114,LDHA,Pyruvate metabolism,0.0008339799782804918,0,0,1,0.000885421702111591
115,LDHA,Pyruvate metabolism,0.0009254898781696722,1,0,1,0.0009825761343882475
116,AL1A1,Ethanol oxidation,0.0008655670471253053,0,0,1,0.0009189571310063653
117,AL1A1,Ethanol oxidation,1.4384373450473983e-05,1,0,1,1.5271633319767645e-05
118,AL1A1,RA biosynthesis pathway,0.0008655670471253053,0,0,1,0.0009189571310063653
119,AL1A1,RA biosynthesis pathway,1.4384373450473983e-05,1,0,1,1.5271633319767645e-05
120,AL1A1,Fructose catabolism,0.0008655670471253053,0,0,1,0.0009189571310063653
121,AL1A1,Fructose catabolism,1.4384373450473983e-05,1,0,1,1.5271633319767645e-05
122,DHE3,Transcriptional activation of mitochondrial biogenesis,9.103546333531754e-05,0,0,1,9.665073143010692e-05
123,DHE3,Transcriptional activation of mitochondrial biogenesis,0.00017917885122700183,1,0,1,0.00019023099782672874
124,DHE3,Glutamate and glutamine metabolism,9.103546333531754e-05,0,0,1,9.665073143010692e-05
125,DHE3,Glutamate and glutamine metabolism,0.00017917885122700183,1,0,1,0.00019023099782672874
126,CERU,Metal ion SLC transporters,0.00015409531837528177,0,0,1,0.00016360025736418936
127,CERU,Metal ion SLC transporters,0.00023113225072127645,1,0,1,0.0002453889975493944
128,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00015409531837528177,0,0,1,0.00016360025736418936
129,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00023113225072127645,1,0,1,0.0002453889975493944
130,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00015409531837528177,0,0,1,0.00016360025736418936
131,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00023113225072127645,1,0,1,0.0002453889975493944
132,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00015409531837528177,0,0,1,0.00016360025736418936
133,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00023113225072127645,1,0,1,0.0002453889975493944
134,CERU,Post-translational protein phosphorylation,0.00015409531837528177,0,0,1,0.00016360025736418936
135,CERU,Post-translational protein phosphorylation,0.00023113225072127645,1,0,1,0.0002453889975493944
136,OTC,Urea cycle,0.0002847351877300688,0,0,1,0.00030229828189739675
137,OTC,Urea cycle,0.00017865459465860213,1,0,1,0.0001896744039573019
138,OTC,Mitochondrial protein import,0.0002847351877300688,0,0,1,0.00030229828189739675
139,OTC,Mitochondrial protein import,0.00017865459465860213,1,0,1,0.0001896744039573019
140,F13A,Interleukin-4 and Interleukin-13 signaling,0.00016002755552393366,0,0,1,0.00016989840797964982
141,F13A,Interleukin-4 and Interleukin-13 signaling,0.0003261148812159175,1,0,1,0.00034623036611198144
142,F13A,Platelet degranulation ,0.00016002755552393366,0,0,1,0.00016989840797964982
143,F13A,Platelet degranulation ,0.0003261148812159175,1,0,1,0.00034623036611198144
144,F13A,Common Pathway of Fibrin Clot Formation,0.00016002755552393366,0,0,1,0.00016989840797964982
145,F13A,Common Pathway of Fibrin Clot Formation,0.0003261148812159175,1,0,1,0.00034623036611198144
146,PGK1,Glycolysis,0.00010889713197924684,0,0,1,0.00011561414717765141
147,PGK1,Glycolysis,0.00036460465144692227,1,0,1,0.0003870942702336201
148,PGK1,Gluconeogenesis,0.00010889713197924684,0,0,1,0.00011561414717765141
149,PGK1,Gluconeogenesis,0.00036460465144692227,1,0,1,0.0003870942702336201
150,PGK1,Response of Mtb to phagocytosis,0.00010889713197924684,0,0,1,0.00011561414717765141
151,PGK1,Response of Mtb to phagocytosis,0.00036460465144692227,1,0,1,0.0003870942702336201
152,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004779926988544387,0,0,1,0.005074763424047901
153,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002078459385369787,1,0,1,0.002206663342875813
154,THRB,Regulation of Complement cascade,0.004779926988544387,0,0,1,0.005074763424047901
155,THRB,Regulation of Complement cascade,0.002078459385369787,1,0,1,0.002206663342875813
156,THRB,Class A/1 (Rhodopsin-like receptors),0.004779926988544387,0,0,1,0.005074763424047901
157,THRB,Class A/1 (Rhodopsin-like receptors),0.002078459385369787,1,0,1,0.002206663342875813
158,THRB,G alpha (q) signalling events,0.004779926988544387,0,0,1,0.005074763424047901
159,THRB,G alpha (q) signalling events,0.002078459385369787,1,0,1,0.002206663342875813
160,THRB,Defective factor XII causes hereditary angioedema,0.004779926988544387,0,0,1,0.005074763424047901
161,THRB,Defective factor XII causes hereditary angioedema,0.002078459385369787,1,0,1,0.002206663342875813
162,THRB,Defective factor VIII causes hemophilia A,0.004779926988544387,0,0,1,0.005074763424047901
163,THRB,Defective factor VIII causes hemophilia A,0.002078459385369787,1,0,1,0.002206663342875813
164,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.004779926988544387,0,0,1,0.005074763424047901
165,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.002078459385369787,1,0,1,0.002206663342875813
166,THRB,Common Pathway of Fibrin Clot Formation,0.004779926988544387,0,0,1,0.005074763424047901
167,THRB,Common Pathway of Fibrin Clot Formation,0.002078459385369787,1,0,1,0.002206663342875813
168,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004779926988544387,0,0,1,0.005074763424047901
169,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002078459385369787,1,0,1,0.002206663342875813
170,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.004779926988544387,0,0,1,0.005074763424047901
171,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.002078459385369787,1,0,1,0.002206663342875813
172,C1R,Initial triggering of complement,2.2671233914592205e-05,0,0,1,2.4069645608298907e-05
173,C1R,Initial triggering of complement,9.599239494741365e-05,1,0,1,0.00010191341751314947
174,C1R,Regulation of Complement cascade,2.2671233914592205e-05,0,0,1,2.4069645608298907e-05
175,C1R,Regulation of Complement cascade,9.599239494741365e-05,1,0,1,0.00010191341751314947
176,HPT,Neutrophil degranulation,0.00023679205067998142,0,0,1,0.0002513979064483587
177,HPT,Neutrophil degranulation,0.00010937019364719902,1,0,1,0.0001161163883322959
178,HPT,Scavenging of heme from plasma,0.00023679205067998142,0,0,1,0.0002513979064483587
179,HPT,Scavenging of heme from plasma,0.00010937019364719902,1,0,1,0.0001161163883322959
180,HPTR,Scavenging of heme from plasma,0.0002179565819771024,0,0,1,0.0002314006245071804
181,HPTR,Scavenging of heme from plasma,8.015247119012922e-05,1,0,1,8.509645233442958e-05
182,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00035985513565382575,0,0,1,0.00038205179383460634
183,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0004648729269241545,1,0,1,0.0004935473140151887
184,FA9,Defective factor VIII causes hemophilia A,0.00035985513565382575,0,0,1,0.00038205179383460634
185,FA9,Defective factor VIII causes hemophilia A,0.0004648729269241545,1,0,1,0.0004935473140151887
186,FA9,Defective factor IX causes hemophilia B,0.00035985513565382575,0,0,1,0.00038205179383460634
187,FA9,Defective factor IX causes hemophilia B,0.0004648729269241545,1,0,1,0.0004935473140151887
188,FA9,Defective factor IX causes thrombophilia,0.00035985513565382575,0,0,1,0.00038205179383460634
189,FA9,Defective factor IX causes thrombophilia,0.0004648729269241545,1,0,1,0.0004935473140151887
190,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.00035985513565382575,0,0,1,0.00038205179383460634
191,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.0004648729269241545,1,0,1,0.0004935473140151887
192,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.00035985513565382575,0,0,1,0.00038205179383460634
193,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.0004648729269241545,1,0,1,0.0004935473140151887
194,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0033579679979462746,0,0,1,0.0035650948677545618
195,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0014427306812275522,1,0,1,0.001531721490598518
196,FA10,Defective factor VIII causes hemophilia A,0.0033579679979462746,0,0,1,0.0035650948677545618
197,FA10,Defective factor VIII causes hemophilia A,0.0014427306812275522,1,0,1,0.001531721490598518
198,FA10,Defective factor IX causes hemophilia B,0.0033579679979462746,0,0,1,0.0035650948677545618
199,FA10,Defective factor IX causes hemophilia B,0.0014427306812275522,1,0,1,0.001531721490598518
200,FA10,Defective factor IX causes thrombophilia,0.0033579679979462746,0,0,1,0.0035650948677545618
201,FA10,Defective factor IX causes thrombophilia,0.0014427306812275522,1,0,1,0.001531721490598518
202,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.0033579679979462746,0,0,1,0.0035650948677545618
203,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.0014427306812275522,1,0,1,0.001531721490598518
204,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.0033579679979462746,0,0,1,0.0035650948677545618
205,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.0014427306812275522,1,0,1,0.001531721490598518
206,FA10,Common Pathway of Fibrin Clot Formation,0.0033579679979462746,0,0,1,0.0035650948677545618
207,FA10,Common Pathway of Fibrin Clot Formation,0.0014427306812275522,1,0,1,0.001531721490598518
208,CFAD,Initial triggering of complement,0.00020694954242931942,0,0,1,0.0002197146464916149
209,CFAD,Initial triggering of complement,6.765211760504454e-06,1,0,1,7.182504937926189e-06
210,CFAD,Platelet degranulation ,0.00020694954242931942,0,0,1,0.0002197146464916149
211,CFAD,Platelet degranulation ,6.765211760504454e-06,1,0,1,7.182504937926189e-06
212,CFAD,Neutrophil degranulation,0.00020694954242931942,0,0,1,0.0002197146464916149
213,CFAD,Neutrophil degranulation,6.765211760504454e-06,1,0,1,7.182504937926189e-06
214,PLMN,Platelet degranulation ,0.0006919656932438146,0,0,1,0.0007346476628587633
215,PLMN,Platelet degranulation ,0.0004432420236224195,1,0,1,0.0004705821689056836
216,PLMN,Dissolution of Fibrin Clot,0.0006919656932438146,0,0,1,0.0007346476628587633
217,PLMN,Dissolution of Fibrin Clot,0.0004432420236224195,1,0,1,0.0004705821689056836
218,PLMN,Activation of Matrix Metalloproteinases,0.0006919656932438146,0,0,1,0.0007346476628587633
219,PLMN,Activation of Matrix Metalloproteinases,0.0004432420236224195,1,0,1,0.0004705821689056836
220,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006919656932438146,0,0,1,0.0007346476628587633
221,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004432420236224195,1,0,1,0.0004705821689056836
222,PLMN,Signaling by PDGF,0.0006919656932438146,0,0,1,0.0007346476628587633
223,PLMN,Signaling by PDGF,0.0004432420236224195,1,0,1,0.0004705821689056836
224,FA12,Defective factor XII causes hereditary angioedema,0.0001792449498171654,0,0,1,0.0001903011735236687
225,FA12,Defective factor XII causes hereditary angioedema,0.00017431316362820275,1,0,1,0.00018506518388889943
226,FA12,Defective SERPING1 causes hereditary angioedema,0.0001792449498171654,0,0,1,0.0001903011735236687
227,FA12,Defective SERPING1 causes hereditary angioedema,0.00017431316362820275,1,0,1,0.00018506518388889943
228,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0001792449498171654,0,0,1,0.0001903011735236687
229,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.00017431316362820275,1,0,1,0.00018506518388889943
230,CFAB,Initial triggering of complement,0.0005746861627208114,0,0,1,0.0006101340723135466
231,CFAB,Initial triggering of complement,0.00015507223415359587,1,0,1,0.0001646374314616275
232,CFAB,Activation of C3 and C5,0.0005746861627208114,0,0,1,0.0006101340723135466
233,CFAB,Activation of C3 and C5,0.00015507223415359587,1,0,1,0.0001646374314616275
234,CFAB,Regulation of Complement cascade,0.0005746861627208114,0,0,1,0.0006101340723135466
235,CFAB,Regulation of Complement cascade,0.00015507223415359587,1,0,1,0.0001646374314616275
236,CAH1,Interleukin-12 family signaling,0.00031783585857825936,0,0,1,0.00033744067510432725
237,CAH1,Interleukin-12 family signaling,0.0004583657770169297,1,0,1,0.0004866387887546309
238,CAH1,Reversible hydration of carbon dioxide,0.00031783585857825936,0,0,1,0.00033744067510432725
239,CAH1,Reversible hydration of carbon dioxide,0.0004583657770169297,1,0,1,0.0004866387887546309
240,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.00031783585857825936,0,0,1,0.00033744067510432725
241,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.0004583657770169297,1,0,1,0.0004866387887546309
242,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.00031783585857825936,0,0,1,0.00033744067510432725
243,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.0004583657770169297,1,0,1,0.0004866387887546309
244,CAH2,Reversible hydration of carbon dioxide,0.0014730986783299878,0,0,1,0.001563962652718018
245,CAH2,Reversible hydration of carbon dioxide,0.0018961435901284748,1,0,1,0.0020131019074115936
246,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.0014730986783299878,0,0,1,0.001563962652718018
247,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.0018961435901284748,1,0,1,0.0020131019074115936
248,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.0014730986783299878,0,0,1,0.001563962652718018
249,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.0018961435901284748,1,0,1,0.0020131019074115936
250,ASSY,Urea cycle,0.00015287235855517274,0,0,1,0.00016230186268597705
251,ASSY,Urea cycle,1.229054447520206e-05,1,0,1,1.3048652356797445e-05
252,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.0001962052676466911,0,0,1,0.00020830764115126627
253,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.000424049456745854,1,0,1,0.00045020576218813077
254,ANT3,Common Pathway of Fibrin Clot Formation,0.0001962052676466911,0,0,1,0.00020830764115126627
255,ANT3,Common Pathway of Fibrin Clot Formation,0.000424049456745854,1,0,1,0.00045020576218813077
256,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001962052676466911,0,0,1,0.00020830764115126627
257,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.000424049456745854,1,0,1,0.00045020576218813077
258,ANT3,Post-translational protein phosphorylation,0.0001962052676466911,0,0,1,0.00020830764115126627
259,ANT3,Post-translational protein phosphorylation,0.000424049456745854,1,0,1,0.00045020576218813077
260,A1AT,COPII-mediated vesicle transport,0.0008307813875362995,0,0,1,0.0008820258152379993
261,A1AT,COPII-mediated vesicle transport,0.0011923154104744274,1,0,1,0.0012658600538262377
262,A1AT,Cargo concentration in the ER,0.0008307813875362995,0,0,1,0.0008820258152379993
263,A1AT,Cargo concentration in the ER,0.0011923154104744274,1,0,1,0.0012658600538262377
264,A1AT,Platelet degranulation ,0.0008307813875362995,0,0,1,0.0008820258152379993
265,A1AT,Platelet degranulation ,0.0011923154104744274,1,0,1,0.0012658600538262377
266,A1AT,Neutrophil degranulation,0.0008307813875362995,0,0,1,0.0008820258152379993
267,A1AT,Neutrophil degranulation,0.0011923154104744274,1,0,1,0.0012658600538262377
268,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008307813875362995,0,0,1,0.0008820258152379993
269,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011923154104744274,1,0,1,0.0012658600538262377
270,A1AT,Post-translational protein phosphorylation,0.0008307813875362995,0,0,1,0.0008820258152379993
271,A1AT,Post-translational protein phosphorylation,0.0011923154104744274,1,0,1,0.0012658600538262377
272,AACT,Platelet degranulation ,3.549776142490419e-05,0,0,1,3.7687341615554773e-05
273,AACT,Platelet degranulation ,7.331762175474834e-05,1,0,1,7.784001431630246e-05
274,AACT,Neutrophil degranulation,3.549776142490419e-05,0,0,1,3.7687341615554773e-05
275,AACT,Neutrophil degranulation,7.331762175474834e-05,1,0,1,7.784001431630246e-05
276,ANGT,Class A/1 (Rhodopsin-like receptors),0.0014304985524717184,0,0,1,0.0015187348571714554
277,ANGT,Class A/1 (Rhodopsin-like receptors),6.556168734490258e-05,1,0,1,6.96056767716644e-05
278,ANGT,G alpha (q) signalling events,0.0014304985524717184,0,0,1,0.0015187348571714554
279,ANGT,G alpha (q) signalling events,6.556168734490258e-05,1,0,1,6.96056767716644e-05
280,ANGT,G alpha (i) signalling events,0.0014304985524717184,0,0,1,0.0015187348571714554
281,ANGT,G alpha (i) signalling events,6.556168734490258e-05,1,0,1,6.96056767716644e-05
282,ANGT,PPARA activates gene expression,0.0014304985524717184,0,0,1,0.0015187348571714554
283,ANGT,PPARA activates gene expression,6.556168734490258e-05,1,0,1,6.96056767716644e-05
284,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0014304985524717184,0,0,1,0.0015187348571714554
285,ANGT,Metabolism of Angiotensinogen to Angiotensins,6.556168734490258e-05,1,0,1,6.96056767716644e-05
286,A2MG,Platelet degranulation ,0.00027755561753885124,0,0,1,0.0002946758599871678
287,A2MG,Platelet degranulation ,0.0011879225443129048,1,0,1,0.0012611962259944194
288,A2MG,HDL assembly,0.00027755561753885124,0,0,1,0.0002946758599871678
289,A2MG,HDL assembly,0.0011879225443129048,1,0,1,0.0012611962259944194
290,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.00027755561753885124,0,0,1,0.0002946758599871678
291,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.0011879225443129048,1,0,1,0.0012611962259944194
292,CO3,Initial triggering of complement,0.0005396942597825483,0,0,1,0.0005729837916514128
293,CO3,Initial triggering of complement,0.0005922020587872263,1,0,1,0.0006287303874686315
294,CO3,Activation of C3 and C5,0.0005396942597825483,0,0,1,0.0005729837916514128
295,CO3,Activation of C3 and C5,0.0005922020587872263,1,0,1,0.0006287303874686315
296,CO3,Regulation of Complement cascade,0.0005396942597825483,0,0,1,0.0005729837916514128
297,CO3,Regulation of Complement cascade,0.0005922020587872263,1,0,1,0.0006287303874686315
298,CO3,Class A/1 (Rhodopsin-like receptors),0.0005396942597825483,0,0,1,0.0005729837916514128
299,CO3,Class A/1 (Rhodopsin-like receptors),0.0005922020587872263,1,0,1,0.0006287303874686315
300,CO3,G alpha (i) signalling events,0.0005396942597825483,0,0,1,0.0005729837916514128
301,CO3,G alpha (i) signalling events,0.0005922020587872263,1,0,1,0.0006287303874686315
302,CO3,Cell recruitment (pro-inflammatory response),0.0005396942597825483,0,0,1,0.0005729837916514128
303,CO3,Cell recruitment (pro-inflammatory response),0.0005922020587872263,1,0,1,0.0006287303874686315
304,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005396942597825483,0,0,1,0.0005729837916514128
305,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005922020587872263,1,0,1,0.0006287303874686315
306,CO3,Neutrophil degranulation,0.0005396942597825483,0,0,1,0.0005729837916514128
307,CO3,Neutrophil degranulation,0.0005922020587872263,1,0,1,0.0006287303874686315
308,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005396942597825483,0,0,1,0.0005729837916514128
309,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005922020587872263,1,0,1,0.0006287303874686315
310,CO3,Post-translational protein phosphorylation,0.0005396942597825483,0,0,1,0.0005729837916514128
311,CO3,Post-translational protein phosphorylation,0.0005922020587872263,1,0,1,0.0006287303874686315
312,CO5,Terminal pathway of complement,0.00015783130999615734,0,0,1,0.00016756669318540728
313,CO5,Terminal pathway of complement,0.0003473297612492785,1,0,1,0.0003687538267206654
314,CO5,Activation of C3 and C5,0.00015783130999615734,0,0,1,0.00016756669318540728
315,CO5,Activation of C3 and C5,0.0003473297612492785,1,0,1,0.0003687538267206654
316,CO5,Regulation of Complement cascade,0.00015783130999615734,0,0,1,0.00016756669318540728
317,CO5,Regulation of Complement cascade,0.0003473297612492785,1,0,1,0.0003687538267206654
318,CO5,Class A/1 (Rhodopsin-like receptors),0.00015783130999615734,0,0,1,0.00016756669318540728
319,CO5,Class A/1 (Rhodopsin-like receptors),0.0003473297612492785,1,0,1,0.0003687538267206654
320,CO5,G alpha (i) signalling events,0.00015783130999615734,0,0,1,0.00016756669318540728
321,CO5,G alpha (i) signalling events,0.0003473297612492785,1,0,1,0.0003687538267206654
322,TIMP1,Interleukin-10 signaling,0.00014200030797173019,0,0,1,0.0001507592000516981
323,TIMP1,Interleukin-10 signaling,0.0012803052237765496,1,0,1,0.00135927727281401
324,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.00014200030797173019,0,0,1,0.0001507592000516981
325,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0012803052237765496,1,0,1,0.00135927727281401
326,TIMP1,Platelet degranulation ,0.00014200030797173019,0,0,1,0.0001507592000516981
327,TIMP1,Platelet degranulation ,0.0012803052237765496,1,0,1,0.00135927727281401
328,TIMP1,Activation of Matrix Metalloproteinases,0.00014200030797173019,0,0,1,0.0001507592000516981
329,TIMP1,Activation of Matrix Metalloproteinases,0.0012803052237765496,1,0,1,0.00135927727281401
330,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00014200030797173019,0,0,1,0.0001507592000516981
331,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012803052237765496,1,0,1,0.00135927727281401
332,TIMP1,Post-translational protein phosphorylation,0.00014200030797173019,0,0,1,0.0001507592000516981
333,TIMP1,Post-translational protein phosphorylation,0.0012803052237765496,1,0,1,0.00135927727281401
334,CYTC,Neutrophil degranulation,0.0003953946124388933,0,0,1,0.00041978342390571393
335,CYTC,Neutrophil degranulation,0.0009483231046481147,1,0,1,0.0010068177646188985
336,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003953946124388933,0,0,1,0.00041978342390571393
337,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009483231046481147,1,0,1,0.0010068177646188985
338,CYTC,Amyloid fiber formation,0.0003953946124388933,0,0,1,0.00041978342390571393
339,CYTC,Amyloid fiber formation,0.0009483231046481147,1,0,1,0.0010068177646188985
340,CYTC,Post-translational protein phosphorylation,0.0003953946124388933,0,0,1,0.00041978342390571393
341,CYTC,Post-translational protein phosphorylation,0.0009483231046481147,1,0,1,0.0010068177646188985
342,KNG1,Class A/1 (Rhodopsin-like receptors),0.0015678028144620055,0,0,1,0.0016645083487716666
343,KNG1,Class A/1 (Rhodopsin-like receptors),0.0010561588537827359,1,0,1,0.001121305060517916
344,KNG1,G alpha (q) signalling events,0.0015678028144620055,0,0,1,0.0016645083487716666
345,KNG1,G alpha (q) signalling events,0.0010561588537827359,1,0,1,0.001121305060517916
346,KNG1,G alpha (i) signalling events,0.0015678028144620055,0,0,1,0.0016645083487716666
347,KNG1,G alpha (i) signalling events,0.0010561588537827359,1,0,1,0.001121305060517916
348,KNG1,Platelet degranulation ,0.0015678028144620055,0,0,1,0.0016645083487716666
349,KNG1,Platelet degranulation ,0.0010561588537827359,1,0,1,0.001121305060517916
350,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.0015678028144620055,0,0,1,0.0016645083487716666
351,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.0010561588537827359,1,0,1,0.001121305060517916
352,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0015678028144620055,0,0,1,0.0016645083487716666
353,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010561588537827359,1,0,1,0.001121305060517916
354,KNG1,Post-translational protein phosphorylation,0.0015678028144620055,0,0,1,0.0016645083487716666
355,KNG1,Post-translational protein phosphorylation,0.0010561588537827359,1,0,1,0.001121305060517916
356,IGF2,IGF1R signaling cascade,0.0002087401468615962,0,0,1,0.0002216156993532243
357,IGF2,IGF1R signaling cascade,0.0003136675377321679,1,0,1,0.00033301524303807657
358,IGF2,Platelet degranulation ,0.0002087401468615962,0,0,1,0.0002216156993532243
359,IGF2,Platelet degranulation ,0.0003136675377321679,1,0,1,0.00033301524303807657
360,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002087401468615962,0,0,1,0.0002216156993532243
361,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003136675377321679,1,0,1,0.00033301524303807657
362,IGJ,Scavenging of heme from plasma,8.125010617068533e-05,0,0,1,8.626179186066739e-05
363,IGJ,Scavenging of heme from plasma,3.5260282145211326e-05,1,0,1,3.743521409029281e-05
364,KVD33,Initial triggering of complement,0.0013436141190200934,0,0,1,0.0014264912003005162
365,KVD33,Initial triggering of complement,0.0009724975159603909,1,0,1,0.0010324833069209971
366,KVD33,Regulation of Complement cascade,0.0013436141190200934,0,0,1,0.0014264912003005162
367,KVD33,Regulation of Complement cascade,0.0009724975159603909,1,0,1,0.0010324833069209971
368,KVD33,FCGR activation,0.0013436141190200934,0,0,1,0.0014264912003005162
369,KVD33,FCGR activation,0.0009724975159603909,1,0,1,0.0010324833069209971
370,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0013436141190200934,0,0,1,0.0014264912003005162
371,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0009724975159603909,1,0,1,0.0010324833069209971
372,KVD33,Role of phospholipids in phagocytosis,0.0013436141190200934,0,0,1,0.0014264912003005162
373,KVD33,Role of phospholipids in phagocytosis,0.0009724975159603909,1,0,1,0.0010324833069209971
374,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013436141190200934,0,0,1,0.0014264912003005162
375,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009724975159603909,1,0,1,0.0010324833069209971
376,KVD33,FCERI mediated MAPK activation,0.0013436141190200934,0,0,1,0.0014264912003005162
377,KVD33,FCERI mediated MAPK activation,0.0009724975159603909,1,0,1,0.0010324833069209971
378,KVD33,FCERI mediated Ca+2 mobilization,0.0013436141190200934,0,0,1,0.0014264912003005162
379,KVD33,FCERI mediated Ca+2 mobilization,0.0009724975159603909,1,0,1,0.0010324833069209971
380,KVD33,FCERI mediated NF-kB activation,0.0013436141190200934,0,0,1,0.0014264912003005162
381,KVD33,FCERI mediated NF-kB activation,0.0009724975159603909,1,0,1,0.0010324833069209971
382,KVD33,Parasite infection,0.0013436141190200934,0,0,1,0.0014264912003005162
383,KVD33,Parasite infection,0.0009724975159603909,1,0,1,0.0010324833069209971
384,KVD33,Leishmania parasite growth and survival,0.0013436141190200934,0,0,1,0.0014264912003005162
385,KVD33,Leishmania parasite growth and survival,0.0009724975159603909,1,0,1,0.0010324833069209971
386,KVD33,Potential therapeutics for SARS,0.0013436141190200934,0,0,1,0.0014264912003005162
387,KVD33,Potential therapeutics for SARS,0.0009724975159603909,1,0,1,0.0010324833069209971
388,KVD33,CD22 mediated BCR regulation,0.0013436141190200934,0,0,1,0.0014264912003005162
389,KVD33,CD22 mediated BCR regulation,0.0009724975159603909,1,0,1,0.0010324833069209971
390,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013436141190200934,0,0,1,0.0014264912003005162
391,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009724975159603909,1,0,1,0.0010324833069209971
392,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013436141190200934,0,0,1,0.0014264912003005162
393,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009724975159603909,1,0,1,0.0010324833069209971
394,KVD33,Scavenging of heme from plasma,0.0013436141190200934,0,0,1,0.0014264912003005162
395,KVD33,Scavenging of heme from plasma,0.0009724975159603909,1,0,1,0.0010324833069209971
396,KVD16,Initial triggering of complement,6.410405121291234e-05,0,0,1,6.80581304292364e-05
397,KVD16,Initial triggering of complement,0.00016871570824612367,1,0,1,0.00017912246511750556
398,KVD16,Regulation of Complement cascade,6.410405121291234e-05,0,0,1,6.80581304292364e-05
399,KVD16,Regulation of Complement cascade,0.00016871570824612367,1,0,1,0.00017912246511750556
400,KVD16,FCGR activation,6.410405121291234e-05,0,0,1,6.80581304292364e-05
401,KVD16,FCGR activation,0.00016871570824612367,1,0,1,0.00017912246511750556
402,KVD16,Regulation of actin dynamics for phagocytic cup formation,6.410405121291234e-05,0,0,1,6.80581304292364e-05
403,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.00016871570824612367,1,0,1,0.00017912246511750556
404,KVD16,Role of phospholipids in phagocytosis,6.410405121291234e-05,0,0,1,6.80581304292364e-05
405,KVD16,Role of phospholipids in phagocytosis,0.00016871570824612367,1,0,1,0.00017912246511750556
406,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,6.410405121291234e-05,0,0,1,6.80581304292364e-05
407,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.00016871570824612367,1,0,1,0.00017912246511750556
408,KVD16,FCERI mediated MAPK activation,6.410405121291234e-05,0,0,1,6.80581304292364e-05
409,KVD16,FCERI mediated MAPK activation,0.00016871570824612367,1,0,1,0.00017912246511750556
410,KVD16,FCERI mediated Ca+2 mobilization,6.410405121291234e-05,0,0,1,6.80581304292364e-05
411,KVD16,FCERI mediated Ca+2 mobilization,0.00016871570824612367,1,0,1,0.00017912246511750556
412,KVD16,FCERI mediated NF-kB activation,6.410405121291234e-05,0,0,1,6.80581304292364e-05
413,KVD16,FCERI mediated NF-kB activation,0.00016871570824612367,1,0,1,0.00017912246511750556
414,KVD16,Parasite infection,6.410405121291234e-05,0,0,1,6.80581304292364e-05
415,KVD16,Parasite infection,0.00016871570824612367,1,0,1,0.00017912246511750556
416,KVD16,Leishmania parasite growth and survival,6.410405121291234e-05,0,0,1,6.80581304292364e-05
417,KVD16,Leishmania parasite growth and survival,0.00016871570824612367,1,0,1,0.00017912246511750556
418,KVD16,Potential therapeutics for SARS,6.410405121291234e-05,0,0,1,6.80581304292364e-05
419,KVD16,Potential therapeutics for SARS,0.00016871570824612367,1,0,1,0.00017912246511750556
420,KVD16,CD22 mediated BCR regulation,6.410405121291234e-05,0,0,1,6.80581304292364e-05
421,KVD16,CD22 mediated BCR regulation,0.00016871570824612367,1,0,1,0.00017912246511750556
422,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,6.410405121291234e-05,0,0,1,6.80581304292364e-05
423,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00016871570824612367,1,0,1,0.00017912246511750556
424,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,6.410405121291234e-05,0,0,1,6.80581304292364e-05
425,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00016871570824612367,1,0,1,0.00017912246511750556
426,KVD16,Scavenging of heme from plasma,6.410405121291234e-05,0,0,1,6.80581304292364e-05
427,KVD16,Scavenging of heme from plasma,0.00016871570824612367,1,0,1,0.00017912246511750556
428,KV105,Initial triggering of complement,0.0002148251008080931,0,0,1,0.000228075986675333
429,KV105,Initial triggering of complement,0.00022396229199331418,1,0,1,0.00023777677995866583
430,KV105,Regulation of Complement cascade,0.0002148251008080931,0,0,1,0.000228075986675333
431,KV105,Regulation of Complement cascade,0.00022396229199331418,1,0,1,0.00023777677995866583
432,KV105,FCGR activation,0.0002148251008080931,0,0,1,0.000228075986675333
433,KV105,FCGR activation,0.00022396229199331418,1,0,1,0.00023777677995866583
434,KV105,Regulation of actin dynamics for phagocytic cup formation,0.0002148251008080931,0,0,1,0.000228075986675333
435,KV105,Regulation of actin dynamics for phagocytic cup formation,0.00022396229199331418,1,0,1,0.00023777677995866583
436,KV105,Role of phospholipids in phagocytosis,0.0002148251008080931,0,0,1,0.000228075986675333
437,KV105,Role of phospholipids in phagocytosis,0.00022396229199331418,1,0,1,0.00023777677995866583
438,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.0002148251008080931,0,0,1,0.000228075986675333
439,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.00022396229199331418,1,0,1,0.00023777677995866583
440,KV105,FCERI mediated MAPK activation,0.0002148251008080931,0,0,1,0.000228075986675333
441,KV105,FCERI mediated MAPK activation,0.00022396229199331418,1,0,1,0.00023777677995866583
442,KV105,FCERI mediated Ca+2 mobilization,0.0002148251008080931,0,0,1,0.000228075986675333
443,KV105,FCERI mediated Ca+2 mobilization,0.00022396229199331418,1,0,1,0.00023777677995866583
444,KV105,FCERI mediated NF-kB activation,0.0002148251008080931,0,0,1,0.000228075986675333
445,KV105,FCERI mediated NF-kB activation,0.00022396229199331418,1,0,1,0.00023777677995866583
446,KV105,Parasite infection,0.0002148251008080931,0,0,1,0.000228075986675333
447,KV105,Parasite infection,0.00022396229199331418,1,0,1,0.00023777677995866583
448,KV105,Leishmania parasite growth and survival,0.0002148251008080931,0,0,1,0.000228075986675333
449,KV105,Leishmania parasite growth and survival,0.00022396229199331418,1,0,1,0.00023777677995866583
450,KV105,Potential therapeutics for SARS,0.0002148251008080931,0,0,1,0.000228075986675333
451,KV105,Potential therapeutics for SARS,0.00022396229199331418,1,0,1,0.00023777677995866583
452,KV105,CD22 mediated BCR regulation,0.0002148251008080931,0,0,1,0.000228075986675333
453,KV105,CD22 mediated BCR regulation,0.00022396229199331418,1,0,1,0.00023777677995866583
454,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0002148251008080931,0,0,1,0.000228075986675333
455,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00022396229199331418,1,0,1,0.00023777677995866583
456,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002148251008080931,0,0,1,0.000228075986675333
457,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00022396229199331418,1,0,1,0.00023777677995866583
458,KV105,Scavenging of heme from plasma,0.0002148251008080931,0,0,1,0.000228075986675333
459,KV105,Scavenging of heme from plasma,0.00022396229199331418,1,0,1,0.00023777677995866583
460,KVD12,Initial triggering of complement,0.001034319053148008,0,0,1,0.0010981181328273391
461,KVD12,Initial triggering of complement,0.0010959322101181787,1,0,1,0.001163531725164983
462,KVD12,Regulation of Complement cascade,0.001034319053148008,0,0,1,0.0010981181328273391
463,KVD12,Regulation of Complement cascade,0.0010959322101181787,1,0,1,0.001163531725164983
464,KVD12,FCGR activation,0.001034319053148008,0,0,1,0.0010981181328273391
465,KVD12,FCGR activation,0.0010959322101181787,1,0,1,0.001163531725164983
466,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.001034319053148008,0,0,1,0.0010981181328273391
467,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.0010959322101181787,1,0,1,0.001163531725164983
468,KVD12,Role of phospholipids in phagocytosis,0.001034319053148008,0,0,1,0.0010981181328273391
469,KVD12,Role of phospholipids in phagocytosis,0.0010959322101181787,1,0,1,0.001163531725164983
470,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.001034319053148008,0,0,1,0.0010981181328273391
471,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.0010959322101181787,1,0,1,0.001163531725164983
472,KVD12,FCERI mediated MAPK activation,0.001034319053148008,0,0,1,0.0010981181328273391
473,KVD12,FCERI mediated MAPK activation,0.0010959322101181787,1,0,1,0.001163531725164983
474,KVD12,FCERI mediated Ca+2 mobilization,0.001034319053148008,0,0,1,0.0010981181328273391
475,KVD12,FCERI mediated Ca+2 mobilization,0.0010959322101181787,1,0,1,0.001163531725164983
476,KVD12,FCERI mediated NF-kB activation,0.001034319053148008,0,0,1,0.0010981181328273391
477,KVD12,FCERI mediated NF-kB activation,0.0010959322101181787,1,0,1,0.001163531725164983
478,KVD12,Parasite infection,0.001034319053148008,0,0,1,0.0010981181328273391
479,KVD12,Parasite infection,0.0010959322101181787,1,0,1,0.001163531725164983
480,KVD12,Leishmania parasite growth and survival,0.001034319053148008,0,0,1,0.0010981181328273391
481,KVD12,Leishmania parasite growth and survival,0.0010959322101181787,1,0,1,0.001163531725164983
482,KVD12,Potential therapeutics for SARS,0.001034319053148008,0,0,1,0.0010981181328273391
483,KVD12,Potential therapeutics for SARS,0.0010959322101181787,1,0,1,0.001163531725164983
484,KVD12,CD22 mediated BCR regulation,0.001034319053148008,0,0,1,0.0010981181328273391
485,KVD12,CD22 mediated BCR regulation,0.0010959322101181787,1,0,1,0.001163531725164983
486,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001034319053148008,0,0,1,0.0010981181328273391
487,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0010959322101181787,1,0,1,0.001163531725164983
488,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001034319053148008,0,0,1,0.0010981181328273391
489,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010959322101181787,1,0,1,0.001163531725164983
490,KVD12,Scavenging of heme from plasma,0.001034319053148008,0,0,1,0.0010981181328273391
491,KVD12,Scavenging of heme from plasma,0.0010959322101181787,1,0,1,0.001163531725164983
492,KVD40,Initial triggering of complement,0.00026680166349031076,0,0,1,0.00028325857834244456
493,KVD40,Initial triggering of complement,0.00016956585268463424,1,0,1,0.00018002504833939382
494,KVD40,Regulation of Complement cascade,0.00026680166349031076,0,0,1,0.00028325857834244456
495,KVD40,Regulation of Complement cascade,0.00016956585268463424,1,0,1,0.00018002504833939382
496,KVD40,FCGR activation,0.00026680166349031076,0,0,1,0.00028325857834244456
497,KVD40,FCGR activation,0.00016956585268463424,1,0,1,0.00018002504833939382
498,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.00026680166349031076,0,0,1,0.00028325857834244456
499,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.00016956585268463424,1,0,1,0.00018002504833939382
500,KVD40,Role of phospholipids in phagocytosis,0.00026680166349031076,0,0,1,0.00028325857834244456
501,KVD40,Role of phospholipids in phagocytosis,0.00016956585268463424,1,0,1,0.00018002504833939382
502,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.00026680166349031076,0,0,1,0.00028325857834244456
503,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.00016956585268463424,1,0,1,0.00018002504833939382
504,KVD40,FCERI mediated MAPK activation,0.00026680166349031076,0,0,1,0.00028325857834244456
505,KVD40,FCERI mediated MAPK activation,0.00016956585268463424,1,0,1,0.00018002504833939382
506,KVD40,FCERI mediated Ca+2 mobilization,0.00026680166349031076,0,0,1,0.00028325857834244456
507,KVD40,FCERI mediated Ca+2 mobilization,0.00016956585268463424,1,0,1,0.00018002504833939382
508,KVD40,FCERI mediated NF-kB activation,0.00026680166349031076,0,0,1,0.00028325857834244456
509,KVD40,FCERI mediated NF-kB activation,0.00016956585268463424,1,0,1,0.00018002504833939382
510,KVD40,Parasite infection,0.00026680166349031076,0,0,1,0.00028325857834244456
511,KVD40,Parasite infection,0.00016956585268463424,1,0,1,0.00018002504833939382
512,KVD40,Leishmania parasite growth and survival,0.00026680166349031076,0,0,1,0.00028325857834244456
513,KVD40,Leishmania parasite growth and survival,0.00016956585268463424,1,0,1,0.00018002504833939382
514,KVD40,Potential therapeutics for SARS,0.00026680166349031076,0,0,1,0.00028325857834244456
515,KVD40,Potential therapeutics for SARS,0.00016956585268463424,1,0,1,0.00018002504833939382
516,KVD40,CD22 mediated BCR regulation,0.00026680166349031076,0,0,1,0.00028325857834244456
517,KVD40,CD22 mediated BCR regulation,0.00016956585268463424,1,0,1,0.00018002504833939382
518,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00026680166349031076,0,0,1,0.00028325857834244456
519,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00016956585268463424,1,0,1,0.00018002504833939382
520,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00026680166349031076,0,0,1,0.00028325857834244456
521,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00016956585268463424,1,0,1,0.00018002504833939382
522,KVD40,Scavenging of heme from plasma,0.00026680166349031076,0,0,1,0.00028325857834244456
523,KVD40,Scavenging of heme from plasma,0.00016956585268463424,1,0,1,0.00018002504833939382
524,KV320,Initial triggering of complement,0.0006870448840179287,0,0,1,0.0007294233272703555
525,KV320,Initial triggering of complement,0.0008898216045903619,1,0,1,0.0009447077630526552
526,KV320,Regulation of Complement cascade,0.0006870448840179287,0,0,1,0.0007294233272703555
527,KV320,Regulation of Complement cascade,0.0008898216045903619,1,0,1,0.0009447077630526552
528,KV320,FCGR activation,0.0006870448840179287,0,0,1,0.0007294233272703555
529,KV320,FCGR activation,0.0008898216045903619,1,0,1,0.0009447077630526552
530,KV320,Regulation of actin dynamics for phagocytic cup formation,0.0006870448840179287,0,0,1,0.0007294233272703555
531,KV320,Regulation of actin dynamics for phagocytic cup formation,0.0008898216045903619,1,0,1,0.0009447077630526552
532,KV320,Role of phospholipids in phagocytosis,0.0006870448840179287,0,0,1,0.0007294233272703555
533,KV320,Role of phospholipids in phagocytosis,0.0008898216045903619,1,0,1,0.0009447077630526552
534,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006870448840179287,0,0,1,0.0007294233272703555
535,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008898216045903619,1,0,1,0.0009447077630526552
536,KV320,FCERI mediated MAPK activation,0.0006870448840179287,0,0,1,0.0007294233272703555
537,KV320,FCERI mediated MAPK activation,0.0008898216045903619,1,0,1,0.0009447077630526552
538,KV320,FCERI mediated Ca+2 mobilization,0.0006870448840179287,0,0,1,0.0007294233272703555
539,KV320,FCERI mediated Ca+2 mobilization,0.0008898216045903619,1,0,1,0.0009447077630526552
540,KV320,FCERI mediated NF-kB activation,0.0006870448840179287,0,0,1,0.0007294233272703555
541,KV320,FCERI mediated NF-kB activation,0.0008898216045903619,1,0,1,0.0009447077630526552
542,KV320,Parasite infection,0.0006870448840179287,0,0,1,0.0007294233272703555
543,KV320,Parasite infection,0.0008898216045903619,1,0,1,0.0009447077630526552
544,KV320,Leishmania parasite growth and survival,0.0006870448840179287,0,0,1,0.0007294233272703555
545,KV320,Leishmania parasite growth and survival,0.0008898216045903619,1,0,1,0.0009447077630526552
546,KV320,Potential therapeutics for SARS,0.0006870448840179287,0,0,1,0.0007294233272703555
547,KV320,Potential therapeutics for SARS,0.0008898216045903619,1,0,1,0.0009447077630526552
548,KV320,CD22 mediated BCR regulation,0.0006870448840179287,0,0,1,0.0007294233272703555
549,KV320,CD22 mediated BCR regulation,0.0008898216045903619,1,0,1,0.0009447077630526552
550,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006870448840179287,0,0,1,0.0007294233272703555
551,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008898216045903619,1,0,1,0.0009447077630526552
552,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006870448840179287,0,0,1,0.0007294233272703555
553,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008898216045903619,1,0,1,0.0009447077630526552
554,KV320,Scavenging of heme from plasma,0.0006870448840179287,0,0,1,0.0007294233272703555
555,KV320,Scavenging of heme from plasma,0.0008898216045903619,1,0,1,0.0009447077630526552
556,LV147,Initial triggering of complement,0.0006217762153065095,0,0,1,0.0006601287431675393
557,LV147,Initial triggering of complement,0.0003841426105305237,1,0,1,0.00040783737371106435
558,LV147,Regulation of Complement cascade,0.0006217762153065095,0,0,1,0.0006601287431675393
559,LV147,Regulation of Complement cascade,0.0003841426105305237,1,0,1,0.00040783737371106435
560,LV147,FCGR activation,0.0006217762153065095,0,0,1,0.0006601287431675393
561,LV147,FCGR activation,0.0003841426105305237,1,0,1,0.00040783737371106435
562,LV147,Regulation of actin dynamics for phagocytic cup formation,0.0006217762153065095,0,0,1,0.0006601287431675393
563,LV147,Regulation of actin dynamics for phagocytic cup formation,0.0003841426105305237,1,0,1,0.00040783737371106435
564,LV147,Role of phospholipids in phagocytosis,0.0006217762153065095,0,0,1,0.0006601287431675393
565,LV147,Role of phospholipids in phagocytosis,0.0003841426105305237,1,0,1,0.00040783737371106435
566,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006217762153065095,0,0,1,0.0006601287431675393
567,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.0003841426105305237,1,0,1,0.00040783737371106435
568,LV147,FCERI mediated MAPK activation,0.0006217762153065095,0,0,1,0.0006601287431675393
569,LV147,FCERI mediated MAPK activation,0.0003841426105305237,1,0,1,0.00040783737371106435
570,LV147,FCERI mediated Ca+2 mobilization,0.0006217762153065095,0,0,1,0.0006601287431675393
571,LV147,FCERI mediated Ca+2 mobilization,0.0003841426105305237,1,0,1,0.00040783737371106435
572,LV147,FCERI mediated NF-kB activation,0.0006217762153065095,0,0,1,0.0006601287431675393
573,LV147,FCERI mediated NF-kB activation,0.0003841426105305237,1,0,1,0.00040783737371106435
574,LV147,Parasite infection,0.0006217762153065095,0,0,1,0.0006601287431675393
575,LV147,Parasite infection,0.0003841426105305237,1,0,1,0.00040783737371106435
576,LV147,Leishmania parasite growth and survival,0.0006217762153065095,0,0,1,0.0006601287431675393
577,LV147,Leishmania parasite growth and survival,0.0003841426105305237,1,0,1,0.00040783737371106435
578,LV147,Potential therapeutics for SARS,0.0006217762153065095,0,0,1,0.0006601287431675393
579,LV147,Potential therapeutics for SARS,0.0003841426105305237,1,0,1,0.00040783737371106435
580,LV147,CD22 mediated BCR regulation,0.0006217762153065095,0,0,1,0.0006601287431675393
581,LV147,CD22 mediated BCR regulation,0.0003841426105305237,1,0,1,0.00040783737371106435
582,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006217762153065095,0,0,1,0.0006601287431675393
583,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0003841426105305237,1,0,1,0.00040783737371106435
584,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006217762153065095,0,0,1,0.0006601287431675393
585,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003841426105305237,1,0,1,0.00040783737371106435
586,LV147,Scavenging of heme from plasma,0.0006217762153065095,0,0,1,0.0006601287431675393
587,LV147,Scavenging of heme from plasma,0.0003841426105305237,1,0,1,0.00040783737371106435
588,LV319,Initial triggering of complement,0.0001448359316089935,0,0,1,0.0001537697312069306
589,LV319,Initial triggering of complement,0.00027542047692160737,1,0,1,0.00029240901918906433
590,LV319,Regulation of Complement cascade,0.0001448359316089935,0,0,1,0.0001537697312069306
591,LV319,Regulation of Complement cascade,0.00027542047692160737,1,0,1,0.00029240901918906433
592,LV319,FCGR activation,0.0001448359316089935,0,0,1,0.0001537697312069306
593,LV319,FCGR activation,0.00027542047692160737,1,0,1,0.00029240901918906433
594,LV319,Regulation of actin dynamics for phagocytic cup formation,0.0001448359316089935,0,0,1,0.0001537697312069306
595,LV319,Regulation of actin dynamics for phagocytic cup formation,0.00027542047692160737,1,0,1,0.00029240901918906433
596,LV319,Role of phospholipids in phagocytosis,0.0001448359316089935,0,0,1,0.0001537697312069306
597,LV319,Role of phospholipids in phagocytosis,0.00027542047692160737,1,0,1,0.00029240901918906433
598,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.0001448359316089935,0,0,1,0.0001537697312069306
599,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.00027542047692160737,1,0,1,0.00029240901918906433
600,LV319,FCERI mediated MAPK activation,0.0001448359316089935,0,0,1,0.0001537697312069306
601,LV319,FCERI mediated MAPK activation,0.00027542047692160737,1,0,1,0.00029240901918906433
602,LV319,FCERI mediated Ca+2 mobilization,0.0001448359316089935,0,0,1,0.0001537697312069306
603,LV319,FCERI mediated Ca+2 mobilization,0.00027542047692160737,1,0,1,0.00029240901918906433
604,LV319,FCERI mediated NF-kB activation,0.0001448359316089935,0,0,1,0.0001537697312069306
605,LV319,FCERI mediated NF-kB activation,0.00027542047692160737,1,0,1,0.00029240901918906433
606,LV319,Parasite infection,0.0001448359316089935,0,0,1,0.0001537697312069306
607,LV319,Parasite infection,0.00027542047692160737,1,0,1,0.00029240901918906433
608,LV319,Leishmania parasite growth and survival,0.0001448359316089935,0,0,1,0.0001537697312069306
609,LV319,Leishmania parasite growth and survival,0.00027542047692160737,1,0,1,0.00029240901918906433
610,LV319,Potential therapeutics for SARS,0.0001448359316089935,0,0,1,0.0001537697312069306
611,LV319,Potential therapeutics for SARS,0.00027542047692160737,1,0,1,0.00029240901918906433
612,LV319,CD22 mediated BCR regulation,0.0001448359316089935,0,0,1,0.0001537697312069306
613,LV319,CD22 mediated BCR regulation,0.00027542047692160737,1,0,1,0.00029240901918906433
614,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0001448359316089935,0,0,1,0.0001537697312069306
615,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00027542047692160737,1,0,1,0.00029240901918906433
616,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0001448359316089935,0,0,1,0.0001537697312069306
617,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00027542047692160737,1,0,1,0.00029240901918906433
618,LV319,Scavenging of heme from plasma,0.0001448359316089935,0,0,1,0.0001537697312069306
619,LV319,Scavenging of heme from plasma,0.00027542047692160737,1,0,1,0.00029240901918906433
620,LV325,Initial triggering of complement,0.0007603784644032452,0,0,1,0.0008072802845807454
621,LV325,Initial triggering of complement,0.0006876047971102796,1,0,1,0.0007300177770367468
622,LV325,Regulation of Complement cascade,0.0007603784644032452,0,0,1,0.0008072802845807454
623,LV325,Regulation of Complement cascade,0.0006876047971102796,1,0,1,0.0007300177770367468
624,LV325,FCGR activation,0.0007603784644032452,0,0,1,0.0008072802845807454
625,LV325,FCGR activation,0.0006876047971102796,1,0,1,0.0007300177770367468
626,LV325,Regulation of actin dynamics for phagocytic cup formation,0.0007603784644032452,0,0,1,0.0008072802845807454
627,LV325,Regulation of actin dynamics for phagocytic cup formation,0.0006876047971102796,1,0,1,0.0007300177770367468
628,LV325,Role of phospholipids in phagocytosis,0.0007603784644032452,0,0,1,0.0008072802845807454
629,LV325,Role of phospholipids in phagocytosis,0.0006876047971102796,1,0,1,0.0007300177770367468
630,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007603784644032452,0,0,1,0.0008072802845807454
631,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006876047971102796,1,0,1,0.0007300177770367468
632,LV325,FCERI mediated MAPK activation,0.0007603784644032452,0,0,1,0.0008072802845807454
633,LV325,FCERI mediated MAPK activation,0.0006876047971102796,1,0,1,0.0007300177770367468
634,LV325,FCERI mediated Ca+2 mobilization,0.0007603784644032452,0,0,1,0.0008072802845807454
635,LV325,FCERI mediated Ca+2 mobilization,0.0006876047971102796,1,0,1,0.0007300177770367468
636,LV325,FCERI mediated NF-kB activation,0.0007603784644032452,0,0,1,0.0008072802845807454
637,LV325,FCERI mediated NF-kB activation,0.0006876047971102796,1,0,1,0.0007300177770367468
638,LV325,Parasite infection,0.0007603784644032452,0,0,1,0.0008072802845807454
639,LV325,Parasite infection,0.0006876047971102796,1,0,1,0.0007300177770367468
640,LV325,Leishmania parasite growth and survival,0.0007603784644032452,0,0,1,0.0008072802845807454
641,LV325,Leishmania parasite growth and survival,0.0006876047971102796,1,0,1,0.0007300177770367468
642,LV325,Potential therapeutics for SARS,0.0007603784644032452,0,0,1,0.0008072802845807454
643,LV325,Potential therapeutics for SARS,0.0006876047971102796,1,0,1,0.0007300177770367468
644,LV325,CD22 mediated BCR regulation,0.0007603784644032452,0,0,1,0.0008072802845807454
645,LV325,CD22 mediated BCR regulation,0.0006876047971102796,1,0,1,0.0007300177770367468
646,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007603784644032452,0,0,1,0.0008072802845807454
647,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006876047971102796,1,0,1,0.0007300177770367468
648,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007603784644032452,0,0,1,0.0008072802845807454
649,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006876047971102796,1,0,1,0.0007300177770367468
650,LV325,Scavenging of heme from plasma,0.0007603784644032452,0,0,1,0.0008072802845807454
651,LV325,Scavenging of heme from plasma,0.0006876047971102796,1,0,1,0.0007300177770367468
652,HV169,Initial triggering of complement,0.0009161788565394912,0,0,1,0.0009726907884148457
653,HV169,Initial triggering of complement,0.0004025301634100043,1,0,1,0.00042735911139328597
654,HV169,Regulation of Complement cascade,0.0009161788565394912,0,0,1,0.0009726907884148457
655,HV169,Regulation of Complement cascade,0.0004025301634100043,1,0,1,0.00042735911139328597
656,HV169,FCGR activation,0.0009161788565394912,0,0,1,0.0009726907884148457
657,HV169,FCGR activation,0.0004025301634100043,1,0,1,0.00042735911139328597
658,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0009161788565394912,0,0,1,0.0009726907884148457
659,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0004025301634100043,1,0,1,0.00042735911139328597
660,HV169,Role of phospholipids in phagocytosis,0.0009161788565394912,0,0,1,0.0009726907884148457
661,HV169,Role of phospholipids in phagocytosis,0.0004025301634100043,1,0,1,0.00042735911139328597
662,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009161788565394912,0,0,1,0.0009726907884148457
663,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004025301634100043,1,0,1,0.00042735911139328597
664,HV169,FCERI mediated MAPK activation,0.0009161788565394912,0,0,1,0.0009726907884148457
665,HV169,FCERI mediated MAPK activation,0.0004025301634100043,1,0,1,0.00042735911139328597
666,HV169,FCERI mediated Ca+2 mobilization,0.0009161788565394912,0,0,1,0.0009726907884148457
667,HV169,FCERI mediated Ca+2 mobilization,0.0004025301634100043,1,0,1,0.00042735911139328597
668,HV169,FCERI mediated NF-kB activation,0.0009161788565394912,0,0,1,0.0009726907884148457
669,HV169,FCERI mediated NF-kB activation,0.0004025301634100043,1,0,1,0.00042735911139328597
670,HV169,Parasite infection,0.0009161788565394912,0,0,1,0.0009726907884148457
671,HV169,Parasite infection,0.0004025301634100043,1,0,1,0.00042735911139328597
672,HV169,Leishmania parasite growth and survival,0.0009161788565394912,0,0,1,0.0009726907884148457
673,HV169,Leishmania parasite growth and survival,0.0004025301634100043,1,0,1,0.00042735911139328597
674,HV169,Potential therapeutics for SARS,0.0009161788565394912,0,0,1,0.0009726907884148457
675,HV169,Potential therapeutics for SARS,0.0004025301634100043,1,0,1,0.00042735911139328597
676,HV169,CD22 mediated BCR regulation,0.0009161788565394912,0,0,1,0.0009726907884148457
677,HV169,CD22 mediated BCR regulation,0.0004025301634100043,1,0,1,0.00042735911139328597
678,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009161788565394912,0,0,1,0.0009726907884148457
679,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004025301634100043,1,0,1,0.00042735911139328597
680,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009161788565394912,0,0,1,0.0009726907884148457
681,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004025301634100043,1,0,1,0.00042735911139328597
682,HV169,Scavenging of heme from plasma,0.0009161788565394912,0,0,1,0.0009726907884148457
683,HV169,Scavenging of heme from plasma,0.0004025301634100043,1,0,1,0.00042735911139328597
684,HV146,Initial triggering of complement,0.00025496970991570827,0,0,1,0.00027069680378410336
685,HV146,Initial triggering of complement,7.885180679609093e-05,1,0,1,8.37155600928439e-05
686,HV146,Regulation of Complement cascade,0.00025496970991570827,0,0,1,0.00027069680378410336
687,HV146,Regulation of Complement cascade,7.885180679609093e-05,1,0,1,8.37155600928439e-05
688,HV146,FCGR activation,0.00025496970991570827,0,0,1,0.00027069680378410336
689,HV146,FCGR activation,7.885180679609093e-05,1,0,1,8.37155600928439e-05
690,HV146,Regulation of actin dynamics for phagocytic cup formation,0.00025496970991570827,0,0,1,0.00027069680378410336
691,HV146,Regulation of actin dynamics for phagocytic cup formation,7.885180679609093e-05,1,0,1,8.37155600928439e-05
692,HV146,Role of phospholipids in phagocytosis,0.00025496970991570827,0,0,1,0.00027069680378410336
693,HV146,Role of phospholipids in phagocytosis,7.885180679609093e-05,1,0,1,8.37155600928439e-05
694,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.00025496970991570827,0,0,1,0.00027069680378410336
695,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,7.885180679609093e-05,1,0,1,8.37155600928439e-05
696,HV146,FCERI mediated MAPK activation,0.00025496970991570827,0,0,1,0.00027069680378410336
697,HV146,FCERI mediated MAPK activation,7.885180679609093e-05,1,0,1,8.37155600928439e-05
698,HV146,FCERI mediated Ca+2 mobilization,0.00025496970991570827,0,0,1,0.00027069680378410336
699,HV146,FCERI mediated Ca+2 mobilization,7.885180679609093e-05,1,0,1,8.37155600928439e-05
700,HV146,FCERI mediated NF-kB activation,0.00025496970991570827,0,0,1,0.00027069680378410336
701,HV146,FCERI mediated NF-kB activation,7.885180679609093e-05,1,0,1,8.37155600928439e-05
702,HV146,Parasite infection,0.00025496970991570827,0,0,1,0.00027069680378410336
703,HV146,Parasite infection,7.885180679609093e-05,1,0,1,8.37155600928439e-05
704,HV146,Leishmania parasite growth and survival,0.00025496970991570827,0,0,1,0.00027069680378410336
705,HV146,Leishmania parasite growth and survival,7.885180679609093e-05,1,0,1,8.37155600928439e-05
706,HV146,Potential therapeutics for SARS,0.00025496970991570827,0,0,1,0.00027069680378410336
707,HV146,Potential therapeutics for SARS,7.885180679609093e-05,1,0,1,8.37155600928439e-05
708,HV146,CD22 mediated BCR regulation,0.00025496970991570827,0,0,1,0.00027069680378410336
709,HV146,CD22 mediated BCR regulation,7.885180679609093e-05,1,0,1,8.37155600928439e-05
710,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00025496970991570827,0,0,1,0.00027069680378410336
711,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,7.885180679609093e-05,1,0,1,8.37155600928439e-05
712,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00025496970991570827,0,0,1,0.00027069680378410336
713,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,7.885180679609093e-05,1,0,1,8.37155600928439e-05
714,HV146,Scavenging of heme from plasma,0.00025496970991570827,0,0,1,0.00027069680378410336
715,HV146,Scavenging of heme from plasma,7.885180679609093e-05,1,0,1,8.37155600928439e-05
716,HV348,Initial triggering of complement,0.0014407280100916756,0,0,1,0.0015295952902914633
717,HV348,Initial triggering of complement,0.0009667236388245351,1,0,1,0.0010263532843130764
718,HV348,Regulation of Complement cascade,0.0014407280100916756,0,0,1,0.0015295952902914633
719,HV348,Regulation of Complement cascade,0.0009667236388245351,1,0,1,0.0010263532843130764
720,HV348,FCGR activation,0.0014407280100916756,0,0,1,0.0015295952902914633
721,HV348,FCGR activation,0.0009667236388245351,1,0,1,0.0010263532843130764
722,HV348,Regulation of actin dynamics for phagocytic cup formation,0.0014407280100916756,0,0,1,0.0015295952902914633
723,HV348,Regulation of actin dynamics for phagocytic cup formation,0.0009667236388245351,1,0,1,0.0010263532843130764
724,HV348,Role of phospholipids in phagocytosis,0.0014407280100916756,0,0,1,0.0015295952902914633
725,HV348,Role of phospholipids in phagocytosis,0.0009667236388245351,1,0,1,0.0010263532843130764
726,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.0014407280100916756,0,0,1,0.0015295952902914633
727,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009667236388245351,1,0,1,0.0010263532843130764
728,HV348,FCERI mediated MAPK activation,0.0014407280100916756,0,0,1,0.0015295952902914633
729,HV348,FCERI mediated MAPK activation,0.0009667236388245351,1,0,1,0.0010263532843130764
730,HV348,FCERI mediated Ca+2 mobilization,0.0014407280100916756,0,0,1,0.0015295952902914633
731,HV348,FCERI mediated Ca+2 mobilization,0.0009667236388245351,1,0,1,0.0010263532843130764
732,HV348,FCERI mediated NF-kB activation,0.0014407280100916756,0,0,1,0.0015295952902914633
733,HV348,FCERI mediated NF-kB activation,0.0009667236388245351,1,0,1,0.0010263532843130764
734,HV348,Parasite infection,0.0014407280100916756,0,0,1,0.0015295952902914633
735,HV348,Parasite infection,0.0009667236388245351,1,0,1,0.0010263532843130764
736,HV348,Leishmania parasite growth and survival,0.0014407280100916756,0,0,1,0.0015295952902914633
737,HV348,Leishmania parasite growth and survival,0.0009667236388245351,1,0,1,0.0010263532843130764
738,HV348,Potential therapeutics for SARS,0.0014407280100916756,0,0,1,0.0015295952902914633
739,HV348,Potential therapeutics for SARS,0.0009667236388245351,1,0,1,0.0010263532843130764
740,HV348,CD22 mediated BCR regulation,0.0014407280100916756,0,0,1,0.0015295952902914633
741,HV348,CD22 mediated BCR regulation,0.0009667236388245351,1,0,1,0.0010263532843130764
742,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0014407280100916756,0,0,1,0.0015295952902914633
743,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009667236388245351,1,0,1,0.0010263532843130764
744,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0014407280100916756,0,0,1,0.0015295952902914633
745,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009667236388245351,1,0,1,0.0010263532843130764
746,HV348,Scavenging of heme from plasma,0.0014407280100916756,0,0,1,0.0015295952902914633
747,HV348,Scavenging of heme from plasma,0.0009667236388245351,1,0,1,0.0010263532843130764
748,HV323,Initial triggering of complement,0.0022066287747477915,0,0,1,0.0023427385027803213
749,HV323,Initial triggering of complement,0.00202238074427146,1,0,1,0.002147125647551567
750,HV323,Regulation of Complement cascade,0.0022066287747477915,0,0,1,0.0023427385027803213
751,HV323,Regulation of Complement cascade,0.00202238074427146,1,0,1,0.002147125647551567
752,HV323,FCGR activation,0.0022066287747477915,0,0,1,0.0023427385027803213
753,HV323,FCGR activation,0.00202238074427146,1,0,1,0.002147125647551567
754,HV323,Regulation of actin dynamics for phagocytic cup formation,0.0022066287747477915,0,0,1,0.0023427385027803213
755,HV323,Regulation of actin dynamics for phagocytic cup formation,0.00202238074427146,1,0,1,0.002147125647551567
756,HV323,Role of phospholipids in phagocytosis,0.0022066287747477915,0,0,1,0.0023427385027803213
757,HV323,Role of phospholipids in phagocytosis,0.00202238074427146,1,0,1,0.002147125647551567
758,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.0022066287747477915,0,0,1,0.0023427385027803213
759,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.00202238074427146,1,0,1,0.002147125647551567
760,HV323,FCERI mediated MAPK activation,0.0022066287747477915,0,0,1,0.0023427385027803213
761,HV323,FCERI mediated MAPK activation,0.00202238074427146,1,0,1,0.002147125647551567
762,HV323,FCERI mediated Ca+2 mobilization,0.0022066287747477915,0,0,1,0.0023427385027803213
763,HV323,FCERI mediated Ca+2 mobilization,0.00202238074427146,1,0,1,0.002147125647551567
764,HV323,FCERI mediated NF-kB activation,0.0022066287747477915,0,0,1,0.0023427385027803213
765,HV323,FCERI mediated NF-kB activation,0.00202238074427146,1,0,1,0.002147125647551567
766,HV323,Parasite infection,0.0022066287747477915,0,0,1,0.0023427385027803213
767,HV323,Parasite infection,0.00202238074427146,1,0,1,0.002147125647551567
768,HV323,Leishmania parasite growth and survival,0.0022066287747477915,0,0,1,0.0023427385027803213
769,HV323,Leishmania parasite growth and survival,0.00202238074427146,1,0,1,0.002147125647551567
770,HV323,Potential therapeutics for SARS,0.0022066287747477915,0,0,1,0.0023427385027803213
771,HV323,Potential therapeutics for SARS,0.00202238074427146,1,0,1,0.002147125647551567
772,HV323,CD22 mediated BCR regulation,0.0022066287747477915,0,0,1,0.0023427385027803213
773,HV323,CD22 mediated BCR regulation,0.00202238074427146,1,0,1,0.002147125647551567
774,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0022066287747477915,0,0,1,0.0023427385027803213
775,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00202238074427146,1,0,1,0.002147125647551567
776,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0022066287747477915,0,0,1,0.0023427385027803213
777,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00202238074427146,1,0,1,0.002147125647551567
778,HV323,Scavenging of heme from plasma,0.0022066287747477915,0,0,1,0.0023427385027803213
779,HV323,Scavenging of heme from plasma,0.00202238074427146,1,0,1,0.002147125647551567
780,HV313,Initial triggering of complement,0.001508988349382774,0,0,1,0.0016020660778113904
781,HV313,Initial triggering of complement,0.0013160823905147786,1,0,1,0.0013972612540786521
782,HV313,Regulation of Complement cascade,0.001508988349382774,0,0,1,0.0016020660778113904
783,HV313,Regulation of Complement cascade,0.0013160823905147786,1,0,1,0.0013972612540786521
784,HV313,FCGR activation,0.001508988349382774,0,0,1,0.0016020660778113904
785,HV313,FCGR activation,0.0013160823905147786,1,0,1,0.0013972612540786521
786,HV313,Regulation of actin dynamics for phagocytic cup formation,0.001508988349382774,0,0,1,0.0016020660778113904
787,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0013160823905147786,1,0,1,0.0013972612540786521
788,HV313,Role of phospholipids in phagocytosis,0.001508988349382774,0,0,1,0.0016020660778113904
789,HV313,Role of phospholipids in phagocytosis,0.0013160823905147786,1,0,1,0.0013972612540786521
790,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.001508988349382774,0,0,1,0.0016020660778113904
791,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013160823905147786,1,0,1,0.0013972612540786521
792,HV313,FCERI mediated MAPK activation,0.001508988349382774,0,0,1,0.0016020660778113904
793,HV313,FCERI mediated MAPK activation,0.0013160823905147786,1,0,1,0.0013972612540786521
794,HV313,FCERI mediated Ca+2 mobilization,0.001508988349382774,0,0,1,0.0016020660778113904
795,HV313,FCERI mediated Ca+2 mobilization,0.0013160823905147786,1,0,1,0.0013972612540786521
796,HV313,FCERI mediated NF-kB activation,0.001508988349382774,0,0,1,0.0016020660778113904
797,HV313,FCERI mediated NF-kB activation,0.0013160823905147786,1,0,1,0.0013972612540786521
798,HV313,Parasite infection,0.001508988349382774,0,0,1,0.0016020660778113904
799,HV313,Parasite infection,0.0013160823905147786,1,0,1,0.0013972612540786521
800,HV313,Leishmania parasite growth and survival,0.001508988349382774,0,0,1,0.0016020660778113904
801,HV313,Leishmania parasite growth and survival,0.0013160823905147786,1,0,1,0.0013972612540786521
802,HV313,Potential therapeutics for SARS,0.001508988349382774,0,0,1,0.0016020660778113904
803,HV313,Potential therapeutics for SARS,0.0013160823905147786,1,0,1,0.0013972612540786521
804,HV313,CD22 mediated BCR regulation,0.001508988349382774,0,0,1,0.0016020660778113904
805,HV313,CD22 mediated BCR regulation,0.0013160823905147786,1,0,1,0.0013972612540786521
806,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001508988349382774,0,0,1,0.0016020660778113904
807,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013160823905147786,1,0,1,0.0013972612540786521
808,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001508988349382774,0,0,1,0.0016020660778113904
809,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013160823905147786,1,0,1,0.0013972612540786521
810,HV313,Scavenging of heme from plasma,0.001508988349382774,0,0,1,0.0016020660778113904
811,HV313,Scavenging of heme from plasma,0.0013160823905147786,1,0,1,0.0013972612540786521
812,HV353,Initial triggering of complement,0.0018372196809927634,0,0,1,0.0019505434416441296
813,HV353,Initial triggering of complement,0.0015477843096285944,1,0,1,0.0016432550584230506
814,HV353,Regulation of Complement cascade,0.0018372196809927634,0,0,1,0.0019505434416441296
815,HV353,Regulation of Complement cascade,0.0015477843096285944,1,0,1,0.0016432550584230506
816,HV353,FCGR activation,0.0018372196809927634,0,0,1,0.0019505434416441296
817,HV353,FCGR activation,0.0015477843096285944,1,0,1,0.0016432550584230506
818,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0018372196809927634,0,0,1,0.0019505434416441296
819,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0015477843096285944,1,0,1,0.0016432550584230506
820,HV353,Role of phospholipids in phagocytosis,0.0018372196809927634,0,0,1,0.0019505434416441296
821,HV353,Role of phospholipids in phagocytosis,0.0015477843096285944,1,0,1,0.0016432550584230506
822,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0018372196809927634,0,0,1,0.0019505434416441296
823,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0015477843096285944,1,0,1,0.0016432550584230506
824,HV353,FCERI mediated MAPK activation,0.0018372196809927634,0,0,1,0.0019505434416441296
825,HV353,FCERI mediated MAPK activation,0.0015477843096285944,1,0,1,0.0016432550584230506
826,HV353,FCERI mediated Ca+2 mobilization,0.0018372196809927634,0,0,1,0.0019505434416441296
827,HV353,FCERI mediated Ca+2 mobilization,0.0015477843096285944,1,0,1,0.0016432550584230506
828,HV353,FCERI mediated NF-kB activation,0.0018372196809927634,0,0,1,0.0019505434416441296
829,HV353,FCERI mediated NF-kB activation,0.0015477843096285944,1,0,1,0.0016432550584230506
830,HV353,Parasite infection,0.0018372196809927634,0,0,1,0.0019505434416441296
831,HV353,Parasite infection,0.0015477843096285944,1,0,1,0.0016432550584230506
832,HV353,Leishmania parasite growth and survival,0.0018372196809927634,0,0,1,0.0019505434416441296
833,HV353,Leishmania parasite growth and survival,0.0015477843096285944,1,0,1,0.0016432550584230506
834,HV353,Potential therapeutics for SARS,0.0018372196809927634,0,0,1,0.0019505434416441296
835,HV353,Potential therapeutics for SARS,0.0015477843096285944,1,0,1,0.0016432550584230506
836,HV353,CD22 mediated BCR regulation,0.0018372196809927634,0,0,1,0.0019505434416441296
837,HV353,CD22 mediated BCR regulation,0.0015477843096285944,1,0,1,0.0016432550584230506
838,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0018372196809927634,0,0,1,0.0019505434416441296
839,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0015477843096285944,1,0,1,0.0016432550584230506
840,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0018372196809927634,0,0,1,0.0019505434416441296
841,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015477843096285944,1,0,1,0.0016432550584230506
842,HV353,Scavenging of heme from plasma,0.0018372196809927634,0,0,1,0.0019505434416441296
843,HV353,Scavenging of heme from plasma,0.0015477843096285944,1,0,1,0.0016432550584230506
844,HV307,Initial triggering of complement,0.0004408805666317505,0,0,1,0.0004680750520412567
845,HV307,Initial triggering of complement,0.0011311950741765954,1,0,1,0.0012009696804265804
846,HV307,Regulation of Complement cascade,0.0004408805666317505,0,0,1,0.0004680750520412567
847,HV307,Regulation of Complement cascade,0.0011311950741765954,1,0,1,0.0012009696804265804
848,HV307,FCGR activation,0.0004408805666317505,0,0,1,0.0004680750520412567
849,HV307,FCGR activation,0.0011311950741765954,1,0,1,0.0012009696804265804
850,HV307,Regulation of actin dynamics for phagocytic cup formation,0.0004408805666317505,0,0,1,0.0004680750520412567
851,HV307,Regulation of actin dynamics for phagocytic cup formation,0.0011311950741765954,1,0,1,0.0012009696804265804
852,HV307,Role of phospholipids in phagocytosis,0.0004408805666317505,0,0,1,0.0004680750520412567
853,HV307,Role of phospholipids in phagocytosis,0.0011311950741765954,1,0,1,0.0012009696804265804
854,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004408805666317505,0,0,1,0.0004680750520412567
855,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.0011311950741765954,1,0,1,0.0012009696804265804
856,HV307,FCERI mediated MAPK activation,0.0004408805666317505,0,0,1,0.0004680750520412567
857,HV307,FCERI mediated MAPK activation,0.0011311950741765954,1,0,1,0.0012009696804265804
858,HV307,FCERI mediated Ca+2 mobilization,0.0004408805666317505,0,0,1,0.0004680750520412567
859,HV307,FCERI mediated Ca+2 mobilization,0.0011311950741765954,1,0,1,0.0012009696804265804
860,HV307,FCERI mediated NF-kB activation,0.0004408805666317505,0,0,1,0.0004680750520412567
861,HV307,FCERI mediated NF-kB activation,0.0011311950741765954,1,0,1,0.0012009696804265804
862,HV307,Parasite infection,0.0004408805666317505,0,0,1,0.0004680750520412567
863,HV307,Parasite infection,0.0011311950741765954,1,0,1,0.0012009696804265804
864,HV307,Leishmania parasite growth and survival,0.0004408805666317505,0,0,1,0.0004680750520412567
865,HV307,Leishmania parasite growth and survival,0.0011311950741765954,1,0,1,0.0012009696804265804
866,HV307,Potential therapeutics for SARS,0.0004408805666317505,0,0,1,0.0004680750520412567
867,HV307,Potential therapeutics for SARS,0.0011311950741765954,1,0,1,0.0012009696804265804
868,HV307,CD22 mediated BCR regulation,0.0004408805666317505,0,0,1,0.0004680750520412567
869,HV307,CD22 mediated BCR regulation,0.0011311950741765954,1,0,1,0.0012009696804265804
870,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004408805666317505,0,0,1,0.0004680750520412567
871,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0011311950741765954,1,0,1,0.0012009696804265804
872,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004408805666317505,0,0,1,0.0004680750520412567
873,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011311950741765954,1,0,1,0.0012009696804265804
874,HV307,Scavenging of heme from plasma,0.0004408805666317505,0,0,1,0.0004680750520412567
875,HV307,Scavenging of heme from plasma,0.0011311950741765954,1,0,1,0.0012009696804265804
876,PIGR,Neutrophil degranulation,8.627883300209875e-05,0,0,1,9.160070165044988e-05
877,PIGR,Neutrophil degranulation,7.191040020582241e-05,1,0,1,7.634599223957696e-05
878,IGKC,Initial triggering of complement,0.0009756458748135979,0,0,1,0.0010358258634898157
879,IGKC,Initial triggering of complement,0.0013941827284845185,1,0,1,0.0014801789930910865
880,IGKC,Regulation of Complement cascade,0.0009756458748135979,0,0,1,0.0010358258634898157
881,IGKC,Regulation of Complement cascade,0.0013941827284845185,1,0,1,0.0014801789930910865
882,IGKC,FCGR activation,0.0009756458748135979,0,0,1,0.0010358258634898157
883,IGKC,FCGR activation,0.0013941827284845185,1,0,1,0.0014801789930910865
884,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0009756458748135979,0,0,1,0.0010358258634898157
885,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0013941827284845185,1,0,1,0.0014801789930910865
886,IGKC,Role of phospholipids in phagocytosis,0.0009756458748135979,0,0,1,0.0010358258634898157
887,IGKC,Role of phospholipids in phagocytosis,0.0013941827284845185,1,0,1,0.0014801789930910865
888,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009756458748135979,0,0,1,0.0010358258634898157
889,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013941827284845185,1,0,1,0.0014801789930910865
890,IGKC,FCERI mediated MAPK activation,0.0009756458748135979,0,0,1,0.0010358258634898157
891,IGKC,FCERI mediated MAPK activation,0.0013941827284845185,1,0,1,0.0014801789930910865
892,IGKC,FCERI mediated Ca+2 mobilization,0.0009756458748135979,0,0,1,0.0010358258634898157
893,IGKC,FCERI mediated Ca+2 mobilization,0.0013941827284845185,1,0,1,0.0014801789930910865
894,IGKC,FCERI mediated NF-kB activation,0.0009756458748135979,0,0,1,0.0010358258634898157
895,IGKC,FCERI mediated NF-kB activation,0.0013941827284845185,1,0,1,0.0014801789930910865
896,IGKC,Parasite infection,0.0009756458748135979,0,0,1,0.0010358258634898157
897,IGKC,Parasite infection,0.0013941827284845185,1,0,1,0.0014801789930910865
898,IGKC,Leishmania parasite growth and survival,0.0009756458748135979,0,0,1,0.0010358258634898157
899,IGKC,Leishmania parasite growth and survival,0.0013941827284845185,1,0,1,0.0014801789930910865
900,IGKC,Potential therapeutics for SARS,0.0009756458748135979,0,0,1,0.0010358258634898157
901,IGKC,Potential therapeutics for SARS,0.0013941827284845185,1,0,1,0.0014801789930910865
902,IGKC,CD22 mediated BCR regulation,0.0009756458748135979,0,0,1,0.0010358258634898157
903,IGKC,CD22 mediated BCR regulation,0.0013941827284845185,1,0,1,0.0014801789930910865
904,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009756458748135979,0,0,1,0.0010358258634898157
905,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013941827284845185,1,0,1,0.0014801789930910865
906,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009756458748135979,0,0,1,0.0010358258634898157
907,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013941827284845185,1,0,1,0.0014801789930910865
908,IGKC,Scavenging of heme from plasma,0.0009756458748135979,0,0,1,0.0010358258634898157
909,IGKC,Scavenging of heme from plasma,0.0013941827284845185,1,0,1,0.0014801789930910865
910,IGHG1,Initial triggering of complement,0.0011359782176607715,0,0,1,0.0012060478587468022
911,IGHG1,Initial triggering of complement,0.00041952025759399723,1,0,1,0.00044539719204654565
912,IGHG1,Regulation of Complement cascade,0.0011359782176607715,0,0,1,0.0012060478587468022
913,IGHG1,Regulation of Complement cascade,0.00041952025759399723,1,0,1,0.00044539719204654565
914,IGHG1,FCGR activation,0.0011359782176607715,0,0,1,0.0012060478587468022
915,IGHG1,FCGR activation,0.00041952025759399723,1,0,1,0.00044539719204654565
916,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.0011359782176607715,0,0,1,0.0012060478587468022
917,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.00041952025759399723,1,0,1,0.00044539719204654565
918,IGHG1,Role of phospholipids in phagocytosis,0.0011359782176607715,0,0,1,0.0012060478587468022
919,IGHG1,Role of phospholipids in phagocytosis,0.00041952025759399723,1,0,1,0.00044539719204654565
920,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.0011359782176607715,0,0,1,0.0012060478587468022
921,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.00041952025759399723,1,0,1,0.00044539719204654565
922,IGHG1,Parasite infection,0.0011359782176607715,0,0,1,0.0012060478587468022
923,IGHG1,Parasite infection,0.00041952025759399723,1,0,1,0.00044539719204654565
924,IGHG1,Leishmania parasite growth and survival,0.0011359782176607715,0,0,1,0.0012060478587468022
925,IGHG1,Leishmania parasite growth and survival,0.00041952025759399723,1,0,1,0.00044539719204654565
926,IGHG2,Initial triggering of complement,0.0004306392946836965,0,0,1,0.0004572020758593466
927,IGHG2,Initial triggering of complement,0.0006074742994367966,1,0,1,0.0006449446535939178
928,IGHG2,Regulation of Complement cascade,0.0004306392946836965,0,0,1,0.0004572020758593466
929,IGHG2,Regulation of Complement cascade,0.0006074742994367966,1,0,1,0.0006449446535939178
930,IGHG2,FCGR activation,0.0004306392946836965,0,0,1,0.0004572020758593466
931,IGHG2,FCGR activation,0.0006074742994367966,1,0,1,0.0006449446535939178
932,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.0004306392946836965,0,0,1,0.0004572020758593466
933,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.0006074742994367966,1,0,1,0.0006449446535939178
934,IGHG2,Role of phospholipids in phagocytosis,0.0004306392946836965,0,0,1,0.0004572020758593466
935,IGHG2,Role of phospholipids in phagocytosis,0.0006074742994367966,1,0,1,0.0006449446535939178
936,IGHG2,Parasite infection,0.0004306392946836965,0,0,1,0.0004572020758593466
937,IGHG2,Parasite infection,0.0006074742994367966,1,0,1,0.0006449446535939178
938,IGHG2,Leishmania parasite growth and survival,0.0004306392946836965,0,0,1,0.0004572020758593466
939,IGHG2,Leishmania parasite growth and survival,0.0006074742994367966,1,0,1,0.0006449446535939178
940,IGHG3,Initial triggering of complement,0.0006505472390645405,0,0,1,0.0006906744271057226
941,IGHG3,Initial triggering of complement,0.0008760384027417725,1,0,1,0.0009300743829246481
942,IGHG3,Regulation of Complement cascade,0.0006505472390645405,0,0,1,0.0006906744271057226
943,IGHG3,Regulation of Complement cascade,0.0008760384027417725,1,0,1,0.0009300743829246481
944,IGHG3,FCGR activation,0.0006505472390645405,0,0,1,0.0006906744271057226
945,IGHG3,FCGR activation,0.0008760384027417725,1,0,1,0.0009300743829246481
946,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0006505472390645405,0,0,1,0.0006906744271057226
947,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0008760384027417725,1,0,1,0.0009300743829246481
948,IGHG3,Role of phospholipids in phagocytosis,0.0006505472390645405,0,0,1,0.0006906744271057226
949,IGHG3,Role of phospholipids in phagocytosis,0.0008760384027417725,1,0,1,0.0009300743829246481
950,IGHG3,Parasite infection,0.0006505472390645405,0,0,1,0.0006906744271057226
951,IGHG3,Parasite infection,0.0008760384027417725,1,0,1,0.0009300743829246481
952,IGHG3,Leishmania parasite growth and survival,0.0006505472390645405,0,0,1,0.0006906744271057226
953,IGHG3,Leishmania parasite growth and survival,0.0008760384027417725,1,0,1,0.0009300743829246481
954,IGHG4,Initial triggering of complement,0.00032452288405678827,0,0,1,0.0003445401710580194
955,IGHG4,Initial triggering of complement,0.0007114960545096682,1,0,1,0.0007553826998683092
956,IGHG4,Regulation of Complement cascade,0.00032452288405678827,0,0,1,0.0003445401710580194
957,IGHG4,Regulation of Complement cascade,0.0007114960545096682,1,0,1,0.0007553826998683092
958,IGHG4,FCGR activation,0.00032452288405678827,0,0,1,0.0003445401710580194
959,IGHG4,FCGR activation,0.0007114960545096682,1,0,1,0.0007553826998683092
960,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.00032452288405678827,0,0,1,0.0003445401710580194
961,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0007114960545096682,1,0,1,0.0007553826998683092
962,IGHG4,Role of phospholipids in phagocytosis,0.00032452288405678827,0,0,1,0.0003445401710580194
963,IGHG4,Role of phospholipids in phagocytosis,0.0007114960545096682,1,0,1,0.0007553826998683092
964,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.00032452288405678827,0,0,1,0.0003445401710580194
965,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0007114960545096682,1,0,1,0.0007553826998683092
966,IGHG4,Parasite infection,0.00032452288405678827,0,0,1,0.0003445401710580194
967,IGHG4,Parasite infection,0.0007114960545096682,1,0,1,0.0007553826998683092
968,IGHG4,Leishmania parasite growth and survival,0.00032452288405678827,0,0,1,0.0003445401710580194
969,IGHG4,Leishmania parasite growth and survival,0.0007114960545096682,1,0,1,0.0007553826998683092
970,IGHM,Potential therapeutics for SARS,0.00010497939016844321,0,0,1,0.00011145475041406531
971,IGHM,Potential therapeutics for SARS,5.243092779285223e-05,1,0,1,5.5664983019560664e-05
972,IGHM,CD22 mediated BCR regulation,0.00010497939016844321,0,0,1,0.00011145475041406531
973,IGHM,CD22 mediated BCR regulation,5.243092779285223e-05,1,0,1,5.5664983019560664e-05
974,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00010497939016844321,0,0,1,0.00011145475041406531
975,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,5.243092779285223e-05,1,0,1,5.5664983019560664e-05
976,IGHA1,Scavenging of heme from plasma,0.00019351892089113518,0,0,1,0.00020545559460493265
977,IGHA1,Scavenging of heme from plasma,8.397305431073415e-05,1,0,1,8.91526974455887e-05
978,IGHA2,Scavenging of heme from plasma,0.00021674141527891784,0,0,1,0.00023011050364783522
979,IGHA2,Scavenging of heme from plasma,9.317455191988389e-05,1,0,1,9.892176371486183e-05
980,IGHD,Potential therapeutics for SARS,2.4292915228524028e-05,0,0,1,2.5791355801179766e-05
981,IGHD,Potential therapeutics for SARS,1.931521694601418e-05,1,0,1,2.0506622113705687e-05
982,IGHD,CD22 mediated BCR regulation,2.4292915228524028e-05,0,0,1,2.5791355801179766e-05
983,IGHD,CD22 mediated BCR regulation,1.931521694601418e-05,1,0,1,2.0506622113705687e-05
984,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,2.4292915228524028e-05,0,0,1,2.5791355801179766e-05
985,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1.931521694601418e-05,1,0,1,2.0506622113705687e-05
986,P01891,Antigen processing-Cross presentation,0.0019322149228035155,0,0,1,0.002051398199416611
987,P01891,Antigen processing-Cross presentation,0.001108111009098646,1,0,1,0.0011764617393185525
988,P01891,Interferon gamma signaling,0.0019322149228035155,0,0,1,0.002051398199416611
989,P01891,Interferon gamma signaling,0.001108111009098646,1,0,1,0.0011764617393185525
990,P01891,Interferon alpha/beta signaling,0.0019322149228035155,0,0,1,0.002051398199416611
991,P01891,Interferon alpha/beta signaling,0.001108111009098646,1,0,1,0.0011764617393185525
992,P01891,SARS-CoV-2 Infection,0.0019322149228035155,0,0,1,0.002051398199416611
993,P01891,SARS-CoV-2 Infection,0.001108111009098646,1,0,1,0.0011764617393185525
994,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0019322149228035155,0,0,1,0.002051398199416611
995,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.001108111009098646,1,0,1,0.0011764617393185525
996,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019322149228035155,0,0,1,0.002051398199416611
997,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001108111009098646,1,0,1,0.0011764617393185525
998,MYG,Intracellular oxygen transport,6.437205539547678e-05,0,0,1,6.83426657006808e-05
999,MYG,Intracellular oxygen transport,7.176650663306535e-05,1,0,1,7.619322299399368e-05
1000,CO1A1,Collagen chain trimerization,0.0034580808840538398,0,0,1,0.003671382937407538
1001,CO1A1,Collagen chain trimerization,0.0004141973594354577,1,0,1,0.0004397459657935868
1002,CO1A1,Anchoring fibril formation,0.0034580808840538398,0,0,1,0.003671382937407538
1003,CO1A1,Anchoring fibril formation,0.0004141973594354577,1,0,1,0.0004397459657935868
1004,CO1A1,Crosslinking of collagen fibrils,0.0034580808840538398,0,0,1,0.003671382937407538
1005,CO1A1,Crosslinking of collagen fibrils,0.0004141973594354577,1,0,1,0.0004397459657935868
1006,CO1A1,Transcriptional regulation by RUNX2,0.0034580808840538398,0,0,1,0.003671382937407538
1007,CO1A1,Transcriptional regulation by RUNX2,0.0004141973594354577,1,0,1,0.0004397459657935868
1008,CO1A1,MET promotes cell motility,0.0034580808840538398,0,0,1,0.003671382937407538
1009,CO1A1,MET promotes cell motility,0.0004141973594354577,1,0,1,0.0004397459657935868
1010,CO1A1,Platelet Adhesion to exposed collagen,0.0034580808840538398,0,0,1,0.003671382937407538
1011,CO1A1,Platelet Adhesion to exposed collagen,0.0004141973594354577,1,0,1,0.0004397459657935868
1012,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0034580808840538398,0,0,1,0.003671382937407538
1013,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004141973594354577,1,0,1,0.0004397459657935868
1014,CO1A1,Collagen degradation,0.0034580808840538398,0,0,1,0.003671382937407538
1015,CO1A1,Collagen degradation,0.0004141973594354577,1,0,1,0.0004397459657935868
1016,CO1A1,Integrin cell surface interactions,0.0034580808840538398,0,0,1,0.003671382937407538
1017,CO1A1,Integrin cell surface interactions,0.0004141973594354577,1,0,1,0.0004397459657935868
1018,CO1A1,ECM proteoglycans,0.0034580808840538398,0,0,1,0.003671382937407538
1019,CO1A1,ECM proteoglycans,0.0004141973594354577,1,0,1,0.0004397459657935868
1020,CO1A1,Scavenging by Class A Receptors,0.0034580808840538398,0,0,1,0.003671382937407538
1021,CO1A1,Scavenging by Class A Receptors,0.0004141973594354577,1,0,1,0.0004397459657935868
1022,CO1A1,Syndecan interactions,0.0034580808840538398,0,0,1,0.003671382937407538
1023,CO1A1,Syndecan interactions,0.0004141973594354577,1,0,1,0.0004397459657935868
1024,CO1A1,GPVI-mediated activation cascade,0.0034580808840538398,0,0,1,0.003671382937407538
1025,CO1A1,GPVI-mediated activation cascade,0.0004141973594354577,1,0,1,0.0004397459657935868
1026,CO1A1,GP1b-IX-V activation signalling,0.0034580808840538398,0,0,1,0.003671382937407538
1027,CO1A1,GP1b-IX-V activation signalling,0.0004141973594354577,1,0,1,0.0004397459657935868
1028,K1C14,Type I hemidesmosome assembly,0.0004050366368190844,0,0,1,0.00043002018960854586
1029,K1C14,Type I hemidesmosome assembly,0.00020195143459084667,1,0,1,0.00021440824434176687
1030,K1C14,Formation of the cornified envelope,0.0004050366368190844,0,0,1,0.00043002018960854586
1031,K1C14,Formation of the cornified envelope,0.00020195143459084667,1,0,1,0.00021440824434176687
1032,K2C6A,Formation of the cornified envelope,3.0709591832936466e-05,0,0,1,3.260382716613098e-05
1033,K2C6A,Formation of the cornified envelope,1.77277973702734e-06,1,0,1,1.882128699856826e-06
1034,APOA1,PPARA activates gene expression,0.00556617784879591,0,0,1,0.005909511970896667
1035,APOA1,PPARA activates gene expression,0.0031072795399179343,1,0,1,0.003298943392913604
1036,APOA1,Defective ABCA1 causes TGD,0.00556617784879591,0,0,1,0.005909511970896667
1037,APOA1,Defective ABCA1 causes TGD,0.0031072795399179343,1,0,1,0.003298943392913604
1038,APOA1,Platelet degranulation ,0.00556617784879591,0,0,1,0.005909511970896667
1039,APOA1,Platelet degranulation ,0.0031072795399179343,1,0,1,0.003298943392913604
1040,APOA1,Chylomicron assembly,0.00556617784879591,0,0,1,0.005909511970896667
1041,APOA1,Chylomicron assembly,0.0031072795399179343,1,0,1,0.003298943392913604
1042,APOA1,HDL assembly,0.00556617784879591,0,0,1,0.005909511970896667
1043,APOA1,HDL assembly,0.0031072795399179343,1,0,1,0.003298943392913604
1044,APOA1,Chylomicron remodeling,0.00556617784879591,0,0,1,0.005909511970896667
1045,APOA1,Chylomicron remodeling,0.0031072795399179343,1,0,1,0.003298943392913604
1046,APOA1,HDL remodeling,0.00556617784879591,0,0,1,0.005909511970896667
1047,APOA1,HDL remodeling,0.0031072795399179343,1,0,1,0.003298943392913604
1048,APOA1,HDL clearance,0.00556617784879591,0,0,1,0.005909511970896667
1049,APOA1,HDL clearance,0.0031072795399179343,1,0,1,0.003298943392913604
1050,APOA1,Scavenging of heme from plasma,0.00556617784879591,0,0,1,0.005909511970896667
1051,APOA1,Scavenging of heme from plasma,0.0031072795399179343,1,0,1,0.003298943392913604
1052,APOA1,Scavenging by Class B Receptors,0.00556617784879591,0,0,1,0.005909511970896667
1053,APOA1,Scavenging by Class B Receptors,0.0031072795399179343,1,0,1,0.003298943392913604
1054,APOA1,Scavenging by Class A Receptors,0.00556617784879591,0,0,1,0.005909511970896667
1055,APOA1,Scavenging by Class A Receptors,0.0031072795399179343,1,0,1,0.003298943392913604
1056,APOA1,Retinoid metabolism and transport,0.00556617784879591,0,0,1,0.005909511970896667
1057,APOA1,Retinoid metabolism and transport,0.0031072795399179343,1,0,1,0.003298943392913604
1058,APOA1,Heme signaling,0.00556617784879591,0,0,1,0.005909511970896667
1059,APOA1,Heme signaling,0.0031072795399179343,1,0,1,0.003298943392913604
1060,APOA1,ABC transporters in lipid homeostasis,0.00556617784879591,0,0,1,0.005909511970896667
1061,APOA1,ABC transporters in lipid homeostasis,0.0031072795399179343,1,0,1,0.003298943392913604
1062,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00556617784879591,0,0,1,0.005909511970896667
1063,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0031072795399179343,1,0,1,0.003298943392913604
1064,APOA1,Amyloid fiber formation,0.00556617784879591,0,0,1,0.005909511970896667
1065,APOA1,Amyloid fiber formation,0.0031072795399179343,1,0,1,0.003298943392913604
1066,APOA1,Post-translational protein phosphorylation,0.00556617784879591,0,0,1,0.005909511970896667
1067,APOA1,Post-translational protein phosphorylation,0.0031072795399179343,1,0,1,0.003298943392913604
1068,APOE,Nuclear signaling by ERBB4,0.003089054810994076,0,0,1,0.0032795945225275835
1069,APOE,Nuclear signaling by ERBB4,0.004934539696064971,1,0,1,0.005238912984260622
1070,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.003089054810994076,0,0,1,0.0032795945225275835
1071,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.004934539696064971,1,0,1,0.005238912984260622
1072,APOE,Chylomicron assembly,0.003089054810994076,0,0,1,0.0032795945225275835
1073,APOE,Chylomicron assembly,0.004934539696064971,1,0,1,0.005238912984260622
1074,APOE,Chylomicron remodeling,0.003089054810994076,0,0,1,0.0032795945225275835
1075,APOE,Chylomicron remodeling,0.004934539696064971,1,0,1,0.005238912984260622
1076,APOE,HDL remodeling,0.003089054810994076,0,0,1,0.0032795945225275835
1077,APOE,HDL remodeling,0.004934539696064971,1,0,1,0.005238912984260622
1078,APOE,Chylomicron clearance,0.003089054810994076,0,0,1,0.0032795945225275835
1079,APOE,Chylomicron clearance,0.004934539696064971,1,0,1,0.005238912984260622
1080,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.003089054810994076,0,0,1,0.0032795945225275835
1081,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.004934539696064971,1,0,1,0.005238912984260622
1082,APOE,Scavenging by Class A Receptors,0.003089054810994076,0,0,1,0.0032795945225275835
1083,APOE,Scavenging by Class A Receptors,0.004934539696064971,1,0,1,0.005238912984260622
1084,APOE,Retinoid metabolism and transport,0.003089054810994076,0,0,1,0.0032795945225275835
1085,APOE,Retinoid metabolism and transport,0.004934539696064971,1,0,1,0.005238912984260622
1086,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003089054810994076,0,0,1,0.0032795945225275835
1087,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004934539696064971,1,0,1,0.005238912984260622
1088,APOE,Amyloid fiber formation,0.003089054810994076,0,0,1,0.0032795945225275835
1089,APOE,Amyloid fiber formation,0.004934539696064971,1,0,1,0.005238912984260622
1090,APOE,Post-translational protein phosphorylation,0.003089054810994076,0,0,1,0.0032795945225275835
1091,APOE,Post-translational protein phosphorylation,0.004934539696064971,1,0,1,0.005238912984260622
1092,APOA2,PPARA activates gene expression,0.0006844929199812633,0,0,1,0.0007267139524653024
1093,APOA2,PPARA activates gene expression,0.0016874596663255205,1,0,1,0.0017915458990792293
1094,APOA2,Chylomicron assembly,0.0006844929199812633,0,0,1,0.0007267139524653024
1095,APOA2,Chylomicron assembly,0.0016874596663255205,1,0,1,0.0017915458990792293
1096,APOA2,Chylomicron remodeling,0.0006844929199812633,0,0,1,0.0007267139524653024
1097,APOA2,Chylomicron remodeling,0.0016874596663255205,1,0,1,0.0017915458990792293
1098,APOA2,Retinoid metabolism and transport,0.0006844929199812633,0,0,1,0.0007267139524653024
1099,APOA2,Retinoid metabolism and transport,0.0016874596663255205,1,0,1,0.0017915458990792293
1100,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006844929199812633,0,0,1,0.0007267139524653024
1101,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0016874596663255205,1,0,1,0.0017915458990792293
1102,APOA2,Post-translational protein phosphorylation,0.0006844929199812633,0,0,1,0.0007267139524653024
1103,APOA2,Post-translational protein phosphorylation,0.0016874596663255205,1,0,1,0.0017915458990792293
1104,APOC1,VLDL assembly,0.00039785375539917007,0,0,1,0.00042239425222573344
1105,APOC1,VLDL assembly,0.0012069139983405105,1,0,1,0.0012813591147790722
1106,APOC1,VLDL clearance,0.00039785375539917007,0,0,1,0.00042239425222573344
1107,APOC1,VLDL clearance,0.0012069139983405105,1,0,1,0.0012813591147790722
1108,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00039785375539917007,0,0,1,0.00042239425222573344
1109,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0012069139983405105,1,0,1,0.0012813591147790722
1110,APOC2,Chylomicron assembly,0.0013921098397063152,0,0,1,0.0014779782439627094
1111,APOC2,Chylomicron assembly,0.00027310301467028687,1,0,1,0.0002899486107565091
1112,APOC2,Assembly of active LPL and LIPC lipase complexes,0.0013921098397063152,0,0,1,0.0014779782439627094
1113,APOC2,Assembly of active LPL and LIPC lipase complexes,0.00027310301467028687,1,0,1,0.0002899486107565091
1114,APOC2,Chylomicron remodeling,0.0013921098397063152,0,0,1,0.0014779782439627094
1115,APOC2,Chylomicron remodeling,0.00027310301467028687,1,0,1,0.0002899486107565091
1116,APOC2,HDL remodeling,0.0013921098397063152,0,0,1,0.0014779782439627094
1117,APOC2,HDL remodeling,0.00027310301467028687,1,0,1,0.0002899486107565091
1118,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0013921098397063152,0,0,1,0.0014779782439627094
1119,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00027310301467028687,1,0,1,0.0002899486107565091
1120,APOC2,Retinoid metabolism and transport,0.0013921098397063152,0,0,1,0.0014779782439627094
1121,APOC2,Retinoid metabolism and transport,0.00027310301467028687,1,0,1,0.0002899486107565091
1122,APOC3,Chylomicron assembly,0.0021834364508996366,0,0,1,0.002318115625262451
1123,APOC3,Chylomicron assembly,0.0011059593964673326,1,0,1,0.001174177410476234
1124,APOC3,Chylomicron remodeling,0.0021834364508996366,0,0,1,0.002318115625262451
1125,APOC3,Chylomicron remodeling,0.0011059593964673326,1,0,1,0.001174177410476234
1126,APOC3,HDL remodeling,0.0021834364508996366,0,0,1,0.002318115625262451
1127,APOC3,HDL remodeling,0.0011059593964673326,1,0,1,0.001174177410476234
1128,APOC3,Retinoid metabolism and transport,0.0021834364508996366,0,0,1,0.002318115625262451
1129,APOC3,Retinoid metabolism and transport,0.0011059593964673326,1,0,1,0.001174177410476234
1130,FIBA,Antigen processing-Cross presentation,0.0014274030763887734,0,0,1,0.001515448445298765
1131,FIBA,Antigen processing-Cross presentation,0.00246317822243581,1,0,1,0.002615112486045559
1132,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.0014274030763887734,0,0,1,0.001515448445298765
1133,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.00246317822243581,1,0,1,0.002615112486045559
1134,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.0014274030763887734,0,0,1,0.001515448445298765
1135,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.00246317822243581,1,0,1,0.002615112486045559
1136,FIBA,Regulation of TLR by endogenous ligand,0.0014274030763887734,0,0,1,0.001515448445298765
1137,FIBA,Regulation of TLR by endogenous ligand,0.00246317822243581,1,0,1,0.002615112486045559
1138,FIBA,MyD88 deficiency (TLR2/4),0.0014274030763887734,0,0,1,0.001515448445298765
1139,FIBA,MyD88 deficiency (TLR2/4),0.00246317822243581,1,0,1,0.002615112486045559
1140,FIBA,IRAK4 deficiency (TLR2/4),0.0014274030763887734,0,0,1,0.001515448445298765
1141,FIBA,IRAK4 deficiency (TLR2/4),0.00246317822243581,1,0,1,0.002615112486045559
1142,FIBA,RAF/MAP kinase cascade,0.0014274030763887734,0,0,1,0.001515448445298765
1143,FIBA,RAF/MAP kinase cascade,0.00246317822243581,1,0,1,0.002615112486045559
1144,FIBA,Signaling by RAS mutants,0.0014274030763887734,0,0,1,0.001515448445298765
1145,FIBA,Signaling by RAS mutants,0.00246317822243581,1,0,1,0.002615112486045559
1146,FIBA,Signaling by moderate kinase activity BRAF mutants,0.0014274030763887734,0,0,1,0.001515448445298765
1147,FIBA,Signaling by moderate kinase activity BRAF mutants,0.00246317822243581,1,0,1,0.002615112486045559
1148,FIBA,Signaling by high-kinase activity BRAF mutants,0.0014274030763887734,0,0,1,0.001515448445298765
1149,FIBA,Signaling by high-kinase activity BRAF mutants,0.00246317822243581,1,0,1,0.002615112486045559
1150,FIBA,Signaling by BRAF and RAF1 fusions,0.0014274030763887734,0,0,1,0.001515448445298765
1151,FIBA,Signaling by BRAF and RAF1 fusions,0.00246317822243581,1,0,1,0.002615112486045559
1152,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0014274030763887734,0,0,1,0.001515448445298765
1153,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00246317822243581,1,0,1,0.002615112486045559
1154,FIBA,Signaling by RAF1 mutants,0.0014274030763887734,0,0,1,0.001515448445298765
1155,FIBA,Signaling by RAF1 mutants,0.00246317822243581,1,0,1,0.002615112486045559
1156,FIBA,Platelet degranulation ,0.0014274030763887734,0,0,1,0.001515448445298765
1157,FIBA,Platelet degranulation ,0.00246317822243581,1,0,1,0.002615112486045559
1158,FIBA,Common Pathway of Fibrin Clot Formation,0.0014274030763887734,0,0,1,0.001515448445298765
1159,FIBA,Common Pathway of Fibrin Clot Formation,0.00246317822243581,1,0,1,0.002615112486045559
1160,FIBA,Integrin cell surface interactions,0.0014274030763887734,0,0,1,0.001515448445298765
1161,FIBA,Integrin cell surface interactions,0.00246317822243581,1,0,1,0.002615112486045559
1162,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0014274030763887734,0,0,1,0.001515448445298765
1163,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00246317822243581,1,0,1,0.002615112486045559
1164,FIBA,p130Cas linkage to MAPK signaling for integrins,0.0014274030763887734,0,0,1,0.001515448445298765
1165,FIBA,p130Cas linkage to MAPK signaling for integrins,0.00246317822243581,1,0,1,0.002615112486045559
1166,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0014274030763887734,0,0,1,0.001515448445298765
1167,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00246317822243581,1,0,1,0.002615112486045559
1168,FIBA,Amyloid fiber formation,0.0014274030763887734,0,0,1,0.001515448445298765
1169,FIBA,Amyloid fiber formation,0.00246317822243581,1,0,1,0.002615112486045559
1170,FIBA,Post-translational protein phosphorylation,0.0014274030763887734,0,0,1,0.001515448445298765
1171,FIBA,Post-translational protein phosphorylation,0.00246317822243581,1,0,1,0.002615112486045559
1172,FIBB,Antigen processing-Cross presentation,0.0003697096048006707,0,0,1,0.00039251410836570053
1173,FIBB,Antigen processing-Cross presentation,0.0007118763360082953,1,0,1,0.0007557864379682216
1174,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0003697096048006707,0,0,1,0.00039251410836570053
1175,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0007118763360082953,1,0,1,0.0007557864379682216
1176,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0003697096048006707,0,0,1,0.00039251410836570053
1177,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0007118763360082953,1,0,1,0.0007557864379682216
1178,FIBB,Regulation of TLR by endogenous ligand,0.0003697096048006707,0,0,1,0.00039251410836570053
1179,FIBB,Regulation of TLR by endogenous ligand,0.0007118763360082953,1,0,1,0.0007557864379682216
1180,FIBB,MyD88 deficiency (TLR2/4),0.0003697096048006707,0,0,1,0.00039251410836570053
1181,FIBB,MyD88 deficiency (TLR2/4),0.0007118763360082953,1,0,1,0.0007557864379682216
1182,FIBB,IRAK4 deficiency (TLR2/4),0.0003697096048006707,0,0,1,0.00039251410836570053
1183,FIBB,IRAK4 deficiency (TLR2/4),0.0007118763360082953,1,0,1,0.0007557864379682216
1184,FIBB,RAF/MAP kinase cascade,0.0003697096048006707,0,0,1,0.00039251410836570053
1185,FIBB,RAF/MAP kinase cascade,0.0007118763360082953,1,0,1,0.0007557864379682216
1186,FIBB,Signaling by RAS mutants,0.0003697096048006707,0,0,1,0.00039251410836570053
1187,FIBB,Signaling by RAS mutants,0.0007118763360082953,1,0,1,0.0007557864379682216
1188,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0003697096048006707,0,0,1,0.00039251410836570053
1189,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0007118763360082953,1,0,1,0.0007557864379682216
1190,FIBB,Signaling by high-kinase activity BRAF mutants,0.0003697096048006707,0,0,1,0.00039251410836570053
1191,FIBB,Signaling by high-kinase activity BRAF mutants,0.0007118763360082953,1,0,1,0.0007557864379682216
1192,FIBB,Signaling by BRAF and RAF1 fusions,0.0003697096048006707,0,0,1,0.00039251410836570053
1193,FIBB,Signaling by BRAF and RAF1 fusions,0.0007118763360082953,1,0,1,0.0007557864379682216
1194,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0003697096048006707,0,0,1,0.00039251410836570053
1195,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0007118763360082953,1,0,1,0.0007557864379682216
1196,FIBB,Signaling by RAF1 mutants,0.0003697096048006707,0,0,1,0.00039251410836570053
1197,FIBB,Signaling by RAF1 mutants,0.0007118763360082953,1,0,1,0.0007557864379682216
1198,FIBB,Platelet degranulation ,0.0003697096048006707,0,0,1,0.00039251410836570053
1199,FIBB,Platelet degranulation ,0.0007118763360082953,1,0,1,0.0007557864379682216
1200,FIBB,Common Pathway of Fibrin Clot Formation,0.0003697096048006707,0,0,1,0.00039251410836570053
1201,FIBB,Common Pathway of Fibrin Clot Formation,0.0007118763360082953,1,0,1,0.0007557864379682216
1202,FIBB,Integrin cell surface interactions,0.0003697096048006707,0,0,1,0.00039251410836570053
1203,FIBB,Integrin cell surface interactions,0.0007118763360082953,1,0,1,0.0007557864379682216
1204,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0003697096048006707,0,0,1,0.00039251410836570053
1205,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0007118763360082953,1,0,1,0.0007557864379682216
1206,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0003697096048006707,0,0,1,0.00039251410836570053
1207,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0007118763360082953,1,0,1,0.0007557864379682216
1208,FIBG,Antigen processing-Cross presentation,0.0008919742728264702,0,0,1,0.0009469932126117998
1209,FIBG,Antigen processing-Cross presentation,0.001919462280101918,1,0,1,0.0020378589455959735
1210,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0008919742728264702,0,0,1,0.0009469932126117998
1211,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.001919462280101918,1,0,1,0.0020378589455959735
1212,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0008919742728264702,0,0,1,0.0009469932126117998
1213,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.001919462280101918,1,0,1,0.0020378589455959735
1214,FIBG,Regulation of TLR by endogenous ligand,0.0008919742728264702,0,0,1,0.0009469932126117998
1215,FIBG,Regulation of TLR by endogenous ligand,0.001919462280101918,1,0,1,0.0020378589455959735
1216,FIBG,MyD88 deficiency (TLR2/4),0.0008919742728264702,0,0,1,0.0009469932126117998
1217,FIBG,MyD88 deficiency (TLR2/4),0.001919462280101918,1,0,1,0.0020378589455959735
1218,FIBG,IRAK4 deficiency (TLR2/4),0.0008919742728264702,0,0,1,0.0009469932126117998
1219,FIBG,IRAK4 deficiency (TLR2/4),0.001919462280101918,1,0,1,0.0020378589455959735
1220,FIBG,RAF/MAP kinase cascade,0.0008919742728264702,0,0,1,0.0009469932126117998
1221,FIBG,RAF/MAP kinase cascade,0.001919462280101918,1,0,1,0.0020378589455959735
1222,FIBG,Signaling by RAS mutants,0.0008919742728264702,0,0,1,0.0009469932126117998
1223,FIBG,Signaling by RAS mutants,0.001919462280101918,1,0,1,0.0020378589455959735
1224,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0008919742728264702,0,0,1,0.0009469932126117998
1225,FIBG,Signaling by moderate kinase activity BRAF mutants,0.001919462280101918,1,0,1,0.0020378589455959735
1226,FIBG,Signaling by high-kinase activity BRAF mutants,0.0008919742728264702,0,0,1,0.0009469932126117998
1227,FIBG,Signaling by high-kinase activity BRAF mutants,0.001919462280101918,1,0,1,0.0020378589455959735
1228,FIBG,Signaling by BRAF and RAF1 fusions,0.0008919742728264702,0,0,1,0.0009469932126117998
1229,FIBG,Signaling by BRAF and RAF1 fusions,0.001919462280101918,1,0,1,0.0020378589455959735
1230,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0008919742728264702,0,0,1,0.0009469932126117998
1231,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.001919462280101918,1,0,1,0.0020378589455959735
1232,FIBG,Signaling by RAF1 mutants,0.0008919742728264702,0,0,1,0.0009469932126117998
1233,FIBG,Signaling by RAF1 mutants,0.001919462280101918,1,0,1,0.0020378589455959735
1234,FIBG,Platelet degranulation ,0.0008919742728264702,0,0,1,0.0009469932126117998
1235,FIBG,Platelet degranulation ,0.001919462280101918,1,0,1,0.0020378589455959735
1236,FIBG,Common Pathway of Fibrin Clot Formation,0.0008919742728264702,0,0,1,0.0009469932126117998
1237,FIBG,Common Pathway of Fibrin Clot Formation,0.001919462280101918,1,0,1,0.0020378589455959735
1238,FIBG,Integrin cell surface interactions,0.0008919742728264702,0,0,1,0.0009469932126117998
1239,FIBG,Integrin cell surface interactions,0.001919462280101918,1,0,1,0.0020378589455959735
1240,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0008919742728264702,0,0,1,0.0009469932126117998
1241,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.001919462280101918,1,0,1,0.0020378589455959735
1242,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0008919742728264702,0,0,1,0.0009469932126117998
1243,FIBG,p130Cas linkage to MAPK signaling for integrins,0.001919462280101918,1,0,1,0.0020378589455959735
1244,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008919742728264702,0,0,1,0.0009469932126117998
1245,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001919462280101918,1,0,1,0.0020378589455959735
1246,FIBG,Post-translational protein phosphorylation,0.0008919742728264702,0,0,1,0.0009469932126117998
1247,FIBG,Post-translational protein phosphorylation,0.001919462280101918,1,0,1,0.0020378589455959735
1248,B3AT,Bicarbonate transporters,0.0002059467881223598,0,0,1,0.00021865004008811526
1249,B3AT,Bicarbonate transporters,0.0005250603729104954,1,0,1,0.0005574472543720926
1250,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0002059467881223598,0,0,1,0.00021865004008811526
1251,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0005250603729104954,1,0,1,0.0005574472543720926
1252,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0002059467881223598,0,0,1,0.00021865004008811526
1253,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0005250603729104954,1,0,1,0.0005574472543720926
1254,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0002059467881223598,0,0,1,0.00021865004008811526
1255,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0005250603729104954,1,0,1,0.0005574472543720926
1256,CRP,Initial triggering of complement,8.09285570298285e-05,0,0,1,8.592040885984646e-05
1257,CRP,Initial triggering of complement,6.743708957797856e-05,1,0,1,7.159675794938966e-05
1258,SAMP,Amyloid fiber formation,8.961145251996779e-05,0,0,1,9.513888448798736e-05
1259,SAMP,Amyloid fiber formation,0.00026424545054803,1,0,1,0.0002805446925499098
1260,C1QA,Initial triggering of complement,1.2663195492235664e-06,0,0,1,1.3444289310187872e-06
1261,C1QA,Initial triggering of complement,7.781469081736053e-05,1,0,1,8.261447251389755e-05
1262,C1QA,Regulation of Complement cascade,1.2663195492235664e-06,0,0,1,1.3444289310187872e-06
1263,C1QA,Regulation of Complement cascade,7.781469081736053e-05,1,0,1,8.261447251389755e-05
1264,C1QB,Initial triggering of complement,6.372747912475724e-06,0,0,1,6.765833054441247e-06
1265,C1QB,Initial triggering of complement,0.00012523555917486593,1,0,1,0.00013296036458588983
1266,C1QB,Regulation of Complement cascade,6.372747912475724e-06,0,0,1,6.765833054441247e-06
1267,C1QB,Regulation of Complement cascade,0.00012523555917486593,1,0,1,0.00013296036458588983
1268,C1QC,Initial triggering of complement,0.00011370815194462976,0,0,1,0.00012072192146190348
1269,C1QC,Initial triggering of complement,2.1535006930372288e-05,1,0,1,2.286333363852311e-05
1270,C1QC,Regulation of Complement cascade,0.00011370815194462976,0,0,1,0.00012072192146190348
1271,C1QC,Regulation of Complement cascade,2.1535006930372288e-05,1,0,1,2.286333363852311e-05
1272,CO9,Terminal pathway of complement,0.0001456285590323985,0,0,1,0.00015461124963740726
1273,CO9,Terminal pathway of complement,0.0002553244017412723,1,0,1,0.0002710733737834977
1274,CO9,Regulation of Complement cascade,0.0001456285590323985,0,0,1,0.00015461124963740726
1275,CO9,Regulation of Complement cascade,0.0002553244017412723,1,0,1,0.0002710733737834977
1276,APOH,Platelet degranulation ,6.950389244266469e-05,0,0,1,7.37910457716856e-05
1277,APOH,Platelet degranulation ,0.00013889533072715448,1,0,1,0.00014746270096477953
1278,A2GL,Neutrophil degranulation,0.0002478455564612559,0,0,1,0.0002631332168371468
1279,A2GL,Neutrophil degranulation,0.0002028854235736686,1,0,1,0.00021539984382432128
1280,FINC,G alpha (s) signalling events,0.0015259643901533175,0,0,1,0.0016200892382056738
1281,FINC,G alpha (s) signalling events,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1282,FINC,Interleukin-4 and Interleukin-13 signaling,0.0015259643901533175,0,0,1,0.0016200892382056738
1283,FINC,Interleukin-4 and Interleukin-13 signaling,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1284,FINC,RAF/MAP kinase cascade,0.0015259643901533175,0,0,1,0.0016200892382056738
1285,FINC,RAF/MAP kinase cascade,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1286,FINC,Signaling by RAS mutants,0.0015259643901533175,0,0,1,0.0016200892382056738
1287,FINC,Signaling by RAS mutants,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1288,FINC,Signaling by moderate kinase activity BRAF mutants,0.0015259643901533175,0,0,1,0.0016200892382056738
1289,FINC,Signaling by moderate kinase activity BRAF mutants,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1290,FINC,Signaling by high-kinase activity BRAF mutants,0.0015259643901533175,0,0,1,0.0016200892382056738
1291,FINC,Signaling by high-kinase activity BRAF mutants,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1292,FINC,Signaling by BRAF and RAF1 fusions,0.0015259643901533175,0,0,1,0.0016200892382056738
1293,FINC,Signaling by BRAF and RAF1 fusions,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1294,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0015259643901533175,0,0,1,0.0016200892382056738
1295,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1296,FINC,Signaling by RAF1 mutants,0.0015259643901533175,0,0,1,0.0016200892382056738
1297,FINC,Signaling by RAF1 mutants,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1298,FINC,MET promotes cell motility,0.0015259643901533175,0,0,1,0.0016200892382056738
1299,FINC,MET promotes cell motility,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1300,FINC,Platelet degranulation ,0.0015259643901533175,0,0,1,0.0016200892382056738
1301,FINC,Platelet degranulation ,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1302,FINC,ALK mutants bind TKIs,0.0015259643901533175,0,0,1,0.0016200892382056738
1303,FINC,ALK mutants bind TKIs,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1304,FINC,Signaling by ALK fusions and activated point mutants,0.0015259643901533175,0,0,1,0.0016200892382056738
1305,FINC,Signaling by ALK fusions and activated point mutants,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1306,FINC,Fibronectin matrix formation,0.0015259643901533175,0,0,1,0.0016200892382056738
1307,FINC,Fibronectin matrix formation,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1308,FINC,Integrin cell surface interactions,0.0015259643901533175,0,0,1,0.0016200892382056738
1309,FINC,Integrin cell surface interactions,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1310,FINC,ECM proteoglycans,0.0015259643901533175,0,0,1,0.0016200892382056738
1311,FINC,ECM proteoglycans,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1312,FINC,Molecules associated with elastic fibres,0.0015259643901533175,0,0,1,0.0016200892382056738
1313,FINC,Molecules associated with elastic fibres,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1314,FINC,Syndecan interactions,0.0015259643901533175,0,0,1,0.0016200892382056738
1315,FINC,Syndecan interactions,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1316,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0015259643901533175,0,0,1,0.0016200892382056738
1317,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1318,FINC,p130Cas linkage to MAPK signaling for integrins,0.0015259643901533175,0,0,1,0.0016200892382056738
1319,FINC,p130Cas linkage to MAPK signaling for integrins,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1320,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0015259643901533175,0,0,1,0.0016200892382056738
1321,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1322,FINC,Post-translational protein phosphorylation,0.0015259643901533175,0,0,1,0.0016200892382056738
1323,FINC,Post-translational protein phosphorylation,3.9989717478833255e-05,1,0,1,4.2456371422817925e-05
1324,RET4,Retinoid cycle disease events,0.00012112441841277435,0,0,1,0.00012859563959729162
1325,RET4,Retinoid cycle disease events,0.0001440533019007406,1,0,1,0.00015293882717271967
1326,RET4,Retinoid metabolism disease events,0.00012112441841277435,0,0,1,0.00012859563959729162
1327,RET4,Retinoid metabolism disease events,0.0001440533019007406,1,0,1,0.00015293882717271967
1328,RET4,The canonical retinoid cycle in rods (twilight vision),0.00012112441841277435,0,0,1,0.00012859563959729162
1329,RET4,The canonical retinoid cycle in rods (twilight vision),0.0001440533019007406,1,0,1,0.00015293882717271967
1330,RET4,Retinoid metabolism and transport,0.00012112441841277435,0,0,1,0.00012859563959729162
1331,RET4,Retinoid metabolism and transport,0.0001440533019007406,1,0,1,0.00015293882717271967
1332,AMBP,Scavenging of heme from plasma,0.00028103365464885843,0,0,1,0.0002983684300945453
1333,AMBP,Scavenging of heme from plasma,0.00011814513495814912,1,0,1,0.00012543258737041912
1334,A1AG1,Platelet degranulation ,7.487130728021513e-05,0,0,1,7.948953459056768e-05
1335,A1AG1,Platelet degranulation ,3.501792512684075e-05,1,0,1,3.717790795667698e-05
1336,A1AG1,Neutrophil degranulation,7.487130728021513e-05,0,0,1,7.948953459056768e-05
1337,A1AG1,Neutrophil degranulation,3.501792512684075e-05,1,0,1,3.717790795667698e-05
1338,FETUA,Platelet degranulation ,3.821940442155301e-05,0,0,1,4.0576861552953565e-05
1339,FETUA,Platelet degranulation ,4.247068397396295e-05,1,0,1,4.509036940143696e-05
1340,FETUA,Neutrophil degranulation,3.821940442155301e-05,0,0,1,4.0576861552953565e-05
1341,FETUA,Neutrophil degranulation,4.247068397396295e-05,1,0,1,4.509036940143696e-05
1342,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3.821940442155301e-05,0,0,1,4.0576861552953565e-05
1343,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4.247068397396295e-05,1,0,1,4.509036940143696e-05
1344,FETUA,Post-translational protein phosphorylation,3.821940442155301e-05,0,0,1,4.0576861552953565e-05
1345,FETUA,Post-translational protein phosphorylation,4.247068397396295e-05,1,0,1,4.509036940143696e-05
1346,TTHY,Retinoid cycle disease events,0.00016195165836289946,0,0,1,0.00017194119372401196
1347,TTHY,Retinoid cycle disease events,0.00027466141076940617,1,0,1,0.0002916031321629957
1348,TTHY,Neutrophil degranulation,0.00016195165836289946,0,0,1,0.00017194119372401196
1349,TTHY,Neutrophil degranulation,0.00027466141076940617,1,0,1,0.0002916031321629957
1350,TTHY,The canonical retinoid cycle in rods (twilight vision),0.00016195165836289946,0,0,1,0.00017194119372401196
1351,TTHY,The canonical retinoid cycle in rods (twilight vision),0.00027466141076940617,1,0,1,0.0002916031321629957
1352,TTHY,Retinoid metabolism and transport,0.00016195165836289946,0,0,1,0.00017194119372401196
1353,TTHY,Retinoid metabolism and transport,0.00027466141076940617,1,0,1,0.0002916031321629957
1354,TTHY,Amyloid fiber formation,0.00016195165836289946,0,0,1,0.00017194119372401196
1355,TTHY,Amyloid fiber formation,0.00027466141076940617,1,0,1,0.0002916031321629957
1356,ALBU,Bile acid and bile salt metabolism,0.0024499197615515753,0,0,1,0.002601036214061544
1357,ALBU,Bile acid and bile salt metabolism,0.0005746810586573203,1,0,1,0.0006101286534201659
1358,ALBU,Platelet degranulation ,0.0024499197615515753,0,0,1,0.002601036214061544
1359,ALBU,Platelet degranulation ,0.0005746810586573203,1,0,1,0.0006101286534201659
1360,ALBU,HDL remodeling,0.0024499197615515753,0,0,1,0.002601036214061544
1361,ALBU,HDL remodeling,0.0005746810586573203,1,0,1,0.0006101286534201659
1362,ALBU,Cytoprotection by HMOX1,0.0024499197615515753,0,0,1,0.002601036214061544
1363,ALBU,Cytoprotection by HMOX1,0.0005746810586573203,1,0,1,0.0006101286534201659
1364,ALBU,Heme biosynthesis,0.0024499197615515753,0,0,1,0.002601036214061544
1365,ALBU,Heme biosynthesis,0.0005746810586573203,1,0,1,0.0006101286534201659
1366,ALBU,Heme degradation,0.0024499197615515753,0,0,1,0.002601036214061544
1367,ALBU,Heme degradation,0.0005746810586573203,1,0,1,0.0006101286534201659
1368,ALBU,Scavenging of heme from plasma,0.0024499197615515753,0,0,1,0.002601036214061544
1369,ALBU,Scavenging of heme from plasma,0.0005746810586573203,1,0,1,0.0006101286534201659
1370,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0024499197615515753,0,0,1,0.002601036214061544
1371,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005746810586573203,1,0,1,0.0006101286534201659
1372,ALBU,Post-translational protein phosphorylation,0.0024499197615515753,0,0,1,0.002601036214061544
1373,ALBU,Post-translational protein phosphorylation,0.0005746810586573203,1,0,1,0.0006101286534201659
1374,ALBU,Aspirin ADME,0.0024499197615515753,0,0,1,0.002601036214061544
1375,ALBU,Aspirin ADME,0.0005746810586573203,1,0,1,0.0006101286534201659
1376,VTDB,Vitamin D (calciferol) metabolism,4.989996638206338e-06,0,0,1,5.297790632865512e-06
1377,VTDB,Vitamin D (calciferol) metabolism,5.970743057042668e-05,1,0,1,6.339031653179134e-05
1378,CXCL7,Class A/1 (Rhodopsin-like receptors),6.0200607878717855e-05,0,0,1,6.391391410382216e-05
1379,CXCL7,Class A/1 (Rhodopsin-like receptors),9.675426034454324e-05,1,0,1,0.00010272227644774554
1380,CXCL7,G alpha (i) signalling events,6.0200607878717855e-05,0,0,1,6.391391410382216e-05
1381,CXCL7,G alpha (i) signalling events,9.675426034454324e-05,1,0,1,0.00010272227644774554
1382,CXCL7,Platelet degranulation ,6.0200607878717855e-05,0,0,1,6.391391410382216e-05
1383,CXCL7,Platelet degranulation ,9.675426034454324e-05,1,0,1,0.00010272227644774554
1384,CXCL7,Neutrophil degranulation,6.0200607878717855e-05,0,0,1,6.391391410382216e-05
1385,CXCL7,Neutrophil degranulation,9.675426034454324e-05,1,0,1,0.00010272227644774554
1386,PLF4,Transcriptional regulation by RUNX1,0.0014609914355164365,0,0,1,0.001551108608473508
1387,PLF4,Transcriptional regulation by RUNX1,3.9428957196640176e-05,1,0,1,4.186102221004704e-05
1388,PLF4,Class A/1 (Rhodopsin-like receptors),0.0014609914355164365,0,0,1,0.001551108608473508
1389,PLF4,Class A/1 (Rhodopsin-like receptors),3.9428957196640176e-05,1,0,1,4.186102221004704e-05
1390,PLF4,G alpha (i) signalling events,0.0014609914355164365,0,0,1,0.001551108608473508
1391,PLF4,G alpha (i) signalling events,3.9428957196640176e-05,1,0,1,4.186102221004704e-05
1392,PLF4,Platelet degranulation ,0.0014609914355164365,0,0,1,0.001551108608473508
1393,PLF4,Platelet degranulation ,3.9428957196640176e-05,1,0,1,4.186102221004704e-05
1394,PLF4,Common Pathway of Fibrin Clot Formation,0.0014609914355164365,0,0,1,0.001551108608473508
1395,PLF4,Common Pathway of Fibrin Clot Formation,3.9428957196640176e-05,1,0,1,4.186102221004704e-05
1396,TFR1,RHO GTPase cycle,7.899676703480943e-05,0,0,1,8.386946179869693e-05
1397,TFR1,RHO GTPase cycle,0.00046499504319999594,1,0,1,0.0004936769626921678
1398,TFR1,Golgi Associated Vesicle Biogenesis,7.899676703480943e-05,0,0,1,8.386946179869693e-05
1399,TFR1,Golgi Associated Vesicle Biogenesis,0.00046499504319999594,1,0,1,0.0004936769626921678
1400,TFR1,Cargo recognition for clathrin-mediated endocytosis,7.899676703480943e-05,0,0,1,8.386946179869693e-05
1401,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.00046499504319999594,1,0,1,0.0004936769626921678
1402,TFR1,Transferrin endocytosis and recycling,7.899676703480943e-05,0,0,1,8.386946179869693e-05
1403,TFR1,Transferrin endocytosis and recycling,0.00046499504319999594,1,0,1,0.0004936769626921678
1404,TRFE,Platelet degranulation ,0.0008107754554930118,0,0,1,0.0008607858731969219
1405,TRFE,Platelet degranulation ,0.00016601960836860736,1,0,1,0.00017626006385514518
1406,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0008107754554930118,0,0,1,0.0008607858731969219
1407,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.00016601960836860736,1,0,1,0.00017626006385514518
1408,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008107754554930118,0,0,1,0.0008607858731969219
1409,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00016601960836860736,1,0,1,0.00017626006385514518
1410,TRFE,Post-translational protein phosphorylation,0.0008107754554930118,0,0,1,0.0008607858731969219
1411,TRFE,Post-translational protein phosphorylation,0.00016601960836860736,1,0,1,0.00017626006385514518
1412,TRFE,Transferrin endocytosis and recycling,0.0008107754554930118,0,0,1,0.0008607858731969219
1413,TRFE,Transferrin endocytosis and recycling,0.00016601960836860736,1,0,1,0.00017626006385514518
1414,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.0008050151650030355,0,0,1,0.0008546702752891545
1415,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.0017173793456436793,1,0,1,0.0018233110901850612
1416,TRFL,Metal sequestration by antimicrobial proteins,0.0008050151650030355,0,0,1,0.0008546702752891545
1417,TRFL,Metal sequestration by antimicrobial proteins,0.0017173793456436793,1,0,1,0.0018233110901850612
1418,TRFL,Neutrophil degranulation,0.0008050151650030355,0,0,1,0.0008546702752891545
1419,TRFL,Neutrophil degranulation,0.0017173793456436793,1,0,1,0.0018233110901850612
1420,TRFL,Amyloid fiber formation,0.0008050151650030355,0,0,1,0.0008546702752891545
1421,TRFL,Amyloid fiber formation,0.0017173793456436793,1,0,1,0.0018233110901850612
1422,HEMO,Scavenging of heme from plasma,8.757402985948687e-05,0,0,1,9.29757891056699e-05
1423,HEMO,Scavenging of heme from plasma,3.158883998864975e-05,1,0,1,3.353730928666733e-05
1424,ANGI,Adherens junctions interactions,0.0006144891016502618,0,0,1,0.0006523921442742439
1425,ANGI,Adherens junctions interactions,0.0007692159642598374,1,0,1,0.0008166629009135358
1426,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0006144891016502618,0,0,1,0.0006523921442742439
1427,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0007692159642598374,1,0,1,0.0008166629009135358
1428,FA11,Defective factor IX causes hemophilia B,0.0010248088245522374,0,0,1,0.0010880212923634958
1429,FA11,Defective factor IX causes hemophilia B,0.0002354396345780224,1,0,1,0.0002499620703394048
1430,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0010248088245522374,0,0,1,0.0010880212923634958
1431,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0002354396345780224,1,0,1,0.0002499620703394048
1432,KLKB1,Defective factor XII causes hereditary angioedema,0.00021436626960590776,0,0,1,0.00022758885375295936
1433,KLKB1,Defective factor XII causes hereditary angioedema,0.00017351915313632018,1,0,1,0.00018422219707923208
1434,KLKB1,Defective SERPING1 causes hereditary angioedema,0.00021436626960590776,0,0,1,0.00022758885375295936
1435,KLKB1,Defective SERPING1 causes hereditary angioedema,0.00017351915313632018,1,0,1,0.00018422219707923208
1436,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.00021436626960590776,0,0,1,0.00022758885375295936
1437,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.00017351915313632018,1,0,1,0.00018422219707923208
1438,KLKB1,Activation of Matrix Metalloproteinases,0.00021436626960590776,0,0,1,0.00022758885375295936
1439,KLKB1,Activation of Matrix Metalloproteinases,0.00017351915313632018,1,0,1,0.00018422219707923208
1440,C4BPA,Regulation of Complement cascade,4.94684627836834e-05,0,0,1,5.251978663694188e-05
1441,C4BPA,Regulation of Complement cascade,6.103453057255106e-06,1,0,1,6.479927498805546e-06
1442,VTNC,Regulation of Complement cascade,2.6437747571497793e-05,0,0,1,2.80684861320246e-05
1443,VTNC,Regulation of Complement cascade,0.0001495677478473928,1,0,1,0.00015879341630368918
1444,VTNC,Integrin cell surface interactions,2.6437747571497793e-05,0,0,1,2.80684861320246e-05
1445,VTNC,Integrin cell surface interactions,0.0001495677478473928,1,0,1,0.00015879341630368918
1446,VTNC,ECM proteoglycans,2.6437747571497793e-05,0,0,1,2.80684861320246e-05
1447,VTNC,ECM proteoglycans,0.0001495677478473928,1,0,1,0.00015879341630368918
1448,VTNC,Molecules associated with elastic fibres,2.6437747571497793e-05,0,0,1,2.80684861320246e-05
1449,VTNC,Molecules associated with elastic fibres,0.0001495677478473928,1,0,1,0.00015879341630368918
1450,VTNC,Syndecan interactions,2.6437747571497793e-05,0,0,1,2.80684861320246e-05
1451,VTNC,Syndecan interactions,0.0001495677478473928,1,0,1,0.00015879341630368918
1452,CATA,FOXO-mediated transcription,0.0007422201770953456,0,0,1,0.0007880019540760477
1453,CATA,FOXO-mediated transcription,0.0009723151561232085,1,0,1,0.0010322896987269878
1454,CATA,Detoxification of Reactive Oxygen Species,0.0007422201770953456,0,0,1,0.0007880019540760477
1455,CATA,Detoxification of Reactive Oxygen Species,0.0009723151561232085,1,0,1,0.0010322896987269878
1456,CATA,Neutrophil degranulation,0.0007422201770953456,0,0,1,0.0007880019540760477
1457,CATA,Neutrophil degranulation,0.0009723151561232085,1,0,1,0.0010322896987269878
1458,FUCO,Neutrophil degranulation,0.0003158550894598188,0,0,1,0.0003353377277794338
1459,FUCO,Neutrophil degranulation,0.0002630079606238299,1,0,1,0.00027923087151874985
1460,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0009826485260381916,0,0,1,0.0010432604536814859
1461,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00035462438392058055,1,0,1,0.0003764983978016197
1462,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.0009826485260381916,0,0,1,0.0010432604536814859
1463,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.00035462438392058055,1,0,1,0.0003764983978016197
1464,PROC,Common Pathway of Fibrin Clot Formation,0.0009826485260381916,0,0,1,0.0010432604536814859
1465,PROC,Common Pathway of Fibrin Clot Formation,0.00035462438392058055,1,0,1,0.0003764983978016197
1466,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009826485260381916,0,0,1,0.0010432604536814859
1467,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00035462438392058055,1,0,1,0.0003764983978016197
1468,PROC,Post-translational protein phosphorylation,0.0009826485260381916,0,0,1,0.0010432604536814859
1469,PROC,Post-translational protein phosphorylation,0.00035462438392058055,1,0,1,0.0003764983978016197
1470,ALDOA,Glycolysis,4.9182224650620566e-05,0,0,1,5.221589270472988e-05
1471,ALDOA,Glycolysis,0.00011881873222004343,1,0,1,0.00012614773359658377
1472,ALDOA,Gluconeogenesis,4.9182224650620566e-05,0,0,1,5.221589270472988e-05
1473,ALDOA,Gluconeogenesis,0.00011881873222004343,1,0,1,0.00012614773359658377
1474,ALDOA,Platelet degranulation ,4.9182224650620566e-05,0,0,1,5.221589270472988e-05
1475,ALDOA,Platelet degranulation ,0.00011881873222004343,1,0,1,0.00012614773359658377
1476,ALDOA,Neutrophil degranulation,4.9182224650620566e-05,0,0,1,5.221589270472988e-05
1477,ALDOA,Neutrophil degranulation,0.00011881873222004343,1,0,1,0.00012614773359658377
1478,APOB,Regulation of TLR by endogenous ligand,0.006405384601381347,0,0,1,0.006800482846276398
1479,APOB,Regulation of TLR by endogenous ligand,0.004701205988089549,1,0,1,0.004991186738719843
1480,APOB,Cargo recognition for clathrin-mediated endocytosis,0.006405384601381347,0,0,1,0.006800482846276398
1481,APOB,Cargo recognition for clathrin-mediated endocytosis,0.004701205988089549,1,0,1,0.004991186738719843
1482,APOB,VLDL assembly,0.006405384601381347,0,0,1,0.006800482846276398
1483,APOB,VLDL assembly,0.004701205988089549,1,0,1,0.004991186738719843
1484,APOB,Chylomicron assembly,0.006405384601381347,0,0,1,0.006800482846276398
1485,APOB,Chylomicron assembly,0.004701205988089549,1,0,1,0.004991186738719843
1486,APOB,Chylomicron remodeling,0.006405384601381347,0,0,1,0.006800482846276398
1487,APOB,Chylomicron remodeling,0.004701205988089549,1,0,1,0.004991186738719843
1488,APOB,LDL remodeling,0.006405384601381347,0,0,1,0.006800482846276398
1489,APOB,LDL remodeling,0.004701205988089549,1,0,1,0.004991186738719843
1490,APOB,Chylomicron clearance,0.006405384601381347,0,0,1,0.006800482846276398
1491,APOB,Chylomicron clearance,0.004701205988089549,1,0,1,0.004991186738719843
1492,APOB,LDL clearance,0.006405384601381347,0,0,1,0.006800482846276398
1493,APOB,LDL clearance,0.004701205988089549,1,0,1,0.004991186738719843
1494,APOB,VLDL clearance,0.006405384601381347,0,0,1,0.006800482846276398
1495,APOB,VLDL clearance,0.004701205988089549,1,0,1,0.004991186738719843
1496,APOB,Scavenging by Class B Receptors,0.006405384601381347,0,0,1,0.006800482846276398
1497,APOB,Scavenging by Class B Receptors,0.004701205988089549,1,0,1,0.004991186738719843
1498,APOB,Scavenging by Class A Receptors,0.006405384601381347,0,0,1,0.006800482846276398
1499,APOB,Scavenging by Class A Receptors,0.004701205988089549,1,0,1,0.004991186738719843
1500,APOB,Scavenging by Class F Receptors,0.006405384601381347,0,0,1,0.006800482846276398
1501,APOB,Scavenging by Class F Receptors,0.004701205988089549,1,0,1,0.004991186738719843
1502,APOB,Scavenging by Class H Receptors,0.006405384601381347,0,0,1,0.006800482846276398
1503,APOB,Scavenging by Class H Receptors,0.004701205988089549,1,0,1,0.004991186738719843
1504,APOB,Retinoid metabolism and transport,0.006405384601381347,0,0,1,0.006800482846276398
1505,APOB,Retinoid metabolism and transport,0.004701205988089549,1,0,1,0.004991186738719843
1506,APOB,Heme signaling,0.006405384601381347,0,0,1,0.006800482846276398
1507,APOB,Heme signaling,0.004701205988089549,1,0,1,0.004991186738719843
1508,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006405384601381347,0,0,1,0.006800482846276398
1509,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004701205988089549,1,0,1,0.004991186738719843
1510,APOB,Platelet sensitization by LDL,0.006405384601381347,0,0,1,0.006800482846276398
1511,APOB,Platelet sensitization by LDL,0.004701205988089549,1,0,1,0.004991186738719843
1512,APOB,Post-translational protein phosphorylation,0.006405384601381347,0,0,1,0.006800482846276398
1513,APOB,Post-translational protein phosphorylation,0.004701205988089549,1,0,1,0.004991186738719843
1514,SODM,FOXO-mediated transcription,0.0001367359872702639,0,0,1,0.00014517016444251721
1515,SODM,FOXO-mediated transcription,0.00016600024014570144,1,0,1,0.00017623950095754708
1516,SODM,Interleukin-12 family signaling,0.0001367359872702639,0,0,1,0.00014517016444251721
1517,SODM,Interleukin-12 family signaling,0.00016600024014570144,1,0,1,0.00017623950095754708
1518,SODM,Neurodegenerative Diseases,0.0001367359872702639,0,0,1,0.00014517016444251721
1519,SODM,Neurodegenerative Diseases,0.00016600024014570144,1,0,1,0.00017623950095754708
1520,SODM,Detoxification of Reactive Oxygen Species,0.0001367359872702639,0,0,1,0.00014517016444251721
1521,SODM,Detoxification of Reactive Oxygen Species,0.00016600024014570144,1,0,1,0.00017623950095754708
1522,SODM,Transcriptional activation of mitochondrial biogenesis,0.0001367359872702639,0,0,1,0.00014517016444251721
1523,SODM,Transcriptional activation of mitochondrial biogenesis,0.00016600024014570144,1,0,1,0.00017623950095754708
1524,LCAT,HDL remodeling,3.3356988471873625e-05,0,0,1,3.541452106677504e-05
1525,LCAT,HDL remodeling,3.516181198507717e-05,1,0,1,3.733067007357318e-05
1526,HRG,Platelet degranulation ,6.580593269638177e-05,0,0,1,6.98649877149384e-05
1527,HRG,Platelet degranulation ,0.0003886455895116374,1,0,1,0.00041261810636396447
1528,HRG,Dissolution of Fibrin Clot,6.580593269638177e-05,0,0,1,6.98649877149384e-05
1529,HRG,Dissolution of Fibrin Clot,0.0003886455895116374,1,0,1,0.00041261810636396447
1530,LV743,Initial triggering of complement,0.0009075241021423723,0,0,1,0.0009635021896843886
1531,LV743,Initial triggering of complement,0.0009080050481708415,1,0,1,0.0009640128015242904
1532,LV743,Regulation of Complement cascade,0.0009075241021423723,0,0,1,0.0009635021896843886
1533,LV743,Regulation of Complement cascade,0.0009080050481708415,1,0,1,0.0009640128015242904
1534,LV743,FCGR activation,0.0009075241021423723,0,0,1,0.0009635021896843886
1535,LV743,FCGR activation,0.0009080050481708415,1,0,1,0.0009640128015242904
1536,LV743,Regulation of actin dynamics for phagocytic cup formation,0.0009075241021423723,0,0,1,0.0009635021896843886
1537,LV743,Regulation of actin dynamics for phagocytic cup formation,0.0009080050481708415,1,0,1,0.0009640128015242904
1538,LV743,Role of phospholipids in phagocytosis,0.0009075241021423723,0,0,1,0.0009635021896843886
1539,LV743,Role of phospholipids in phagocytosis,0.0009080050481708415,1,0,1,0.0009640128015242904
1540,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009075241021423723,0,0,1,0.0009635021896843886
1541,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009080050481708415,1,0,1,0.0009640128015242904
1542,LV743,FCERI mediated MAPK activation,0.0009075241021423723,0,0,1,0.0009635021896843886
1543,LV743,FCERI mediated MAPK activation,0.0009080050481708415,1,0,1,0.0009640128015242904
1544,LV743,FCERI mediated Ca+2 mobilization,0.0009075241021423723,0,0,1,0.0009635021896843886
1545,LV743,FCERI mediated Ca+2 mobilization,0.0009080050481708415,1,0,1,0.0009640128015242904
1546,LV743,FCERI mediated NF-kB activation,0.0009075241021423723,0,0,1,0.0009635021896843886
1547,LV743,FCERI mediated NF-kB activation,0.0009080050481708415,1,0,1,0.0009640128015242904
1548,LV743,Parasite infection,0.0009075241021423723,0,0,1,0.0009635021896843886
1549,LV743,Parasite infection,0.0009080050481708415,1,0,1,0.0009640128015242904
1550,LV743,Leishmania parasite growth and survival,0.0009075241021423723,0,0,1,0.0009635021896843886
1551,LV743,Leishmania parasite growth and survival,0.0009080050481708415,1,0,1,0.0009640128015242904
1552,LV743,Potential therapeutics for SARS,0.0009075241021423723,0,0,1,0.0009635021896843886
1553,LV743,Potential therapeutics for SARS,0.0009080050481708415,1,0,1,0.0009640128015242904
1554,LV743,CD22 mediated BCR regulation,0.0009075241021423723,0,0,1,0.0009635021896843886
1555,LV743,CD22 mediated BCR regulation,0.0009080050481708415,1,0,1,0.0009640128015242904
1556,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009075241021423723,0,0,1,0.0009635021896843886
1557,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009080050481708415,1,0,1,0.0009640128015242904
1558,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009075241021423723,0,0,1,0.0009635021896843886
1559,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009080050481708415,1,0,1,0.0009640128015242904
1560,LV743,Scavenging of heme from plasma,0.0009075241021423723,0,0,1,0.0009635021896843886
1561,LV743,Scavenging of heme from plasma,0.0009080050481708415,1,0,1,0.0009640128015242904
1562,A1BG,Platelet degranulation ,0.00015329712722148215,0,0,1,0.00016275283202016035
1563,A1BG,Platelet degranulation ,4.079847973039876e-05,1,0,1,4.331501991323035e-05
1564,A1BG,Neutrophil degranulation,0.00015329712722148215,0,0,1,0.00016275283202016035
1565,A1BG,Neutrophil degranulation,4.079847973039876e-05,1,0,1,4.331501991323035e-05
1566,K2C6B,Formation of the cornified envelope,7.93720631789136e-05,0,0,1,8.426790703642764e-05
1567,K2C6B,Formation of the cornified envelope,3.1693069096989985e-06,1,0,1,3.3647967476215796e-06
1568,K2C1,Neutrophil degranulation,0.00011302930789926978,0,0,1,0.00012000120481910084
1569,K2C1,Neutrophil degranulation,0.0001160554753861905,1,0,1,0.00012321403298875137
1570,K2C1,Formation of the cornified envelope,0.00011302930789926978,0,0,1,0.00012000120481910084
1571,K2C1,Formation of the cornified envelope,0.0001160554753861905,1,0,1,0.00012321403298875137
1572,VWF,RAF/MAP kinase cascade,0.0004088103751171979,0,0,1,0.00043402670040527816
1573,VWF,RAF/MAP kinase cascade,7.651988593419087e-05,1,0,1,8.123980121073e-05
1574,VWF,Signaling by RAS mutants,0.0004088103751171979,0,0,1,0.00043402670040527816
1575,VWF,Signaling by RAS mutants,7.651988593419087e-05,1,0,1,8.123980121073e-05
1576,VWF,Signaling by moderate kinase activity BRAF mutants,0.0004088103751171979,0,0,1,0.00043402670040527816
1577,VWF,Signaling by moderate kinase activity BRAF mutants,7.651988593419087e-05,1,0,1,8.123980121073e-05
1578,VWF,Signaling by high-kinase activity BRAF mutants,0.0004088103751171979,0,0,1,0.00043402670040527816
1579,VWF,Signaling by high-kinase activity BRAF mutants,7.651988593419087e-05,1,0,1,8.123980121073e-05
1580,VWF,Signaling by BRAF and RAF1 fusions,0.0004088103751171979,0,0,1,0.00043402670040527816
1581,VWF,Signaling by BRAF and RAF1 fusions,7.651988593419087e-05,1,0,1,8.123980121073e-05
1582,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0004088103751171979,0,0,1,0.00043402670040527816
1583,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,7.651988593419087e-05,1,0,1,8.123980121073e-05
1584,VWF,Signaling by RAF1 mutants,0.0004088103751171979,0,0,1,0.00043402670040527816
1585,VWF,Signaling by RAF1 mutants,7.651988593419087e-05,1,0,1,8.123980121073e-05
1586,VWF,Platelet degranulation ,0.0004088103751171979,0,0,1,0.00043402670040527816
1587,VWF,Platelet degranulation ,7.651988593419087e-05,1,0,1,8.123980121073e-05
1588,VWF,Defective factor VIII causes hemophilia A,0.0004088103751171979,0,0,1,0.00043402670040527816
1589,VWF,Defective factor VIII causes hemophilia A,7.651988593419087e-05,1,0,1,8.123980121073e-05
1590,VWF,Platelet Adhesion to exposed collagen,0.0004088103751171979,0,0,1,0.00043402670040527816
1591,VWF,Platelet Adhesion to exposed collagen,7.651988593419087e-05,1,0,1,8.123980121073e-05
1592,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.0004088103751171979,0,0,1,0.00043402670040527816
1593,VWF,Intrinsic Pathway of Fibrin Clot Formation,7.651988593419087e-05,1,0,1,8.123980121073e-05
1594,VWF,Integrin cell surface interactions,0.0004088103751171979,0,0,1,0.00043402670040527816
1595,VWF,Integrin cell surface interactions,7.651988593419087e-05,1,0,1,8.123980121073e-05
1596,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0004088103751171979,0,0,1,0.00043402670040527816
1597,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,7.651988593419087e-05,1,0,1,8.123980121073e-05
1598,VWF,p130Cas linkage to MAPK signaling for integrins,0.0004088103751171979,0,0,1,0.00043402670040527816
1599,VWF,p130Cas linkage to MAPK signaling for integrins,7.651988593419087e-05,1,0,1,8.123980121073e-05
1600,VWF,GP1b-IX-V activation signalling,0.0004088103751171979,0,0,1,0.00043402670040527816
1601,VWF,GP1b-IX-V activation signalling,7.651988593419087e-05,1,0,1,8.123980121073e-05
1602,G3P,Glycolysis,0.00015914687135009812,0,0,1,0.00016896340126422728
1603,G3P,Glycolysis,0.0007316074068161664,1,0,1,0.0007767345647268641
1604,G3P,Gluconeogenesis,0.00015914687135009812,0,0,1,0.00016896340126422728
1605,G3P,Gluconeogenesis,0.0007316074068161664,1,0,1,0.0007767345647268641
1606,ARLY,Urea cycle,0.0006941621900042093,0,0,1,0.000736979644382206
1607,ARLY,Urea cycle,4.9739633215588395e-05,1,0,1,5.2807683458967146e-05
1608,KV116,Initial triggering of complement,0.0002268634923046673,0,0,1,0.00024085693270183036
1609,KV116,Initial triggering of complement,0.0008718405331272585,1,0,1,0.0009256175794567891
1610,KV116,Regulation of Complement cascade,0.0002268634923046673,0,0,1,0.00024085693270183036
1611,KV116,Regulation of Complement cascade,0.0008718405331272585,1,0,1,0.0009256175794567891
1612,KV116,FCGR activation,0.0002268634923046673,0,0,1,0.00024085693270183036
1613,KV116,FCGR activation,0.0008718405331272585,1,0,1,0.0009256175794567891
1614,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0002268634923046673,0,0,1,0.00024085693270183036
1615,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0008718405331272585,1,0,1,0.0009256175794567891
1616,KV116,Role of phospholipids in phagocytosis,0.0002268634923046673,0,0,1,0.00024085693270183036
1617,KV116,Role of phospholipids in phagocytosis,0.0008718405331272585,1,0,1,0.0009256175794567891
1618,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0002268634923046673,0,0,1,0.00024085693270183036
1619,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008718405331272585,1,0,1,0.0009256175794567891
1620,KV116,FCERI mediated MAPK activation,0.0002268634923046673,0,0,1,0.00024085693270183036
1621,KV116,FCERI mediated MAPK activation,0.0008718405331272585,1,0,1,0.0009256175794567891
1622,KV116,FCERI mediated Ca+2 mobilization,0.0002268634923046673,0,0,1,0.00024085693270183036
1623,KV116,FCERI mediated Ca+2 mobilization,0.0008718405331272585,1,0,1,0.0009256175794567891
1624,KV116,FCERI mediated NF-kB activation,0.0002268634923046673,0,0,1,0.00024085693270183036
1625,KV116,FCERI mediated NF-kB activation,0.0008718405331272585,1,0,1,0.0009256175794567891
1626,KV116,Parasite infection,0.0002268634923046673,0,0,1,0.00024085693270183036
1627,KV116,Parasite infection,0.0008718405331272585,1,0,1,0.0009256175794567891
1628,KV116,Leishmania parasite growth and survival,0.0002268634923046673,0,0,1,0.00024085693270183036
1629,KV116,Leishmania parasite growth and survival,0.0008718405331272585,1,0,1,0.0009256175794567891
1630,KV116,Potential therapeutics for SARS,0.0002268634923046673,0,0,1,0.00024085693270183036
1631,KV116,Potential therapeutics for SARS,0.0008718405331272585,1,0,1,0.0009256175794567891
1632,KV116,CD22 mediated BCR regulation,0.0002268634923046673,0,0,1,0.00024085693270183036
1633,KV116,CD22 mediated BCR regulation,0.0008718405331272585,1,0,1,0.0009256175794567891
1634,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0002268634923046673,0,0,1,0.00024085693270183036
1635,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008718405331272585,1,0,1,0.0009256175794567891
1636,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002268634923046673,0,0,1,0.00024085693270183036
1637,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008718405331272585,1,0,1,0.0009256175794567891
1638,KV116,Scavenging of heme from plasma,0.0002268634923046673,0,0,1,0.00024085693270183036
1639,KV116,Scavenging of heme from plasma,0.0008718405331272585,1,0,1,0.0009256175794567891
1640,KV311,Initial triggering of complement,0.0003835985270157133,0,0,1,0.00040725972992545757
1641,KV311,Initial triggering of complement,0.0006981455171487793,1,0,1,0.0007412086719275486
1642,KV311,Regulation of Complement cascade,0.0003835985270157133,0,0,1,0.00040725972992545757
1643,KV311,Regulation of Complement cascade,0.0006981455171487793,1,0,1,0.0007412086719275486
1644,KV311,FCGR activation,0.0003835985270157133,0,0,1,0.00040725972992545757
1645,KV311,FCGR activation,0.0006981455171487793,1,0,1,0.0007412086719275486
1646,KV311,Regulation of actin dynamics for phagocytic cup formation,0.0003835985270157133,0,0,1,0.00040725972992545757
1647,KV311,Regulation of actin dynamics for phagocytic cup formation,0.0006981455171487793,1,0,1,0.0007412086719275486
1648,KV311,Role of phospholipids in phagocytosis,0.0003835985270157133,0,0,1,0.00040725972992545757
1649,KV311,Role of phospholipids in phagocytosis,0.0006981455171487793,1,0,1,0.0007412086719275486
1650,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.0003835985270157133,0,0,1,0.00040725972992545757
1651,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006981455171487793,1,0,1,0.0007412086719275486
1652,KV311,FCERI mediated MAPK activation,0.0003835985270157133,0,0,1,0.00040725972992545757
1653,KV311,FCERI mediated MAPK activation,0.0006981455171487793,1,0,1,0.0007412086719275486
1654,KV311,FCERI mediated Ca+2 mobilization,0.0003835985270157133,0,0,1,0.00040725972992545757
1655,KV311,FCERI mediated Ca+2 mobilization,0.0006981455171487793,1,0,1,0.0007412086719275486
1656,KV311,FCERI mediated NF-kB activation,0.0003835985270157133,0,0,1,0.00040725972992545757
1657,KV311,FCERI mediated NF-kB activation,0.0006981455171487793,1,0,1,0.0007412086719275486
1658,KV311,Parasite infection,0.0003835985270157133,0,0,1,0.00040725972992545757
1659,KV311,Parasite infection,0.0006981455171487793,1,0,1,0.0007412086719275486
1660,KV311,Leishmania parasite growth and survival,0.0003835985270157133,0,0,1,0.00040725972992545757
1661,KV311,Leishmania parasite growth and survival,0.0006981455171487793,1,0,1,0.0007412086719275486
1662,KV311,Potential therapeutics for SARS,0.0003835985270157133,0,0,1,0.00040725972992545757
1663,KV311,Potential therapeutics for SARS,0.0006981455171487793,1,0,1,0.0007412086719275486
1664,KV311,CD22 mediated BCR regulation,0.0003835985270157133,0,0,1,0.00040725972992545757
1665,KV311,CD22 mediated BCR regulation,0.0006981455171487793,1,0,1,0.0007412086719275486
1666,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0003835985270157133,0,0,1,0.00040725972992545757
1667,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006981455171487793,1,0,1,0.0007412086719275486
1668,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003835985270157133,0,0,1,0.00040725972992545757
1669,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006981455171487793,1,0,1,0.0007412086719275486
1670,KV311,Scavenging of heme from plasma,0.0003835985270157133,0,0,1,0.00040725972992545757
1671,KV311,Scavenging of heme from plasma,0.0006981455171487793,1,0,1,0.0007412086719275486
1672,MT1A,Metallothioneins bind metals,0.0006801379419955411,0,0,1,0.0007220903498355042
1673,MT1A,Metallothioneins bind metals,0.00017745530532394077,1,0,1,0.00018840113981226868
1674,MT1E,Metallothioneins bind metals,0.0007099838684216085,0,0,1,0.000753777238808249
1675,MT1E,Metallothioneins bind metals,0.00019224437736217075,1,0,1,0.00020410243442097026
1676,H2A1B,Packaging Of Telomere Ends,0.0014118550845828419,0,0,1,0.0014989414190778132
1677,H2A1B,Packaging Of Telomere Ends,0.0003051361365046409,1,0,1,0.00032395760617268257
1678,H2A1B,Inhibition of DNA recombination at telomere,0.0014118550845828419,0,0,1,0.0014989414190778132
1679,H2A1B,Inhibition of DNA recombination at telomere,0.0003051361365046409,1,0,1,0.00032395760617268257
1680,H2A1B,Pre-NOTCH Transcription and Translation,0.0014118550845828419,0,0,1,0.0014989414190778132
1681,H2A1B,Pre-NOTCH Transcription and Translation,0.0003051361365046409,1,0,1,0.00032395760617268257
1682,H2A1B,RHO GTPase Effectors,0.0014118550845828419,0,0,1,0.0014989414190778132
1683,H2A1B,RHO GTPase Effectors,0.0003051361365046409,1,0,1,0.00032395760617268257
1684,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.0014118550845828419,0,0,1,0.0014989414190778132
1685,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.0003051361365046409,1,0,1,0.00032395760617268257
1686,H2A1B,Transcriptional regulation by RUNX1,0.0014118550845828419,0,0,1,0.0014989414190778132
1687,H2A1B,Transcriptional regulation by RUNX1,0.0003051361365046409,1,0,1,0.00032395760617268257
1688,H2A1B,Oxidative Stress Induced Senescence,0.0014118550845828419,0,0,1,0.0014989414190778132
1689,H2A1B,Oxidative Stress Induced Senescence,0.0003051361365046409,1,0,1,0.00032395760617268257
1690,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.0014118550845828419,0,0,1,0.0014989414190778132
1691,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.0003051361365046409,1,0,1,0.00032395760617268257
1692,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.0014118550845828419,0,0,1,0.0014989414190778132
1693,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.0003051361365046409,1,0,1,0.00032395760617268257
1694,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0014118550845828419,0,0,1,0.0014989414190778132
1695,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0003051361365046409,1,0,1,0.00032395760617268257
1696,H2A1B,B-WICH complex positively regulates rRNA expression,0.0014118550845828419,0,0,1,0.0014989414190778132
1697,H2A1B,B-WICH complex positively regulates rRNA expression,0.0003051361365046409,1,0,1,0.00032395760617268257
1698,H2A1B,SIRT1 negatively regulates rRNA expression,0.0014118550845828419,0,0,1,0.0014989414190778132
1699,H2A1B,SIRT1 negatively regulates rRNA expression,0.0003051361365046409,1,0,1,0.00032395760617268257
1700,H2A1B,NoRC negatively regulates rRNA expression,0.0014118550845828419,0,0,1,0.0014989414190778132
1701,H2A1B,NoRC negatively regulates rRNA expression,0.0003051361365046409,1,0,1,0.00032395760617268257
1702,H2A1B,UCH proteinases,0.0014118550845828419,0,0,1,0.0014989414190778132
1703,H2A1B,UCH proteinases,0.0003051361365046409,1,0,1,0.00032395760617268257
1704,H2A1B,Ub-specific processing proteases,0.0014118550845828419,0,0,1,0.0014989414190778132
1705,H2A1B,Ub-specific processing proteases,0.0003051361365046409,1,0,1,0.00032395760617268257
1706,H2A1B,Metalloprotease DUBs,0.0014118550845828419,0,0,1,0.0014989414190778132
1707,H2A1B,Metalloprotease DUBs,0.0003051361365046409,1,0,1,0.00032395760617268257
1708,H2A1B,Assembly of the ORC complex at the origin of replication,0.0014118550845828419,0,0,1,0.0014989414190778132
1709,H2A1B,Assembly of the ORC complex at the origin of replication,0.0003051361365046409,1,0,1,0.00032395760617268257
1710,H2A1B,Mitotic Prophase,0.0014118550845828419,0,0,1,0.0014989414190778132
1711,H2A1B,Mitotic Prophase,0.0003051361365046409,1,0,1,0.00032395760617268257
1712,H2A1B,RNA Polymerase I Promoter Opening,0.0014118550845828419,0,0,1,0.0014989414190778132
1713,H2A1B,RNA Polymerase I Promoter Opening,0.0003051361365046409,1,0,1,0.00032395760617268257
1714,H2A1B,RNA Polymerase I Promoter Escape,0.0014118550845828419,0,0,1,0.0014989414190778132
1715,H2A1B,RNA Polymerase I Promoter Escape,0.0003051361365046409,1,0,1,0.00032395760617268257
1716,H2A1B,Depurination,0.0014118550845828419,0,0,1,0.0014989414190778132
1717,H2A1B,Depurination,0.0003051361365046409,1,0,1,0.00032395760617268257
1718,H2A1B,Depyrimidination,0.0014118550845828419,0,0,1,0.0014989414190778132
1719,H2A1B,Depyrimidination,0.0003051361365046409,1,0,1,0.00032395760617268257
1720,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.0014118550845828419,0,0,1,0.0014989414190778132
1721,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.0003051361365046409,1,0,1,0.00032395760617268257
1722,H2A1B,Estrogen-dependent gene expression,0.0014118550845828419,0,0,1,0.0014989414190778132
1723,H2A1B,Estrogen-dependent gene expression,0.0003051361365046409,1,0,1,0.00032395760617268257
1724,H2A1B,HCMV Early Events,0.0014118550845828419,0,0,1,0.0014989414190778132
1725,H2A1B,HCMV Early Events,0.0003051361365046409,1,0,1,0.00032395760617268257
1726,H2A1B,HCMV Late Events,0.0014118550845828419,0,0,1,0.0014989414190778132
1727,H2A1B,HCMV Late Events,0.0003051361365046409,1,0,1,0.00032395760617268257
1728,H2A1B,Transcriptional regulation of granulopoiesis,0.0014118550845828419,0,0,1,0.0014989414190778132
1729,H2A1B,Transcriptional regulation of granulopoiesis,0.0003051361365046409,1,0,1,0.00032395760617268257
1730,H2A1B,Meiotic synapsis,0.0014118550845828419,0,0,1,0.0014989414190778132
1731,H2A1B,Meiotic synapsis,0.0003051361365046409,1,0,1,0.00032395760617268257
1732,H2A1B,Meiotic recombination,0.0014118550845828419,0,0,1,0.0014989414190778132
1733,H2A1B,Meiotic recombination,0.0003051361365046409,1,0,1,0.00032395760617268257
1734,H2A1B,Transcriptional regulation by small RNAs,0.0014118550845828419,0,0,1,0.0014989414190778132
1735,H2A1B,Transcriptional regulation by small RNAs,0.0003051361365046409,1,0,1,0.00032395760617268257
1736,H2A1B,PRC2 methylates histones and DNA,0.0014118550845828419,0,0,1,0.0014989414190778132
1737,H2A1B,PRC2 methylates histones and DNA,0.0003051361365046409,1,0,1,0.00032395760617268257
1738,H2A1B,DNA methylation,0.0014118550845828419,0,0,1,0.0014989414190778132
1739,H2A1B,DNA methylation,0.0003051361365046409,1,0,1,0.00032395760617268257
1740,H2A1B,HDACs deacetylate histones,0.0014118550845828419,0,0,1,0.0014989414190778132
1741,H2A1B,HDACs deacetylate histones,0.0003051361365046409,1,0,1,0.00032395760617268257
1742,H2A1B,HATs acetylate histones,0.0014118550845828419,0,0,1,0.0014989414190778132
1743,H2A1B,HATs acetylate histones,0.0003051361365046409,1,0,1,0.00032395760617268257
1744,H2A1B,RMTs methylate histone arginines,0.0014118550845828419,0,0,1,0.0014989414190778132
1745,H2A1B,RMTs methylate histone arginines,0.0003051361365046409,1,0,1,0.00032395760617268257
1746,H2A1B,Amyloid fiber formation,0.0014118550845828419,0,0,1,0.0014989414190778132
1747,H2A1B,Amyloid fiber formation,0.0003051361365046409,1,0,1,0.00032395760617268257
1748,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0014118550845828419,0,0,1,0.0014989414190778132
1749,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0003051361365046409,1,0,1,0.00032395760617268257
1750,H2A1B,Defective pyroptosis,0.0014118550845828419,0,0,1,0.0014989414190778132
1751,H2A1B,Defective pyroptosis,0.0003051361365046409,1,0,1,0.00032395760617268257
1752,IGF1,IGF1R signaling cascade,0.0012844350888644377,0,0,1,0.0013636618770861034
1753,IGF1,IGF1R signaling cascade,0.0010316865533462674,1,0,1,0.0010953232546336547
1754,IGF1,Platelet degranulation ,0.0012844350888644377,0,0,1,0.0013636618770861034
1755,IGF1,Platelet degranulation ,0.0010316865533462674,1,0,1,0.0010953232546336547
1756,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0012844350888644377,0,0,1,0.0013636618770861034
1757,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0010316865533462674,1,0,1,0.0010953232546336547
1758,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012844350888644377,0,0,1,0.0013636618770861034
1759,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010316865533462674,1,0,1,0.0010953232546336547
1760,ALDOB,Fructose catabolism,0.001583750718433515,0,0,1,0.0016814399546223016
1761,ALDOB,Fructose catabolism,0.0018764052342357253,1,0,1,0.001992146046207975
1762,ALDOB,Hereditary fructose intolerance,0.001583750718433515,0,0,1,0.0016814399546223016
1763,ALDOB,Hereditary fructose intolerance,0.0018764052342357253,1,0,1,0.001992146046207975
1764,ALDOB,Glycolysis,0.001583750718433515,0,0,1,0.0016814399546223016
1765,ALDOB,Glycolysis,0.0018764052342357253,1,0,1,0.001992146046207975
1766,ALDOB,Gluconeogenesis,0.001583750718433515,0,0,1,0.0016814399546223016
1767,ALDOB,Gluconeogenesis,0.0018764052342357253,1,0,1,0.001992146046207975
1768,APOD,Transport of fatty acids,0.0005482847056378162,0,0,1,0.0005821041151473692
1769,APOD,Transport of fatty acids,7.651396479290123e-05,1,0,1,8.12335148403906e-05
1770,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0005482847056378162,0,0,1,0.0005821041151473692
1771,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,7.651396479290123e-05,1,0,1,8.12335148403906e-05
1772,ALDH2,Serotonin clearance from the synaptic cleft,2.7102661770180615e-05,0,0,1,2.8774413704494333e-05
1773,ALDH2,Serotonin clearance from the synaptic cleft,0.0002835140748807527,1,0,1,0.0003010018481152081
1774,ALDH2,Ethanol oxidation,2.7102661770180615e-05,0,0,1,2.8774413704494333e-05
1775,ALDH2,Ethanol oxidation,0.0002835140748807527,1,0,1,0.0003010018481152081
1776,ALDH2,Smooth Muscle Contraction,2.7102661770180615e-05,0,0,1,2.8774413704494333e-05
1777,ALDH2,Smooth Muscle Contraction,0.0002835140748807527,1,0,1,0.0003010018481152081
1778,ITB3,TGF-beta receptor signaling activates SMADs,0.0006748988013300894,0,0,1,0.0007165280474224767
1779,ITB3,TGF-beta receptor signaling activates SMADs,0.001143725068298958,1,0,1,0.0012142725522127171
1780,ITB3,VEGFA-VEGFR2 Pathway,0.0006748988013300894,0,0,1,0.0007165280474224767
1781,ITB3,VEGFA-VEGFR2 Pathway,0.001143725068298958,1,0,1,0.0012142725522127171
1782,ITB3,L1CAM interactions,0.0006748988013300894,0,0,1,0.0007165280474224767
1783,ITB3,L1CAM interactions,0.001143725068298958,1,0,1,0.0012142725522127171
1784,ITB3,RAF/MAP kinase cascade,0.0006748988013300894,0,0,1,0.0007165280474224767
1785,ITB3,RAF/MAP kinase cascade,0.001143725068298958,1,0,1,0.0012142725522127171
1786,ITB3,Signaling by RAS mutants,0.0006748988013300894,0,0,1,0.0007165280474224767
1787,ITB3,Signaling by RAS mutants,0.001143725068298958,1,0,1,0.0012142725522127171
1788,ITB3,Signaling by moderate kinase activity BRAF mutants,0.0006748988013300894,0,0,1,0.0007165280474224767
1789,ITB3,Signaling by moderate kinase activity BRAF mutants,0.001143725068298958,1,0,1,0.0012142725522127171
1790,ITB3,Signaling by high-kinase activity BRAF mutants,0.0006748988013300894,0,0,1,0.0007165280474224767
1791,ITB3,Signaling by high-kinase activity BRAF mutants,0.001143725068298958,1,0,1,0.0012142725522127171
1792,ITB3,Signaling by BRAF and RAF1 fusions,0.0006748988013300894,0,0,1,0.0007165280474224767
1793,ITB3,Signaling by BRAF and RAF1 fusions,0.001143725068298958,1,0,1,0.0012142725522127171
1794,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0006748988013300894,0,0,1,0.0007165280474224767
1795,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.001143725068298958,1,0,1,0.0012142725522127171
1796,ITB3,Signaling by RAF1 mutants,0.0006748988013300894,0,0,1,0.0007165280474224767
1797,ITB3,Signaling by RAF1 mutants,0.001143725068298958,1,0,1,0.0012142725522127171
1798,ITB3,Platelet degranulation ,0.0006748988013300894,0,0,1,0.0007165280474224767
1799,ITB3,Platelet degranulation ,0.001143725068298958,1,0,1,0.0012142725522127171
1800,ITB3,Integrin cell surface interactions,0.0006748988013300894,0,0,1,0.0007165280474224767
1801,ITB3,Integrin cell surface interactions,0.001143725068298958,1,0,1,0.0012142725522127171
1802,ITB3,ECM proteoglycans,0.0006748988013300894,0,0,1,0.0007165280474224767
1803,ITB3,ECM proteoglycans,0.001143725068298958,1,0,1,0.0012142725522127171
1804,ITB3,Molecules associated with elastic fibres,0.0006748988013300894,0,0,1,0.0007165280474224767
1805,ITB3,Molecules associated with elastic fibres,0.001143725068298958,1,0,1,0.0012142725522127171
1806,ITB3,PECAM1 interactions,0.0006748988013300894,0,0,1,0.0007165280474224767
1807,ITB3,PECAM1 interactions,0.001143725068298958,1,0,1,0.0012142725522127171
1808,ITB3,Syndecan interactions,0.0006748988013300894,0,0,1,0.0007165280474224767
1809,ITB3,Syndecan interactions,0.001143725068298958,1,0,1,0.0012142725522127171
1810,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0006748988013300894,0,0,1,0.0007165280474224767
1811,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.001143725068298958,1,0,1,0.0012142725522127171
1812,ITB3,p130Cas linkage to MAPK signaling for integrins,0.0006748988013300894,0,0,1,0.0007165280474224767
1813,ITB3,p130Cas linkage to MAPK signaling for integrins,0.001143725068298958,1,0,1,0.0012142725522127171
1814,S10A8,Antigen processing-Cross presentation,0.002215212232711445,0,0,1,0.002351851407356102
1815,S10A8,Antigen processing-Cross presentation,0.0038485696473466776,1,0,1,0.004085957908575383
1816,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.002215212232711445,0,0,1,0.002351851407356102
1817,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.0038485696473466776,1,0,1,0.004085957908575383
1818,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.002215212232711445,0,0,1,0.002351851407356102
1819,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.0038485696473466776,1,0,1,0.004085957908575383
1820,S10A8,Regulation of TLR by endogenous ligand,0.002215212232711445,0,0,1,0.002351851407356102
1821,S10A8,Regulation of TLR by endogenous ligand,0.0038485696473466776,1,0,1,0.004085957908575383
1822,S10A8,RHO GTPase Effectors,0.002215212232711445,0,0,1,0.002351851407356102
1823,S10A8,RHO GTPase Effectors,0.0038485696473466776,1,0,1,0.004085957908575383
1824,S10A8,MyD88 deficiency (TLR2/4),0.002215212232711445,0,0,1,0.002351851407356102
1825,S10A8,MyD88 deficiency (TLR2/4),0.0038485696473466776,1,0,1,0.004085957908575383
1826,S10A8,IRAK4 deficiency (TLR2/4),0.002215212232711445,0,0,1,0.002351851407356102
1827,S10A8,IRAK4 deficiency (TLR2/4),0.0038485696473466776,1,0,1,0.004085957908575383
1828,S10A8,Metal sequestration by antimicrobial proteins,0.002215212232711445,0,0,1,0.002351851407356102
1829,S10A8,Metal sequestration by antimicrobial proteins,0.0038485696473466776,1,0,1,0.004085957908575383
1830,S10A8,Neutrophil degranulation,0.002215212232711445,0,0,1,0.002351851407356102
1831,S10A8,Neutrophil degranulation,0.0038485696473466776,1,0,1,0.004085957908575383
1832,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,4.322328483764982e-05,0,0,1,4.588939234574098e-05
1833,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0004859495715079782,1,0,1,0.0005159240125070245
1834,PAI1,Platelet degranulation ,4.322328483764982e-05,0,0,1,4.588939234574098e-05
1835,PAI1,Platelet degranulation ,0.0004859495715079782,1,0,1,0.0005159240125070245
1836,PAI1,Dissolution of Fibrin Clot,4.322328483764982e-05,0,0,1,4.588939234574098e-05
1837,PAI1,Dissolution of Fibrin Clot,0.0004859495715079782,1,0,1,0.0005159240125070245
1838,PAI1,ECM proteoglycans,4.322328483764982e-05,0,0,1,4.588939234574098e-05
1839,PAI1,ECM proteoglycans,0.0004859495715079782,1,0,1,0.0005159240125070245
1840,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",4.322328483764982e-05,0,0,1,4.588939234574098e-05
1841,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0004859495715079782,1,0,1,0.0005159240125070245
1842,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0006107042676847201,0,0,1,0.0006483738534048525
1843,IPSP,Intrinsic Pathway of Fibrin Clot Formation,1.2219476980481623e-05,1,0,1,1.2973201262312039e-05
1844,IPSP,Common Pathway of Fibrin Clot Formation,0.0006107042676847201,0,0,1,0.0006483738534048525
1845,IPSP,Common Pathway of Fibrin Clot Formation,1.2219476980481623e-05,1,0,1,1.2973201262312039e-05
1846,IC1,Regulation of Complement cascade,0.00014345709039124014,0,0,1,0.00015230584002277772
1847,IC1,Regulation of Complement cascade,0.0008416159927812979,1,0,1,0.0008935287228227988
1848,IC1,Platelet degranulation ,0.00014345709039124014,0,0,1,0.00015230584002277772
1849,IC1,Platelet degranulation ,0.0008416159927812979,1,0,1,0.0008935287228227988
1850,IC1,Defective SERPING1 causes hereditary angioedema,0.00014345709039124014,0,0,1,0.00015230584002277772
1851,IC1,Defective SERPING1 causes hereditary angioedema,0.0008416159927812979,1,0,1,0.0008935287228227988
1852,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.00014345709039124014,0,0,1,0.00015230584002277772
1853,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.0008416159927812979,1,0,1,0.0008935287228227988
1854,CFAI,Regulation of Complement cascade,6.941994421004214e-05,0,0,1,7.370191942698464e-05
1855,CFAI,Regulation of Complement cascade,8.14211668218116e-06,1,0,1,8.644340390991205e-06
1856,F13B,Common Pathway of Fibrin Clot Formation,0.000672899751609367,0,0,1,0.0007144056919074473
1857,F13B,Common Pathway of Fibrin Clot Formation,1.1897428515004779e-05,1,0,1,1.263128813742761e-05
1858,PERM,Events associated with phagocytolytic activity of PMN cells,0.001068717404150494,0,0,1,0.0011346382499616253
1859,PERM,Events associated with phagocytolytic activity of PMN cells,0.0021056364695801575,1,0,1,0.002235516769560696
1860,PERM,Neutrophil degranulation,0.001068717404150494,0,0,1,0.0011346382499616253
1861,PERM,Neutrophil degranulation,0.0021056364695801575,1,0,1,0.002235516769560696
1862,ICAM1,Interleukin-10 signaling,0.0006078213623853112,0,0,1,0.000645313124150306
1863,ICAM1,Interleukin-10 signaling,0.0012061718856794098,1,0,1,0.0012805712269728146
1864,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.0006078213623853112,0,0,1,0.000645313124150306
1865,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.0012061718856794098,1,0,1,0.0012805712269728146
1866,ICAM1,Interferon gamma signaling,0.0006078213623853112,0,0,1,0.000645313124150306
1867,ICAM1,Interferon gamma signaling,0.0012061718856794098,1,0,1,0.0012805712269728146
1868,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006078213623853112,0,0,1,0.000645313124150306
1869,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0012061718856794098,1,0,1,0.0012805712269728146
1870,ICAM1,Integrin cell surface interactions,0.0006078213623853112,0,0,1,0.000645313124150306
1871,ICAM1,Integrin cell surface interactions,0.0012061718856794098,1,0,1,0.0012805712269728146
1872,TETN,Platelet degranulation ,3.654684802754465e-05,0,0,1,3.880113819288696e-05
1873,TETN,Platelet degranulation ,7.127346777606409e-05,1,0,1,7.566977241323359e-05
1874,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.00027689919274362276,0,0,1,0.000293978945463275
1875,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0001486311442640911,1,0,1,0.00015779904094633272
1876,HEP2,Common Pathway of Fibrin Clot Formation,0.00027689919274362276,0,0,1,0.000293978945463275
1877,HEP2,Common Pathway of Fibrin Clot Formation,0.0001486311442640911,1,0,1,0.00015779904094633272
1878,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00027689919274362276,0,0,1,0.000293978945463275
1879,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001486311442640911,1,0,1,0.00015779904094633272
1880,HEP2,Post-translational protein phosphorylation,0.00027689919274362276,0,0,1,0.000293978945463275
1881,HEP2,Post-translational protein phosphorylation,0.0001486311442640911,1,0,1,0.00015779904094633272
1882,K2C8,Formation of the cornified envelope,4.09595062693984e-05,0,0,1,4.348597892418906e-05
1883,K2C8,Formation of the cornified envelope,4.048133648115287e-06,1,0,1,4.297831456912909e-06
1884,CHLE,Glycerophospholipid biosynthesis,0.00022727558412666694,0,0,1,0.0002412944432559968
1885,CHLE,Glycerophospholipid biosynthesis,4.773432861067962e-05,1,0,1,5.067868724470388e-05
1886,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.00022727558412666694,0,0,1,0.0002412944432559968
1887,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",4.773432861067962e-05,1,0,1,5.067868724470388e-05
1888,CHLE,Aspirin ADME,0.00022727558412666694,0,0,1,0.0002412944432559968
1889,CHLE,Aspirin ADME,4.773432861067962e-05,1,0,1,5.067868724470388e-05
1890,KV230,Initial triggering of complement,0.00043193578312639147,0,0,1,0.0004585785345677029
1891,KV230,Initial triggering of complement,0.00035040497834582077,1,0,1,0.00037201872998800413
1892,KV230,Regulation of Complement cascade,0.00043193578312639147,0,0,1,0.0004585785345677029
1893,KV230,Regulation of Complement cascade,0.00035040497834582077,1,0,1,0.00037201872998800413
1894,KV230,FCGR activation,0.00043193578312639147,0,0,1,0.0004585785345677029
1895,KV230,FCGR activation,0.00035040497834582077,1,0,1,0.00037201872998800413
1896,KV230,Regulation of actin dynamics for phagocytic cup formation,0.00043193578312639147,0,0,1,0.0004585785345677029
1897,KV230,Regulation of actin dynamics for phagocytic cup formation,0.00035040497834582077,1,0,1,0.00037201872998800413
1898,KV230,Role of phospholipids in phagocytosis,0.00043193578312639147,0,0,1,0.0004585785345677029
1899,KV230,Role of phospholipids in phagocytosis,0.00035040497834582077,1,0,1,0.00037201872998800413
1900,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.00043193578312639147,0,0,1,0.0004585785345677029
1901,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.00035040497834582077,1,0,1,0.00037201872998800413
1902,KV230,FCERI mediated MAPK activation,0.00043193578312639147,0,0,1,0.0004585785345677029
1903,KV230,FCERI mediated MAPK activation,0.00035040497834582077,1,0,1,0.00037201872998800413
1904,KV230,FCERI mediated Ca+2 mobilization,0.00043193578312639147,0,0,1,0.0004585785345677029
1905,KV230,FCERI mediated Ca+2 mobilization,0.00035040497834582077,1,0,1,0.00037201872998800413
1906,KV230,FCERI mediated NF-kB activation,0.00043193578312639147,0,0,1,0.0004585785345677029
1907,KV230,FCERI mediated NF-kB activation,0.00035040497834582077,1,0,1,0.00037201872998800413
1908,KV230,Parasite infection,0.00043193578312639147,0,0,1,0.0004585785345677029
1909,KV230,Parasite infection,0.00035040497834582077,1,0,1,0.00037201872998800413
1910,KV230,Leishmania parasite growth and survival,0.00043193578312639147,0,0,1,0.0004585785345677029
1911,KV230,Leishmania parasite growth and survival,0.00035040497834582077,1,0,1,0.00037201872998800413
1912,KV230,Potential therapeutics for SARS,0.00043193578312639147,0,0,1,0.0004585785345677029
1913,KV230,Potential therapeutics for SARS,0.00035040497834582077,1,0,1,0.00037201872998800413
1914,KV230,CD22 mediated BCR regulation,0.00043193578312639147,0,0,1,0.0004585785345677029
1915,KV230,CD22 mediated BCR regulation,0.00035040497834582077,1,0,1,0.00037201872998800413
1916,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00043193578312639147,0,0,1,0.0004585785345677029
1917,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00035040497834582077,1,0,1,0.00037201872998800413
1918,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00043193578312639147,0,0,1,0.0004585785345677029
1919,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00035040497834582077,1,0,1,0.00037201872998800413
1920,KV230,Scavenging of heme from plasma,0.00043193578312639147,0,0,1,0.0004585785345677029
1921,KV230,Scavenging of heme from plasma,0.00035040497834582077,1,0,1,0.00037201872998800413
1922,KV401,Initial triggering of complement,0.0013665802208762507,0,0,1,0.0014508739019551448
1923,KV401,Initial triggering of complement,0.002044074347574406,1,0,1,0.0021701573601365996
1924,KV401,Regulation of Complement cascade,0.0013665802208762507,0,0,1,0.0014508739019551448
1925,KV401,Regulation of Complement cascade,0.002044074347574406,1,0,1,0.0021701573601365996
1926,KV401,FCGR activation,0.0013665802208762507,0,0,1,0.0014508739019551448
1927,KV401,FCGR activation,0.002044074347574406,1,0,1,0.0021701573601365996
1928,KV401,Regulation of actin dynamics for phagocytic cup formation,0.0013665802208762507,0,0,1,0.0014508739019551448
1929,KV401,Regulation of actin dynamics for phagocytic cup formation,0.002044074347574406,1,0,1,0.0021701573601365996
1930,KV401,Role of phospholipids in phagocytosis,0.0013665802208762507,0,0,1,0.0014508739019551448
1931,KV401,Role of phospholipids in phagocytosis,0.002044074347574406,1,0,1,0.0021701573601365996
1932,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013665802208762507,0,0,1,0.0014508739019551448
1933,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.002044074347574406,1,0,1,0.0021701573601365996
1934,KV401,FCERI mediated MAPK activation,0.0013665802208762507,0,0,1,0.0014508739019551448
1935,KV401,FCERI mediated MAPK activation,0.002044074347574406,1,0,1,0.0021701573601365996
1936,KV401,FCERI mediated Ca+2 mobilization,0.0013665802208762507,0,0,1,0.0014508739019551448
1937,KV401,FCERI mediated Ca+2 mobilization,0.002044074347574406,1,0,1,0.0021701573601365996
1938,KV401,FCERI mediated NF-kB activation,0.0013665802208762507,0,0,1,0.0014508739019551448
1939,KV401,FCERI mediated NF-kB activation,0.002044074347574406,1,0,1,0.0021701573601365996
1940,KV401,Parasite infection,0.0013665802208762507,0,0,1,0.0014508739019551448
1941,KV401,Parasite infection,0.002044074347574406,1,0,1,0.0021701573601365996
1942,KV401,Leishmania parasite growth and survival,0.0013665802208762507,0,0,1,0.0014508739019551448
1943,KV401,Leishmania parasite growth and survival,0.002044074347574406,1,0,1,0.0021701573601365996
1944,KV401,Potential therapeutics for SARS,0.0013665802208762507,0,0,1,0.0014508739019551448
1945,KV401,Potential therapeutics for SARS,0.002044074347574406,1,0,1,0.0021701573601365996
1946,KV401,CD22 mediated BCR regulation,0.0013665802208762507,0,0,1,0.0014508739019551448
1947,KV401,CD22 mediated BCR regulation,0.002044074347574406,1,0,1,0.0021701573601365996
1948,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013665802208762507,0,0,1,0.0014508739019551448
1949,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002044074347574406,1,0,1,0.0021701573601365996
1950,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013665802208762507,0,0,1,0.0014508739019551448
1951,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002044074347574406,1,0,1,0.0021701573601365996
1952,KV401,Scavenging of heme from plasma,0.0013665802208762507,0,0,1,0.0014508739019551448
1953,KV401,Scavenging of heme from plasma,0.002044074347574406,1,0,1,0.0021701573601365996
1954,HV434,Initial triggering of complement,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1955,HV434,Initial triggering of complement,0.0001666070731694555,1,0,1,0.00017688376478016028
1956,HV434,Regulation of Complement cascade,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1957,HV434,Regulation of Complement cascade,0.0001666070731694555,1,0,1,0.00017688376478016028
1958,HV434,FCGR activation,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1959,HV434,FCGR activation,0.0001666070731694555,1,0,1,0.00017688376478016028
1960,HV434,Regulation of actin dynamics for phagocytic cup formation,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1961,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0001666070731694555,1,0,1,0.00017688376478016028
1962,HV434,Role of phospholipids in phagocytosis,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1963,HV434,Role of phospholipids in phagocytosis,0.0001666070731694555,1,0,1,0.00017688376478016028
1964,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1965,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0001666070731694555,1,0,1,0.00017688376478016028
1966,HV434,FCERI mediated MAPK activation,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1967,HV434,FCERI mediated MAPK activation,0.0001666070731694555,1,0,1,0.00017688376478016028
1968,HV434,FCERI mediated Ca+2 mobilization,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1969,HV434,FCERI mediated Ca+2 mobilization,0.0001666070731694555,1,0,1,0.00017688376478016028
1970,HV434,FCERI mediated NF-kB activation,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1971,HV434,FCERI mediated NF-kB activation,0.0001666070731694555,1,0,1,0.00017688376478016028
1972,HV434,Parasite infection,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1973,HV434,Parasite infection,0.0001666070731694555,1,0,1,0.00017688376478016028
1974,HV434,Leishmania parasite growth and survival,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1975,HV434,Leishmania parasite growth and survival,0.0001666070731694555,1,0,1,0.00017688376478016028
1976,HV434,Potential therapeutics for SARS,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1977,HV434,Potential therapeutics for SARS,0.0001666070731694555,1,0,1,0.00017688376478016028
1978,HV434,CD22 mediated BCR regulation,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1979,HV434,CD22 mediated BCR regulation,0.0001666070731694555,1,0,1,0.00017688376478016028
1980,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1981,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0001666070731694555,1,0,1,0.00017688376478016028
1982,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1983,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0001666070731694555,1,0,1,0.00017688376478016028
1984,HV434,Scavenging of heme from plasma,4.294120504074632e-05,0,0,1,4.5589913245030976e-05
1985,HV434,Scavenging of heme from plasma,0.0001666070731694555,1,0,1,0.00017688376478016028
1986,GELS,Apoptotic cleavage of cellular proteins,0.00047311553040722153,0,0,1,0.0005022983394544992
1987,GELS,Apoptotic cleavage of cellular proteins,2.7032515267176235e-05,1,0,1,2.8699940410524647e-05
1988,GELS,Neutrophil degranulation,0.00047311553040722153,0,0,1,0.0005022983394544992
1989,GELS,Neutrophil degranulation,2.7032515267176235e-05,1,0,1,2.8699940410524647e-05
1990,GELS,Amyloid fiber formation,0.00047311553040722153,0,0,1,0.0005022983394544992
1991,GELS,Amyloid fiber formation,2.7032515267176235e-05,1,0,1,2.8699940410524647e-05
1992,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.00047311553040722153,0,0,1,0.0005022983394544992
1993,GELS,Sensory processing of sound by outer hair cells of the cochlea,2.7032515267176235e-05,1,0,1,2.8699940410524647e-05
1994,CO2,Initial triggering of complement,0.000673736702683435,0,0,1,0.0007152942679690852
1995,CO2,Initial triggering of complement,0.00015916708698257353,1,0,1,0.00016898486384148547
1996,CO2,Activation of C3 and C5,0.000673736702683435,0,0,1,0.0007152942679690852
1997,CO2,Activation of C3 and C5,0.00015916708698257353,1,0,1,0.00016898486384148547
1998,CO2,Regulation of Complement cascade,0.000673736702683435,0,0,1,0.0007152942679690852
1999,CO2,Regulation of Complement cascade,0.00015916708698257353,1,0,1,0.00016898486384148547
2000,S10A9,Antigen processing-Cross presentation,0.0003683456812621739,0,0,1,0.0003910660550161515
2001,S10A9,Antigen processing-Cross presentation,0.00045232481322277703,1,0,1,0.00048022520499445314
2002,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0003683456812621739,0,0,1,0.0003910660550161515
2003,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.00045232481322277703,1,0,1,0.00048022520499445314
2004,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0003683456812621739,0,0,1,0.0003910660550161515
2005,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.00045232481322277703,1,0,1,0.00048022520499445314
2006,S10A9,Regulation of TLR by endogenous ligand,0.0003683456812621739,0,0,1,0.0003910660550161515
2007,S10A9,Regulation of TLR by endogenous ligand,0.00045232481322277703,1,0,1,0.00048022520499445314
2008,S10A9,RHO GTPase Effectors,0.0003683456812621739,0,0,1,0.0003910660550161515
2009,S10A9,RHO GTPase Effectors,0.00045232481322277703,1,0,1,0.00048022520499445314
2010,S10A9,MyD88 deficiency (TLR2/4),0.0003683456812621739,0,0,1,0.0003910660550161515
2011,S10A9,MyD88 deficiency (TLR2/4),0.00045232481322277703,1,0,1,0.00048022520499445314
2012,S10A9,IRAK4 deficiency (TLR2/4),0.0003683456812621739,0,0,1,0.0003910660550161515
2013,S10A9,IRAK4 deficiency (TLR2/4),0.00045232481322277703,1,0,1,0.00048022520499445314
2014,S10A9,Metal sequestration by antimicrobial proteins,0.0003683456812621739,0,0,1,0.0003910660550161515
2015,S10A9,Metal sequestration by antimicrobial proteins,0.00045232481322277703,1,0,1,0.00048022520499445314
2016,S10A9,Neutrophil degranulation,0.0003683456812621739,0,0,1,0.0003910660550161515
2017,S10A9,Neutrophil degranulation,0.00045232481322277703,1,0,1,0.00048022520499445314
2018,APOA4,Chylomicron assembly,0.002761037452570365,0,0,1,0.0029313443302190234
2019,APOA4,Chylomicron assembly,0.0019566135719342958,1,0,1,0.002077301811020262
2020,APOA4,Assembly of active LPL and LIPC lipase complexes,0.002761037452570365,0,0,1,0.0029313443302190234
2021,APOA4,Assembly of active LPL and LIPC lipase complexes,0.0019566135719342958,1,0,1,0.002077301811020262
2022,APOA4,Chylomicron remodeling,0.002761037452570365,0,0,1,0.0029313443302190234
2023,APOA4,Chylomicron remodeling,0.0019566135719342958,1,0,1,0.002077301811020262
2024,APOA4,Retinoid metabolism and transport,0.002761037452570365,0,0,1,0.0029313443302190234
2025,APOA4,Retinoid metabolism and transport,0.0019566135719342958,1,0,1,0.002077301811020262
2026,APOA4,Amyloid fiber formation,0.002761037452570365,0,0,1,0.0029313443302190234
2027,APOA4,Amyloid fiber formation,0.0019566135719342958,1,0,1,0.002077301811020262
2028,ENOA,Glycolysis,0.000247205547871113,0,0,1,0.00026245373110606404
2029,ENOA,Glycolysis,0.0002456395135605046,1,0,1,0.00026079110034636286
2030,ENOA,Gluconeogenesis,0.000247205547871113,0,0,1,0.00026245373110606404
2031,ENOA,Gluconeogenesis,0.0002456395135605046,1,0,1,0.00026079110034636286
2032,ENOA,Response of Mtb to phagocytosis,0.000247205547871113,0,0,1,0.00026245373110606404
2033,ENOA,Response of Mtb to phagocytosis,0.0002456395135605046,1,0,1,0.00026079110034636286
2034,PYGL,Glycogen breakdown (glycogenolysis),0.000530364588189629,0,0,1,0.0005630786453444514
2035,PYGL,Glycogen breakdown (glycogenolysis),9.191606831184333e-05,1,0,1,9.758565406315502e-05
2036,PYGL,Neutrophil degranulation,0.000530364588189629,0,0,1,0.0005630786453444514
2037,PYGL,Neutrophil degranulation,9.191606831184333e-05,1,0,1,9.758565406315502e-05
2038,G6PI,Transcriptional Regulation by TP53,0.00021196352788465815,0,0,1,0.00022503790562474442
2039,G6PI,Transcriptional Regulation by TP53,0.00012083197017382006,1,0,1,0.00012828515250616463
2040,G6PI,Glycolysis,0.00021196352788465815,0,0,1,0.00022503790562474442
2041,G6PI,Glycolysis,0.00012083197017382006,1,0,1,0.00012828515250616463
2042,G6PI,Gluconeogenesis,0.00021196352788465815,0,0,1,0.00022503790562474442
2043,G6PI,Gluconeogenesis,0.00012083197017382006,1,0,1,0.00012828515250616463
2044,G6PI,Neutrophil degranulation,0.00021196352788465815,0,0,1,0.00022503790562474442
2045,G6PI,Neutrophil degranulation,0.00012083197017382006,1,0,1,0.00012828515250616463
2046,TPM3,RHO GTPase cycle,0.000282853717684065,0,0,1,0.0003003007586306639
2047,TPM3,RHO GTPase cycle,0.0007417878965719551,1,0,1,0.0007875430095368764
2048,TPM3,Signaling by ALK fusions and activated point mutants,0.000282853717684065,0,0,1,0.0003003007586306639
2049,TPM3,Signaling by ALK fusions and activated point mutants,0.0007417878965719551,1,0,1,0.0007875430095368764
2050,TPM3,Striated Muscle Contraction,0.000282853717684065,0,0,1,0.0003003007586306639
2051,TPM3,Striated Muscle Contraction,0.0007417878965719551,1,0,1,0.0007875430095368764
2052,TPM3,Smooth Muscle Contraction,0.000282853717684065,0,0,1,0.0003003007586306639
2053,TPM3,Smooth Muscle Contraction,0.0007417878965719551,1,0,1,0.0007875430095368764
2054,FABPL,PPARA activates gene expression,0.002383868704044123,0,0,1,0.0025309109816967334
2055,FABPL,PPARA activates gene expression,0.0006157204566102683,1,0,1,0.0006536994519230923
2056,FABPL,Triglyceride catabolism,0.002383868704044123,0,0,1,0.0025309109816967334
2057,FABPL,Triglyceride catabolism,0.0006157204566102683,1,0,1,0.0006536994519230923
2058,FABPL,Cytoprotection by HMOX1,0.002383868704044123,0,0,1,0.0025309109816967334
2059,FABPL,Cytoprotection by HMOX1,0.0006157204566102683,1,0,1,0.0006536994519230923
2060,FABPL,Heme degradation,0.002383868704044123,0,0,1,0.0025309109816967334
2061,FABPL,Heme degradation,0.0006157204566102683,1,0,1,0.0006536994519230923
2062,LDHB,Pyruvate metabolism,0.00031669910509630854,0,0,1,0.0003362338041612797
2063,LDHB,Pyruvate metabolism,0.00044838083710640737,1,0,1,0.00047603795573549195
2064,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0008044979786248446,0,0,1,0.0008541211877148571
2065,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",7.364673227159978e-05,1,0,1,7.818942509546078e-05
2066,PROS,Regulation of Complement cascade,0.0008044979786248446,0,0,1,0.0008541211877148571
2067,PROS,Regulation of Complement cascade,7.364673227159978e-05,1,0,1,7.818942509546078e-05
2068,PROS,Platelet degranulation ,0.0008044979786248446,0,0,1,0.0008541211877148571
2069,PROS,Platelet degranulation ,7.364673227159978e-05,1,0,1,7.818942509546078e-05
2070,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.0008044979786248446,0,0,1,0.0008541211877148571
2071,PROS,Intrinsic Pathway of Fibrin Clot Formation,7.364673227159978e-05,1,0,1,7.818942509546078e-05
2072,PROS,Common Pathway of Fibrin Clot Formation,0.0008044979786248446,0,0,1,0.0008541211877148571
2073,PROS,Common Pathway of Fibrin Clot Formation,7.364673227159978e-05,1,0,1,7.818942509546078e-05
2074,PDIA1,Interleukin-12 family signaling,0.00040894387525371585,0,0,1,0.0004341684351245595
2075,PDIA1,Interleukin-12 family signaling,0.0004422382482913734,1,0,1,0.0004695164784990807
2076,PDIA1,VLDL assembly,0.00040894387525371585,0,0,1,0.0004341684351245595
2077,PDIA1,VLDL assembly,0.0004422382482913734,1,0,1,0.0004695164784990807
2078,PDIA1,Chylomicron assembly,0.00040894387525371585,0,0,1,0.0004341684351245595
2079,PDIA1,Chylomicron assembly,0.0004422382482913734,1,0,1,0.0004695164784990807
2080,PDIA1,LDL remodeling,0.00040894387525371585,0,0,1,0.0004341684351245595
2081,PDIA1,LDL remodeling,0.0004422382482913734,1,0,1,0.0004695164784990807
2082,PDIA1,Detoxification of Reactive Oxygen Species,0.00040894387525371585,0,0,1,0.0004341684351245595
2083,PDIA1,Detoxification of Reactive Oxygen Species,0.0004422382482913734,1,0,1,0.0004695164784990807
2084,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00040894387525371585,0,0,1,0.0004341684351245595
2085,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004422382482913734,1,0,1,0.0004695164784990807
2086,PDIA1,Hedgehog ligand biogenesis,0.00040894387525371585,0,0,1,0.0004341684351245595
2087,PDIA1,Hedgehog ligand biogenesis,0.0004422382482913734,1,0,1,0.0004695164784990807
2088,PDIA1,Post-translational protein phosphorylation,0.00040894387525371585,0,0,1,0.0004341684351245595
2089,PDIA1,Post-translational protein phosphorylation,0.0004422382482913734,1,0,1,0.0004695164784990807
2090,ADH1A,Ethanol oxidation,0.00040222075457571236,0,0,1,0.000427030617539906
2091,ADH1A,Ethanol oxidation,0.0001582616694272451,1,0,1,0.00016802359813506706
2092,ADH1A,RA biosynthesis pathway,0.00040222075457571236,0,0,1,0.000427030617539906
2093,ADH1A,RA biosynthesis pathway,0.0001582616694272451,1,0,1,0.00016802359813506706
2094,ADH1A,Abacavir metabolism,0.00040222075457571236,0,0,1,0.000427030617539906
2095,ADH1A,Abacavir metabolism,0.0001582616694272451,1,0,1,0.00016802359813506706
2096,CSF1R,Transcriptional Regulation by VENTX,0.0024558283704176997,0,0,1,0.0026073092789499147
2097,CSF1R,Transcriptional Regulation by VENTX,0.0034665752646659835,1,0,1,0.003680401270144368
2098,CSF1R,Other interleukin signaling,0.0024558283704176997,0,0,1,0.0026073092789499147
2099,CSF1R,Other interleukin signaling,0.0034665752646659835,1,0,1,0.003680401270144368
2100,CATD,Estrogen-dependent gene expression,0.0012294454353082651,0,0,1,0.0013052803404566265
2101,CATD,Estrogen-dependent gene expression,0.0009056472725962964,1,0,1,0.0009615095931538506
2102,CATD,MHC class II antigen presentation,0.0012294454353082651,0,0,1,0.0013052803404566265
2103,CATD,MHC class II antigen presentation,0.0009056472725962964,1,0,1,0.0009615095931538506
2104,CATD,Collagen degradation,0.0012294454353082651,0,0,1,0.0013052803404566265
2105,CATD,Collagen degradation,0.0009056472725962964,1,0,1,0.0009615095931538506
2106,CATD,Neutrophil degranulation,0.0012294454353082651,0,0,1,0.0013052803404566265
2107,CATD,Neutrophil degranulation,0.0009056472725962964,1,0,1,0.0009615095931538506
2108,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0012294454353082651,0,0,1,0.0013052803404566265
2109,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0009056472725962964,1,0,1,0.0009615095931538506
2110,CO8A,Terminal pathway of complement,9.52820965216381e-05,0,0,1,0.00010115930631439614
2111,CO8A,Terminal pathway of complement,6.910731134514651e-05,1,0,1,7.337000267768492e-05
2112,CO8A,Regulation of Complement cascade,9.52820965216381e-05,0,0,1,0.00010115930631439614
2113,CO8A,Regulation of Complement cascade,6.910731134514651e-05,1,0,1,7.337000267768492e-05
2114,CO8B,Terminal pathway of complement,0.0003608637699762582,0,0,1,0.00038312264294589754
2115,CO8B,Terminal pathway of complement,0.0006228505670262009,1,0,1,0.000661269363270047
2116,CO8B,Regulation of Complement cascade,0.0003608637699762582,0,0,1,0.00038312264294589754
2117,CO8B,Regulation of Complement cascade,0.0006228505670262009,1,0,1,0.000661269363270047
2118,GP1BA,Transcriptional regulation by RUNX1,0.00023807340917855196,0,0,1,0.00025275830196427824
2119,GP1BA,Transcriptional regulation by RUNX1,0.0005771177039151798,1,0,1,0.0006127155963298798
2120,GP1BA,Defective factor IX causes hemophilia B,0.00023807340917855196,0,0,1,0.00025275830196427824
2121,GP1BA,Defective factor IX causes hemophilia B,0.0005771177039151798,1,0,1,0.0006127155963298798
2122,GP1BA,Platelet Adhesion to exposed collagen,0.00023807340917855196,0,0,1,0.00025275830196427824
2123,GP1BA,Platelet Adhesion to exposed collagen,0.0005771177039151798,1,0,1,0.0006127155963298798
2124,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.00023807340917855196,0,0,1,0.00025275830196427824
2125,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.0005771177039151798,1,0,1,0.0006127155963298798
2126,GP1BA,GP1b-IX-V activation signalling,0.00023807340917855196,0,0,1,0.00025275830196427824
2127,GP1BA,GP1b-IX-V activation signalling,0.0005771177039151798,1,0,1,0.0006127155963298798
2128,CO8G,Terminal pathway of complement,0.00024885966070952944,0,0,1,0.00026420987327136516
2129,CO8G,Terminal pathway of complement,0.00032832083412026364,1,0,1,0.0003485723870551836
2130,CO8G,Regulation of Complement cascade,0.00024885966070952944,0,0,1,0.00026420987327136516
2131,CO8G,Regulation of Complement cascade,0.00032832083412026364,1,0,1,0.0003485723870551836
2132,TBB5,G2/M Transition,0.00015137914234807524,0,0,1,0.0001607165416109617
2133,TBB5,G2/M Transition,0.0002569965731963009,1,0,1,0.00027284868846069954
2134,TBB5,Mitotic Prometaphase,0.00015137914234807524,0,0,1,0.0001607165416109617
2135,TBB5,Mitotic Prometaphase,0.0002569965731963009,1,0,1,0.00027284868846069954
2136,TBB5,Potential therapeutics for SARS,0.00015137914234807524,0,0,1,0.0001607165416109617
2137,TBB5,Potential therapeutics for SARS,0.0002569965731963009,1,0,1,0.00027284868846069954
2138,TBB5,Neutrophil degranulation,0.00015137914234807524,0,0,1,0.0001607165416109617
2139,TBB5,Neutrophil degranulation,0.0002569965731963009,1,0,1,0.00027284868846069954
2140,TBB5,Anchoring of the basal body to the plasma membrane,0.00015137914234807524,0,0,1,0.0001607165416109617
2141,TBB5,Anchoring of the basal body to the plasma membrane,0.0002569965731963009,1,0,1,0.00027284868846069954
2142,CAH3,Reversible hydration of carbon dioxide,0.00011487556777662257,0,0,1,0.00012196134607634841
2143,CAH3,Reversible hydration of carbon dioxide,0.00026231980605581585,1,0,1,0.00027850027005972783
2144,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0002616500993453514,0,0,1,0.0002777892543627832
2145,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",4.686791616523427e-05,1,0,1,4.975883256934514e-05
2146,TRY1,Activation of Matrix Metalloproteinases,0.0002616500993453514,0,0,1,0.0002777892543627832
2147,TRY1,Activation of Matrix Metalloproteinases,4.686791616523427e-05,1,0,1,4.975883256934514e-05
2148,TRY2,Defensins,0.0004568229806000783,0,0,1,0.000485000829253209
2149,TRY2,Defensins,0.0004370631358313237,1,0,1,0.00046402215369233454
2150,TRY2,Collagen degradation,0.0004568229806000783,0,0,1,0.000485000829253209
2151,TRY2,Collagen degradation,0.0004370631358313237,1,0,1,0.00046402215369233454
2152,TRY2,Activation of Matrix Metalloproteinases,0.0004568229806000783,0,0,1,0.000485000829253209
2153,TRY2,Activation of Matrix Metalloproteinases,0.0004370631358313237,1,0,1,0.00046402215369233454
2154,TRY2,Neutrophil degranulation,0.0004568229806000783,0,0,1,0.000485000829253209
2155,TRY2,Neutrophil degranulation,0.0004370631358313237,1,0,1,0.00046402215369233454
2156,SAP,Class A/1 (Rhodopsin-like receptors),0.00031589613169630244,0,0,1,0.0003353813015915542
2157,SAP,Class A/1 (Rhodopsin-like receptors),8.04409194947212e-05,1,0,1,8.540269276642366e-05
2158,SAP,G alpha (i) signalling events,0.00031589613169630244,0,0,1,0.0003353813015915542
2159,SAP,G alpha (i) signalling events,8.04409194947212e-05,1,0,1,8.540269276642366e-05
2160,SAP,Glycosphingolipid metabolism,0.00031589613169630244,0,0,1,0.0003353813015915542
2161,SAP,Glycosphingolipid metabolism,8.04409194947212e-05,1,0,1,8.540269276642366e-05
2162,SAP,Platelet degranulation ,0.00031589613169630244,0,0,1,0.0003353813015915542
2163,SAP,Platelet degranulation ,8.04409194947212e-05,1,0,1,8.540269276642366e-05
2164,SAP,Neutrophil degranulation,0.00031589613169630244,0,0,1,0.0003353813015915542
2165,SAP,Neutrophil degranulation,8.04409194947212e-05,1,0,1,8.540269276642366e-05
2166,PROF1,RHO GTPase Effectors,0.00043891143624083263,0,0,1,0.00046598446134626064
2167,PROF1,RHO GTPase Effectors,0.00012830067500803365,1,0,1,0.00013621454352165773
2168,PROF1,Signaling by ROBO receptors,0.00043891143624083263,0,0,1,0.00046598446134626064
2169,PROF1,Signaling by ROBO receptors,0.00012830067500803365,1,0,1,0.00013621454352165773
2170,PROF1,PCP/CE pathway,0.00043891143624083263,0,0,1,0.00046598446134626064
2171,PROF1,PCP/CE pathway,0.00012830067500803365,1,0,1,0.00013621454352165773
2172,PROF1,Platelet degranulation ,0.00043891143624083263,0,0,1,0.00046598446134626064
2173,PROF1,Platelet degranulation ,0.00012830067500803365,1,0,1,0.00013621454352165773
2174,CATB,Trafficking and processing of endosomal TLR,0.0027241665680259276,0,0,1,0.0028921991682224414
2175,CATB,Trafficking and processing of endosomal TLR,0.002563542749928925,1,0,1,0.002721667718879568
2176,CATB,MHC class II antigen presentation,0.0027241665680259276,0,0,1,0.0028921991682224414
2177,CATB,MHC class II antigen presentation,0.002563542749928925,1,0,1,0.002721667718879568
2178,CATB,Collagen degradation,0.0027241665680259276,0,0,1,0.0028921991682224414
2179,CATB,Collagen degradation,0.002563542749928925,1,0,1,0.002721667718879568
2180,CATB,Neutrophil degranulation,0.0027241665680259276,0,0,1,0.0028921991682224414
2181,CATB,Neutrophil degranulation,0.002563542749928925,1,0,1,0.002721667718879568
2182,HS90A,Downregulation of ERBB2 signaling,0.0010918975734745204,0,0,1,0.0011592482232375204
2183,HS90A,Downregulation of ERBB2 signaling,0.0021292857381368653,1,0,1,0.002260624777144221
2184,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.0010918975734745204,0,0,1,0.0011592482232375204
2185,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.0021292857381368653,1,0,1,0.002260624777144221
2186,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.0010918975734745204,0,0,1,0.0011592482232375204
2187,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.0021292857381368653,1,0,1,0.002260624777144221
2188,HS90A,Signaling by ERBB2 KD Mutants,0.0010918975734745204,0,0,1,0.0011592482232375204
2189,HS90A,Signaling by ERBB2 KD Mutants,0.0021292857381368653,1,0,1,0.002260624777144221
2190,HS90A,Drug resistance in ERBB2 KD mutants,0.0010918975734745204,0,0,1,0.0011592482232375204
2191,HS90A,Drug resistance in ERBB2 KD mutants,0.0021292857381368653,1,0,1,0.002260624777144221
2192,HS90A,Signaling by ERBB2 ECD mutants,0.0010918975734745204,0,0,1,0.0011592482232375204
2193,HS90A,Signaling by ERBB2 ECD mutants,0.0021292857381368653,1,0,1,0.002260624777144221
2194,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.0010918975734745204,0,0,1,0.0011592482232375204
2195,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.0021292857381368653,1,0,1,0.002260624777144221
2196,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.0010918975734745204,0,0,1,0.0011592482232375204
2197,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.0021292857381368653,1,0,1,0.002260624777144221
2198,HS90A,Signaling by EGFRvIII in Cancer,0.0010918975734745204,0,0,1,0.0011592482232375204
2199,HS90A,Signaling by EGFRvIII in Cancer,0.0021292857381368653,1,0,1,0.002260624777144221
2200,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.0010918975734745204,0,0,1,0.0011592482232375204
2201,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.0021292857381368653,1,0,1,0.002260624777144221
2202,HS90A,Influenza Viral RNA Transcription and Replication,0.0010918975734745204,0,0,1,0.0011592482232375204
2203,HS90A,Influenza Viral RNA Transcription and Replication,0.0021292857381368653,1,0,1,0.002260624777144221
2204,HS90A,VEGFA-VEGFR2 Pathway,0.0010918975734745204,0,0,1,0.0011592482232375204
2205,HS90A,VEGFA-VEGFR2 Pathway,0.0021292857381368653,1,0,1,0.002260624777144221
2206,HS90A,RHO GTPase cycle,0.0010918975734745204,0,0,1,0.0011592482232375204
2207,HS90A,RHO GTPase cycle,0.0021292857381368653,1,0,1,0.002260624777144221
2208,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.0010918975734745204,0,0,1,0.0011592482232375204
2209,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.0021292857381368653,1,0,1,0.002260624777144221
2210,HS90A,HSF1 activation,0.0010918975734745204,0,0,1,0.0011592482232375204
2211,HS90A,HSF1 activation,0.0021292857381368653,1,0,1,0.002260624777144221
2212,HS90A,HSF1-dependent transactivation,0.0010918975734745204,0,0,1,0.0011592482232375204
2213,HS90A,HSF1-dependent transactivation,0.0021292857381368653,1,0,1,0.002260624777144221
2214,HS90A,Semaphorin interactions,0.0010918975734745204,0,0,1,0.0011592482232375204
2215,HS90A,Semaphorin interactions,0.0021292857381368653,1,0,1,0.002260624777144221
2216,HS90A,Interleukin-4 and Interleukin-13 signaling,0.0010918975734745204,0,0,1,0.0011592482232375204
2217,HS90A,Interleukin-4 and Interleukin-13 signaling,0.0021292857381368653,1,0,1,0.002260624777144221
2218,HS90A,G2/M Transition,0.0010918975734745204,0,0,1,0.0011592482232375204
2219,HS90A,G2/M Transition,0.0021292857381368653,1,0,1,0.002260624777144221
2220,HS90A,Regulation of necroptotic cell death,0.0010918975734745204,0,0,1,0.0011592482232375204
2221,HS90A,Regulation of necroptotic cell death,0.0021292857381368653,1,0,1,0.002260624777144221
2222,HS90A,Uptake and function of diphtheria toxin,0.0010918975734745204,0,0,1,0.0011592482232375204
2223,HS90A,Uptake and function of diphtheria toxin,0.0021292857381368653,1,0,1,0.002260624777144221
2224,HS90A,Mitotic Prometaphase,0.0010918975734745204,0,0,1,0.0011592482232375204
2225,HS90A,Mitotic Prometaphase,0.0021292857381368653,1,0,1,0.002260624777144221
2226,HS90A,Extra-nuclear estrogen signaling,0.0010918975734745204,0,0,1,0.0011592482232375204
2227,HS90A,Extra-nuclear estrogen signaling,0.0021292857381368653,1,0,1,0.002260624777144221
2228,HS90A,Estrogen-dependent gene expression,0.0010918975734745204,0,0,1,0.0011592482232375204
2229,HS90A,Estrogen-dependent gene expression,0.0021292857381368653,1,0,1,0.002260624777144221
2230,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.0010918975734745204,0,0,1,0.0011592482232375204
2231,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.0021292857381368653,1,0,1,0.002260624777144221
2232,HS90A,Aggrephagy,0.0010918975734745204,0,0,1,0.0011592482232375204
2233,HS90A,Aggrephagy,0.0021292857381368653,1,0,1,0.002260624777144221
2234,HS90A,Potential therapeutics for SARS,0.0010918975734745204,0,0,1,0.0011592482232375204
2235,HS90A,Potential therapeutics for SARS,0.0021292857381368653,1,0,1,0.002260624777144221
2236,HS90A,SARS-CoV-2 Infection,0.0010918975734745204,0,0,1,0.0011592482232375204
2237,HS90A,SARS-CoV-2 Infection,0.0021292857381368653,1,0,1,0.002260624777144221
2238,HS90A,Neutrophil degranulation,0.0010918975734745204,0,0,1,0.0011592482232375204
2239,HS90A,Neutrophil degranulation,0.0021292857381368653,1,0,1,0.002260624777144221
2240,HS90A,eNOS activation,0.0010918975734745204,0,0,1,0.0011592482232375204
2241,HS90A,eNOS activation,0.0021292857381368653,1,0,1,0.002260624777144221
2242,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.0010918975734745204,0,0,1,0.0011592482232375204
2243,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.0021292857381368653,1,0,1,0.002260624777144221
2244,HS90A,Scavenging by Class F Receptors,0.0010918975734745204,0,0,1,0.0011592482232375204
2245,HS90A,Scavenging by Class F Receptors,0.0021292857381368653,1,0,1,0.002260624777144221
2246,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0010918975734745204,0,0,1,0.0011592482232375204
2247,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0021292857381368653,1,0,1,0.002260624777144221
2248,HS90A,Anchoring of the basal body to the plasma membrane,0.0010918975734745204,0,0,1,0.0011592482232375204
2249,HS90A,Anchoring of the basal body to the plasma membrane,0.0021292857381368653,1,0,1,0.002260624777144221
2250,HS90A,Chaperone Mediated Autophagy,0.0010918975734745204,0,0,1,0.0011592482232375204
2251,HS90A,Chaperone Mediated Autophagy,0.0021292857381368653,1,0,1,0.002260624777144221
2252,FUMH,Citric acid cycle (TCA cycle),0.0005590615750923942,0,0,1,0.0005935457256708986
2253,FUMH,Citric acid cycle (TCA cycle),0.00025589624246219553,1,0,1,0.0002716804869008899
2254,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.0016255566402962479,0,0,1,0.0017258245579198108
2255,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.0014306309202752137,1,0,1,0.0015188753897129165
2256,PSPB,Defective CSF2RB causes SMDP5,0.0016255566402962479,0,0,1,0.0017258245579198108
2257,PSPB,Defective CSF2RB causes SMDP5,0.0014306309202752137,1,0,1,0.0015188753897129165
2258,PSPB,Defective CSF2RA causes SMDP4,0.0016255566402962479,0,0,1,0.0017258245579198108
2259,PSPB,Defective CSF2RA causes SMDP4,0.0014306309202752137,1,0,1,0.0015188753897129165
2260,PSPB,Surfactant metabolism,0.0016255566402962479,0,0,1,0.0017258245579198108
2261,PSPB,Surfactant metabolism,0.0014306309202752137,1,0,1,0.0015188753897129165
2262,TSP1,Transcriptional regulation by RUNX1,0.0010639938564337094,0,0,1,0.0011296233434071254
2263,TSP1,Transcriptional regulation by RUNX1,0.0013902828020779688,1,0,1,0.0014760385106251685
2264,TSP1,Diseases associated with O-glycosylation of proteins,0.0010639938564337094,0,0,1,0.0011296233434071254
2265,TSP1,Diseases associated with O-glycosylation of proteins,0.0013902828020779688,1,0,1,0.0014760385106251685
2266,TSP1,O-glycosylation of TSR domain-containing proteins,0.0010639938564337094,0,0,1,0.0011296233434071254
2267,TSP1,O-glycosylation of TSR domain-containing proteins,0.0013902828020779688,1,0,1,0.0014760385106251685
2268,TSP1,Platelet degranulation ,0.0010639938564337094,0,0,1,0.0011296233434071254
2269,TSP1,Platelet degranulation ,0.0013902828020779688,1,0,1,0.0014760385106251685
2270,TSP1,Integrin cell surface interactions,0.0010639938564337094,0,0,1,0.0011296233434071254
2271,TSP1,Integrin cell surface interactions,0.0013902828020779688,1,0,1,0.0014760385106251685
2272,TSP1,Syndecan interactions,0.0010639938564337094,0,0,1,0.0011296233434071254
2273,TSP1,Syndecan interactions,0.0013902828020779688,1,0,1,0.0014760385106251685
2274,TSP1,Signaling by PDGF,0.0010639938564337094,0,0,1,0.0011296233434071254
2275,TSP1,Signaling by PDGF,0.0013902828020779688,1,0,1,0.0014760385106251685
2276,RNAS1,Chaperone Mediated Autophagy,0.0007966075858127029,0,0,1,0.0008457440980772136
2277,RNAS1,Chaperone Mediated Autophagy,0.0015172621777836575,1,0,1,0.0016108502541902932
2278,RNAS1,Late endosomal microautophagy,0.0007966075858127029,0,0,1,0.0008457440980772136
2279,RNAS1,Late endosomal microautophagy,0.0015172621777836575,1,0,1,0.0016108502541902932
2280,CO1A2,Collagen chain trimerization,0.0027663472225549182,0,0,1,0.002936981618523279
2281,CO1A2,Collagen chain trimerization,0.0020216770782159063,1,0,1,0.0021463785778222536
2282,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0027663472225549182,0,0,1,0.002936981618523279
2283,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0020216770782159063,1,0,1,0.0021463785778222536
2284,CO1A2,Anchoring fibril formation,0.0027663472225549182,0,0,1,0.002936981618523279
2285,CO1A2,Anchoring fibril formation,0.0020216770782159063,1,0,1,0.0021463785778222536
2286,CO1A2,Crosslinking of collagen fibrils,0.0027663472225549182,0,0,1,0.002936981618523279
2287,CO1A2,Crosslinking of collagen fibrils,0.0020216770782159063,1,0,1,0.0021463785778222536
2288,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.0027663472225549182,0,0,1,0.002936981618523279
2289,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.0020216770782159063,1,0,1,0.0021463785778222536
2290,CO1A2,MET promotes cell motility,0.0027663472225549182,0,0,1,0.002936981618523279
2291,CO1A2,MET promotes cell motility,0.0020216770782159063,1,0,1,0.0021463785778222536
2292,CO1A2,Platelet Adhesion to exposed collagen,0.0027663472225549182,0,0,1,0.002936981618523279
2293,CO1A2,Platelet Adhesion to exposed collagen,0.0020216770782159063,1,0,1,0.0021463785778222536
2294,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0027663472225549182,0,0,1,0.002936981618523279
2295,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0020216770782159063,1,0,1,0.0021463785778222536
2296,CO1A2,Collagen degradation,0.0027663472225549182,0,0,1,0.002936981618523279
2297,CO1A2,Collagen degradation,0.0020216770782159063,1,0,1,0.0021463785778222536
2298,CO1A2,Integrin cell surface interactions,0.0027663472225549182,0,0,1,0.002936981618523279
2299,CO1A2,Integrin cell surface interactions,0.0020216770782159063,1,0,1,0.0021463785778222536
2300,CO1A2,ECM proteoglycans,0.0027663472225549182,0,0,1,0.002936981618523279
2301,CO1A2,ECM proteoglycans,0.0020216770782159063,1,0,1,0.0021463785778222536
2302,CO1A2,Scavenging by Class A Receptors,0.0027663472225549182,0,0,1,0.002936981618523279
2303,CO1A2,Scavenging by Class A Receptors,0.0020216770782159063,1,0,1,0.0021463785778222536
2304,CO1A2,Syndecan interactions,0.0027663472225549182,0,0,1,0.002936981618523279
2305,CO1A2,Syndecan interactions,0.0020216770782159063,1,0,1,0.0021463785778222536
2306,CO1A2,GPVI-mediated activation cascade,0.0027663472225549182,0,0,1,0.002936981618523279
2307,CO1A2,GPVI-mediated activation cascade,0.0020216770782159063,1,0,1,0.0021463785778222536
2308,CO1A2,GP1b-IX-V activation signalling,0.0027663472225549182,0,0,1,0.002936981618523279
2309,CO1A2,GP1b-IX-V activation signalling,0.0020216770782159063,1,0,1,0.0021463785778222536
2310,CBG,Metabolism of steroid hormones,0.0008445058077820346,0,0,1,0.0008965967879842856
2311,CBG,Metabolism of steroid hormones,1.6808270076800034e-05,1,0,1,1.784504123424678e-05
2312,4F2,Amino acid transport across the plasma membrane,0.00010375933618837882,0,0,1,0.0001101594408145184
2313,4F2,Amino acid transport across the plasma membrane,0.00021583885262111026,1,0,1,0.00022915226893531124
2314,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.00010375933618837882,0,0,1,0.0001101594408145184
2315,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.00021583885262111026,1,0,1,0.00022915226893531124
2316,4F2,Basigin interactions,0.00010375933618837882,0,0,1,0.0001101594408145184
2317,4F2,Basigin interactions,0.00021583885262111026,1,0,1,0.00022915226893531124
2318,4F2,Tryptophan catabolism,0.00010375933618837882,0,0,1,0.0001101594408145184
2319,4F2,Tryptophan catabolism,0.00021583885262111026,1,0,1,0.00022915226893531124
2320,HS90B,Inflammasomes,0.0016547369709838805,0,0,1,0.0017568047957414593
2321,HS90B,Inflammasomes,0.001035128651555571,1,0,1,0.0010989776690496944
2322,HS90B,RHO GTPase cycle,0.0016547369709838805,0,0,1,0.0017568047957414593
2323,HS90B,RHO GTPase cycle,0.001035128651555571,1,0,1,0.0010989776690496944
2324,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.0016547369709838805,0,0,1,0.0017568047957414593
2325,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.001035128651555571,1,0,1,0.0010989776690496944
2326,HS90B,Aryl hydrocarbon receptor signalling,0.0016547369709838805,0,0,1,0.0017568047957414593
2327,HS90B,Aryl hydrocarbon receptor signalling,0.001035128651555571,1,0,1,0.0010989776690496944
2328,HS90B,HSF1 activation,0.0016547369709838805,0,0,1,0.0017568047957414593
2329,HS90B,HSF1 activation,0.001035128651555571,1,0,1,0.0010989776690496944
2330,HS90B,HSF1-dependent transactivation,0.0016547369709838805,0,0,1,0.0017568047957414593
2331,HS90B,HSF1-dependent transactivation,0.001035128651555571,1,0,1,0.0010989776690496944
2332,HS90B,Semaphorin interactions,0.0016547369709838805,0,0,1,0.0017568047957414593
2333,HS90B,Semaphorin interactions,0.001035128651555571,1,0,1,0.0010989776690496944
2334,HS90B,G2/M Transition,0.0016547369709838805,0,0,1,0.0017568047957414593
2335,HS90B,G2/M Transition,0.001035128651555571,1,0,1,0.0010989776690496944
2336,HS90B,Uptake and function of diphtheria toxin,0.0016547369709838805,0,0,1,0.0017568047957414593
2337,HS90B,Uptake and function of diphtheria toxin,0.001035128651555571,1,0,1,0.0010989776690496944
2338,HS90B,Estrogen-dependent gene expression,0.0016547369709838805,0,0,1,0.0017568047957414593
2339,HS90B,Estrogen-dependent gene expression,0.001035128651555571,1,0,1,0.0010989776690496944
2340,HS90B,Cell recruitment (pro-inflammatory response),0.0016547369709838805,0,0,1,0.0017568047957414593
2341,HS90B,Cell recruitment (pro-inflammatory response),0.001035128651555571,1,0,1,0.0010989776690496944
2342,HS90B,Potential therapeutics for SARS,0.0016547369709838805,0,0,1,0.0017568047957414593
2343,HS90B,Potential therapeutics for SARS,0.001035128651555571,1,0,1,0.0010989776690496944
2344,HS90B,SARS-CoV-2 Infection,0.0016547369709838805,0,0,1,0.0017568047957414593
2345,HS90B,SARS-CoV-2 Infection,0.001035128651555571,1,0,1,0.0010989776690496944
2346,HS90B,Neutrophil degranulation,0.0016547369709838805,0,0,1,0.0017568047957414593
2347,HS90B,Neutrophil degranulation,0.001035128651555571,1,0,1,0.0010989776690496944
2348,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0016547369709838805,0,0,1,0.0017568047957414593
2349,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001035128651555571,1,0,1,0.0010989776690496944
2350,HS90B,Chaperone Mediated Autophagy,0.0016547369709838805,0,0,1,0.0017568047957414593
2351,HS90B,Chaperone Mediated Autophagy,0.001035128651555571,1,0,1,0.0010989776690496944
2352,SODE,Detoxification of Reactive Oxygen Species,0.00022765856853216917,0,0,1,0.00024170105098403975
2353,SODE,Detoxification of Reactive Oxygen Species,5.2309097703715076e-05,1,0,1,5.5535638181912836e-05
2354,ITA2B,Transcriptional regulation by RUNX1,0.0003022578765192493,0,0,1,0.00032090180876536404
2355,ITA2B,Transcriptional regulation by RUNX1,0.00042854538491719074,1,0,1,0.0004549790091217611
2356,ITA2B,L1CAM interactions,0.0003022578765192493,0,0,1,0.00032090180876536404
2357,ITA2B,L1CAM interactions,0.00042854538491719074,1,0,1,0.0004549790091217611
2358,ITA2B,RAF/MAP kinase cascade,0.0003022578765192493,0,0,1,0.00032090180876536404
2359,ITA2B,RAF/MAP kinase cascade,0.00042854538491719074,1,0,1,0.0004549790091217611
2360,ITA2B,Signaling by RAS mutants,0.0003022578765192493,0,0,1,0.00032090180876536404
2361,ITA2B,Signaling by RAS mutants,0.00042854538491719074,1,0,1,0.0004549790091217611
2362,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0003022578765192493,0,0,1,0.00032090180876536404
2363,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.00042854538491719074,1,0,1,0.0004549790091217611
2364,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0003022578765192493,0,0,1,0.00032090180876536404
2365,ITA2B,Signaling by high-kinase activity BRAF mutants,0.00042854538491719074,1,0,1,0.0004549790091217611
2366,ITA2B,Signaling by BRAF and RAF1 fusions,0.0003022578765192493,0,0,1,0.00032090180876536404
2367,ITA2B,Signaling by BRAF and RAF1 fusions,0.00042854538491719074,1,0,1,0.0004549790091217611
2368,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0003022578765192493,0,0,1,0.00032090180876536404
2369,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00042854538491719074,1,0,1,0.0004549790091217611
2370,ITA2B,Signaling by RAF1 mutants,0.0003022578765192493,0,0,1,0.00032090180876536404
2371,ITA2B,Signaling by RAF1 mutants,0.00042854538491719074,1,0,1,0.0004549790091217611
2372,ITA2B,Platelet degranulation ,0.0003022578765192493,0,0,1,0.00032090180876536404
2373,ITA2B,Platelet degranulation ,0.00042854538491719074,1,0,1,0.0004549790091217611
2374,ITA2B,Integrin cell surface interactions,0.0003022578765192493,0,0,1,0.00032090180876536404
2375,ITA2B,Integrin cell surface interactions,0.00042854538491719074,1,0,1,0.0004549790091217611
2376,ITA2B,ECM proteoglycans,0.0003022578765192493,0,0,1,0.00032090180876536404
2377,ITA2B,ECM proteoglycans,0.00042854538491719074,1,0,1,0.0004549790091217611
2378,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0003022578765192493,0,0,1,0.00032090180876536404
2379,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00042854538491719074,1,0,1,0.0004549790091217611
2380,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0003022578765192493,0,0,1,0.00032090180876536404
2381,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.00042854538491719074,1,0,1,0.0004549790091217611
2382,APOA,LDL remodeling,0.00019454678374240111,0,0,1,0.00020654685830311112
2383,APOA,LDL remodeling,0.00010076542194240246,1,0,1,0.00010698085533682609
2384,PLEK,Platelet degranulation ,3.822364445616858e-05,0,0,1,4.058136312225271e-05
2385,PLEK,Platelet degranulation ,7.460320973089249e-05,1,0,1,7.920490019329759e-05
2386,CD14,Antigen processing-Cross presentation,0.005148929688416709,0,0,1,0.005466527024030679
2387,CD14,Antigen processing-Cross presentation,0.008352100162127623,1,0,1,0.00886727611495529
2388,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.005148929688416709,0,0,1,0.005466527024030679
2389,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.008352100162127623,1,0,1,0.00886727611495529
2390,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.005148929688416709,0,0,1,0.005466527024030679
2391,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.008352100162127623,1,0,1,0.00886727611495529
2392,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.005148929688416709,0,0,1,0.005466527024030679
2393,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.008352100162127623,1,0,1,0.00886727611495529
2394,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.005148929688416709,0,0,1,0.005466527024030679
2395,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.008352100162127623,1,0,1,0.00886727611495529
2396,CD14,Regulation of TLR by endogenous ligand,0.005148929688416709,0,0,1,0.005466527024030679
2397,CD14,Regulation of TLR by endogenous ligand,0.008352100162127623,1,0,1,0.00886727611495529
2398,CD14,Caspase activation via Death Receptors in the presence of ligand,0.005148929688416709,0,0,1,0.005466527024030679
2399,CD14,Caspase activation via Death Receptors in the presence of ligand,0.008352100162127623,1,0,1,0.00886727611495529
2400,CD14,MyD88 deficiency (TLR2/4),0.005148929688416709,0,0,1,0.005466527024030679
2401,CD14,MyD88 deficiency (TLR2/4),0.008352100162127623,1,0,1,0.00886727611495529
2402,CD14,IRAK4 deficiency (TLR2/4),0.005148929688416709,0,0,1,0.005466527024030679
2403,CD14,IRAK4 deficiency (TLR2/4),0.008352100162127623,1,0,1,0.00886727611495529
2404,CD14,Neutrophil degranulation,0.005148929688416709,0,0,1,0.005466527024030679
2405,CD14,Neutrophil degranulation,0.008352100162127623,1,0,1,0.00886727611495529
2406,CFAH,Regulation of Complement cascade,9.780097392993569e-05,0,0,1,0.0001038335536348938
2407,CFAH,Regulation of Complement cascade,1.0785818461816553e-05,1,0,1,1.145111152526529e-05
2408,FCG3A,FCGR activation,0.0002619045095197857,0,0,1,0.0002780593571177038
2409,FCG3A,FCGR activation,0.0002635786224373493,1,0,1,0.0002798367330111303
2410,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0002619045095197857,0,0,1,0.0002780593571177038
2411,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0002635786224373493,1,0,1,0.0002798367330111303
2412,FCG3A,Role of phospholipids in phagocytosis,0.0002619045095197857,0,0,1,0.0002780593571177038
2413,FCG3A,Role of phospholipids in phagocytosis,0.0002635786224373493,1,0,1,0.0002798367330111303
2414,FCG3A,Parasite infection,0.0002619045095197857,0,0,1,0.0002780593571177038
2415,FCG3A,Parasite infection,0.0002635786224373493,1,0,1,0.0002798367330111303
2416,FCG3A,Leishmania parasite growth and survival,0.0002619045095197857,0,0,1,0.0002780593571177038
2417,FCG3A,Leishmania parasite growth and survival,0.0002635786224373493,1,0,1,0.0002798367330111303
2418,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002619045095197857,0,0,1,0.0002780593571177038
2419,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002635786224373493,1,0,1,0.0002798367330111303
2420,A2AP,Platelet degranulation ,8.639450831736318e-05,0,0,1,9.172351207420237e-05
2421,A2AP,Platelet degranulation ,0.00027460367593637897,1,0,1,0.0002915418361181728
2422,A2AP,Dissolution of Fibrin Clot,8.639450831736318e-05,0,0,1,9.172351207420237e-05
2423,A2AP,Dissolution of Fibrin Clot,0.00027460367593637897,1,0,1,0.0002915418361181728
2424,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00013083275864700768,0,0,1,0.00013890281166225723
2425,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0008466352830076032,1,0,1,0.0008988576139368642
2426,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.00013083275864700768,0,0,1,0.00013890281166225723
2427,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.0008466352830076032,1,0,1,0.0008988576139368642
2428,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00013083275864700768,0,0,1,0.00013890281166225723
2429,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0008466352830076032,1,0,1,0.0008988576139368642
2430,K1C16,Formation of the cornified envelope,0.00010353187630945807,0,0,1,0.0001099179507087591
2431,K1C16,Formation of the cornified envelope,1.2264388147120607e-05,1,0,1,1.3020882648730086e-05
2432,ENOG,Glycolysis,3.110993398492984e-05,0,0,1,3.30288633047393e-05
2433,ENOG,Glycolysis,0.00024462938113705383,1,0,1,0.0002597186607278795
2434,ENOG,Gluconeogenesis,3.110993398492984e-05,0,0,1,3.30288633047393e-05
2435,ENOG,Gluconeogenesis,0.00024462938113705383,1,0,1,0.0002597186607278795
2436,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,9.167739073450436e-05,0,0,1,9.73322543266061e-05
2437,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,2.0280000081598e-05,1,0,1,2.1530915200259712e-05
2438,THIK,Peroxisomal lipid metabolism,9.167739073450436e-05,0,0,1,9.73322543266061e-05
2439,THIK,Peroxisomal lipid metabolism,2.0280000081598e-05,1,0,1,2.1530915200259712e-05
2440,THIK,Neutrophil degranulation,9.167739073450436e-05,0,0,1,9.73322543266061e-05
2441,THIK,Neutrophil degranulation,2.0280000081598e-05,1,0,1,2.1530915200259712e-05
2442,THIK,TYSND1 cleaves peroxisomal proteins,9.167739073450436e-05,0,0,1,9.73322543266061e-05
2443,THIK,TYSND1 cleaves peroxisomal proteins,2.0280000081598e-05,1,0,1,2.1530915200259712e-05
2444,DOPO,Catecholamine biosynthesis,0.0001435241123923555,0,0,1,0.00015237699608869294
2445,DOPO,Catecholamine biosynthesis,7.894498743054806e-05,1,0,1,8.381448831428032e-05
2446,F16P1,Gluconeogenesis,2.8209712092510866e-05,0,0,1,2.9949749331546e-05
2447,F16P1,Gluconeogenesis,0.00015808593008361714,1,0,1,0.00016783701880125157
2448,C1S,Initial triggering of complement,1.5711911516557982e-05,0,0,1,1.6681056860742262e-05
2449,C1S,Initial triggering of complement,0.00011452864910247603,1,0,1,0.00012159302869348937
2450,C1S,Regulation of Complement cascade,1.5711911516557982e-05,0,0,1,1.6681056860742262e-05
2451,C1S,Regulation of Complement cascade,0.00011452864910247603,1,0,1,0.00012159302869348937
2452,LKHA4,Arachidonic acid metabolism,1.2702069238580545e-05,0,0,1,1.3485560874916685e-05
2453,LKHA4,Arachidonic acid metabolism,0.00039654242056232834,1,0,1,0.0004210020313649059
2454,LKHA4,Biosynthesis of DHA-derived SPMs,1.2702069238580545e-05,0,0,1,1.3485560874916685e-05
2455,LKHA4,Biosynthesis of DHA-derived SPMs,0.00039654242056232834,1,0,1,0.0004210020313649059
2456,LKHA4,Biosynthesis of EPA-derived SPMs,1.2702069238580545e-05,0,0,1,1.3485560874916685e-05
2457,LKHA4,Biosynthesis of EPA-derived SPMs,0.00039654242056232834,1,0,1,0.0004210020313649059
2458,LKHA4,Neutrophil degranulation,1.2702069238580545e-05,0,0,1,1.3485560874916685e-05
2459,LKHA4,Neutrophil degranulation,0.00039654242056232834,1,0,1,0.0004210020313649059
2460,CO4A,Initial triggering of complement,4.880300771922089e-05,0,0,1,5.181328483689866e-05
2461,CO4A,Initial triggering of complement,5.8181362694401934e-05,1,0,1,6.177011742447752e-05
2462,CO4A,Activation of C3 and C5,4.880300771922089e-05,0,0,1,5.181328483689866e-05
2463,CO4A,Activation of C3 and C5,5.8181362694401934e-05,1,0,1,6.177011742447752e-05
2464,CO4A,Regulation of Complement cascade,4.880300771922089e-05,0,0,1,5.181328483689866e-05
2465,CO4A,Regulation of Complement cascade,5.8181362694401934e-05,1,0,1,6.177011742447752e-05
2466,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4.880300771922089e-05,0,0,1,5.181328483689866e-05
2467,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5.8181362694401934e-05,1,0,1,6.177011742447752e-05
2468,CO4A,Post-translational protein phosphorylation,4.880300771922089e-05,0,0,1,5.181328483689866e-05
2469,CO4A,Post-translational protein phosphorylation,5.8181362694401934e-05,1,0,1,6.177011742447752e-05
2470,CO4B,Initial triggering of complement,8.352809137411015e-06,0,0,1,8.86802882139732e-06
2471,CO4B,Initial triggering of complement,1.301046122735438e-05,1,0,1,1.3812975161505076e-05
2472,CO4B,Activation of C3 and C5,8.352809137411015e-06,0,0,1,8.86802882139732e-06
2473,CO4B,Activation of C3 and C5,1.301046122735438e-05,1,0,1,1.3812975161505076e-05
2474,CO4B,Regulation of Complement cascade,8.352809137411015e-06,0,0,1,8.86802882139732e-06
2475,CO4B,Regulation of Complement cascade,1.301046122735438e-05,1,0,1,1.3812975161505076e-05
2476,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2477,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2478,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2479,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2480,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2481,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2482,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2483,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2484,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2485,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2486,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2487,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2488,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0009318715061508232,0,0,1,0.0009893513952535789
2489,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.00033575938983349294,1,0,1,0.0003564697692854369
2490,SAA1,TRAF6 mediated NF-kB activation,0.0009318715061508232,0,0,1,0.0009893513952535789
2491,SAA1,TRAF6 mediated NF-kB activation,0.00033575938983349294,1,0,1,0.0003564697692854369
2492,SAA1,Class A/1 (Rhodopsin-like receptors),0.0009318715061508232,0,0,1,0.0009893513952535789
2493,SAA1,Class A/1 (Rhodopsin-like receptors),0.00033575938983349294,1,0,1,0.0003564697692854369
2494,SAA1,G alpha (q) signalling events,0.0009318715061508232,0,0,1,0.0009893513952535789
2495,SAA1,G alpha (q) signalling events,0.00033575938983349294,1,0,1,0.0003564697692854369
2496,SAA1,G alpha (i) signalling events,0.0009318715061508232,0,0,1,0.0009893513952535789
2497,SAA1,G alpha (i) signalling events,0.00033575938983349294,1,0,1,0.0003564697692854369
2498,SAA1,Interleukin-1 family signaling,0.0009318715061508232,0,0,1,0.0009893513952535789
2499,SAA1,Interleukin-1 family signaling,0.00033575938983349294,1,0,1,0.0003564697692854369
2500,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0009318715061508232,0,0,1,0.0009893513952535789
2501,SAA1,Interleukin-4 and Interleukin-13 signaling,0.00033575938983349294,1,0,1,0.0003564697692854369
2502,SAA1,Advanced glycosylation endproduct receptor signaling,0.0009318715061508232,0,0,1,0.0009893513952535789
2503,SAA1,Advanced glycosylation endproduct receptor signaling,0.00033575938983349294,1,0,1,0.0003564697692854369
2504,SAA1,Scavenging by Class B Receptors,0.0009318715061508232,0,0,1,0.0009893513952535789
2505,SAA1,Scavenging by Class B Receptors,0.00033575938983349294,1,0,1,0.0003564697692854369
2506,SAA1,Amyloid fiber formation,0.0009318715061508232,0,0,1,0.0009893513952535789
2507,SAA1,Amyloid fiber formation,0.00033575938983349294,1,0,1,0.0003564697692854369
2508,OSTP,Transcriptional regulation by RUNX3,0.000255920215708388,0,0,1,0.000271705938869764
2509,OSTP,Transcriptional regulation by RUNX3,0.0003020624418300931,1,0,1,0.0003206943192336835
2510,OSTP,Integrin cell surface interactions,0.000255920215708388,0,0,1,0.000271705938869764
2511,OSTP,Integrin cell surface interactions,0.0003020624418300931,1,0,1,0.0003206943192336835
2512,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.000255920215708388,0,0,1,0.000271705938869764
2513,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003020624418300931,1,0,1,0.0003206943192336835
2514,OSTP,Post-translational protein phosphorylation,0.000255920215708388,0,0,1,0.000271705938869764
2515,OSTP,Post-translational protein phosphorylation,0.0003020624418300931,1,0,1,0.0003206943192336835
2516,OSTP,Signaling by PDGF,0.000255920215708388,0,0,1,0.000271705938869764
2517,OSTP,Signaling by PDGF,0.0003020624418300931,1,0,1,0.0003206943192336835
2518,CO7,Terminal pathway of complement,0.00012568853245909683,0,0,1,0.00013344127826101396
2519,CO7,Terminal pathway of complement,0.0001366318292463322,1,0,1,0.00014505958172202033
2520,CO7,Regulation of Complement cascade,0.00012568853245909683,0,0,1,0.00013344127826101396
2521,CO7,Regulation of Complement cascade,0.0001366318292463322,1,0,1,0.00014505958172202033
2522,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.000433725743748952,0,0,1,0.0004604789039079932
2523,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0005026963941685987,1,0,1,0.0005337038161129815
2524,CH60,Mitochondrial protein import,0.000433725743748952,0,0,1,0.0004604789039079932
2525,CH60,Mitochondrial protein import,0.0005026963941685987,1,0,1,0.0005337038161129815
2526,CLUS,Terminal pathway of complement,0.0002488089874920111,0,0,1,0.0002641560744180653
2527,CLUS,Terminal pathway of complement,0.0004069525885608001,1,0,1,0.0004320543214780079
2528,CLUS,Regulation of Complement cascade,0.0002488089874920111,0,0,1,0.0002641560744180653
2529,CLUS,Regulation of Complement cascade,0.0004069525885608001,1,0,1,0.0004320543214780079
2530,CLUS,Platelet degranulation ,0.0002488089874920111,0,0,1,0.0002641560744180653
2531,CLUS,Platelet degranulation ,0.0004069525885608001,1,0,1,0.0004320543214780079
2532,BIP,Regulation of HSF1-mediated heat shock response,0.0003756967803140926,0,0,1,0.00039887058606539886
2533,BIP,Regulation of HSF1-mediated heat shock response,0.00028211320375191054,1,0,1,0.0002995145681664787
2534,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0003756967803140926,0,0,1,0.00039887058606539886
2535,BIP,ATF6 (ATF6-alpha) activates chaperones,0.00028211320375191054,1,0,1,0.0002995145681664787
2536,BIP,IRE1alpha activates chaperones,0.0003756967803140926,0,0,1,0.00039887058606539886
2537,BIP,IRE1alpha activates chaperones,0.00028211320375191054,1,0,1,0.0002995145681664787
2538,BIP,PERK regulates gene expression,0.0003756967803140926,0,0,1,0.00039887058606539886
2539,BIP,PERK regulates gene expression,0.00028211320375191054,1,0,1,0.0002995145681664787
2540,BIP,Platelet degranulation ,0.0003756967803140926,0,0,1,0.00039887058606539886
2541,BIP,Platelet degranulation ,0.00028211320375191054,1,0,1,0.0002995145681664787
2542,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0003756967803140926,0,0,1,0.00039887058606539886
2543,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00028211320375191054,1,0,1,0.0002995145681664787
2544,LAMC1,L1CAM interactions,0.00038437430036542604,0,0,1,0.00040808335468581647
2545,LAMC1,L1CAM interactions,0.00057302843714322,1,0,1,0.0006083740945673528
2546,LAMC1,MET promotes cell motility,0.00038437430036542604,0,0,1,0.00040808335468581647
2547,LAMC1,MET promotes cell motility,0.00057302843714322,1,0,1,0.0006083740945673528
2548,LAMC1,Laminin interactions,0.00038437430036542604,0,0,1,0.00040808335468581647
2549,LAMC1,Laminin interactions,0.00057302843714322,1,0,1,0.0006083740945673528
2550,LAMC1,ECM proteoglycans,0.00038437430036542604,0,0,1,0.00040808335468581647
2551,LAMC1,ECM proteoglycans,0.00057302843714322,1,0,1,0.0006083740945673528
2552,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00038437430036542604,0,0,1,0.00040808335468581647
2553,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00057302843714322,1,0,1,0.0006083740945673528
2554,LAMC1,Post-translational protein phosphorylation,0.00038437430036542604,0,0,1,0.00040808335468581647
2555,LAMC1,Post-translational protein phosphorylation,0.00057302843714322,1,0,1,0.0006083740945673528
2556,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.00038437430036542604,0,0,1,0.00040808335468581647
2557,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.00057302843714322,1,0,1,0.0006083740945673528
2558,HSP7C,"GABA synthesis, release, reuptake and degradation",0.000843660737686852,0,0,1,0.0008956995921024098
2559,HSP7C,"GABA synthesis, release, reuptake and degradation",0.0018647700006870298,1,0,1,0.00197979312580047
2560,HSP7C,Lysosome Vesicle Biogenesis,0.000843660737686852,0,0,1,0.0008956995921024098
2561,HSP7C,Lysosome Vesicle Biogenesis,0.0018647700006870298,1,0,1,0.00197979312580047
2562,HSP7C,Golgi Associated Vesicle Biogenesis,0.000843660737686852,0,0,1,0.0008956995921024098
2563,HSP7C,Golgi Associated Vesicle Biogenesis,0.0018647700006870298,1,0,1,0.00197979312580047
2564,HSP7C,Regulation of HSF1-mediated heat shock response,0.000843660737686852,0,0,1,0.0008956995921024098
2565,HSP7C,Regulation of HSF1-mediated heat shock response,0.0018647700006870298,1,0,1,0.00197979312580047
2566,HSP7C,HSF1-dependent transactivation,0.000843660737686852,0,0,1,0.0008956995921024098
2567,HSP7C,HSF1-dependent transactivation,0.0018647700006870298,1,0,1,0.00197979312580047
2568,HSP7C,L1CAM interactions,0.000843660737686852,0,0,1,0.0008956995921024098
2569,HSP7C,L1CAM interactions,0.0018647700006870298,1,0,1,0.00197979312580047
2570,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.000843660737686852,0,0,1,0.0008956995921024098
2571,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.0018647700006870298,1,0,1,0.00197979312580047
2572,HSP7C,mRNA Splicing - Major Pathway,0.000843660737686852,0,0,1,0.0008956995921024098
2573,HSP7C,mRNA Splicing - Major Pathway,0.0018647700006870298,1,0,1,0.00197979312580047
2574,HSP7C,Lipophagy,0.000843660737686852,0,0,1,0.0008956995921024098
2575,HSP7C,Lipophagy,0.0018647700006870298,1,0,1,0.00197979312580047
2576,HSP7C,Neutrophil degranulation,0.000843660737686852,0,0,1,0.0008956995921024098
2577,HSP7C,Neutrophil degranulation,0.0018647700006870298,1,0,1,0.00197979312580047
2578,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.000843660737686852,0,0,1,0.0008956995921024098
2579,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0018647700006870298,1,0,1,0.00197979312580047
2580,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.000843660737686852,0,0,1,0.0008956995921024098
2581,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0018647700006870298,1,0,1,0.00197979312580047
2582,HSP7C,Protein methylation,0.000843660737686852,0,0,1,0.0008956995921024098
2583,HSP7C,Protein methylation,0.0018647700006870298,1,0,1,0.00197979312580047
2584,HSP7C,Chaperone Mediated Autophagy,0.000843660737686852,0,0,1,0.0008956995921024098
2585,HSP7C,Chaperone Mediated Autophagy,0.0018647700006870298,1,0,1,0.00197979312580047
2586,HSP7C,Late endosomal microautophagy,0.000843660737686852,0,0,1,0.0008956995921024098
2587,HSP7C,Late endosomal microautophagy,0.0018647700006870298,1,0,1,0.00197979312580047
2588,PYGB,Glycogen breakdown (glycogenolysis),0.00029567229541711186,0,0,1,0.0003139100145008651
2589,PYGB,Glycogen breakdown (glycogenolysis),0.00013693291122929388,1,0,1,0.00014537923510552086
2590,PYGB,Neutrophil degranulation,0.00029567229541711186,0,0,1,0.0003139100145008651
2591,PYGB,Neutrophil degranulation,0.00013693291122929388,1,0,1,0.00014537923510552086
2592,C1TC,Metabolism of folate and pterines,0.00030954182229234086,0,0,1,0.00032863504437348576
2593,C1TC,Metabolism of folate and pterines,0.0006614065612223103,1,0,1,0.0007022035761969695
2594,CO6A1,Collagen chain trimerization,0.002384200392717609,0,0,1,0.0025312631296589123
2595,CO6A1,Collagen chain trimerization,0.0009636152006046336,1,0,1,0.0010230531107702431
2596,CO6A1,NCAM signaling for neurite out-growth,0.002384200392717609,0,0,1,0.0025312631296589123
2597,CO6A1,NCAM signaling for neurite out-growth,0.0009636152006046336,1,0,1,0.0010230531107702431
2598,CO6A1,Collagen degradation,0.002384200392717609,0,0,1,0.0025312631296589123
2599,CO6A1,Collagen degradation,0.0009636152006046336,1,0,1,0.0010230531107702431
2600,CO6A1,Integrin cell surface interactions,0.002384200392717609,0,0,1,0.0025312631296589123
2601,CO6A1,Integrin cell surface interactions,0.0009636152006046336,1,0,1,0.0010230531107702431
2602,CO6A1,ECM proteoglycans,0.002384200392717609,0,0,1,0.0025312631296589123
2603,CO6A1,ECM proteoglycans,0.0009636152006046336,1,0,1,0.0010230531107702431
2604,CO6A1,Signaling by PDGF,0.002384200392717609,0,0,1,0.0025312631296589123
2605,CO6A1,Signaling by PDGF,0.0009636152006046336,1,0,1,0.0010230531107702431
2606,CO6A3,Collagen chain trimerization,0.003023350055253861,0,0,1,0.003209836952586545
2607,CO6A3,Collagen chain trimerization,0.0017026105336017605,1,0,1,0.0018076313052539127
2608,CO6A3,NCAM signaling for neurite out-growth,0.003023350055253861,0,0,1,0.003209836952586545
2609,CO6A3,NCAM signaling for neurite out-growth,0.0017026105336017605,1,0,1,0.0018076313052539127
2610,CO6A3,Collagen degradation,0.003023350055253861,0,0,1,0.003209836952586545
2611,CO6A3,Collagen degradation,0.0017026105336017605,1,0,1,0.0018076313052539127
2612,CO6A3,Integrin cell surface interactions,0.003023350055253861,0,0,1,0.003209836952586545
2613,CO6A3,Integrin cell surface interactions,0.0017026105336017605,1,0,1,0.0018076313052539127
2614,CO6A3,ECM proteoglycans,0.003023350055253861,0,0,1,0.003209836952586545
2615,CO6A3,ECM proteoglycans,0.0017026105336017605,1,0,1,0.0018076313052539127
2616,CO6A3,Signaling by PDGF,0.003023350055253861,0,0,1,0.003209836952586545
2617,CO6A3,Signaling by PDGF,0.0017026105336017605,1,0,1,0.0018076313052539127
2618,FA5,COPII-mediated vesicle transport,0.0008190442978292627,0,0,1,0.0008695647559597323
2619,FA5,COPII-mediated vesicle transport,0.0012210945475126763,1,0,1,0.001296414351489651
2620,FA5,Cargo concentration in the ER,0.0008190442978292627,0,0,1,0.0008695647559597323
2621,FA5,Cargo concentration in the ER,0.0012210945475126763,1,0,1,0.001296414351489651
2622,FA5,Platelet degranulation ,0.0008190442978292627,0,0,1,0.0008695647559597323
2623,FA5,Platelet degranulation ,0.0012210945475126763,1,0,1,0.001296414351489651
2624,FA5,Common Pathway of Fibrin Clot Formation,0.0008190442978292627,0,0,1,0.0008695647559597323
2625,FA5,Common Pathway of Fibrin Clot Formation,0.0012210945475126763,1,0,1,0.001296414351489651
2626,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008190442978292627,0,0,1,0.0008695647559597323
2627,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012210945475126763,1,0,1,0.001296414351489651
2628,FA5,Post-translational protein phosphorylation,0.0008190442978292627,0,0,1,0.0008695647559597323
2629,FA5,Post-translational protein phosphorylation,0.0012210945475126763,1,0,1,0.001296414351489651
2630,ACTN1,RHO GTPase cycle,0.00030424144690907156,0,0,1,0.0003230077301502343
2631,ACTN1,RHO GTPase cycle,6.697864566125919e-06,1,0,1,7.111003620110346e-06
2632,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.00030424144690907156,0,0,1,0.0003230077301502343
2633,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,6.697864566125919e-06,1,0,1,7.111003620110346e-06
2634,ACTN1,Platelet degranulation ,0.00030424144690907156,0,0,1,0.0003230077301502343
2635,ACTN1,Platelet degranulation ,6.697864566125919e-06,1,0,1,7.111003620110346e-06
2636,ACTN1,Nephrin family interactions,0.00030424144690907156,0,0,1,0.0003230077301502343
2637,ACTN1,Nephrin family interactions,6.697864566125919e-06,1,0,1,7.111003620110346e-06
2638,ACTN1,Syndecan interactions,0.00030424144690907156,0,0,1,0.0003230077301502343
2639,ACTN1,Syndecan interactions,6.697864566125919e-06,1,0,1,7.111003620110346e-06
2640,ICAM2,CD209 (DC-SIGN) signaling,0.00012137657758643316,0,0,1,0.0001288633525047458
2641,ICAM2,CD209 (DC-SIGN) signaling,5.199747452967716e-05,1,0,1,5.520479340342912e-05
2642,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00012137657758643316,0,0,1,0.0001288633525047458
2643,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,5.199747452967716e-05,1,0,1,5.520479340342912e-05
2644,ICAM2,Integrin cell surface interactions,0.00012137657758643316,0,0,1,0.0001288633525047458
2645,ICAM2,Integrin cell surface interactions,5.199747452967716e-05,1,0,1,5.520479340342912e-05
2646,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.004142647871492326,0,0,1,0.0043981755259741295
2647,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.002465713317127813,1,0,1,0.0026178039509675774
2648,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.004142647871492326,0,0,1,0.0043981755259741295
2649,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.002465713317127813,1,0,1,0.0026178039509675774
2650,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.004142647871492326,0,0,1,0.0043981755259741295
2651,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.002465713317127813,1,0,1,0.0026178039509675774
2652,CSPG2,ECM proteoglycans,0.004142647871492326,0,0,1,0.0043981755259741295
2653,CSPG2,ECM proteoglycans,0.002465713317127813,1,0,1,0.0026178039509675774
2654,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004142647871492326,0,0,1,0.0043981755259741295
2655,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002465713317127813,1,0,1,0.0026178039509675774
2656,CSPG2,Post-translational protein phosphorylation,0.004142647871492326,0,0,1,0.0043981755259741295
2657,CSPG2,Post-translational protein phosphorylation,0.002465713317127813,1,0,1,0.0026178039509675774
2658,K1C10,Formation of the cornified envelope,6.333013078444522e-05,0,0,1,6.723647288239082e-05
2659,K1C10,Formation of the cornified envelope,2.2428296841891057e-06,1,0,1,2.381172364132249e-06
2660,K2C5,Type I hemidesmosome assembly,0.00040687608924401254,0,0,1,0.0004319731035146941
2661,K2C5,Type I hemidesmosome assembly,0.0002607733872837297,1,0,1,0.00027685846476821366
2662,K2C5,Formation of the cornified envelope,0.00040687608924401254,0,0,1,0.0004319731035146941
2663,K2C5,Formation of the cornified envelope,0.0002607733872837297,1,0,1,0.00027685846476821366
2664,CO6,Terminal pathway of complement,8.328213773654307e-05,0,0,1,8.841916361375894e-05
2665,CO6,Terminal pathway of complement,5.144670921817387e-05,1,0,1,5.462005567317722e-05
2666,CO6,Regulation of Complement cascade,8.328213773654307e-05,0,0,1,8.841916361375894e-05
2667,CO6,Regulation of Complement cascade,5.144670921817387e-05,1,0,1,5.462005567317722e-05
2668,PRG2,Neutrophil degranulation,6.714888810987353e-05,0,0,1,7.129077957930126e-05
2669,PRG2,Neutrophil degranulation,5.55031256780364e-05,1,0,1,5.8926680843928e-05
2670,PLSL,Interleukin-12 family signaling,4.4132107636578046e-05,0,0,1,4.6854273338692354e-05
2671,PLSL,Interleukin-12 family signaling,4.369189530493505e-05,1,0,1,4.6386907739847305e-05
2672,CD59,Regulation of Complement cascade,0.0025982597811344947,0,0,1,0.002758526173114495
2673,CD59,Regulation of Complement cascade,0.0017271453353959292,1,0,1,0.001833679467717421
2674,CD59,COPII-mediated vesicle transport,0.0025982597811344947,0,0,1,0.002758526173114495
2675,CD59,COPII-mediated vesicle transport,0.0017271453353959292,1,0,1,0.001833679467717421
2676,CD59,Cargo concentration in the ER,0.0025982597811344947,0,0,1,0.002758526173114495
2677,CD59,Cargo concentration in the ER,0.0017271453353959292,1,0,1,0.001833679467717421
2678,CD59,COPI-mediated anterograde transport,0.0025982597811344947,0,0,1,0.002758526173114495
2679,CD59,COPI-mediated anterograde transport,0.0017271453353959292,1,0,1,0.001833679467717421
2680,CD59,Neutrophil degranulation,0.0025982597811344947,0,0,1,0.002758526173114495
2681,CD59,Neutrophil degranulation,0.0017271453353959292,1,0,1,0.001833679467717421
2682,GFAP,Nuclear signaling by ERBB4,0.0002627126752652422,0,0,1,0.0002789173723081951
2683,GFAP,Nuclear signaling by ERBB4,6.875257059817408e-05,1,0,1,7.299338073930185e-05
2684,GFAP,Chaperone Mediated Autophagy,0.0002627126752652422,0,0,1,0.0002789173723081951
2685,GFAP,Chaperone Mediated Autophagy,6.875257059817408e-05,1,0,1,7.299338073930185e-05
2686,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003163874038067532,0,0,1,0.0003359028764489412
2687,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002426080799492892,1,0,1,0.0002575726812262603
2688,LYAM1,Neutrophil degranulation,0.0003163874038067532,0,0,1,0.0003359028764489412
2689,LYAM1,Neutrophil degranulation,0.0002426080799492892,1,0,1,0.0002575726812262603
2690,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.00028729768231189643,0,0,1,0.0003050188367948555
2691,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0005158792060166408,1,0,1,0.0005476997728614595
2692,GLU2B,SARS-CoV-1 Infection,0.00028729768231189643,0,0,1,0.0003050188367948555
2693,GLU2B,SARS-CoV-1 Infection,0.0005158792060166408,1,0,1,0.0005476997728614595
2694,GLU2B,SARS-CoV-2 Infection,0.00028729768231189643,0,0,1,0.0003050188367948555
2695,GLU2B,SARS-CoV-2 Infection,0.0005158792060166408,1,0,1,0.0005476997728614595
2696,GLU2B,Advanced glycosylation endproduct receptor signaling,0.00028729768231189643,0,0,1,0.0003050188367948555
2697,GLU2B,Advanced glycosylation endproduct receptor signaling,0.0005158792060166408,1,0,1,0.0005476997728614595
2698,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00028729768231189643,0,0,1,0.0003050188367948555
2699,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005158792060166408,1,0,1,0.0005476997728614595
2700,GLU2B,Post-translational protein phosphorylation,0.00028729768231189643,0,0,1,0.0003050188367948555
2701,GLU2B,Post-translational protein phosphorylation,0.0005158792060166408,1,0,1,0.0005476997728614595
2702,NID1,Laminin interactions,3.5794527654389884e-05,0,0,1,3.8002413040389495e-05
2703,NID1,Laminin interactions,7.508133859086653e-05,1,0,1,7.971252109554005e-05
2704,PA2GA,Glycerophospholipid biosynthesis,9.080148362532357e-06,0,0,1,9.640231933571875e-06
2705,PA2GA,Glycerophospholipid biosynthesis,0.0006395674372377904,1,0,1,0.0006790173668938774
2706,KPYM,Neutrophil degranulation,1.595403767764603e-06,0,0,1,1.6938117897289378e-06
2707,KPYM,Neutrophil degranulation,1.3179011410166882e-06,1,0,1,1.3991921891215262e-06
2708,ENPL,Trafficking and processing of endosomal TLR,0.0003210206348700788,0,0,1,0.00034082189541966555
2709,ENPL,Trafficking and processing of endosomal TLR,0.0005798479906811251,1,0,1,0.0006156142932033233
2710,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0003210206348700788,0,0,1,0.00034082189541966555
2711,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0005798479906811251,1,0,1,0.0006156142932033233
2712,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0003210206348700788,0,0,1,0.00034082189541966555
2713,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0005798479906811251,1,0,1,0.0006156142932033233
2714,ENPL,Scavenging by Class A Receptors,0.0003210206348700788,0,0,1,0.00034082189541966555
2715,ENPL,Scavenging by Class A Receptors,0.0005798479906811251,1,0,1,0.0006156142932033233
2716,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003210206348700788,0,0,1,0.00034082189541966555
2717,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005798479906811251,1,0,1,0.0006156142932033233
2718,ENPL,Post-translational protein phosphorylation,0.0003210206348700788,0,0,1,0.00034082189541966555
2719,ENPL,Post-translational protein phosphorylation,0.0005798479906811251,1,0,1,0.0006156142932033233
2720,GPIX,Defective factor IX causes hemophilia B,1.3452433980058412e-05,0,0,1,1.4282209768063618e-05
2721,GPIX,Defective factor IX causes hemophilia B,0.00020780626662340851,1,0,1,0.00022062421532291295
2722,GPIX,Platelet Adhesion to exposed collagen,1.3452433980058412e-05,0,0,1,1.4282209768063618e-05
2723,GPIX,Platelet Adhesion to exposed collagen,0.00020780626662340851,1,0,1,0.00022062421532291295
2724,GPIX,Intrinsic Pathway of Fibrin Clot Formation,1.3452433980058412e-05,0,0,1,1.4282209768063618e-05
2725,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.00020780626662340851,1,0,1,0.00022062421532291295
2726,GPIX,GP1b-IX-V activation signalling,1.3452433980058412e-05,0,0,1,1.4282209768063618e-05
2727,GPIX,GP1b-IX-V activation signalling,0.00020780626662340851,1,0,1,0.00022062421532291295
2728,MMP9,EPH-Ephrin signaling,0.00042355200386580156,0,0,1,0.0004496776253176456
2729,MMP9,EPH-Ephrin signaling,0.001153072258362991,1,0,1,0.0012241962975687154
2730,MMP9,Interleukin-4 and Interleukin-13 signaling,0.00042355200386580156,0,0,1,0.0004496776253176456
2731,MMP9,Interleukin-4 and Interleukin-13 signaling,0.001153072258362991,1,0,1,0.0012241962975687154
2732,MMP9,Extra-nuclear estrogen signaling,0.00042355200386580156,0,0,1,0.0004496776253176456
2733,MMP9,Extra-nuclear estrogen signaling,0.001153072258362991,1,0,1,0.0012241962975687154
2734,MMP9,Collagen degradation,0.00042355200386580156,0,0,1,0.0004496776253176456
2735,MMP9,Collagen degradation,0.001153072258362991,1,0,1,0.0012241962975687154
2736,MMP9,Activation of Matrix Metalloproteinases,0.00042355200386580156,0,0,1,0.0004496776253176456
2737,MMP9,Activation of Matrix Metalloproteinases,0.001153072258362991,1,0,1,0.0012241962975687154
2738,MMP9,Neutrophil degranulation,0.00042355200386580156,0,0,1,0.0004496776253176456
2739,MMP9,Neutrophil degranulation,0.001153072258362991,1,0,1,0.0012241962975687154
2740,MMP9,Signaling by SCF-KIT,0.00042355200386580156,0,0,1,0.0004496776253176456
2741,MMP9,Signaling by SCF-KIT,0.001153072258362991,1,0,1,0.0012241962975687154
2742,AMPN,Neutrophil degranulation,0.00025701803631098414,0,0,1,0.0002728714754676186
2743,AMPN,Neutrophil degranulation,7.442172342412904e-05,1,0,1,7.901221941098941e-05
2744,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.00025701803631098414,0,0,1,0.0002728714754676186
2745,AMPN,Metabolism of Angiotensinogen to Angiotensins,7.442172342412904e-05,1,0,1,7.901221941098941e-05
2746,PVR,Adherens junctions interactions,0.00010580904770715168,0,0,1,0.0001123355830590019
2747,PVR,Adherens junctions interactions,9.267390839910972e-05,1,0,1,9.839023939790044e-05
2748,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00010580904770715168,0,0,1,0.0001123355830590019
2749,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,9.267390839910972e-05,1,0,1,9.839023939790044e-05
2750,CBPN,Regulation of Complement cascade,5.115049263198803e-05,0,0,1,5.4305567794852947e-05
2751,CBPN,Regulation of Complement cascade,5.819151195019531e-06,1,0,1,6.178089270874545e-06
2752,B4GT1,Keratan sulfate/keratin metabolism,0.002683492174961651,0,0,1,0.002849015888914488
2753,B4GT1,Keratan sulfate/keratin metabolism,0.0008371071970258282,1,0,1,0.0008887418146040756
2754,B4GT1,Pre-NOTCH Processing in Golgi,0.002683492174961651,0,0,1,0.002849015888914488
2755,B4GT1,Pre-NOTCH Processing in Golgi,0.0008371071970258282,1,0,1,0.0008887418146040756
2756,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.002683492174961651,0,0,1,0.002849015888914488
2757,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.0008371071970258282,1,0,1,0.0008887418146040756
2758,B4GT1,Diseases associated with N-glycosylation of proteins,0.002683492174961651,0,0,1,0.002849015888914488
2759,B4GT1,Diseases associated with N-glycosylation of proteins,0.0008371071970258282,1,0,1,0.0008887418146040756
2760,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.002683492174961651,0,0,1,0.002849015888914488
2761,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.0008371071970258282,1,0,1,0.0008887418146040756
2762,B4GT1,Neutrophil degranulation,0.002683492174961651,0,0,1,0.002849015888914488
2763,B4GT1,Neutrophil degranulation,0.0008371071970258282,1,0,1,0.0008887418146040756
2764,B4GT1,Lactose synthesis,0.002683492174961651,0,0,1,0.002849015888914488
2765,B4GT1,Lactose synthesis,0.0008371071970258282,1,0,1,0.0008887418146040756
2766,EZRI,L1CAM interactions,0.00012587220882333123,0,0,1,0.00013363628418836657
2767,EZRI,L1CAM interactions,0.0005129341527743993,1,0,1,0.0005445730622419418
2768,EZRI,Netrin-1 signaling,0.00012587220882333123,0,0,1,0.00013363628418836657
2769,EZRI,Netrin-1 signaling,0.0005129341527743993,1,0,1,0.0005445730622419418
2770,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.00012587220882333123,0,0,1,0.00013363628418836657
2771,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.0005129341527743993,1,0,1,0.0005445730622419418
2772,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.00012587220882333123,0,0,1,0.00013363628418836657
2773,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.0005129341527743993,1,0,1,0.0005445730622419418
2774,TIMP2,Activation of Matrix Metalloproteinases,0.00017404345386138015,0,0,1,0.00018477883782899932
2775,TIMP2,Activation of Matrix Metalloproteinases,0.0001722884456465153,1,0,1,0.00018291557683797492
2776,TIMP2,Neutrophil degranulation,0.00017404345386138015,0,0,1,0.00018477883782899932
2777,TIMP2,Neutrophil degranulation,0.0001722884456465153,1,0,1,0.00018291557683797492
2778,CD44,Hyaluronan metabolism,0.0008494078010157991,0,0,1,0.0009018011469686922
2779,CD44,Hyaluronan metabolism,0.0006354511775898896,1,0,1,0.000674647207275307
2780,CD44,Interferon gamma signaling,0.0008494078010157991,0,0,1,0.0009018011469686922
2781,CD44,Interferon gamma signaling,0.0006354511775898896,1,0,1,0.000674647207275307
2782,CD44,Integrin cell surface interactions,0.0008494078010157991,0,0,1,0.0009018011469686922
2783,CD44,Integrin cell surface interactions,0.0006354511775898896,1,0,1,0.000674647207275307
2784,CD44,Neutrophil degranulation,0.0008494078010157991,0,0,1,0.0009018011469686922
2785,CD44,Neutrophil degranulation,0.0006354511775898896,1,0,1,0.000674647207275307
2786,CD36,Antigen processing-Cross presentation,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2787,CD36,Antigen processing-Cross presentation,0.0003613245408366869,1,0,1,0.0003836118351689115
2788,CD36,Toll Like Receptor 4 (TLR4) Cascade,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2789,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.0003613245408366869,1,0,1,0.0003836118351689115
2790,CD36,Toll Like Receptor 2 (TLR2) Cascade,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2791,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.0003613245408366869,1,0,1,0.0003836118351689115
2792,CD36,Regulation of TLR by endogenous ligand,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2793,CD36,Regulation of TLR by endogenous ligand,0.0003613245408366869,1,0,1,0.0003836118351689115
2794,CD36,PPARA activates gene expression,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2795,CD36,PPARA activates gene expression,0.0003613245408366869,1,0,1,0.0003836118351689115
2796,CD36,Free fatty acids regulate insulin secretion,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2797,CD36,Free fatty acids regulate insulin secretion,0.0003613245408366869,1,0,1,0.0003836118351689115
2798,CD36,Interleukin-4 and Interleukin-13 signaling,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2799,CD36,Interleukin-4 and Interleukin-13 signaling,0.0003613245408366869,1,0,1,0.0003836118351689115
2800,CD36,MyD88 deficiency (TLR2/4),3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2801,CD36,MyD88 deficiency (TLR2/4),0.0003613245408366869,1,0,1,0.0003836118351689115
2802,CD36,IRAK4 deficiency (TLR2/4),3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2803,CD36,IRAK4 deficiency (TLR2/4),0.0003613245408366869,1,0,1,0.0003836118351689115
2804,CD36,Platelet degranulation ,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2805,CD36,Platelet degranulation ,0.0003613245408366869,1,0,1,0.0003836118351689115
2806,CD36,Transcriptional regulation of white adipocyte differentiation,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2807,CD36,Transcriptional regulation of white adipocyte differentiation,0.0003613245408366869,1,0,1,0.0003836118351689115
2808,CD36,Neutrophil degranulation,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2809,CD36,Neutrophil degranulation,0.0003613245408366869,1,0,1,0.0003836118351689115
2810,CD36,Scavenging by Class B Receptors,3.6095782308325514e-05,0,0,1,3.832224974559036e-05
2811,CD36,Scavenging by Class B Receptors,0.0003613245408366869,1,0,1,0.0003836118351689115
2812,FAAA,Tyrosine catabolism,0.00041501294761815764,0,0,1,0.000440611861253616
2813,FAAA,Tyrosine catabolism,0.00017243640723066205,1,0,1,0.00018307266501885956
2814,HSP76,Regulation of HSF1-mediated heat shock response,4.7102184375380385e-05,0,0,1,5.0007550959210896e-05
2815,HSP76,Regulation of HSF1-mediated heat shock response,4.3243001146316744e-05,1,0,1,4.591032479979727e-05
2816,HSP76,Neutrophil degranulation,4.7102184375380385e-05,0,0,1,5.0007550959210896e-05
2817,HSP76,Neutrophil degranulation,4.3243001146316744e-05,1,0,1,4.591032479979727e-05
2818,AATC,Methionine salvage pathway,6.61859716098758e-06,0,0,1,7.0268468266531865e-06
2819,AATC,Methionine salvage pathway,0.0009229186120700697,1,0,1,0.0009798462669264579
2820,AATC,Gluconeogenesis,6.61859716098758e-06,0,0,1,7.0268468266531865e-06
2821,AATC,Gluconeogenesis,0.0009229186120700697,1,0,1,0.0009798462669264579
2822,AATC,Aspartate and asparagine metabolism,6.61859716098758e-06,0,0,1,7.0268468266531865e-06
2823,AATC,Aspartate and asparagine metabolism,0.0009229186120700697,1,0,1,0.0009798462669264579
2824,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",9.048963907419415e-05,0,0,1,9.607123952511642e-05
2825,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",4.130391138440633e-05,1,0,1,4.385162770603991e-05
2826,CTRB1,Activation of Matrix Metalloproteinases,9.048963907419415e-05,0,0,1,9.607123952511642e-05
2827,CTRB1,Activation of Matrix Metalloproteinases,4.130391138440633e-05,1,0,1,4.385162770603991e-05
2828,IBP3,Transcriptional Regulation by TP53,1.6800945074433383e-05,0,0,1,1.7837264409583887e-05
2829,IBP3,Transcriptional Regulation by TP53,3.5007146669350424e-05,1,0,1,3.7166464660164156e-05
2830,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1.6800945074433383e-05,0,0,1,1.7837264409583887e-05
2831,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3.5007146669350424e-05,1,0,1,3.7166464660164156e-05
2832,IBP3,Post-translational protein phosphorylation,1.6800945074433383e-05,0,0,1,1.7837264409583887e-05
2833,IBP3,Post-translational protein phosphorylation,3.5007146669350424e-05,1,0,1,3.7166464660164156e-05
2834,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00014005029248347468,0,0,1,0.00014868890330870546
2835,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00022272413509988857,1,0,1,0.00023646225081814804
2836,VINC,RAF/MAP kinase cascade,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2837,VINC,RAF/MAP kinase cascade,0.0013478094981368726,1,0,1,0.0014309453596512488
2838,VINC,Signaling by RAS mutants,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2839,VINC,Signaling by RAS mutants,0.0013478094981368726,1,0,1,0.0014309453596512488
2840,VINC,Signaling by moderate kinase activity BRAF mutants,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2841,VINC,Signaling by moderate kinase activity BRAF mutants,0.0013478094981368726,1,0,1,0.0014309453596512488
2842,VINC,Signaling by high-kinase activity BRAF mutants,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2843,VINC,Signaling by high-kinase activity BRAF mutants,0.0013478094981368726,1,0,1,0.0014309453596512488
2844,VINC,Signaling by BRAF and RAF1 fusions,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2845,VINC,Signaling by BRAF and RAF1 fusions,0.0013478094981368726,1,0,1,0.0014309453596512488
2846,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2847,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0013478094981368726,1,0,1,0.0014309453596512488
2848,VINC,Signaling by RAF1 mutants,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2849,VINC,Signaling by RAF1 mutants,0.0013478094981368726,1,0,1,0.0014309453596512488
2850,VINC,Platelet degranulation ,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2851,VINC,Platelet degranulation ,0.0013478094981368726,1,0,1,0.0014309453596512488
2852,VINC,Signaling by ALK fusions and activated point mutants,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2853,VINC,Signaling by ALK fusions and activated point mutants,0.0013478094981368726,1,0,1,0.0014309453596512488
2854,VINC,Neutrophil degranulation,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2855,VINC,Neutrophil degranulation,0.0013478094981368726,1,0,1,0.0014309453596512488
2856,VINC,Smooth Muscle Contraction,4.884376178994026e-05,0,0,1,5.185655270855515e-05
2857,VINC,Smooth Muscle Contraction,0.0013478094981368726,1,0,1,0.0014309453596512488
2858,LBP,Toll Like Receptor 4 (TLR4) Cascade,8.401089488666349e-05,0,0,1,8.919287211167278e-05
2859,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0002022387063708418,1,0,1,0.00021471323567853295
2860,LBP,Regulation of TLR by endogenous ligand,8.401089488666349e-05,0,0,1,8.919287211167278e-05
2861,LBP,Regulation of TLR by endogenous ligand,0.0002022387063708418,1,0,1,0.00021471323567853295
2862,LBP,Interleukin-4 and Interleukin-13 signaling,8.401089488666349e-05,0,0,1,8.919287211167278e-05
2863,LBP,Interleukin-4 and Interleukin-13 signaling,0.0002022387063708418,1,0,1,0.00021471323567853295
2864,ML12A,EPH-Ephrin signaling,0.0010347619830325795,0,0,1,0.0010985883836037691
2865,ML12A,EPH-Ephrin signaling,0.0011286667576485177,1,0,1,0.001198285411760583
2866,ML12A,Smooth Muscle Contraction,0.0010347619830325795,0,0,1,0.0010985883836037691
2867,ML12A,Smooth Muscle Contraction,0.0011286667576485177,1,0,1,0.001198285411760583
2868,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.00014774823489042296,0,0,1,0.00015686167177584573
2869,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.00023882880279634127,1,0,1,0.00025356028992591526
2870,VCAM1,Interferon gamma signaling,0.00014774823489042296,0,0,1,0.00015686167177584573
2871,VCAM1,Interferon gamma signaling,0.00023882880279634127,1,0,1,0.00025356028992591526
2872,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00014774823489042296,0,0,1,0.00015686167177584573
2873,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00023882880279634127,1,0,1,0.00025356028992591526
2874,VCAM1,Integrin cell surface interactions,0.00014774823489042296,0,0,1,0.00015686167177584573
2875,VCAM1,Integrin cell surface interactions,0.00023882880279634127,1,0,1,0.00025356028992591526
2876,A1AG2,Platelet degranulation ,9.808453948208729e-05,0,0,1,0.00010413461013551141
2877,A1AG2,Platelet degranulation ,1.55427218035344e-05,1,0,1,1.650143115318753e-05
2878,A1AG2,Neutrophil degranulation,9.808453948208729e-05,0,0,1,0.00010413461013551141
2879,A1AG2,Neutrophil degranulation,1.55427218035344e-05,1,0,1,1.650143115318753e-05
2880,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.000249171114030779,0,0,1,0.00026454053772016604
2881,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00025270285772107694,1,0,1,0.0002682901271481196
2882,ITIH2,Post-translational protein phosphorylation,0.000249171114030779,0,0,1,0.00026454053772016604
2883,ITIH2,Post-translational protein phosphorylation,0.00025270285772107694,1,0,1,0.0002682901271481196
2884,TYPH,Pyrimidine catabolism,0.0001180124908789025,0,0,1,0.00012529176151190906
2885,TYPH,Pyrimidine catabolism,0.00022304400288722086,1,0,1,0.00023680184875585198
2886,TYPH,Pyrimidine salvage,0.0001180124908789025,0,0,1,0.00012529176151190906
2887,TYPH,Pyrimidine salvage,0.00022304400288722086,1,0,1,0.00023680184875585198
2888,C4BPB,Regulation of Complement cascade,0.0001107364977765359,0,0,1,0.0001175669691127768
2889,C4BPB,Regulation of Complement cascade,1.3446787311797408e-05,1,0,1,1.4276214800854423e-05
2890,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00016114171680806414,0,0,1,0.00017108129318830391
2891,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00033789992862532324,1,0,1,0.00035874234122943723
2892,FLNA,RHO GTPase Effectors,0.00016114171680806414,0,0,1,0.00017108129318830391
2893,FLNA,RHO GTPase Effectors,0.00033789992862532324,1,0,1,0.00035874234122943723
2894,FLNA,Platelet degranulation ,0.00016114171680806414,0,0,1,0.00017108129318830391
2895,FLNA,Platelet degranulation ,0.00033789992862532324,1,0,1,0.00035874234122943723
2896,FLNA,GP1b-IX-V activation signalling,0.00016114171680806414,0,0,1,0.00017108129318830391
2897,FLNA,GP1b-IX-V activation signalling,0.00033789992862532324,1,0,1,0.00035874234122943723
2898,TENX,ECM proteoglycans,0.000296285969700409,0,0,1,0.0003145615415669937
2899,TENX,ECM proteoglycans,2.2479563863102524e-05,1,0,1,2.386615292543653e-05
2900,GPX3,Detoxification of Reactive Oxygen Species,0.0006265433906157972,0,0,1,0.0006651899683606389
2901,GPX3,Detoxification of Reactive Oxygen Species,0.00014628817184576074,1,0,1,0.00015531154882342127
2902,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00010873723672814079,0,0,1,0.00011544438923491787
2903,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00039951693511953675,1,0,1,0.00042416002053825434
2904,IBP4,Post-translational protein phosphorylation,0.00010873723672814079,0,0,1,0.00011544438923491787
2905,IBP4,Post-translational protein phosphorylation,0.00039951693511953675,1,0,1,0.00042416002053825434
2906,CPN2,Regulation of Complement cascade,1.1412614698135863e-05,0,0,1,1.211656993540991e-05
2907,CPN2,Regulation of Complement cascade,1.425570938831934e-06,1,0,1,1.5135032974578973e-06
2908,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0001504470981321186,0,0,1,0.0001597270068527807
2909,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",1.4605691957638418e-05,1,0,1,1.550660324042013e-05
2910,MMP8,Collagen degradation,0.00075310573284987,0,0,1,0.0007995589549101374
2911,MMP8,Collagen degradation,0.00031956679909105935,1,0,1,0.0003392783838443587
2912,MMP8,Activation of Matrix Metalloproteinases,0.00075310573284987,0,0,1,0.0007995589549101374
2913,MMP8,Activation of Matrix Metalloproteinases,0.00031956679909105935,1,0,1,0.0003392783838443587
2914,MMP8,Neutrophil degranulation,0.00075310573284987,0,0,1,0.0007995589549101374
2915,MMP8,Neutrophil degranulation,0.00031956679909105935,1,0,1,0.0003392783838443587
2916,MRC1,Antigen processing-Cross presentation,5.63904218024664e-05,0,0,1,5.986870734963579e-05
2917,MRC1,Antigen processing-Cross presentation,0.00015989697988465343,1,0,1,0.00016975977814704377
2918,MRC1,Modulation by Mtb of host immune system,5.63904218024664e-05,0,0,1,5.986870734963579e-05
2919,MRC1,Modulation by Mtb of host immune system,0.00015989697988465343,1,0,1,0.00016975977814704377
2920,HV102,Initial triggering of complement,0.00019985810690845222,0,0,1,0.0002121857955925241
2921,HV102,Initial triggering of complement,0.0005252475962821373,1,0,1,0.0005576460260940901
2922,HV102,Regulation of Complement cascade,0.00019985810690845222,0,0,1,0.0002121857955925241
2923,HV102,Regulation of Complement cascade,0.0005252475962821373,1,0,1,0.0005576460260940901
2924,HV102,FCGR activation,0.00019985810690845222,0,0,1,0.0002121857955925241
2925,HV102,FCGR activation,0.0005252475962821373,1,0,1,0.0005576460260940901
2926,HV102,Regulation of actin dynamics for phagocytic cup formation,0.00019985810690845222,0,0,1,0.0002121857955925241
2927,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0005252475962821373,1,0,1,0.0005576460260940901
2928,HV102,Role of phospholipids in phagocytosis,0.00019985810690845222,0,0,1,0.0002121857955925241
2929,HV102,Role of phospholipids in phagocytosis,0.0005252475962821373,1,0,1,0.0005576460260940901
2930,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.00019985810690845222,0,0,1,0.0002121857955925241
2931,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0005252475962821373,1,0,1,0.0005576460260940901
2932,HV102,FCERI mediated MAPK activation,0.00019985810690845222,0,0,1,0.0002121857955925241
2933,HV102,FCERI mediated MAPK activation,0.0005252475962821373,1,0,1,0.0005576460260940901
2934,HV102,FCERI mediated Ca+2 mobilization,0.00019985810690845222,0,0,1,0.0002121857955925241
2935,HV102,FCERI mediated Ca+2 mobilization,0.0005252475962821373,1,0,1,0.0005576460260940901
2936,HV102,FCERI mediated NF-kB activation,0.00019985810690845222,0,0,1,0.0002121857955925241
2937,HV102,FCERI mediated NF-kB activation,0.0005252475962821373,1,0,1,0.0005576460260940901
2938,HV102,Parasite infection,0.00019985810690845222,0,0,1,0.0002121857955925241
2939,HV102,Parasite infection,0.0005252475962821373,1,0,1,0.0005576460260940901
2940,HV102,Leishmania parasite growth and survival,0.00019985810690845222,0,0,1,0.0002121857955925241
2941,HV102,Leishmania parasite growth and survival,0.0005252475962821373,1,0,1,0.0005576460260940901
2942,HV102,Potential therapeutics for SARS,0.00019985810690845222,0,0,1,0.0002121857955925241
2943,HV102,Potential therapeutics for SARS,0.0005252475962821373,1,0,1,0.0005576460260940901
2944,HV102,CD22 mediated BCR regulation,0.00019985810690845222,0,0,1,0.0002121857955925241
2945,HV102,CD22 mediated BCR regulation,0.0005252475962821373,1,0,1,0.0005576460260940901
2946,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00019985810690845222,0,0,1,0.0002121857955925241
2947,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005252475962821373,1,0,1,0.0005576460260940901
2948,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00019985810690845222,0,0,1,0.0002121857955925241
2949,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005252475962821373,1,0,1,0.0005576460260940901
2950,HV102,Scavenging of heme from plasma,0.00019985810690845222,0,0,1,0.0002121857955925241
2951,HV102,Scavenging of heme from plasma,0.0005252475962821373,1,0,1,0.0005576460260940901
2952,EST1,Metabolism of Angiotensinogen to Angiotensins,0.0020796761494649924,0,0,1,0.0022079551596631496
2953,EST1,Metabolism of Angiotensinogen to Angiotensins,0.0005889818210303689,1,0,1,0.0006253115183469057
2954,EST1,Physiological factors,0.0020796761494649924,0,0,1,0.0022079551596631496
2955,EST1,Physiological factors,0.0005889818210303689,1,0,1,0.0006253115183469057
2956,EST1,Aspirin ADME,0.0020796761494649924,0,0,1,0.0022079551596631496
2957,EST1,Aspirin ADME,0.0005889818210303689,1,0,1,0.0006253115183469057
2958,FBLN1,Molecules associated with elastic fibres,0.00012563637868721474,0,0,1,0.0001333859075294928
2959,FBLN1,Molecules associated with elastic fibres,8.989076571506971e-05,1,0,1,9.543542633679681e-05
2960,SAHH,Methylation,0.0004447369990949543,0,0,1,0.00047216935776150725
2961,SAHH,Methylation,0.00041346064776709294,1,0,1,0.0004389638121252051
2962,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0004447369990949543,0,0,1,0.00047216935776150725
2963,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00041346064776709294,1,0,1,0.0004389638121252051
2964,SAHH,Defective AHCY causes HMAHCHD,0.0004447369990949543,0,0,1,0.00047216935776150725
2965,SAHH,Defective AHCY causes HMAHCHD,0.00041346064776709294,1,0,1,0.0004389638121252051
2966,PRTN3,Other interleukin signaling,0.0016627373104545094,0,0,1,0.0017652986137898972
2967,PRTN3,Other interleukin signaling,6.619458252710266e-05,1,0,1,7.027761032411875e-05
2968,PRTN3,Common Pathway of Fibrin Clot Formation,0.0016627373104545094,0,0,1,0.0017652986137898972
2969,PRTN3,Common Pathway of Fibrin Clot Formation,6.619458252710266e-05,1,0,1,7.027761032411875e-05
2970,PRTN3,Neutrophil degranulation,0.0016627373104545094,0,0,1,0.0017652986137898972
2971,PRTN3,Neutrophil degranulation,6.619458252710266e-05,1,0,1,7.027761032411875e-05
2972,ALAT1,Alanine metabolism,0.00031666591966484535,0,0,1,0.00033619857177923616
2973,ALAT1,Alanine metabolism,0.00027312264203916537,1,0,1,0.0002899694487847747
2974,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00011820721919307081,0,0,1,0.00012549850109783498
2975,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001861906449508742,1,0,1,0.00019767529444719074
2976,THIL,Utilization of Ketone Bodies,0.00020639259151158248,0,0,1,0.00021912334161329876
2977,THIL,Utilization of Ketone Bodies,0.00022508396245870114,1,0,1,0.00023896763753143263
2978,THIL,Synthesis of Ketone Bodies,0.00020639259151158248,0,0,1,0.00021912334161329876
2979,THIL,Synthesis of Ketone Bodies,0.00022508396245870114,1,0,1,0.00023896763753143263
2980,THIL,Branched-chain amino acid catabolism,0.00020639259151158248,0,0,1,0.00021912334161329876
2981,THIL,Branched-chain amino acid catabolism,0.00022508396245870114,1,0,1,0.00023896763753143263
2982,TENA,Integrin cell surface interactions,0.00014944742039498923,0,0,1,0.0001586656667887217
2983,TENA,Integrin cell surface interactions,0.00037019451039800214,1,0,1,0.00039302892400940205
2984,TENA,ECM proteoglycans,0.00014944742039498923,0,0,1,0.0001586656667887217
2985,TENA,ECM proteoglycans,0.00037019451039800214,1,0,1,0.00039302892400940205
2986,TENA,Syndecan interactions,0.00014944742039498923,0,0,1,0.0001586656667887217
2987,TENA,Syndecan interactions,0.00037019451039800214,1,0,1,0.00039302892400940205
2988,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00014944742039498923,0,0,1,0.0001586656667887217
2989,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00037019451039800214,1,0,1,0.00039302892400940205
2990,TENA,Post-translational protein phosphorylation,0.00014944742039498923,0,0,1,0.0001586656667887217
2991,TENA,Post-translational protein phosphorylation,0.00037019451039800214,1,0,1,0.00039302892400940205
2992,ZA2G,Miscellaneous transport and binding events,5.262316224311666e-05,0,0,1,5.5869074914558616e-05
2993,ZA2G,Miscellaneous transport and binding events,1.0889045217348022e-05,1,0,1,1.1560705534673739e-05
2994,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.0015501563985676028,0,0,1,0.0016457734630378317
2995,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.002201326584991843,1,0,1,0.0023371092622698837
2996,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0015501563985676028,0,0,1,0.0016457734630378317
2997,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.002201326584991843,1,0,1,0.0023371092622698837
2998,PSA1,Antigen processing-Cross presentation,0.0015501563985676028,0,0,1,0.0016457734630378317
2999,PSA1,Antigen processing-Cross presentation,0.002201326584991843,1,0,1,0.0023371092622698837
3000,PSA1,PTEN Regulation,0.0015501563985676028,0,0,1,0.0016457734630378317
3001,PSA1,PTEN Regulation,0.002201326584991843,1,0,1,0.0023371092622698837
3002,PSA1,Host Interactions of HIV factors,0.0015501563985676028,0,0,1,0.0016457734630378317
3003,PSA1,Host Interactions of HIV factors,0.002201326584991843,1,0,1,0.0023371092622698837
3004,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0015501563985676028,0,0,1,0.0016457734630378317
3005,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.002201326584991843,1,0,1,0.0023371092622698837
3006,PSA1,APC/C-mediated degradation of cell cycle proteins,0.0015501563985676028,0,0,1,0.0016457734630378317
3007,PSA1,APC/C-mediated degradation of cell cycle proteins,0.002201326584991843,1,0,1,0.0023371092622698837
3008,PSA1,Degradation of AXIN,0.0015501563985676028,0,0,1,0.0016457734630378317
3009,PSA1,Degradation of AXIN,0.002201326584991843,1,0,1,0.0023371092622698837
3010,PSA1,Degradation of DVL,0.0015501563985676028,0,0,1,0.0016457734630378317
3011,PSA1,Degradation of DVL,0.002201326584991843,1,0,1,0.0023371092622698837
3012,PSA1,Downstream TCR signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3013,PSA1,Downstream TCR signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3014,PSA1,Transcriptional regulation by RUNX3,0.0015501563985676028,0,0,1,0.0016457734630378317
3015,PSA1,Transcriptional regulation by RUNX3,0.002201326584991843,1,0,1,0.0023371092622698837
3016,PSA1,Transcriptional regulation by RUNX2,0.0015501563985676028,0,0,1,0.0016457734630378317
3017,PSA1,Transcriptional regulation by RUNX2,0.002201326584991843,1,0,1,0.0023371092622698837
3018,PSA1,Transcriptional regulation by RUNX1,0.0015501563985676028,0,0,1,0.0016457734630378317
3019,PSA1,Transcriptional regulation by RUNX1,0.002201326584991843,1,0,1,0.0023371092622698837
3020,PSA1,FCERI mediated NF-kB activation,0.0015501563985676028,0,0,1,0.0016457734630378317
3021,PSA1,FCERI mediated NF-kB activation,0.002201326584991843,1,0,1,0.0023371092622698837
3022,PSA1,Mitotic Metaphase and Anaphase,0.0015501563985676028,0,0,1,0.0016457734630378317
3023,PSA1,Mitotic Metaphase and Anaphase,0.002201326584991843,1,0,1,0.0023371092622698837
3024,PSA1,Regulation of ornithine decarboxylase (ODC),0.0015501563985676028,0,0,1,0.0016457734630378317
3025,PSA1,Regulation of ornithine decarboxylase (ODC),0.002201326584991843,1,0,1,0.0023371092622698837
3026,PSA1,Signaling by ROBO receptors,0.0015501563985676028,0,0,1,0.0016457734630378317
3027,PSA1,Signaling by ROBO receptors,0.002201326584991843,1,0,1,0.0023371092622698837
3028,PSA1,PCP/CE pathway,0.0015501563985676028,0,0,1,0.0016457734630378317
3029,PSA1,PCP/CE pathway,0.002201326584991843,1,0,1,0.0023371092622698837
3030,PSA1,Interleukin-1 family signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3031,PSA1,Interleukin-1 family signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3032,PSA1,G2/M Transition,0.0015501563985676028,0,0,1,0.0016457734630378317
3033,PSA1,G2/M Transition,0.002201326584991843,1,0,1,0.0023371092622698837
3034,PSA1,G1/S Transition,0.0015501563985676028,0,0,1,0.0016457734630378317
3035,PSA1,G1/S Transition,0.002201326584991843,1,0,1,0.0023371092622698837
3036,PSA1,Hh mutants are degraded by ERAD,0.0015501563985676028,0,0,1,0.0016457734630378317
3037,PSA1,Hh mutants are degraded by ERAD,0.002201326584991843,1,0,1,0.0023371092622698837
3038,PSA1,CLEC7A (Dectin-1) signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3039,PSA1,CLEC7A (Dectin-1) signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3040,PSA1,Degradation of GLI1 by the proteasome,0.0015501563985676028,0,0,1,0.0016457734630378317
3041,PSA1,Degradation of GLI1 by the proteasome,0.002201326584991843,1,0,1,0.0023371092622698837
3042,PSA1,Degradation of GLI2 by the proteasome,0.0015501563985676028,0,0,1,0.0016457734630378317
3043,PSA1,Degradation of GLI2 by the proteasome,0.002201326584991843,1,0,1,0.0023371092622698837
3044,PSA1,GLI3 is processed to GLI3R by the proteasome,0.0015501563985676028,0,0,1,0.0016457734630378317
3045,PSA1,GLI3 is processed to GLI3R by the proteasome,0.002201326584991843,1,0,1,0.0023371092622698837
3046,PSA1,Defective CFTR causes cystic fibrosis,0.0015501563985676028,0,0,1,0.0016457734630378317
3047,PSA1,Defective CFTR causes cystic fibrosis,0.002201326584991843,1,0,1,0.0023371092622698837
3048,PSA1,NIK-->noncanonical NF-kB signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3049,PSA1,NIK-->noncanonical NF-kB signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3050,PSA1,RAF/MAP kinase cascade,0.0015501563985676028,0,0,1,0.0016457734630378317
3051,PSA1,RAF/MAP kinase cascade,0.002201326584991843,1,0,1,0.0023371092622698837
3052,PSA1,UCH proteinases,0.0015501563985676028,0,0,1,0.0016457734630378317
3053,PSA1,UCH proteinases,0.002201326584991843,1,0,1,0.0023371092622698837
3054,PSA1,Ub-specific processing proteases,0.0015501563985676028,0,0,1,0.0016457734630378317
3055,PSA1,Ub-specific processing proteases,0.002201326584991843,1,0,1,0.0023371092622698837
3056,PSA1,Orc1 removal from chromatin,0.0015501563985676028,0,0,1,0.0016457734630378317
3057,PSA1,Orc1 removal from chromatin,0.002201326584991843,1,0,1,0.0023371092622698837
3058,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.0015501563985676028,0,0,1,0.0016457734630378317
3059,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.002201326584991843,1,0,1,0.0023371092622698837
3060,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.0015501563985676028,0,0,1,0.0016457734630378317
3061,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.002201326584991843,1,0,1,0.0023371092622698837
3062,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.0015501563985676028,0,0,1,0.0016457734630378317
3063,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.002201326584991843,1,0,1,0.0023371092622698837
3064,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.0015501563985676028,0,0,1,0.0016457734630378317
3065,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.002201326584991843,1,0,1,0.0023371092622698837
3066,PSA1,p53-Independent G1/S DNA damage checkpoint,0.0015501563985676028,0,0,1,0.0016457734630378317
3067,PSA1,p53-Independent G1/S DNA damage checkpoint,0.002201326584991843,1,0,1,0.0023371092622698837
3068,PSA1,Negative regulation of NOTCH4 signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3069,PSA1,Negative regulation of NOTCH4 signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3070,PSA1,KEAP1-NFE2L2 pathway,0.0015501563985676028,0,0,1,0.0016457734630378317
3071,PSA1,KEAP1-NFE2L2 pathway,0.002201326584991843,1,0,1,0.0023371092622698837
3072,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.0015501563985676028,0,0,1,0.0016457734630378317
3073,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.002201326584991843,1,0,1,0.0023371092622698837
3074,PSA1,Degradation of beta-catenin by the destruction complex,0.0015501563985676028,0,0,1,0.0016457734630378317
3075,PSA1,Degradation of beta-catenin by the destruction complex,0.002201326584991843,1,0,1,0.0023371092622698837
3076,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015501563985676028,0,0,1,0.0016457734630378317
3077,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002201326584991843,1,0,1,0.0023371092622698837
3078,PSA1,Hedgehog ligand biogenesis,0.0015501563985676028,0,0,1,0.0016457734630378317
3079,PSA1,Hedgehog ligand biogenesis,0.002201326584991843,1,0,1,0.0023371092622698837
3080,PSA1,Hedgehog 'on' state,0.0015501563985676028,0,0,1,0.0016457734630378317
3081,PSA1,Hedgehog 'on' state,0.002201326584991843,1,0,1,0.0023371092622698837
3082,PSA1,MAPK6/MAPK4 signaling,0.0015501563985676028,0,0,1,0.0016457734630378317
3083,PSA1,MAPK6/MAPK4 signaling,0.002201326584991843,1,0,1,0.0023371092622698837
3084,PSA1,Neddylation,0.0015501563985676028,0,0,1,0.0016457734630378317
3085,PSA1,Neddylation,0.002201326584991843,1,0,1,0.0023371092622698837
3086,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.0026090669825077433,0,0,1,0.0027699999864963147
3087,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.004929387463294537,1,0,1,0.005233442950413192
3088,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0026090669825077433,0,0,1,0.0027699999864963147
3089,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004929387463294537,1,0,1,0.005233442950413192
3090,PSA3,Antigen processing-Cross presentation,0.0026090669825077433,0,0,1,0.0027699999864963147
3091,PSA3,Antigen processing-Cross presentation,0.004929387463294537,1,0,1,0.005233442950413192
3092,PSA3,PTEN Regulation,0.0026090669825077433,0,0,1,0.0027699999864963147
3093,PSA3,PTEN Regulation,0.004929387463294537,1,0,1,0.005233442950413192
3094,PSA3,Host Interactions of HIV factors,0.0026090669825077433,0,0,1,0.0027699999864963147
3095,PSA3,Host Interactions of HIV factors,0.004929387463294537,1,0,1,0.005233442950413192
3096,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0026090669825077433,0,0,1,0.0027699999864963147
3097,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004929387463294537,1,0,1,0.005233442950413192
3098,PSA3,APC/C-mediated degradation of cell cycle proteins,0.0026090669825077433,0,0,1,0.0027699999864963147
3099,PSA3,APC/C-mediated degradation of cell cycle proteins,0.004929387463294537,1,0,1,0.005233442950413192
3100,PSA3,Degradation of AXIN,0.0026090669825077433,0,0,1,0.0027699999864963147
3101,PSA3,Degradation of AXIN,0.004929387463294537,1,0,1,0.005233442950413192
3102,PSA3,Degradation of DVL,0.0026090669825077433,0,0,1,0.0027699999864963147
3103,PSA3,Degradation of DVL,0.004929387463294537,1,0,1,0.005233442950413192
3104,PSA3,Downstream TCR signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3105,PSA3,Downstream TCR signaling,0.004929387463294537,1,0,1,0.005233442950413192
3106,PSA3,Transcriptional regulation by RUNX3,0.0026090669825077433,0,0,1,0.0027699999864963147
3107,PSA3,Transcriptional regulation by RUNX3,0.004929387463294537,1,0,1,0.005233442950413192
3108,PSA3,Transcriptional regulation by RUNX2,0.0026090669825077433,0,0,1,0.0027699999864963147
3109,PSA3,Transcriptional regulation by RUNX2,0.004929387463294537,1,0,1,0.005233442950413192
3110,PSA3,Transcriptional regulation by RUNX1,0.0026090669825077433,0,0,1,0.0027699999864963147
3111,PSA3,Transcriptional regulation by RUNX1,0.004929387463294537,1,0,1,0.005233442950413192
3112,PSA3,FCERI mediated NF-kB activation,0.0026090669825077433,0,0,1,0.0027699999864963147
3113,PSA3,FCERI mediated NF-kB activation,0.004929387463294537,1,0,1,0.005233442950413192
3114,PSA3,Mitotic Metaphase and Anaphase,0.0026090669825077433,0,0,1,0.0027699999864963147
3115,PSA3,Mitotic Metaphase and Anaphase,0.004929387463294537,1,0,1,0.005233442950413192
3116,PSA3,Regulation of ornithine decarboxylase (ODC),0.0026090669825077433,0,0,1,0.0027699999864963147
3117,PSA3,Regulation of ornithine decarboxylase (ODC),0.004929387463294537,1,0,1,0.005233442950413192
3118,PSA3,Signaling by ROBO receptors,0.0026090669825077433,0,0,1,0.0027699999864963147
3119,PSA3,Signaling by ROBO receptors,0.004929387463294537,1,0,1,0.005233442950413192
3120,PSA3,PCP/CE pathway,0.0026090669825077433,0,0,1,0.0027699999864963147
3121,PSA3,PCP/CE pathway,0.004929387463294537,1,0,1,0.005233442950413192
3122,PSA3,Interleukin-1 family signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3123,PSA3,Interleukin-1 family signaling,0.004929387463294537,1,0,1,0.005233442950413192
3124,PSA3,G2/M Transition,0.0026090669825077433,0,0,1,0.0027699999864963147
3125,PSA3,G2/M Transition,0.004929387463294537,1,0,1,0.005233442950413192
3126,PSA3,G1/S Transition,0.0026090669825077433,0,0,1,0.0027699999864963147
3127,PSA3,G1/S Transition,0.004929387463294537,1,0,1,0.005233442950413192
3128,PSA3,Hh mutants are degraded by ERAD,0.0026090669825077433,0,0,1,0.0027699999864963147
3129,PSA3,Hh mutants are degraded by ERAD,0.004929387463294537,1,0,1,0.005233442950413192
3130,PSA3,CLEC7A (Dectin-1) signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3131,PSA3,CLEC7A (Dectin-1) signaling,0.004929387463294537,1,0,1,0.005233442950413192
3132,PSA3,Degradation of GLI1 by the proteasome,0.0026090669825077433,0,0,1,0.0027699999864963147
3133,PSA3,Degradation of GLI1 by the proteasome,0.004929387463294537,1,0,1,0.005233442950413192
3134,PSA3,Degradation of GLI2 by the proteasome,0.0026090669825077433,0,0,1,0.0027699999864963147
3135,PSA3,Degradation of GLI2 by the proteasome,0.004929387463294537,1,0,1,0.005233442950413192
3136,PSA3,GLI3 is processed to GLI3R by the proteasome,0.0026090669825077433,0,0,1,0.0027699999864963147
3137,PSA3,GLI3 is processed to GLI3R by the proteasome,0.004929387463294537,1,0,1,0.005233442950413192
3138,PSA3,Defective CFTR causes cystic fibrosis,0.0026090669825077433,0,0,1,0.0027699999864963147
3139,PSA3,Defective CFTR causes cystic fibrosis,0.004929387463294537,1,0,1,0.005233442950413192
3140,PSA3,NIK-->noncanonical NF-kB signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3141,PSA3,NIK-->noncanonical NF-kB signaling,0.004929387463294537,1,0,1,0.005233442950413192
3142,PSA3,RAF/MAP kinase cascade,0.0026090669825077433,0,0,1,0.0027699999864963147
3143,PSA3,RAF/MAP kinase cascade,0.004929387463294537,1,0,1,0.005233442950413192
3144,PSA3,UCH proteinases,0.0026090669825077433,0,0,1,0.0027699999864963147
3145,PSA3,UCH proteinases,0.004929387463294537,1,0,1,0.005233442950413192
3146,PSA3,Ub-specific processing proteases,0.0026090669825077433,0,0,1,0.0027699999864963147
3147,PSA3,Ub-specific processing proteases,0.004929387463294537,1,0,1,0.005233442950413192
3148,PSA3,Orc1 removal from chromatin,0.0026090669825077433,0,0,1,0.0027699999864963147
3149,PSA3,Orc1 removal from chromatin,0.004929387463294537,1,0,1,0.005233442950413192
3150,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.0026090669825077433,0,0,1,0.0027699999864963147
3151,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.004929387463294537,1,0,1,0.005233442950413192
3152,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.0026090669825077433,0,0,1,0.0027699999864963147
3153,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.004929387463294537,1,0,1,0.005233442950413192
3154,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.0026090669825077433,0,0,1,0.0027699999864963147
3155,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.004929387463294537,1,0,1,0.005233442950413192
3156,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.0026090669825077433,0,0,1,0.0027699999864963147
3157,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.004929387463294537,1,0,1,0.005233442950413192
3158,PSA3,p53-Independent G1/S DNA damage checkpoint,0.0026090669825077433,0,0,1,0.0027699999864963147
3159,PSA3,p53-Independent G1/S DNA damage checkpoint,0.004929387463294537,1,0,1,0.005233442950413192
3160,PSA3,Negative regulation of NOTCH4 signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3161,PSA3,Negative regulation of NOTCH4 signaling,0.004929387463294537,1,0,1,0.005233442950413192
3162,PSA3,KEAP1-NFE2L2 pathway,0.0026090669825077433,0,0,1,0.0027699999864963147
3163,PSA3,KEAP1-NFE2L2 pathway,0.004929387463294537,1,0,1,0.005233442950413192
3164,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.0026090669825077433,0,0,1,0.0027699999864963147
3165,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.004929387463294537,1,0,1,0.005233442950413192
3166,PSA3,Degradation of beta-catenin by the destruction complex,0.0026090669825077433,0,0,1,0.0027699999864963147
3167,PSA3,Degradation of beta-catenin by the destruction complex,0.004929387463294537,1,0,1,0.005233442950413192
3168,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0026090669825077433,0,0,1,0.0027699999864963147
3169,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004929387463294537,1,0,1,0.005233442950413192
3170,PSA3,Hedgehog ligand biogenesis,0.0026090669825077433,0,0,1,0.0027699999864963147
3171,PSA3,Hedgehog ligand biogenesis,0.004929387463294537,1,0,1,0.005233442950413192
3172,PSA3,Hedgehog 'on' state,0.0026090669825077433,0,0,1,0.0027699999864963147
3173,PSA3,Hedgehog 'on' state,0.004929387463294537,1,0,1,0.005233442950413192
3174,PSA3,MAPK6/MAPK4 signaling,0.0026090669825077433,0,0,1,0.0027699999864963147
3175,PSA3,MAPK6/MAPK4 signaling,0.004929387463294537,1,0,1,0.005233442950413192
3176,PSA3,Neddylation,0.0026090669825077433,0,0,1,0.0027699999864963147
3177,PSA3,Neddylation,0.004929387463294537,1,0,1,0.005233442950413192
3178,PTX3,Neutrophil degranulation,0.00016934936526373292,0,0,1,0.00017979520749705682
3179,PTX3,Neutrophil degranulation,0.00014023457418626108,1,0,1,0.0001488845519132266
3180,HGFL,Signaling by MST1,0.0001095648774991376,0,0,1,0.00011632308071346374
3181,HGFL,Signaling by MST1,0.00013943728504244314,1,0,1,0.0001480380842171437
3182,STOM,RHO GTPase cycle,0.0003269796039871304,0,0,1,0.00034714842689027566
3183,STOM,RHO GTPase cycle,0.0004309425807113613,1,0,1,0.00045752406923788697
3184,STOM,Neutrophil degranulation,0.0003269796039871304,0,0,1,0.00034714842689027566
3185,STOM,Neutrophil degranulation,0.0004309425807113613,1,0,1,0.00045752406923788697
3186,STOM,Stimuli-sensing channels,0.0003269796039871304,0,0,1,0.00034714842689027566
3187,STOM,Stimuli-sensing channels,0.0004309425807113613,1,0,1,0.00045752406923788697
3188,PON1,Arachidonic acid metabolism,0.0016047270838789515,0,0,1,0.0017037101885373975
3189,PON1,Arachidonic acid metabolism,0.0007074188173725173,1,0,1,0.0007510539697549892
3190,PON1,Atorvastatin ADME,0.0016047270838789515,0,0,1,0.0017037101885373975
3191,PON1,Atorvastatin ADME,0.0007074188173725173,1,0,1,0.0007510539697549892
3192,1433T,Activation of BH3-only proteins,0.00011205430257574833,0,0,1,0.00011896605901751916
3193,1433T,Activation of BH3-only proteins,0.00023892203060470445,1,0,1,0.00025365926823104826
3194,1433T,RHO GTPase Effectors,0.00011205430257574833,0,0,1,0.00011896605901751916
3195,1433T,RHO GTPase Effectors,0.00023892203060470445,1,0,1,0.00025365926823104826
3196,1433T,Transcriptional Regulation by TP53,0.00011205430257574833,0,0,1,0.00011896605901751916
3197,1433T,Transcriptional Regulation by TP53,0.00023892203060470445,1,0,1,0.00025365926823104826
3198,1433T,FOXO-mediated transcription,0.00011205430257574833,0,0,1,0.00011896605901751916
3199,1433T,FOXO-mediated transcription,0.00023892203060470445,1,0,1,0.00025365926823104826
3200,1433T,G2/M DNA damage checkpoint,0.00011205430257574833,0,0,1,0.00011896605901751916
3201,1433T,G2/M DNA damage checkpoint,0.00023892203060470445,1,0,1,0.00025365926823104826
3202,1433T,SARS-CoV-2 Infection,0.00011205430257574833,0,0,1,0.00011896605901751916
3203,1433T,SARS-CoV-2 Infection,0.00023892203060470445,1,0,1,0.00025365926823104826
3204,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00011205430257574833,0,0,1,0.00011896605901751916
3205,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00023892203060470445,1,0,1,0.00025365926823104826
3206,CALR,Antigen processing-Cross presentation,0.003465207699605921,0,0,1,0.003678949350656174
3207,CALR,Antigen processing-Cross presentation,0.0028075226647590245,1,0,1,0.002980696852786728
3208,CALR,Virus Assembly and Release,0.003465207699605921,0,0,1,0.003678949350656174
3209,CALR,Virus Assembly and Release,0.0028075226647590245,1,0,1,0.002980696852786728
3210,CALR,ATF6 (ATF6-alpha) activates chaperones,0.003465207699605921,0,0,1,0.003678949350656174
3211,CALR,ATF6 (ATF6-alpha) activates chaperones,0.0028075226647590245,1,0,1,0.002980696852786728
3212,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.003465207699605921,0,0,1,0.003678949350656174
3213,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0028075226647590245,1,0,1,0.002980696852786728
3214,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.003465207699605921,0,0,1,0.003678949350656174
3215,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0028075226647590245,1,0,1,0.002980696852786728
3216,CALR,Scavenging by Class A Receptors,0.003465207699605921,0,0,1,0.003678949350656174
3217,CALR,Scavenging by Class A Receptors,0.0028075226647590245,1,0,1,0.002980696852786728
3218,CALR,Scavenging by Class F Receptors,0.003465207699605921,0,0,1,0.003678949350656174
3219,CALR,Scavenging by Class F Receptors,0.0028075226647590245,1,0,1,0.002980696852786728
3220,PROP,Initial triggering of complement,0.0008193954694288931,0,0,1,0.0008699375885978961
3221,PROP,Initial triggering of complement,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3222,PROP,Activation of C3 and C5,0.0008193954694288931,0,0,1,0.0008699375885978961
3223,PROP,Activation of C3 and C5,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3224,PROP,Regulation of Complement cascade,0.0008193954694288931,0,0,1,0.0008699375885978961
3225,PROP,Regulation of Complement cascade,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3226,PROP,Diseases associated with O-glycosylation of proteins,0.0008193954694288931,0,0,1,0.0008699375885978961
3227,PROP,Diseases associated with O-glycosylation of proteins,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3228,PROP,O-glycosylation of TSR domain-containing proteins,0.0008193954694288931,0,0,1,0.0008699375885978961
3229,PROP,O-glycosylation of TSR domain-containing proteins,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3230,PROP,Neutrophil degranulation,0.0008193954694288931,0,0,1,0.0008699375885978961
3231,PROP,Neutrophil degranulation,4.012779684889404e-05,1,0,1,4.2602967832863395e-05
3232,IL1R2,Interleukin-1 family signaling,0.0004286179398062407,0,0,1,0.0004550560393563377
3233,IL1R2,Interleukin-1 family signaling,2.1513371863129762e-05,1,0,1,2.2840364072631765e-05
3234,IL1R2,Interleukin-10 signaling,0.0004286179398062407,0,0,1,0.0004550560393563377
3235,IL1R2,Interleukin-10 signaling,2.1513371863129762e-05,1,0,1,2.2840364072631765e-05
3236,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.0013737960834987462,0,0,1,0.001458534854893831
3237,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.0007963644117258754,1,0,1,0.000845485924476557
3238,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0013737960834987462,0,0,1,0.001458534854893831
3239,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0007963644117258754,1,0,1,0.000845485924476557
3240,PSA5,Antigen processing-Cross presentation,0.0013737960834987462,0,0,1,0.001458534854893831
3241,PSA5,Antigen processing-Cross presentation,0.0007963644117258754,1,0,1,0.000845485924476557
3242,PSA5,PTEN Regulation,0.0013737960834987462,0,0,1,0.001458534854893831
3243,PSA5,PTEN Regulation,0.0007963644117258754,1,0,1,0.000845485924476557
3244,PSA5,Host Interactions of HIV factors,0.0013737960834987462,0,0,1,0.001458534854893831
3245,PSA5,Host Interactions of HIV factors,0.0007963644117258754,1,0,1,0.000845485924476557
3246,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0013737960834987462,0,0,1,0.001458534854893831
3247,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0007963644117258754,1,0,1,0.000845485924476557
3248,PSA5,APC/C-mediated degradation of cell cycle proteins,0.0013737960834987462,0,0,1,0.001458534854893831
3249,PSA5,APC/C-mediated degradation of cell cycle proteins,0.0007963644117258754,1,0,1,0.000845485924476557
3250,PSA5,Degradation of AXIN,0.0013737960834987462,0,0,1,0.001458534854893831
3251,PSA5,Degradation of AXIN,0.0007963644117258754,1,0,1,0.000845485924476557
3252,PSA5,Degradation of DVL,0.0013737960834987462,0,0,1,0.001458534854893831
3253,PSA5,Degradation of DVL,0.0007963644117258754,1,0,1,0.000845485924476557
3254,PSA5,Downstream TCR signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3255,PSA5,Downstream TCR signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3256,PSA5,Transcriptional regulation by RUNX3,0.0013737960834987462,0,0,1,0.001458534854893831
3257,PSA5,Transcriptional regulation by RUNX3,0.0007963644117258754,1,0,1,0.000845485924476557
3258,PSA5,Transcriptional regulation by RUNX2,0.0013737960834987462,0,0,1,0.001458534854893831
3259,PSA5,Transcriptional regulation by RUNX2,0.0007963644117258754,1,0,1,0.000845485924476557
3260,PSA5,Transcriptional regulation by RUNX1,0.0013737960834987462,0,0,1,0.001458534854893831
3261,PSA5,Transcriptional regulation by RUNX1,0.0007963644117258754,1,0,1,0.000845485924476557
3262,PSA5,FCERI mediated NF-kB activation,0.0013737960834987462,0,0,1,0.001458534854893831
3263,PSA5,FCERI mediated NF-kB activation,0.0007963644117258754,1,0,1,0.000845485924476557
3264,PSA5,Mitotic Metaphase and Anaphase,0.0013737960834987462,0,0,1,0.001458534854893831
3265,PSA5,Mitotic Metaphase and Anaphase,0.0007963644117258754,1,0,1,0.000845485924476557
3266,PSA5,Regulation of ornithine decarboxylase (ODC),0.0013737960834987462,0,0,1,0.001458534854893831
3267,PSA5,Regulation of ornithine decarboxylase (ODC),0.0007963644117258754,1,0,1,0.000845485924476557
3268,PSA5,Signaling by ROBO receptors,0.0013737960834987462,0,0,1,0.001458534854893831
3269,PSA5,Signaling by ROBO receptors,0.0007963644117258754,1,0,1,0.000845485924476557
3270,PSA5,PCP/CE pathway,0.0013737960834987462,0,0,1,0.001458534854893831
3271,PSA5,PCP/CE pathway,0.0007963644117258754,1,0,1,0.000845485924476557
3272,PSA5,Interleukin-1 family signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3273,PSA5,Interleukin-1 family signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3274,PSA5,G2/M Transition,0.0013737960834987462,0,0,1,0.001458534854893831
3275,PSA5,G2/M Transition,0.0007963644117258754,1,0,1,0.000845485924476557
3276,PSA5,G1/S Transition,0.0013737960834987462,0,0,1,0.001458534854893831
3277,PSA5,G1/S Transition,0.0007963644117258754,1,0,1,0.000845485924476557
3278,PSA5,Hh mutants are degraded by ERAD,0.0013737960834987462,0,0,1,0.001458534854893831
3279,PSA5,Hh mutants are degraded by ERAD,0.0007963644117258754,1,0,1,0.000845485924476557
3280,PSA5,CLEC7A (Dectin-1) signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3281,PSA5,CLEC7A (Dectin-1) signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3282,PSA5,Degradation of GLI1 by the proteasome,0.0013737960834987462,0,0,1,0.001458534854893831
3283,PSA5,Degradation of GLI1 by the proteasome,0.0007963644117258754,1,0,1,0.000845485924476557
3284,PSA5,Degradation of GLI2 by the proteasome,0.0013737960834987462,0,0,1,0.001458534854893831
3285,PSA5,Degradation of GLI2 by the proteasome,0.0007963644117258754,1,0,1,0.000845485924476557
3286,PSA5,GLI3 is processed to GLI3R by the proteasome,0.0013737960834987462,0,0,1,0.001458534854893831
3287,PSA5,GLI3 is processed to GLI3R by the proteasome,0.0007963644117258754,1,0,1,0.000845485924476557
3288,PSA5,Defective CFTR causes cystic fibrosis,0.0013737960834987462,0,0,1,0.001458534854893831
3289,PSA5,Defective CFTR causes cystic fibrosis,0.0007963644117258754,1,0,1,0.000845485924476557
3290,PSA5,NIK-->noncanonical NF-kB signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3291,PSA5,NIK-->noncanonical NF-kB signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3292,PSA5,RAF/MAP kinase cascade,0.0013737960834987462,0,0,1,0.001458534854893831
3293,PSA5,RAF/MAP kinase cascade,0.0007963644117258754,1,0,1,0.000845485924476557
3294,PSA5,UCH proteinases,0.0013737960834987462,0,0,1,0.001458534854893831
3295,PSA5,UCH proteinases,0.0007963644117258754,1,0,1,0.000845485924476557
3296,PSA5,Ub-specific processing proteases,0.0013737960834987462,0,0,1,0.001458534854893831
3297,PSA5,Ub-specific processing proteases,0.0007963644117258754,1,0,1,0.000845485924476557
3298,PSA5,Orc1 removal from chromatin,0.0013737960834987462,0,0,1,0.001458534854893831
3299,PSA5,Orc1 removal from chromatin,0.0007963644117258754,1,0,1,0.000845485924476557
3300,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.0013737960834987462,0,0,1,0.001458534854893831
3301,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.0007963644117258754,1,0,1,0.000845485924476557
3302,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.0013737960834987462,0,0,1,0.001458534854893831
3303,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.0007963644117258754,1,0,1,0.000845485924476557
3304,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.0013737960834987462,0,0,1,0.001458534854893831
3305,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.0007963644117258754,1,0,1,0.000845485924476557
3306,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.0013737960834987462,0,0,1,0.001458534854893831
3307,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.0007963644117258754,1,0,1,0.000845485924476557
3308,PSA5,p53-Independent G1/S DNA damage checkpoint,0.0013737960834987462,0,0,1,0.001458534854893831
3309,PSA5,p53-Independent G1/S DNA damage checkpoint,0.0007963644117258754,1,0,1,0.000845485924476557
3310,PSA5,Negative regulation of NOTCH4 signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3311,PSA5,Negative regulation of NOTCH4 signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3312,PSA5,KEAP1-NFE2L2 pathway,0.0013737960834987462,0,0,1,0.001458534854893831
3313,PSA5,KEAP1-NFE2L2 pathway,0.0007963644117258754,1,0,1,0.000845485924476557
3314,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.0013737960834987462,0,0,1,0.001458534854893831
3315,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.0007963644117258754,1,0,1,0.000845485924476557
3316,PSA5,Neutrophil degranulation,0.0013737960834987462,0,0,1,0.001458534854893831
3317,PSA5,Neutrophil degranulation,0.0007963644117258754,1,0,1,0.000845485924476557
3318,PSA5,Degradation of beta-catenin by the destruction complex,0.0013737960834987462,0,0,1,0.001458534854893831
3319,PSA5,Degradation of beta-catenin by the destruction complex,0.0007963644117258754,1,0,1,0.000845485924476557
3320,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0013737960834987462,0,0,1,0.001458534854893831
3321,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0007963644117258754,1,0,1,0.000845485924476557
3322,PSA5,Hedgehog ligand biogenesis,0.0013737960834987462,0,0,1,0.001458534854893831
3323,PSA5,Hedgehog ligand biogenesis,0.0007963644117258754,1,0,1,0.000845485924476557
3324,PSA5,Hedgehog 'on' state,0.0013737960834987462,0,0,1,0.001458534854893831
3325,PSA5,Hedgehog 'on' state,0.0007963644117258754,1,0,1,0.000845485924476557
3326,PSA5,MAPK6/MAPK4 signaling,0.0013737960834987462,0,0,1,0.001458534854893831
3327,PSA5,MAPK6/MAPK4 signaling,0.0007963644117258754,1,0,1,0.000845485924476557
3328,PSA5,Neddylation,0.0013737960834987462,0,0,1,0.001458534854893831
3329,PSA5,Neddylation,0.0007963644117258754,1,0,1,0.000845485924476557
3330,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.002094158517175501,0,0,1,0.0022233308317449697
3331,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.00113082976297057,1,0,1,0.0012005818360199241
3332,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.002094158517175501,0,0,1,0.0022233308317449697
3333,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00113082976297057,1,0,1,0.0012005818360199241
3334,PSB6,Antigen processing-Cross presentation,0.002094158517175501,0,0,1,0.0022233308317449697
3335,PSB6,Antigen processing-Cross presentation,0.00113082976297057,1,0,1,0.0012005818360199241
3336,PSB6,PTEN Regulation,0.002094158517175501,0,0,1,0.0022233308317449697
3337,PSB6,PTEN Regulation,0.00113082976297057,1,0,1,0.0012005818360199241
3338,PSB6,Host Interactions of HIV factors,0.002094158517175501,0,0,1,0.0022233308317449697
3339,PSB6,Host Interactions of HIV factors,0.00113082976297057,1,0,1,0.0012005818360199241
3340,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.002094158517175501,0,0,1,0.0022233308317449697
3341,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00113082976297057,1,0,1,0.0012005818360199241
3342,PSB6,APC/C-mediated degradation of cell cycle proteins,0.002094158517175501,0,0,1,0.0022233308317449697
3343,PSB6,APC/C-mediated degradation of cell cycle proteins,0.00113082976297057,1,0,1,0.0012005818360199241
3344,PSB6,Degradation of AXIN,0.002094158517175501,0,0,1,0.0022233308317449697
3345,PSB6,Degradation of AXIN,0.00113082976297057,1,0,1,0.0012005818360199241
3346,PSB6,Degradation of DVL,0.002094158517175501,0,0,1,0.0022233308317449697
3347,PSB6,Degradation of DVL,0.00113082976297057,1,0,1,0.0012005818360199241
3348,PSB6,Downstream TCR signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3349,PSB6,Downstream TCR signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3350,PSB6,Transcriptional regulation by RUNX3,0.002094158517175501,0,0,1,0.0022233308317449697
3351,PSB6,Transcriptional regulation by RUNX3,0.00113082976297057,1,0,1,0.0012005818360199241
3352,PSB6,Transcriptional regulation by RUNX2,0.002094158517175501,0,0,1,0.0022233308317449697
3353,PSB6,Transcriptional regulation by RUNX2,0.00113082976297057,1,0,1,0.0012005818360199241
3354,PSB6,Transcriptional regulation by RUNX1,0.002094158517175501,0,0,1,0.0022233308317449697
3355,PSB6,Transcriptional regulation by RUNX1,0.00113082976297057,1,0,1,0.0012005818360199241
3356,PSB6,FCERI mediated NF-kB activation,0.002094158517175501,0,0,1,0.0022233308317449697
3357,PSB6,FCERI mediated NF-kB activation,0.00113082976297057,1,0,1,0.0012005818360199241
3358,PSB6,Mitotic Metaphase and Anaphase,0.002094158517175501,0,0,1,0.0022233308317449697
3359,PSB6,Mitotic Metaphase and Anaphase,0.00113082976297057,1,0,1,0.0012005818360199241
3360,PSB6,Regulation of ornithine decarboxylase (ODC),0.002094158517175501,0,0,1,0.0022233308317449697
3361,PSB6,Regulation of ornithine decarboxylase (ODC),0.00113082976297057,1,0,1,0.0012005818360199241
3362,PSB6,Signaling by ROBO receptors,0.002094158517175501,0,0,1,0.0022233308317449697
3363,PSB6,Signaling by ROBO receptors,0.00113082976297057,1,0,1,0.0012005818360199241
3364,PSB6,PCP/CE pathway,0.002094158517175501,0,0,1,0.0022233308317449697
3365,PSB6,PCP/CE pathway,0.00113082976297057,1,0,1,0.0012005818360199241
3366,PSB6,Interleukin-1 family signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3367,PSB6,Interleukin-1 family signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3368,PSB6,G2/M Transition,0.002094158517175501,0,0,1,0.0022233308317449697
3369,PSB6,G2/M Transition,0.00113082976297057,1,0,1,0.0012005818360199241
3370,PSB6,G1/S Transition,0.002094158517175501,0,0,1,0.0022233308317449697
3371,PSB6,G1/S Transition,0.00113082976297057,1,0,1,0.0012005818360199241
3372,PSB6,Hh mutants are degraded by ERAD,0.002094158517175501,0,0,1,0.0022233308317449697
3373,PSB6,Hh mutants are degraded by ERAD,0.00113082976297057,1,0,1,0.0012005818360199241
3374,PSB6,CLEC7A (Dectin-1) signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3375,PSB6,CLEC7A (Dectin-1) signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3376,PSB6,Degradation of GLI1 by the proteasome,0.002094158517175501,0,0,1,0.0022233308317449697
3377,PSB6,Degradation of GLI1 by the proteasome,0.00113082976297057,1,0,1,0.0012005818360199241
3378,PSB6,Degradation of GLI2 by the proteasome,0.002094158517175501,0,0,1,0.0022233308317449697
3379,PSB6,Degradation of GLI2 by the proteasome,0.00113082976297057,1,0,1,0.0012005818360199241
3380,PSB6,GLI3 is processed to GLI3R by the proteasome,0.002094158517175501,0,0,1,0.0022233308317449697
3381,PSB6,GLI3 is processed to GLI3R by the proteasome,0.00113082976297057,1,0,1,0.0012005818360199241
3382,PSB6,Defective CFTR causes cystic fibrosis,0.002094158517175501,0,0,1,0.0022233308317449697
3383,PSB6,Defective CFTR causes cystic fibrosis,0.00113082976297057,1,0,1,0.0012005818360199241
3384,PSB6,NIK-->noncanonical NF-kB signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3385,PSB6,NIK-->noncanonical NF-kB signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3386,PSB6,RAF/MAP kinase cascade,0.002094158517175501,0,0,1,0.0022233308317449697
3387,PSB6,RAF/MAP kinase cascade,0.00113082976297057,1,0,1,0.0012005818360199241
3388,PSB6,UCH proteinases,0.002094158517175501,0,0,1,0.0022233308317449697
3389,PSB6,UCH proteinases,0.00113082976297057,1,0,1,0.0012005818360199241
3390,PSB6,Ub-specific processing proteases,0.002094158517175501,0,0,1,0.0022233308317449697
3391,PSB6,Ub-specific processing proteases,0.00113082976297057,1,0,1,0.0012005818360199241
3392,PSB6,Orc1 removal from chromatin,0.002094158517175501,0,0,1,0.0022233308317449697
3393,PSB6,Orc1 removal from chromatin,0.00113082976297057,1,0,1,0.0012005818360199241
3394,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.002094158517175501,0,0,1,0.0022233308317449697
3395,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.00113082976297057,1,0,1,0.0012005818360199241
3396,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.002094158517175501,0,0,1,0.0022233308317449697
3397,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.00113082976297057,1,0,1,0.0012005818360199241
3398,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.002094158517175501,0,0,1,0.0022233308317449697
3399,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.00113082976297057,1,0,1,0.0012005818360199241
3400,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.002094158517175501,0,0,1,0.0022233308317449697
3401,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.00113082976297057,1,0,1,0.0012005818360199241
3402,PSB6,p53-Independent G1/S DNA damage checkpoint,0.002094158517175501,0,0,1,0.0022233308317449697
3403,PSB6,p53-Independent G1/S DNA damage checkpoint,0.00113082976297057,1,0,1,0.0012005818360199241
3404,PSB6,Negative regulation of NOTCH4 signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3405,PSB6,Negative regulation of NOTCH4 signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3406,PSB6,KEAP1-NFE2L2 pathway,0.002094158517175501,0,0,1,0.0022233308317449697
3407,PSB6,KEAP1-NFE2L2 pathway,0.00113082976297057,1,0,1,0.0012005818360199241
3408,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.002094158517175501,0,0,1,0.0022233308317449697
3409,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.00113082976297057,1,0,1,0.0012005818360199241
3410,PSB6,Degradation of beta-catenin by the destruction complex,0.002094158517175501,0,0,1,0.0022233308317449697
3411,PSB6,Degradation of beta-catenin by the destruction complex,0.00113082976297057,1,0,1,0.0012005818360199241
3412,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002094158517175501,0,0,1,0.0022233308317449697
3413,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00113082976297057,1,0,1,0.0012005818360199241
3414,PSB6,Hedgehog ligand biogenesis,0.002094158517175501,0,0,1,0.0022233308317449697
3415,PSB6,Hedgehog ligand biogenesis,0.00113082976297057,1,0,1,0.0012005818360199241
3416,PSB6,Hedgehog 'on' state,0.002094158517175501,0,0,1,0.0022233308317449697
3417,PSB6,Hedgehog 'on' state,0.00113082976297057,1,0,1,0.0012005818360199241
3418,PSB6,MAPK6/MAPK4 signaling,0.002094158517175501,0,0,1,0.0022233308317449697
3419,PSB6,MAPK6/MAPK4 signaling,0.00113082976297057,1,0,1,0.0012005818360199241
3420,PSB6,Neddylation,0.002094158517175501,0,0,1,0.0022233308317449697
3421,PSB6,Neddylation,0.00113082976297057,1,0,1,0.0012005818360199241
3422,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.0015000426248874194,0,0,1,0.0015925685613055033
3423,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.0021806440247000587,1,0,1,0.0023151509560581027
3424,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0015000426248874194,0,0,1,0.0015925685613055033
3425,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0021806440247000587,1,0,1,0.0023151509560581027
3426,PSB5,Antigen processing-Cross presentation,0.0015000426248874194,0,0,1,0.0015925685613055033
3427,PSB5,Antigen processing-Cross presentation,0.0021806440247000587,1,0,1,0.0023151509560581027
3428,PSB5,PTEN Regulation,0.0015000426248874194,0,0,1,0.0015925685613055033
3429,PSB5,PTEN Regulation,0.0021806440247000587,1,0,1,0.0023151509560581027
3430,PSB5,Host Interactions of HIV factors,0.0015000426248874194,0,0,1,0.0015925685613055033
3431,PSB5,Host Interactions of HIV factors,0.0021806440247000587,1,0,1,0.0023151509560581027
3432,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0015000426248874194,0,0,1,0.0015925685613055033
3433,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0021806440247000587,1,0,1,0.0023151509560581027
3434,PSB5,APC/C-mediated degradation of cell cycle proteins,0.0015000426248874194,0,0,1,0.0015925685613055033
3435,PSB5,APC/C-mediated degradation of cell cycle proteins,0.0021806440247000587,1,0,1,0.0023151509560581027
3436,PSB5,Degradation of AXIN,0.0015000426248874194,0,0,1,0.0015925685613055033
3437,PSB5,Degradation of AXIN,0.0021806440247000587,1,0,1,0.0023151509560581027
3438,PSB5,Degradation of DVL,0.0015000426248874194,0,0,1,0.0015925685613055033
3439,PSB5,Degradation of DVL,0.0021806440247000587,1,0,1,0.0023151509560581027
3440,PSB5,Downstream TCR signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3441,PSB5,Downstream TCR signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3442,PSB5,Transcriptional regulation by RUNX3,0.0015000426248874194,0,0,1,0.0015925685613055033
3443,PSB5,Transcriptional regulation by RUNX3,0.0021806440247000587,1,0,1,0.0023151509560581027
3444,PSB5,Transcriptional regulation by RUNX2,0.0015000426248874194,0,0,1,0.0015925685613055033
3445,PSB5,Transcriptional regulation by RUNX2,0.0021806440247000587,1,0,1,0.0023151509560581027
3446,PSB5,Transcriptional regulation by RUNX1,0.0015000426248874194,0,0,1,0.0015925685613055033
3447,PSB5,Transcriptional regulation by RUNX1,0.0021806440247000587,1,0,1,0.0023151509560581027
3448,PSB5,FCERI mediated NF-kB activation,0.0015000426248874194,0,0,1,0.0015925685613055033
3449,PSB5,FCERI mediated NF-kB activation,0.0021806440247000587,1,0,1,0.0023151509560581027
3450,PSB5,Mitotic Metaphase and Anaphase,0.0015000426248874194,0,0,1,0.0015925685613055033
3451,PSB5,Mitotic Metaphase and Anaphase,0.0021806440247000587,1,0,1,0.0023151509560581027
3452,PSB5,Regulation of ornithine decarboxylase (ODC),0.0015000426248874194,0,0,1,0.0015925685613055033
3453,PSB5,Regulation of ornithine decarboxylase (ODC),0.0021806440247000587,1,0,1,0.0023151509560581027
3454,PSB5,Signaling by ROBO receptors,0.0015000426248874194,0,0,1,0.0015925685613055033
3455,PSB5,Signaling by ROBO receptors,0.0021806440247000587,1,0,1,0.0023151509560581027
3456,PSB5,PCP/CE pathway,0.0015000426248874194,0,0,1,0.0015925685613055033
3457,PSB5,PCP/CE pathway,0.0021806440247000587,1,0,1,0.0023151509560581027
3458,PSB5,Interleukin-1 family signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3459,PSB5,Interleukin-1 family signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3460,PSB5,G2/M Transition,0.0015000426248874194,0,0,1,0.0015925685613055033
3461,PSB5,G2/M Transition,0.0021806440247000587,1,0,1,0.0023151509560581027
3462,PSB5,G1/S Transition,0.0015000426248874194,0,0,1,0.0015925685613055033
3463,PSB5,G1/S Transition,0.0021806440247000587,1,0,1,0.0023151509560581027
3464,PSB5,Hh mutants are degraded by ERAD,0.0015000426248874194,0,0,1,0.0015925685613055033
3465,PSB5,Hh mutants are degraded by ERAD,0.0021806440247000587,1,0,1,0.0023151509560581027
3466,PSB5,CLEC7A (Dectin-1) signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3467,PSB5,CLEC7A (Dectin-1) signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3468,PSB5,Degradation of GLI1 by the proteasome,0.0015000426248874194,0,0,1,0.0015925685613055033
3469,PSB5,Degradation of GLI1 by the proteasome,0.0021806440247000587,1,0,1,0.0023151509560581027
3470,PSB5,Degradation of GLI2 by the proteasome,0.0015000426248874194,0,0,1,0.0015925685613055033
3471,PSB5,Degradation of GLI2 by the proteasome,0.0021806440247000587,1,0,1,0.0023151509560581027
3472,PSB5,GLI3 is processed to GLI3R by the proteasome,0.0015000426248874194,0,0,1,0.0015925685613055033
3473,PSB5,GLI3 is processed to GLI3R by the proteasome,0.0021806440247000587,1,0,1,0.0023151509560581027
3474,PSB5,Defective CFTR causes cystic fibrosis,0.0015000426248874194,0,0,1,0.0015925685613055033
3475,PSB5,Defective CFTR causes cystic fibrosis,0.0021806440247000587,1,0,1,0.0023151509560581027
3476,PSB5,NIK-->noncanonical NF-kB signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3477,PSB5,NIK-->noncanonical NF-kB signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3478,PSB5,RAF/MAP kinase cascade,0.0015000426248874194,0,0,1,0.0015925685613055033
3479,PSB5,RAF/MAP kinase cascade,0.0021806440247000587,1,0,1,0.0023151509560581027
3480,PSB5,UCH proteinases,0.0015000426248874194,0,0,1,0.0015925685613055033
3481,PSB5,UCH proteinases,0.0021806440247000587,1,0,1,0.0023151509560581027
3482,PSB5,Ub-specific processing proteases,0.0015000426248874194,0,0,1,0.0015925685613055033
3483,PSB5,Ub-specific processing proteases,0.0021806440247000587,1,0,1,0.0023151509560581027
3484,PSB5,Orc1 removal from chromatin,0.0015000426248874194,0,0,1,0.0015925685613055033
3485,PSB5,Orc1 removal from chromatin,0.0021806440247000587,1,0,1,0.0023151509560581027
3486,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.0015000426248874194,0,0,1,0.0015925685613055033
3487,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.0021806440247000587,1,0,1,0.0023151509560581027
3488,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.0015000426248874194,0,0,1,0.0015925685613055033
3489,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.0021806440247000587,1,0,1,0.0023151509560581027
3490,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.0015000426248874194,0,0,1,0.0015925685613055033
3491,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.0021806440247000587,1,0,1,0.0023151509560581027
3492,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.0015000426248874194,0,0,1,0.0015925685613055033
3493,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.0021806440247000587,1,0,1,0.0023151509560581027
3494,PSB5,p53-Independent G1/S DNA damage checkpoint,0.0015000426248874194,0,0,1,0.0015925685613055033
3495,PSB5,p53-Independent G1/S DNA damage checkpoint,0.0021806440247000587,1,0,1,0.0023151509560581027
3496,PSB5,Negative regulation of NOTCH4 signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3497,PSB5,Negative regulation of NOTCH4 signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3498,PSB5,KEAP1-NFE2L2 pathway,0.0015000426248874194,0,0,1,0.0015925685613055033
3499,PSB5,KEAP1-NFE2L2 pathway,0.0021806440247000587,1,0,1,0.0023151509560581027
3500,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.0015000426248874194,0,0,1,0.0015925685613055033
3501,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.0021806440247000587,1,0,1,0.0023151509560581027
3502,PSB5,Degradation of beta-catenin by the destruction complex,0.0015000426248874194,0,0,1,0.0015925685613055033
3503,PSB5,Degradation of beta-catenin by the destruction complex,0.0021806440247000587,1,0,1,0.0023151509560581027
3504,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015000426248874194,0,0,1,0.0015925685613055033
3505,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0021806440247000587,1,0,1,0.0023151509560581027
3506,PSB5,Hedgehog ligand biogenesis,0.0015000426248874194,0,0,1,0.0015925685613055033
3507,PSB5,Hedgehog ligand biogenesis,0.0021806440247000587,1,0,1,0.0023151509560581027
3508,PSB5,Hedgehog 'on' state,0.0015000426248874194,0,0,1,0.0015925685613055033
3509,PSB5,Hedgehog 'on' state,0.0021806440247000587,1,0,1,0.0023151509560581027
3510,PSB5,MAPK6/MAPK4 signaling,0.0015000426248874194,0,0,1,0.0015925685613055033
3511,PSB5,MAPK6/MAPK4 signaling,0.0021806440247000587,1,0,1,0.0023151509560581027
3512,PSB5,Neddylation,0.0015000426248874194,0,0,1,0.0015925685613055033
3513,PSB5,Neddylation,0.0021806440247000587,1,0,1,0.0023151509560581027
3514,GRN,Neutrophil degranulation,0.00016641058023358405,0,0,1,0.00017667515172677388
3515,GRN,Neutrophil degranulation,0.00013941302536687973,1,0,1,0.00014801232815130343
3516,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0002439038954772112,0,0,1,0.0002589484255129768
3517,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0008823265497948558,1,0,1,0.0009367503967521603
3518,CCN2,Transcriptional regulation by RUNX3,0.0002439038954772112,0,0,1,0.0002589484255129768
3519,CCN2,Transcriptional regulation by RUNX3,0.0008823265497948558,1,0,1,0.0009367503967521603
3520,TKT,KEAP1-NFE2L2 pathway,0.0008457577184580153,0,0,1,0.0008979259192709911
3521,TKT,KEAP1-NFE2L2 pathway,0.0005771608350722847,1,0,1,0.0006127613879118512
3522,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0008457577184580153,0,0,1,0.0008979259192709911
3523,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0005771608350722847,1,0,1,0.0006127613879118512
3524,TKT,Pentose phosphate pathway,0.0008457577184580153,0,0,1,0.0008979259192709911
3525,TKT,Pentose phosphate pathway,0.0005771608350722847,1,0,1,0.0006127613879118512
3526,KAIN,Platelet degranulation ,5.295889202450448e-06,0,0,1,5.622551324908418e-06
3527,KAIN,Platelet degranulation ,1.0272192626186971e-05,1,0,1,1.0905804115644626e-05
3528,PRDX6,Detoxification of Reactive Oxygen Species,6.077498644487788e-06,0,0,1,6.452372160634086e-06
3529,PRDX6,Detoxification of Reactive Oxygen Species,2.1992034272457413e-05,1,0,1,2.3348551434728345e-05
3530,PRDX6,Neutrophil degranulation,6.077498644487788e-06,0,0,1,6.452372160634086e-06
3531,PRDX6,Neutrophil degranulation,2.1992034272457413e-05,1,0,1,2.3348551434728345e-05
3532,BLVRB,Cytoprotection by HMOX1,0.0019793242002189688,0,0,1,0.0021014132809302455
3533,BLVRB,Cytoprotection by HMOX1,0.0007609835278353924,1,0,1,0.0008079226696594396
3534,BLVRB,Heme degradation,0.0019793242002189688,0,0,1,0.0021014132809302455
3535,BLVRB,Heme degradation,0.0007609835278353924,1,0,1,0.0008079226696594396
3536,PEBP1,RAF/MAP kinase cascade,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3537,PEBP1,RAF/MAP kinase cascade,0.0009237094383407856,1,0,1,0.0009806858731051765
3538,PEBP1,Signaling by RAS mutants,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3539,PEBP1,Signaling by RAS mutants,0.0009237094383407856,1,0,1,0.0009806858731051765
3540,PEBP1,Signaling by moderate kinase activity BRAF mutants,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3541,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0009237094383407856,1,0,1,0.0009806858731051765
3542,PEBP1,Signaling by high-kinase activity BRAF mutants,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3543,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0009237094383407856,1,0,1,0.0009806858731051765
3544,PEBP1,Signaling by BRAF and RAF1 fusions,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3545,PEBP1,Signaling by BRAF and RAF1 fusions,0.0009237094383407856,1,0,1,0.0009806858731051765
3546,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,4.943667971384471e-05,0,0,1,5.248604311727978e-05
3547,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0009237094383407856,1,0,1,0.0009806858731051765
3548,PDIA3,Antigen processing-Cross presentation,0.0005262264088658985,0,0,1,0.0005586852139961174
3549,PDIA3,Antigen processing-Cross presentation,0.0006137026941018454,1,0,1,0.0006515572293743587
3550,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0005262264088658985,0,0,1,0.0005586852139961174
3551,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0006137026941018454,1,0,1,0.0006515572293743587
3552,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0005262264088658985,0,0,1,0.0005586852139961174
3553,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0006137026941018454,1,0,1,0.0006515572293743587
3554,P30443,Antigen processing-Cross presentation,0.003602624688826993,0,0,1,0.0038248425227513077
3555,P30443,Antigen processing-Cross presentation,0.002243574674425618,1,0,1,0.0023819633070091143
3556,P30443,Interferon gamma signaling,0.003602624688826993,0,0,1,0.0038248425227513077
3557,P30443,Interferon gamma signaling,0.002243574674425618,1,0,1,0.0023819633070091143
3558,P30443,Interferon alpha/beta signaling,0.003602624688826993,0,0,1,0.0038248425227513077
3559,P30443,Interferon alpha/beta signaling,0.002243574674425618,1,0,1,0.0023819633070091143
3560,P30443,SARS-CoV-2 Infection,0.003602624688826993,0,0,1,0.0038248425227513077
3561,P30443,SARS-CoV-2 Infection,0.002243574674425618,1,0,1,0.0023819633070091143
3562,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.003602624688826993,0,0,1,0.0038248425227513077
3563,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.002243574674425618,1,0,1,0.0023819633070091143
3564,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003602624688826993,0,0,1,0.0038248425227513077
3565,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002243574674425618,1,0,1,0.0023819633070091143
3566,ILEU,Neutrophil degranulation,0.00017718082661876398,0,0,1,0.0001881097306553821
3567,ILEU,Neutrophil degranulation,0.00014255377036672401,1,0,1,0.0001513468012274968
3568,CPSM,Urea cycle,0.0005818052603839542,0,0,1,0.0006176922916168385
3569,CPSM,Urea cycle,4.622220833258316e-05,1,0,1,4.9073296053910414e-05
3570,1433B,Activation of BH3-only proteins,0.0005900290864697057,0,0,1,0.0006264233814275663
3571,1433B,Activation of BH3-only proteins,0.00026617934000675405,1,0,1,0.0002825978685743145
3572,1433B,Signaling by NTRK1 (TRKA),0.0005900290864697057,0,0,1,0.0006264233814275663
3573,1433B,Signaling by NTRK1 (TRKA),0.00026617934000675405,1,0,1,0.0002825978685743145
3574,1433B,RHO GTPase Effectors,0.0005900290864697057,0,0,1,0.0006264233814275663
3575,1433B,RHO GTPase Effectors,0.00026617934000675405,1,0,1,0.0002825978685743145
3576,1433B,Transcriptional Regulation by TP53,0.0005900290864697057,0,0,1,0.0006264233814275663
3577,1433B,Transcriptional Regulation by TP53,0.00026617934000675405,1,0,1,0.0002825978685743145
3578,1433B,FOXO-mediated transcription,0.0005900290864697057,0,0,1,0.0006264233814275663
3579,1433B,FOXO-mediated transcription,0.00026617934000675405,1,0,1,0.0002825978685743145
3580,1433B,RAF/MAP kinase cascade,0.0005900290864697057,0,0,1,0.0006264233814275663
3581,1433B,RAF/MAP kinase cascade,0.00026617934000675405,1,0,1,0.0002825978685743145
3582,1433B,Signaling by RAS mutants,0.0005900290864697057,0,0,1,0.0006264233814275663
3583,1433B,Signaling by RAS mutants,0.00026617934000675405,1,0,1,0.0002825978685743145
3584,1433B,Signaling by moderate kinase activity BRAF mutants,0.0005900290864697057,0,0,1,0.0006264233814275663
3585,1433B,Signaling by moderate kinase activity BRAF mutants,0.00026617934000675405,1,0,1,0.0002825978685743145
3586,1433B,Signaling by high-kinase activity BRAF mutants,0.0005900290864697057,0,0,1,0.0006264233814275663
3587,1433B,Signaling by high-kinase activity BRAF mutants,0.00026617934000675405,1,0,1,0.0002825978685743145
3588,1433B,Signaling by BRAF and RAF1 fusions,0.0005900290864697057,0,0,1,0.0006264233814275663
3589,1433B,Signaling by BRAF and RAF1 fusions,0.00026617934000675405,1,0,1,0.0002825978685743145
3590,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005900290864697057,0,0,1,0.0006264233814275663
3591,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00026617934000675405,1,0,1,0.0002825978685743145
3592,1433B,Signaling by RAF1 mutants,0.0005900290864697057,0,0,1,0.0006264233814275663
3593,1433B,Signaling by RAF1 mutants,0.00026617934000675405,1,0,1,0.0002825978685743145
3594,1433B,Signaling by MRAS-complex mutants,0.0005900290864697057,0,0,1,0.0006264233814275663
3595,1433B,Signaling by MRAS-complex mutants,0.00026617934000675405,1,0,1,0.0002825978685743145
3596,1433B,G2/M DNA damage checkpoint,0.0005900290864697057,0,0,1,0.0006264233814275663
3597,1433B,G2/M DNA damage checkpoint,0.00026617934000675405,1,0,1,0.0002825978685743145
3598,1433B,SARS-CoV-2 Infection,0.0005900290864697057,0,0,1,0.0006264233814275663
3599,1433B,SARS-CoV-2 Infection,0.00026617934000675405,1,0,1,0.0002825978685743145
3600,1433B,Rap1 signalling,0.0005900290864697057,0,0,1,0.0006264233814275663
3601,1433B,Rap1 signalling,0.00026617934000675405,1,0,1,0.0002825978685743145
3602,1433B,Signaling by Hippo,0.0005900290864697057,0,0,1,0.0006264233814275663
3603,1433B,Signaling by Hippo,0.00026617934000675405,1,0,1,0.0002825978685743145
3604,1433B,mTORC1-mediated signalling,0.0005900290864697057,0,0,1,0.0006264233814275663
3605,1433B,mTORC1-mediated signalling,0.00026617934000675405,1,0,1,0.0002825978685743145
3606,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005900290864697057,0,0,1,0.0006264233814275663
3607,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00026617934000675405,1,0,1,0.0002825978685743145
3608,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0005900290864697057,0,0,1,0.0006264233814275663
3609,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.00026617934000675405,1,0,1,0.0002825978685743145
3610,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0005900290864697057,0,0,1,0.0006264233814275663
3611,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.00026617934000675405,1,0,1,0.0002825978685743145
3612,PRDX2,Transcriptional Regulation by TP53,0.0003319659746071911,0,0,1,0.0003524423678442016
3613,PRDX2,Transcriptional Regulation by TP53,4.899160295808496e-05,1,0,1,5.20135130459133e-05
3614,PRDX2,Neurodegenerative Diseases,0.0003319659746071911,0,0,1,0.0003524423678442016
3615,PRDX2,Neurodegenerative Diseases,4.899160295808496e-05,1,0,1,5.20135130459133e-05
3616,PRDX2,Detoxification of Reactive Oxygen Species,0.0003319659746071911,0,0,1,0.0003524423678442016
3617,PRDX2,Detoxification of Reactive Oxygen Species,4.899160295808496e-05,1,0,1,5.20135130459133e-05
3618,HPPD,Tyrosine catabolism,0.0008014895630288907,0,0,1,0.0008509272064119478
3619,HPPD,Tyrosine catabolism,0.00032563714186724764,1,0,1,0.00034572315874695925
3620,CADH5,VEGFA-VEGFR2 Pathway,0.0002639487981935136,0,0,1,0.0002802297420241035
3621,CADH5,VEGFA-VEGFR2 Pathway,0.00010593048886553772,1,0,1,0.00011246451497579234
3622,CADH5,Adherens junctions interactions,0.0002639487981935136,0,0,1,0.0002802297420241035
3623,CADH5,Adherens junctions interactions,0.00010593048886553772,1,0,1,0.00011246451497579234
3624,MA1A1,Intra-Golgi traffic,8.391518271965481e-05,0,0,1,8.909125620717549e-05
3625,MA1A1,Intra-Golgi traffic,0.00011719107873995462,1,0,1,0.00012441968286116986
3626,HS71L,Regulation of HSF1-mediated heat shock response,0.0017548505297204867,0,0,1,0.0018630935795127183
3627,HS71L,Regulation of HSF1-mediated heat shock response,0.001247290752031533,1,0,1,0.00132422639566099
3628,HS71L,HSF1-dependent transactivation,0.0017548505297204867,0,0,1,0.0018630935795127183
3629,HS71L,HSF1-dependent transactivation,0.001247290752031533,1,0,1,0.00132422639566099
3630,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0017548505297204867,0,0,1,0.0018630935795127183
3631,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001247290752031533,1,0,1,0.00132422639566099
3632,TRY3,Defensins,0.0005624398785917476,0,0,1,0.0005971324103786231
3633,TRY3,Defensins,0.0006560559768931761,1,0,1,0.0006965229560293709
3634,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0005624398785917476,0,0,1,0.0005971324103786231
3635,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0006560559768931761,1,0,1,0.0006965229560293709
3636,TRY3,Neutrophil degranulation,0.0005624398785917476,0,0,1,0.0005971324103786231
3637,TRY3,Neutrophil degranulation,0.0006560559768931761,1,0,1,0.0006965229560293709
3638,CBS,Cysteine formation from homocysteine,0.0002569836826370391,0,0,1,0.0002728350027833211
3639,CBS,Cysteine formation from homocysteine,0.00012293380919791024,1,0,1,0.00013051663759542487
3640,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0002569836826370391,0,0,1,0.0002728350027833211
3641,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00012293380919791024,1,0,1,0.00013051663759542487
3642,K1C9,Formation of the cornified envelope,5.207062421271671e-05,0,0,1,5.5282455120199994e-05
3643,K1C9,Formation of the cornified envelope,2.093362494565633e-06,1,0,1,2.2224857087054435e-06
3644,FBN1,TGF-beta receptor signaling activates SMADs,0.001075303767037195,0,0,1,0.0011416308742328834
3645,FBN1,TGF-beta receptor signaling activates SMADs,0.0025347043141996876,1,0,1,0.002691050464851163
3646,FBN1,Integrin cell surface interactions,0.001075303767037195,0,0,1,0.0011416308742328834
3647,FBN1,Integrin cell surface interactions,0.0025347043141996876,1,0,1,0.002691050464851163
3648,FBN1,Molecules associated with elastic fibres,0.001075303767037195,0,0,1,0.0011416308742328834
3649,FBN1,Molecules associated with elastic fibres,0.0025347043141996876,1,0,1,0.002691050464851163
3650,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001075303767037195,0,0,1,0.0011416308742328834
3651,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025347043141996876,1,0,1,0.002691050464851163
3652,FBN1,Post-translational protein phosphorylation,0.001075303767037195,0,0,1,0.0011416308742328834
3653,FBN1,Post-translational protein phosphorylation,0.0025347043141996876,1,0,1,0.002691050464851163
3654,MYH9,RHO GTPase Effectors,0.0023155316591102083,0,0,1,0.0024583587571608196
3655,MYH9,RHO GTPase Effectors,0.0023031577203176954,1,0,1,0.0024452215665413508
3656,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.0023155316591102083,0,0,1,0.0024583587571608196
3657,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.0023031577203176954,1,0,1,0.0024452215665413508
3658,MYH9,EPH-Ephrin signaling,0.0023155316591102083,0,0,1,0.0024583587571608196
3659,MYH9,EPH-Ephrin signaling,0.0023031577203176954,1,0,1,0.0024452215665413508
3660,MYH9,Semaphorin interactions,0.0023155316591102083,0,0,1,0.0024583587571608196
3661,MYH9,Semaphorin interactions,0.0023031577203176954,1,0,1,0.0024452215665413508
3662,MYH9,Parasite infection,0.0023155316591102083,0,0,1,0.0024583587571608196
3663,MYH9,Parasite infection,0.0023031577203176954,1,0,1,0.0024452215665413508
3664,MYH9,Leishmania parasite growth and survival,0.0023155316591102083,0,0,1,0.0024583587571608196
3665,MYH9,Leishmania parasite growth and survival,0.0023031577203176954,1,0,1,0.0024452215665413508
3666,MYH9,Signaling by ALK fusions and activated point mutants,0.0023155316591102083,0,0,1,0.0024583587571608196
3667,MYH9,Signaling by ALK fusions and activated point mutants,0.0023031577203176954,1,0,1,0.0024452215665413508
3668,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0023155316591102083,0,0,1,0.0024583587571608196
3669,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0023031577203176954,1,0,1,0.0024452215665413508
3670,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.0023155316591102083,0,0,1,0.0024583587571608196
3671,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.0023031577203176954,1,0,1,0.0024452215665413508
3672,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.0023155316591102083,0,0,1,0.0024583587571608196
3673,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.0023031577203176954,1,0,1,0.0024452215665413508
3674,MYH10,RHO GTPase Effectors,1.4525853386292685e-05,0,0,1,1.542184004996459e-05
3675,MYH10,RHO GTPase Effectors,7.035568576433951e-06,1,0,1,7.469537958348718e-06
3676,MYH10,EPH-Ephrin signaling,1.4525853386292685e-05,0,0,1,1.542184004996459e-05
3677,MYH10,EPH-Ephrin signaling,7.035568576433951e-06,1,0,1,7.469537958348718e-06
3678,MYH10,Semaphorin interactions,1.4525853386292685e-05,0,0,1,1.542184004996459e-05
3679,MYH10,Semaphorin interactions,7.035568576433951e-06,1,0,1,7.469537958348718e-06
3680,MYH11,RHO GTPase Effectors,0.00011333310638680264,0,0,1,0.00012032374226716389
3681,MYH11,RHO GTPase Effectors,0.0001820915784606436,1,0,1,0.0001933233884981634
3682,MYH11,EPH-Ephrin signaling,0.00011333310638680264,0,0,1,0.00012032374226716389
3683,MYH11,EPH-Ephrin signaling,0.0001820915784606436,1,0,1,0.0001933233884981634
3684,MYH11,Semaphorin interactions,0.00011333310638680264,0,0,1,0.00012032374226716389
3685,MYH11,Semaphorin interactions,0.0001820915784606436,1,0,1,0.0001933233884981634
3686,MYH11,Smooth Muscle Contraction,0.00011333310638680264,0,0,1,0.00012032374226716389
3687,MYH11,Smooth Muscle Contraction,0.0001820915784606436,1,0,1,0.0001933233884981634
3688,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001649689484457404,0,0,1,0.00017514459691172606
3689,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00026342721301649723,1,0,1,0.00027967598432337043
3690,K1C20,Formation of the cornified envelope,7.163426988914155e-05,0,0,1,7.605282959614723e-05
3691,K1C20,Formation of the cornified envelope,2.981303999214166e-06,1,0,1,3.165197403106587e-06
3692,K22E,Formation of the cornified envelope,0.0001596116304555955,0,0,1,0.00016945682773605915
3693,K22E,Formation of the cornified envelope,6.289026336699307e-06,1,0,1,6.676947347280435e-06
3694,CH3L1,Neutrophil degranulation,7.915992381672852e-05,0,0,1,8.404268245065516e-05
3695,CH3L1,Neutrophil degranulation,6.573958053010714e-05,1,0,1,6.979454280075377e-05
3696,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0005702724508783983,0,0,1,0.0006054481129932797
3697,PGM1,Diseases associated with glycosylation precursor biosynthesis,2.5145016170298567e-05,1,0,1,2.669601620776707e-05
3698,PGM1,Glycogen synthesis,0.0005702724508783983,0,0,1,0.0006054481129932797
3699,PGM1,Glycogen synthesis,2.5145016170298567e-05,1,0,1,2.669601620776707e-05
3700,PGM1,Glycogen breakdown (glycogenolysis),0.0005702724508783983,0,0,1,0.0006054481129932797
3701,PGM1,Glycogen breakdown (glycogenolysis),2.5145016170298567e-05,1,0,1,2.669601620776707e-05
3702,PGM1,Neutrophil degranulation,0.0005702724508783983,0,0,1,0.0006054481129932797
3703,PGM1,Neutrophil degranulation,2.5145016170298567e-05,1,0,1,2.669601620776707e-05
3704,PGM1,Galactose catabolism,0.0005702724508783983,0,0,1,0.0006054481129932797
3705,PGM1,Galactose catabolism,2.5145016170298567e-05,1,0,1,2.669601620776707e-05
3706,FHR2,Regulation of Complement cascade,1.2878701752317149e-05,0,0,1,1.3673088471542408e-05
3707,FHR2,Regulation of Complement cascade,1.5104226627471292e-06,1,0,1,1.6035888627864532e-06
3708,TAGL2,Platelet degranulation ,7.98454053382635e-05,0,0,1,8.477044598379768e-05
3709,TAGL2,Platelet degranulation ,0.00015456343732560336,1,0,1,0.00016409725092348204
3710,TALDO,Interleukin-12 family signaling,0.0006030415340508736,0,0,1,0.0006402384654655678
3711,TALDO,Interleukin-12 family signaling,0.0006355283498825496,1,0,1,0.0006747291397251288
3712,TALDO,Pentose phosphate pathway disease,0.0006030415340508736,0,0,1,0.0006402384654655678
3713,TALDO,Pentose phosphate pathway disease,0.0006355283498825496,1,0,1,0.0006747291397251288
3714,TALDO,KEAP1-NFE2L2 pathway,0.0006030415340508736,0,0,1,0.0006402384654655678
3715,TALDO,KEAP1-NFE2L2 pathway,0.0006355283498825496,1,0,1,0.0006747291397251288
3716,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0006030415340508736,0,0,1,0.0006402384654655678
3717,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0006355283498825496,1,0,1,0.0006747291397251288
3718,TALDO,Pentose phosphate pathway,0.0006030415340508736,0,0,1,0.0006402384654655678
3719,TALDO,Pentose phosphate pathway,0.0006355283498825496,1,0,1,0.0006747291397251288
3720,GRP75,Regulation of HSF1-mediated heat shock response,0.00031384053649818097,0,0,1,0.0003331989127494075
3721,GRP75,Regulation of HSF1-mediated heat shock response,0.00015354439028958275,1,0,1,0.00016301534681947046
3722,GRP75,Interleukin-12 family signaling,0.00031384053649818097,0,0,1,0.0003331989127494075
3723,GRP75,Interleukin-12 family signaling,0.00015354439028958275,1,0,1,0.00016301534681947046
3724,GRP75,Cristae formation,0.00031384053649818097,0,0,1,0.0003331989127494075
3725,GRP75,Cristae formation,0.00015354439028958275,1,0,1,0.00016301534681947046
3726,GRP75,Mitochondrial protein import,0.00031384053649818097,0,0,1,0.0003331989127494075
3727,GRP75,Mitochondrial protein import,0.00015354439028958275,1,0,1,0.00016301534681947046
3728,COIA1,Collagen chain trimerization,0.0009308774180108738,0,0,1,0.000988295989565378
3729,COIA1,Collagen chain trimerization,0.0016222566931725947,1,0,1,0.001722321062781801
3730,COIA1,Collagen degradation,0.0009308774180108738,0,0,1,0.000988295989565378
3731,COIA1,Collagen degradation,0.0016222566931725947,1,0,1,0.001722321062781801
3732,COIA1,Activation of Matrix Metalloproteinases,0.0009308774180108738,0,0,1,0.000988295989565378
3733,COIA1,Activation of Matrix Metalloproteinases,0.0016222566931725947,1,0,1,0.001722321062781801
3734,COIA1,Integrin cell surface interactions,0.0009308774180108738,0,0,1,0.000988295989565378
3735,COIA1,Integrin cell surface interactions,0.0016222566931725947,1,0,1,0.001722321062781801
3736,COIA1,Laminin interactions,0.0009308774180108738,0,0,1,0.000988295989565378
3737,COIA1,Laminin interactions,0.0016222566931725947,1,0,1,0.001722321062781801
3738,MDHC,Gluconeogenesis,3.442095637210929e-05,0,0,1,3.65441168529486e-05
3739,MDHC,Gluconeogenesis,0.0001679431881924304,1,0,1,0.00017830229432363743
3740,MDHM,Gluconeogenesis,0.00014552069225671777,0,0,1,0.00015449672940117637
3741,MDHM,Gluconeogenesis,0.0003732114991951417,1,0,1,0.0003962320073274483
3742,MDHM,Citric acid cycle (TCA cycle),0.00014552069225671777,0,0,1,0.00015449672940117637
3743,MDHM,Citric acid cycle (TCA cycle),0.0003732114991951417,1,0,1,0.0003962320073274483
3744,PTGDS,Arachidonic acid metabolism,0.0002933377189945042,0,0,1,0.00031143143625720417
3745,PTGDS,Arachidonic acid metabolism,9.417681912981639e-05,1,0,1,9.998585297611576e-05
3746,PTGDS,Transcriptional regulation of testis differentiation,0.0002933377189945042,0,0,1,0.00031143143625720417
3747,PTGDS,Transcriptional regulation of testis differentiation,9.417681912981639e-05,1,0,1,9.998585297611576e-05
3748,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.00020463948675371034,0,0,1,0.00021726210148869112
3749,THIM,Mitochondrial Fatty Acid Beta-Oxidation,7.540273519377945e-05,1,0,1,8.005374214954038e-05
3750,MUC18,RHO GTPase cycle,0.00010661924918472346,0,0,1,0.00011319575955005389
3751,MUC18,RHO GTPase cycle,1.7382127905963395e-06,1,0,1,1.8454295879562733e-06
3752,BTD,Biotin transport and metabolism,0.0007061429768175446,0,0,1,0.0007496994325415947
3753,BTD,Biotin transport and metabolism,5.096872071671988e-05,1,0,1,5.4112583787077795e-05
3754,BTD,Defects in biotin (Btn) metabolism,0.0007061429768175446,0,0,1,0.0007496994325415947
3755,BTD,Defects in biotin (Btn) metabolism,5.096872071671988e-05,1,0,1,5.4112583787077795e-05
3756,GSHB,Glutathione conjugation,0.00010288825802573566,0,0,1,0.00010923463263023806
3757,GSHB,Glutathione conjugation,3.707336341771694e-05,1,0,1,3.9360130213193603e-05
3758,GSHB,Defective GSS causes GSS deficiency,0.00010288825802573566,0,0,1,0.00010923463263023806
3759,GSHB,Defective GSS causes GSS deficiency,3.707336341771694e-05,1,0,1,3.9360130213193603e-05
3760,MASP1,Initial triggering of complement,1.2033112628605384e-05,0,0,1,1.2775341546313337e-05
3761,MASP1,Initial triggering of complement,5.0979624597482656e-05,1,0,1,5.412416024324704e-05
3762,MASP1,SARS-CoV-2 Infection,1.2033112628605384e-05,0,0,1,1.2775341546313337e-05
3763,MASP1,SARS-CoV-2 Infection,5.0979624597482656e-05,1,0,1,5.412416024324704e-05
3764,MASP1,Scavenging by Class A Receptors,1.2033112628605384e-05,0,0,1,1.2775341546313337e-05
3765,MASP1,Scavenging by Class A Receptors,5.0979624597482656e-05,1,0,1,5.412416024324704e-05
3766,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.0017292647327646273,0,0,1,0.0018359295941886974
3767,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.001641349484647629,1,0,1,0.0017425915397310699
3768,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0017292647327646273,0,0,1,0.0018359295941886974
3769,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.001641349484647629,1,0,1,0.0017425915397310699
3770,PSB2,Antigen processing-Cross presentation,0.0017292647327646273,0,0,1,0.0018359295941886974
3771,PSB2,Antigen processing-Cross presentation,0.001641349484647629,1,0,1,0.0017425915397310699
3772,PSB2,PTEN Regulation,0.0017292647327646273,0,0,1,0.0018359295941886974
3773,PSB2,PTEN Regulation,0.001641349484647629,1,0,1,0.0017425915397310699
3774,PSB2,Host Interactions of HIV factors,0.0017292647327646273,0,0,1,0.0018359295941886974
3775,PSB2,Host Interactions of HIV factors,0.001641349484647629,1,0,1,0.0017425915397310699
3776,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0017292647327646273,0,0,1,0.0018359295941886974
3777,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.001641349484647629,1,0,1,0.0017425915397310699
3778,PSB2,APC/C-mediated degradation of cell cycle proteins,0.0017292647327646273,0,0,1,0.0018359295941886974
3779,PSB2,APC/C-mediated degradation of cell cycle proteins,0.001641349484647629,1,0,1,0.0017425915397310699
3780,PSB2,Degradation of AXIN,0.0017292647327646273,0,0,1,0.0018359295941886974
3781,PSB2,Degradation of AXIN,0.001641349484647629,1,0,1,0.0017425915397310699
3782,PSB2,Degradation of DVL,0.0017292647327646273,0,0,1,0.0018359295941886974
3783,PSB2,Degradation of DVL,0.001641349484647629,1,0,1,0.0017425915397310699
3784,PSB2,Downstream TCR signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3785,PSB2,Downstream TCR signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3786,PSB2,Transcriptional regulation by RUNX3,0.0017292647327646273,0,0,1,0.0018359295941886974
3787,PSB2,Transcriptional regulation by RUNX3,0.001641349484647629,1,0,1,0.0017425915397310699
3788,PSB2,Transcriptional regulation by RUNX2,0.0017292647327646273,0,0,1,0.0018359295941886974
3789,PSB2,Transcriptional regulation by RUNX2,0.001641349484647629,1,0,1,0.0017425915397310699
3790,PSB2,Transcriptional regulation by RUNX1,0.0017292647327646273,0,0,1,0.0018359295941886974
3791,PSB2,Transcriptional regulation by RUNX1,0.001641349484647629,1,0,1,0.0017425915397310699
3792,PSB2,FCERI mediated NF-kB activation,0.0017292647327646273,0,0,1,0.0018359295941886974
3793,PSB2,FCERI mediated NF-kB activation,0.001641349484647629,1,0,1,0.0017425915397310699
3794,PSB2,Mitotic Metaphase and Anaphase,0.0017292647327646273,0,0,1,0.0018359295941886974
3795,PSB2,Mitotic Metaphase and Anaphase,0.001641349484647629,1,0,1,0.0017425915397310699
3796,PSB2,Regulation of ornithine decarboxylase (ODC),0.0017292647327646273,0,0,1,0.0018359295941886974
3797,PSB2,Regulation of ornithine decarboxylase (ODC),0.001641349484647629,1,0,1,0.0017425915397310699
3798,PSB2,Signaling by ROBO receptors,0.0017292647327646273,0,0,1,0.0018359295941886974
3799,PSB2,Signaling by ROBO receptors,0.001641349484647629,1,0,1,0.0017425915397310699
3800,PSB2,PCP/CE pathway,0.0017292647327646273,0,0,1,0.0018359295941886974
3801,PSB2,PCP/CE pathway,0.001641349484647629,1,0,1,0.0017425915397310699
3802,PSB2,Interleukin-1 family signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3803,PSB2,Interleukin-1 family signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3804,PSB2,G2/M Transition,0.0017292647327646273,0,0,1,0.0018359295941886974
3805,PSB2,G2/M Transition,0.001641349484647629,1,0,1,0.0017425915397310699
3806,PSB2,G1/S Transition,0.0017292647327646273,0,0,1,0.0018359295941886974
3807,PSB2,G1/S Transition,0.001641349484647629,1,0,1,0.0017425915397310699
3808,PSB2,Hh mutants are degraded by ERAD,0.0017292647327646273,0,0,1,0.0018359295941886974
3809,PSB2,Hh mutants are degraded by ERAD,0.001641349484647629,1,0,1,0.0017425915397310699
3810,PSB2,CLEC7A (Dectin-1) signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3811,PSB2,CLEC7A (Dectin-1) signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3812,PSB2,Degradation of GLI1 by the proteasome,0.0017292647327646273,0,0,1,0.0018359295941886974
3813,PSB2,Degradation of GLI1 by the proteasome,0.001641349484647629,1,0,1,0.0017425915397310699
3814,PSB2,Degradation of GLI2 by the proteasome,0.0017292647327646273,0,0,1,0.0018359295941886974
3815,PSB2,Degradation of GLI2 by the proteasome,0.001641349484647629,1,0,1,0.0017425915397310699
3816,PSB2,GLI3 is processed to GLI3R by the proteasome,0.0017292647327646273,0,0,1,0.0018359295941886974
3817,PSB2,GLI3 is processed to GLI3R by the proteasome,0.001641349484647629,1,0,1,0.0017425915397310699
3818,PSB2,Defective CFTR causes cystic fibrosis,0.0017292647327646273,0,0,1,0.0018359295941886974
3819,PSB2,Defective CFTR causes cystic fibrosis,0.001641349484647629,1,0,1,0.0017425915397310699
3820,PSB2,NIK-->noncanonical NF-kB signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3821,PSB2,NIK-->noncanonical NF-kB signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3822,PSB2,RAF/MAP kinase cascade,0.0017292647327646273,0,0,1,0.0018359295941886974
3823,PSB2,RAF/MAP kinase cascade,0.001641349484647629,1,0,1,0.0017425915397310699
3824,PSB2,UCH proteinases,0.0017292647327646273,0,0,1,0.0018359295941886974
3825,PSB2,UCH proteinases,0.001641349484647629,1,0,1,0.0017425915397310699
3826,PSB2,Ub-specific processing proteases,0.0017292647327646273,0,0,1,0.0018359295941886974
3827,PSB2,Ub-specific processing proteases,0.001641349484647629,1,0,1,0.0017425915397310699
3828,PSB2,Orc1 removal from chromatin,0.0017292647327646273,0,0,1,0.0018359295941886974
3829,PSB2,Orc1 removal from chromatin,0.001641349484647629,1,0,1,0.0017425915397310699
3830,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.0017292647327646273,0,0,1,0.0018359295941886974
3831,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.001641349484647629,1,0,1,0.0017425915397310699
3832,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.0017292647327646273,0,0,1,0.0018359295941886974
3833,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.001641349484647629,1,0,1,0.0017425915397310699
3834,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.0017292647327646273,0,0,1,0.0018359295941886974
3835,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.001641349484647629,1,0,1,0.0017425915397310699
3836,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.0017292647327646273,0,0,1,0.0018359295941886974
3837,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.001641349484647629,1,0,1,0.0017425915397310699
3838,PSB2,p53-Independent G1/S DNA damage checkpoint,0.0017292647327646273,0,0,1,0.0018359295941886974
3839,PSB2,p53-Independent G1/S DNA damage checkpoint,0.001641349484647629,1,0,1,0.0017425915397310699
3840,PSB2,Negative regulation of NOTCH4 signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3841,PSB2,Negative regulation of NOTCH4 signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3842,PSB2,KEAP1-NFE2L2 pathway,0.0017292647327646273,0,0,1,0.0018359295941886974
3843,PSB2,KEAP1-NFE2L2 pathway,0.001641349484647629,1,0,1,0.0017425915397310699
3844,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.0017292647327646273,0,0,1,0.0018359295941886974
3845,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.001641349484647629,1,0,1,0.0017425915397310699
3846,PSB2,Degradation of beta-catenin by the destruction complex,0.0017292647327646273,0,0,1,0.0018359295941886974
3847,PSB2,Degradation of beta-catenin by the destruction complex,0.001641349484647629,1,0,1,0.0017425915397310699
3848,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0017292647327646273,0,0,1,0.0018359295941886974
3849,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.001641349484647629,1,0,1,0.0017425915397310699
3850,PSB2,Hedgehog ligand biogenesis,0.0017292647327646273,0,0,1,0.0018359295941886974
3851,PSB2,Hedgehog ligand biogenesis,0.001641349484647629,1,0,1,0.0017425915397310699
3852,PSB2,Hedgehog 'on' state,0.0017292647327646273,0,0,1,0.0018359295941886974
3853,PSB2,Hedgehog 'on' state,0.001641349484647629,1,0,1,0.0017425915397310699
3854,PSB2,MAPK6/MAPK4 signaling,0.0017292647327646273,0,0,1,0.0018359295941886974
3855,PSB2,MAPK6/MAPK4 signaling,0.001641349484647629,1,0,1,0.0017425915397310699
3856,PSB2,Neddylation,0.0017292647327646273,0,0,1,0.0018359295941886974
3857,PSB2,Neddylation,0.001641349484647629,1,0,1,0.0017425915397310699
3858,COMP,Integrin cell surface interactions,8.588646343362823e-05,0,0,1,9.118412986189416e-05
3859,COMP,Integrin cell surface interactions,9.595132226810524e-05,1,0,1,0.0001018698113804237
3860,COMP,ECM proteoglycans,8.588646343362823e-05,0,0,1,9.118412986189416e-05
3861,COMP,ECM proteoglycans,9.595132226810524e-05,1,0,1,0.0001018698113804237
3862,SEPP1,Platelet degranulation ,1.0984514998070819e-06,0,0,1,1.166206410196463e-06
3863,SEPP1,Platelet degranulation ,2.0933975188807227e-06,1,0,1,2.22252289339751e-06
3864,CAMP,Neutrophil degranulation,6.5988017641171e-05,0,0,1,7.005830406058567e-05
3865,CAMP,Neutrophil degranulation,5.4559117138916436e-05,1,0,1,5.792444377675185e-05
3866,MMP14,Collagen degradation,0.0001902414446219159,0,0,1,0.00020197595637320225
3867,MMP14,Collagen degradation,0.000578471660072712,1,0,1,0.0006141530674884302
3868,MMP14,Activation of Matrix Metalloproteinases,0.0001902414446219159,0,0,1,0.00020197595637320225
3869,MMP14,Activation of Matrix Metalloproteinases,0.000578471660072712,1,0,1,0.0006141530674884302
3870,LUM,Keratan sulfate/keratin metabolism,8.771614128657319e-05,0,0,1,9.312666627890817e-05
3871,LUM,Keratan sulfate/keratin metabolism,5.930620246201058e-05,1,0,1,6.296433978901477e-05
3872,LUM,Diseases associated with glycosaminoglycan metabolism,8.771614128657319e-05,0,0,1,9.312666627890817e-05
3873,LUM,Diseases associated with glycosaminoglycan metabolism,5.930620246201058e-05,1,0,1,6.296433978901477e-05
3874,LUM,Integrin cell surface interactions,8.771614128657319e-05,0,0,1,9.312666627890817e-05
3875,LUM,Integrin cell surface interactions,5.930620246201058e-05,1,0,1,6.296433978901477e-05
3876,LUM,ECM proteoglycans,8.771614128657319e-05,0,0,1,9.312666627890817e-05
3877,LUM,ECM proteoglycans,5.930620246201058e-05,1,0,1,6.296433978901477e-05
3878,RIDA,Threonine catabolism,0.00020512811753746395,0,0,1,0.00021778087209652663
3879,RIDA,Threonine catabolism,0.00011059283961603704,1,0,1,0.00011741444980019883
3880,CRIS3,Neutrophil degranulation,8.345041211851374e-05,0,0,1,8.859781753062328e-05
3881,CRIS3,Neutrophil degranulation,7.103527235845407e-05,1,0,1,7.541688457708878e-05
3882,HSP72,Regulation of HSF1-mediated heat shock response,0.001751965313658194,0,0,1,0.0018600303969623386
3883,HSP72,Regulation of HSF1-mediated heat shock response,0.0011710010375591176,1,0,1,0.0012432309633952832
3884,HSP72,HSF1-dependent transactivation,0.001751965313658194,0,0,1,0.0018600303969623386
3885,HSP72,HSF1-dependent transactivation,0.0011710010375591176,1,0,1,0.0012432309633952832
3886,HSP72,Meiotic synapsis,0.001751965313658194,0,0,1,0.0018600303969623386
3887,HSP72,Meiotic synapsis,0.0011710010375591176,1,0,1,0.0012432309633952832
3888,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001751965313658194,0,0,1,0.0018600303969623386
3889,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0011710010375591176,1,0,1,0.0012432309633952832
3890,MFAP4,Molecules associated with elastic fibres,0.000325935857747516,0,0,1,0.00034604030008133547
3891,MFAP4,Molecules associated with elastic fibres,0.00024206096909645954,1,0,1,0.00025699182336975045
3892,CAD13,Adherens junctions interactions,0.00023755931354844045,0,0,1,0.0002522124957822162
3893,CAD13,Adherens junctions interactions,0.00022848654025161004,1,0,1,0.0002425800938246594
3894,DEF1,Defensins,0.00034563157589384666,0,0,1,0.0003669508935483276
3895,DEF1,Defensins,0.0006240099796903146,1,0,1,0.0006625002910635724
3896,DEF1,Neutrophil degranulation,0.00034563157589384666,0,0,1,0.0003669508935483276
3897,DEF1,Neutrophil degranulation,0.0006240099796903146,1,0,1,0.0006625002910635724
3898,TPIS,Glycolysis,7.691761757410249e-05,0,0,1,8.166206581511566e-05
3899,TPIS,Glycolysis,0.0003457800224810475,1,0,1,0.0003671084966483241
3900,TPIS,Gluconeogenesis,7.691761757410249e-05,0,0,1,8.166206581511566e-05
3901,TPIS,Gluconeogenesis,0.0003457800224810475,1,0,1,0.0003671084966483241
3902,MYL6,RHO GTPase Effectors,0.00011377193729907644,0,0,1,0.00012078964123764729
3903,MYL6,RHO GTPase Effectors,0.00013344126638940412,1,0,1,0.00014167221791347917
3904,MYL6,EPH-Ephrin signaling,0.00011377193729907644,0,0,1,0.00012078964123764729
3905,MYL6,EPH-Ephrin signaling,0.00013344126638940412,1,0,1,0.00014167221791347917
3906,MYL6,Semaphorin interactions,0.00011377193729907644,0,0,1,0.00012078964123764729
3907,MYL6,Semaphorin interactions,0.00013344126638940412,1,0,1,0.00014167221791347917
3908,MYL6,Smooth Muscle Contraction,0.00011377193729907644,0,0,1,0.00012078964123764729
3909,MYL6,Smooth Muscle Contraction,0.00013344126638940412,1,0,1,0.00014167221791347917
3910,ACTB,Gap junction trafficking,0.005147500253497589,0,0,1,0.00546500941841411
3911,ACTB,Gap junction trafficking,0.00549034124770944,1,0,1,0.0058289976010495815
3912,ACTB,VEGFA-VEGFR2 Pathway,0.005147500253497589,0,0,1,0.00546500941841411
3913,ACTB,VEGFA-VEGFR2 Pathway,0.00549034124770944,1,0,1,0.0058289976010495815
3914,ACTB,RHO GTPase Effectors,0.005147500253497589,0,0,1,0.00546500941841411
3915,ACTB,RHO GTPase Effectors,0.00549034124770944,1,0,1,0.0058289976010495815
3916,ACTB,RHO GTPase cycle,0.005147500253497589,0,0,1,0.00546500941841411
3917,ACTB,RHO GTPase cycle,0.00549034124770944,1,0,1,0.0058289976010495815
3918,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.005147500253497589,0,0,1,0.00546500941841411
3919,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.00549034124770944,1,0,1,0.0058289976010495815
3920,ACTB,EPH-Ephrin signaling,0.005147500253497589,0,0,1,0.00546500941841411
3921,ACTB,EPH-Ephrin signaling,0.00549034124770944,1,0,1,0.0058289976010495815
3922,ACTB,L1CAM interactions,0.005147500253497589,0,0,1,0.00546500941841411
3923,ACTB,L1CAM interactions,0.00549034124770944,1,0,1,0.0058289976010495815
3924,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.005147500253497589,0,0,1,0.00546500941841411
3925,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00549034124770944,1,0,1,0.0058289976010495815
3926,ACTB,Adherens junctions interactions,0.005147500253497589,0,0,1,0.00546500941841411
3927,ACTB,Adherens junctions interactions,0.00549034124770944,1,0,1,0.0058289976010495815
3928,ACTB,B-WICH complex positively regulates rRNA expression,0.005147500253497589,0,0,1,0.00546500941841411
3929,ACTB,B-WICH complex positively regulates rRNA expression,0.00549034124770944,1,0,1,0.0058289976010495815
3930,ACTB,RAF/MAP kinase cascade,0.005147500253497589,0,0,1,0.00546500941841411
3931,ACTB,RAF/MAP kinase cascade,0.00549034124770944,1,0,1,0.0058289976010495815
3932,ACTB,UCH proteinases,0.005147500253497589,0,0,1,0.00546500941841411
3933,ACTB,UCH proteinases,0.00549034124770944,1,0,1,0.0058289976010495815
3934,ACTB,DNA Damage Recognition in GG-NER,0.005147500253497589,0,0,1,0.00546500941841411
3935,ACTB,DNA Damage Recognition in GG-NER,0.00549034124770944,1,0,1,0.0058289976010495815
3936,ACTB,Signaling by RAS mutants,0.005147500253497589,0,0,1,0.00546500941841411
3937,ACTB,Signaling by RAS mutants,0.00549034124770944,1,0,1,0.0058289976010495815
3938,ACTB,Signaling by moderate kinase activity BRAF mutants,0.005147500253497589,0,0,1,0.00546500941841411
3939,ACTB,Signaling by moderate kinase activity BRAF mutants,0.00549034124770944,1,0,1,0.0058289976010495815
3940,ACTB,Signaling by high-kinase activity BRAF mutants,0.005147500253497589,0,0,1,0.00546500941841411
3941,ACTB,Signaling by high-kinase activity BRAF mutants,0.00549034124770944,1,0,1,0.0058289976010495815
3942,ACTB,Signaling by BRAF and RAF1 fusions,0.005147500253497589,0,0,1,0.00546500941841411
3943,ACTB,Signaling by BRAF and RAF1 fusions,0.00549034124770944,1,0,1,0.0058289976010495815
3944,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005147500253497589,0,0,1,0.00546500941841411
3945,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00549034124770944,1,0,1,0.0058289976010495815
3946,ACTB,Signaling by RAF1 mutants,0.005147500253497589,0,0,1,0.00546500941841411
3947,ACTB,Signaling by RAF1 mutants,0.00549034124770944,1,0,1,0.0058289976010495815
3948,ACTB,Parasite infection,0.005147500253497589,0,0,1,0.00546500941841411
3949,ACTB,Parasite infection,0.00549034124770944,1,0,1,0.0058289976010495815
3950,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005147500253497589,0,0,1,0.00546500941841411
3951,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00549034124770944,1,0,1,0.0058289976010495815
3952,ACTB,HATs acetylate histones,0.005147500253497589,0,0,1,0.00546500941841411
3953,ACTB,HATs acetylate histones,0.00549034124770944,1,0,1,0.0058289976010495815
3954,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.005147500253497589,0,0,1,0.00546500941841411
3955,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.00549034124770944,1,0,1,0.0058289976010495815
3956,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.005147500253497589,0,0,1,0.00546500941841411
3957,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.00549034124770944,1,0,1,0.0058289976010495815
3958,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0020692907941532394,0,0,1,0.0021969292127379902
3959,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0030738457997192435,1,0,1,0.003263447385904278
3960,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0020692907941532394,0,0,1,0.0021969292127379902
3961,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0030738457997192435,1,0,1,0.003263447385904278
3962,PSA6,Antigen processing-Cross presentation,0.0020692907941532394,0,0,1,0.0021969292127379902
3963,PSA6,Antigen processing-Cross presentation,0.0030738457997192435,1,0,1,0.003263447385904278
3964,PSA6,PTEN Regulation,0.0020692907941532394,0,0,1,0.0021969292127379902
3965,PSA6,PTEN Regulation,0.0030738457997192435,1,0,1,0.003263447385904278
3966,PSA6,Host Interactions of HIV factors,0.0020692907941532394,0,0,1,0.0021969292127379902
3967,PSA6,Host Interactions of HIV factors,0.0030738457997192435,1,0,1,0.003263447385904278
3968,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0020692907941532394,0,0,1,0.0021969292127379902
3969,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0030738457997192435,1,0,1,0.003263447385904278
3970,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0020692907941532394,0,0,1,0.0021969292127379902
3971,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0030738457997192435,1,0,1,0.003263447385904278
3972,PSA6,Degradation of AXIN,0.0020692907941532394,0,0,1,0.0021969292127379902
3973,PSA6,Degradation of AXIN,0.0030738457997192435,1,0,1,0.003263447385904278
3974,PSA6,Degradation of DVL,0.0020692907941532394,0,0,1,0.0021969292127379902
3975,PSA6,Degradation of DVL,0.0030738457997192435,1,0,1,0.003263447385904278
3976,PSA6,Downstream TCR signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
3977,PSA6,Downstream TCR signaling,0.0030738457997192435,1,0,1,0.003263447385904278
3978,PSA6,Transcriptional regulation by RUNX3,0.0020692907941532394,0,0,1,0.0021969292127379902
3979,PSA6,Transcriptional regulation by RUNX3,0.0030738457997192435,1,0,1,0.003263447385904278
3980,PSA6,Transcriptional regulation by RUNX2,0.0020692907941532394,0,0,1,0.0021969292127379902
3981,PSA6,Transcriptional regulation by RUNX2,0.0030738457997192435,1,0,1,0.003263447385904278
3982,PSA6,Transcriptional regulation by RUNX1,0.0020692907941532394,0,0,1,0.0021969292127379902
3983,PSA6,Transcriptional regulation by RUNX1,0.0030738457997192435,1,0,1,0.003263447385904278
3984,PSA6,FCERI mediated NF-kB activation,0.0020692907941532394,0,0,1,0.0021969292127379902
3985,PSA6,FCERI mediated NF-kB activation,0.0030738457997192435,1,0,1,0.003263447385904278
3986,PSA6,Mitotic Metaphase and Anaphase,0.0020692907941532394,0,0,1,0.0021969292127379902
3987,PSA6,Mitotic Metaphase and Anaphase,0.0030738457997192435,1,0,1,0.003263447385904278
3988,PSA6,Regulation of ornithine decarboxylase (ODC),0.0020692907941532394,0,0,1,0.0021969292127379902
3989,PSA6,Regulation of ornithine decarboxylase (ODC),0.0030738457997192435,1,0,1,0.003263447385904278
3990,PSA6,Signaling by ROBO receptors,0.0020692907941532394,0,0,1,0.0021969292127379902
3991,PSA6,Signaling by ROBO receptors,0.0030738457997192435,1,0,1,0.003263447385904278
3992,PSA6,PCP/CE pathway,0.0020692907941532394,0,0,1,0.0021969292127379902
3993,PSA6,PCP/CE pathway,0.0030738457997192435,1,0,1,0.003263447385904278
3994,PSA6,Interleukin-1 family signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
3995,PSA6,Interleukin-1 family signaling,0.0030738457997192435,1,0,1,0.003263447385904278
3996,PSA6,G2/M Transition,0.0020692907941532394,0,0,1,0.0021969292127379902
3997,PSA6,G2/M Transition,0.0030738457997192435,1,0,1,0.003263447385904278
3998,PSA6,G1/S Transition,0.0020692907941532394,0,0,1,0.0021969292127379902
3999,PSA6,G1/S Transition,0.0030738457997192435,1,0,1,0.003263447385904278
4000,PSA6,Hh mutants are degraded by ERAD,0.0020692907941532394,0,0,1,0.0021969292127379902
4001,PSA6,Hh mutants are degraded by ERAD,0.0030738457997192435,1,0,1,0.003263447385904278
4002,PSA6,CLEC7A (Dectin-1) signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
4003,PSA6,CLEC7A (Dectin-1) signaling,0.0030738457997192435,1,0,1,0.003263447385904278
4004,PSA6,Degradation of GLI1 by the proteasome,0.0020692907941532394,0,0,1,0.0021969292127379902
4005,PSA6,Degradation of GLI1 by the proteasome,0.0030738457997192435,1,0,1,0.003263447385904278
4006,PSA6,Degradation of GLI2 by the proteasome,0.0020692907941532394,0,0,1,0.0021969292127379902
4007,PSA6,Degradation of GLI2 by the proteasome,0.0030738457997192435,1,0,1,0.003263447385904278
4008,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0020692907941532394,0,0,1,0.0021969292127379902
4009,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0030738457997192435,1,0,1,0.003263447385904278
4010,PSA6,Defective CFTR causes cystic fibrosis,0.0020692907941532394,0,0,1,0.0021969292127379902
4011,PSA6,Defective CFTR causes cystic fibrosis,0.0030738457997192435,1,0,1,0.003263447385904278
4012,PSA6,NIK-->noncanonical NF-kB signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
4013,PSA6,NIK-->noncanonical NF-kB signaling,0.0030738457997192435,1,0,1,0.003263447385904278
4014,PSA6,RAF/MAP kinase cascade,0.0020692907941532394,0,0,1,0.0021969292127379902
4015,PSA6,RAF/MAP kinase cascade,0.0030738457997192435,1,0,1,0.003263447385904278
4016,PSA6,UCH proteinases,0.0020692907941532394,0,0,1,0.0021969292127379902
4017,PSA6,UCH proteinases,0.0030738457997192435,1,0,1,0.003263447385904278
4018,PSA6,Ub-specific processing proteases,0.0020692907941532394,0,0,1,0.0021969292127379902
4019,PSA6,Ub-specific processing proteases,0.0030738457997192435,1,0,1,0.003263447385904278
4020,PSA6,Orc1 removal from chromatin,0.0020692907941532394,0,0,1,0.0021969292127379902
4021,PSA6,Orc1 removal from chromatin,0.0030738457997192435,1,0,1,0.003263447385904278
4022,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0020692907941532394,0,0,1,0.0021969292127379902
4023,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0030738457997192435,1,0,1,0.003263447385904278
4024,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0020692907941532394,0,0,1,0.0021969292127379902
4025,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0030738457997192435,1,0,1,0.003263447385904278
4026,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0020692907941532394,0,0,1,0.0021969292127379902
4027,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0030738457997192435,1,0,1,0.003263447385904278
4028,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0020692907941532394,0,0,1,0.0021969292127379902
4029,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0030738457997192435,1,0,1,0.003263447385904278
4030,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0020692907941532394,0,0,1,0.0021969292127379902
4031,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0030738457997192435,1,0,1,0.003263447385904278
4032,PSA6,Negative regulation of NOTCH4 signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
4033,PSA6,Negative regulation of NOTCH4 signaling,0.0030738457997192435,1,0,1,0.003263447385904278
4034,PSA6,KEAP1-NFE2L2 pathway,0.0020692907941532394,0,0,1,0.0021969292127379902
4035,PSA6,KEAP1-NFE2L2 pathway,0.0030738457997192435,1,0,1,0.003263447385904278
4036,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0020692907941532394,0,0,1,0.0021969292127379902
4037,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0030738457997192435,1,0,1,0.003263447385904278
4038,PSA6,Degradation of beta-catenin by the destruction complex,0.0020692907941532394,0,0,1,0.0021969292127379902
4039,PSA6,Degradation of beta-catenin by the destruction complex,0.0030738457997192435,1,0,1,0.003263447385904278
4040,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0020692907941532394,0,0,1,0.0021969292127379902
4041,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0030738457997192435,1,0,1,0.003263447385904278
4042,PSA6,Hedgehog ligand biogenesis,0.0020692907941532394,0,0,1,0.0021969292127379902
4043,PSA6,Hedgehog ligand biogenesis,0.0030738457997192435,1,0,1,0.003263447385904278
4044,PSA6,Hedgehog 'on' state,0.0020692907941532394,0,0,1,0.0021969292127379902
4045,PSA6,Hedgehog 'on' state,0.0030738457997192435,1,0,1,0.003263447385904278
4046,PSA6,MAPK6/MAPK4 signaling,0.0020692907941532394,0,0,1,0.0021969292127379902
4047,PSA6,MAPK6/MAPK4 signaling,0.0030738457997192435,1,0,1,0.003263447385904278
4048,PSA6,Neddylation,0.0020692907941532394,0,0,1,0.0021969292127379902
4049,PSA6,Neddylation,0.0030738457997192435,1,0,1,0.003263447385904278
4050,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0003106853748000402,0,0,1,0.00032984913372118056
4051,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.00017621034358451993,1,0,1,0.00018707938608785127
4052,RAB10,Neutrophil degranulation,0.0003106853748000402,0,0,1,0.00032984913372118056
4053,RAB10,Neutrophil degranulation,0.00017621034358451993,1,0,1,0.00018707938608785127
4054,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0003106853748000402,0,0,1,0.00032984913372118056
4055,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00017621034358451993,1,0,1,0.00018707938608785127
4056,RAB10,RAB geranylgeranylation,0.0003106853748000402,0,0,1,0.00032984913372118056
4057,RAB10,RAB geranylgeranylation,0.00017621034358451993,1,0,1,0.00018707938608785127
4058,LYSC,Neutrophil degranulation,0.00021077979853045486,0,0,1,0.0002237811612340708
4059,LYSC,Neutrophil degranulation,0.0007948532354096103,1,0,1,0.0008438815354732419
4060,LYSC,Amyloid fiber formation,0.00021077979853045486,0,0,1,0.0002237811612340708
4061,LYSC,Amyloid fiber formation,0.0007948532354096103,1,0,1,0.0008438815354732419
4062,B2MG,Antigen processing-Cross presentation,0.0031395521441735753,0,0,1,0.003333206642554823
4063,B2MG,Antigen processing-Cross presentation,0.003716287723207107,1,0,1,0.003945516543697841
4064,B2MG,Host Interactions of HIV factors,0.0031395521441735753,0,0,1,0.003333206642554823
4065,B2MG,Host Interactions of HIV factors,0.003716287723207107,1,0,1,0.003945516543697841
4066,B2MG,DAP12 signaling,0.0031395521441735753,0,0,1,0.003333206642554823
4067,B2MG,DAP12 signaling,0.003716287723207107,1,0,1,0.003945516543697841
4068,B2MG,Interferon gamma signaling,0.0031395521441735753,0,0,1,0.003333206642554823
4069,B2MG,Interferon gamma signaling,0.003716287723207107,1,0,1,0.003945516543697841
4070,B2MG,Modulation by Mtb of host immune system,0.0031395521441735753,0,0,1,0.003333206642554823
4071,B2MG,Modulation by Mtb of host immune system,0.003716287723207107,1,0,1,0.003945516543697841
4072,B2MG,SARS-CoV-2 Infection,0.0031395521441735753,0,0,1,0.003333206642554823
4073,B2MG,SARS-CoV-2 Infection,0.003716287723207107,1,0,1,0.003945516543697841
4074,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0031395521441735753,0,0,1,0.003333206642554823
4075,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.003716287723207107,1,0,1,0.003945516543697841
4076,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031395521441735753,0,0,1,0.003333206642554823
4077,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003716287723207107,1,0,1,0.003945516543697841
4078,B2MG,Neutrophil degranulation,0.0031395521441735753,0,0,1,0.003333206642554823
4079,B2MG,Neutrophil degranulation,0.003716287723207107,1,0,1,0.003945516543697841
4080,B2MG,Amyloid fiber formation,0.0031395521441735753,0,0,1,0.003333206642554823
4081,B2MG,Amyloid fiber formation,0.003716287723207107,1,0,1,0.003945516543697841
4082,NPC2,LDL clearance,2.647961844212634e-05,0,0,1,2.8112939690270994e-05
4083,NPC2,LDL clearance,5.87665959654555e-05,1,0,1,6.23914491740202e-05
4084,NPC2,Neutrophil degranulation,2.647961844212634e-05,0,0,1,2.8112939690270994e-05
4085,NPC2,Neutrophil degranulation,5.87665959654555e-05,1,0,1,6.23914491740202e-05
4086,1433G,Activation of BH3-only proteins,0.002956533306372839,0,0,1,0.0031388987993160354
4087,1433G,Activation of BH3-only proteins,0.00086922712504703,1,0,1,0.0009228429706040931
4088,1433G,RHO GTPase Effectors,0.002956533306372839,0,0,1,0.0031388987993160354
4089,1433G,RHO GTPase Effectors,0.00086922712504703,1,0,1,0.0009228429706040931
4090,1433G,Transcriptional Regulation by TP53,0.002956533306372839,0,0,1,0.0031388987993160354
4091,1433G,Transcriptional Regulation by TP53,0.00086922712504703,1,0,1,0.0009228429706040931
4092,1433G,FOXO-mediated transcription,0.002956533306372839,0,0,1,0.0031388987993160354
4093,1433G,FOXO-mediated transcription,0.00086922712504703,1,0,1,0.0009228429706040931
4094,1433G,G2/M Transition,0.002956533306372839,0,0,1,0.0031388987993160354
4095,1433G,G2/M Transition,0.00086922712504703,1,0,1,0.0009228429706040931
4096,1433G,Mitotic Prometaphase,0.002956533306372839,0,0,1,0.0031388987993160354
4097,1433G,Mitotic Prometaphase,0.00086922712504703,1,0,1,0.0009228429706040931
4098,1433G,G2/M DNA damage checkpoint,0.002956533306372839,0,0,1,0.0031388987993160354
4099,1433G,G2/M DNA damage checkpoint,0.00086922712504703,1,0,1,0.0009228429706040931
4100,1433G,SARS-CoV-2 Infection,0.002956533306372839,0,0,1,0.0031388987993160354
4101,1433G,SARS-CoV-2 Infection,0.00086922712504703,1,0,1,0.0009228429706040931
4102,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002956533306372839,0,0,1,0.0031388987993160354
4103,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00086922712504703,1,0,1,0.0009228429706040931
4104,1433G,Anchoring of the basal body to the plasma membrane,0.002956533306372839,0,0,1,0.0031388987993160354
4105,1433G,Anchoring of the basal body to the plasma membrane,0.00086922712504703,1,0,1,0.0009228429706040931
4106,1433E,Activation of BH3-only proteins,0.0001874117462029787,0,0,1,0.00019897171591682622
4107,1433E,Activation of BH3-only proteins,0.0010330833738130816,1,0,1,0.0010968062340665913
4108,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.0001874117462029787,0,0,1,0.00019897171591682622
4109,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.0010330833738130816,1,0,1,0.0010968062340665913
4110,1433E,RHO GTPase Effectors,0.0001874117462029787,0,0,1,0.00019897171591682622
4111,1433E,RHO GTPase Effectors,0.0010330833738130816,1,0,1,0.0010968062340665913
4112,1433E,Transcriptional Regulation by TP53,0.0001874117462029787,0,0,1,0.00019897171591682622
4113,1433E,Transcriptional Regulation by TP53,0.0010330833738130816,1,0,1,0.0010968062340665913
4114,1433E,Regulation of HSF1-mediated heat shock response,0.0001874117462029787,0,0,1,0.00019897171591682622
4115,1433E,Regulation of HSF1-mediated heat shock response,0.0010330833738130816,1,0,1,0.0010968062340665913
4116,1433E,HSF1 activation,0.0001874117462029787,0,0,1,0.00019897171591682622
4117,1433E,HSF1 activation,0.0010330833738130816,1,0,1,0.0010968062340665913
4118,1433E,G2/M Transition,0.0001874117462029787,0,0,1,0.00019897171591682622
4119,1433E,G2/M Transition,0.0010330833738130816,1,0,1,0.0010968062340665913
4120,1433E,Mitotic Prometaphase,0.0001874117462029787,0,0,1,0.00019897171591682622
4121,1433E,Mitotic Prometaphase,0.0010330833738130816,1,0,1,0.0010968062340665913
4122,1433E,G2/M DNA damage checkpoint,0.0001874117462029787,0,0,1,0.00019897171591682622
4123,1433E,G2/M DNA damage checkpoint,0.0010330833738130816,1,0,1,0.0010968062340665913
4124,1433E,Neurodegenerative Diseases,0.0001874117462029787,0,0,1,0.00019897171591682622
4125,1433E,Neurodegenerative Diseases,0.0010330833738130816,1,0,1,0.0010968062340665913
4126,1433E,RAB GEFs exchange GTP for GDP on RABs,0.0001874117462029787,0,0,1,0.00019897171591682622
4127,1433E,RAB GEFs exchange GTP for GDP on RABs,0.0010330833738130816,1,0,1,0.0010968062340665913
4128,1433E,SARS-CoV-2 Infection,0.0001874117462029787,0,0,1,0.00019897171591682622
4129,1433E,SARS-CoV-2 Infection,0.0010330833738130816,1,0,1,0.0010968062340665913
4130,1433E,Signaling by Hippo,0.0001874117462029787,0,0,1,0.00019897171591682622
4131,1433E,Signaling by Hippo,0.0010330833738130816,1,0,1,0.0010968062340665913
4132,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0001874117462029787,0,0,1,0.00019897171591682622
4133,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0010330833738130816,1,0,1,0.0010968062340665913
4134,1433E,Anchoring of the basal body to the plasma membrane,0.0001874117462029787,0,0,1,0.00019897171591682622
4135,1433E,Anchoring of the basal body to the plasma membrane,0.0010330833738130816,1,0,1,0.0010968062340665913
4136,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.00038721932110367735,0,0,1,0.0004111038625759448
4137,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0002740386594545788,1,0,1,0.0002909419681740189
4138,ACTA,Smooth Muscle Contraction,0.00038721932110367735,0,0,1,0.0004111038625759448
4139,ACTA,Smooth Muscle Contraction,0.0002740386594545788,1,0,1,0.0002909419681740189
4140,H4,Packaging Of Telomere Ends,0.002328122068057073,0,0,1,0.0024717257702910373
4141,H4,Packaging Of Telomere Ends,0.001749533354742027,1,0,1,0.0018574484294582052
4142,H4,Inhibition of DNA recombination at telomere,0.002328122068057073,0,0,1,0.0024717257702910373
4143,H4,Inhibition of DNA recombination at telomere,0.001749533354742027,1,0,1,0.0018574484294582052
4144,H4,Pre-NOTCH Transcription and Translation,0.002328122068057073,0,0,1,0.0024717257702910373
4145,H4,Pre-NOTCH Transcription and Translation,0.001749533354742027,1,0,1,0.0018574484294582052
4146,H4,RHO GTPase Effectors,0.002328122068057073,0,0,1,0.0024717257702910373
4147,H4,RHO GTPase Effectors,0.001749533354742027,1,0,1,0.0018574484294582052
4148,H4,Formation of the beta-catenin:TCF transactivating complex,0.002328122068057073,0,0,1,0.0024717257702910373
4149,H4,Formation of the beta-catenin:TCF transactivating complex,0.001749533354742027,1,0,1,0.0018574484294582052
4150,H4,Transcriptional regulation by RUNX1,0.002328122068057073,0,0,1,0.0024717257702910373
4151,H4,Transcriptional regulation by RUNX1,0.001749533354742027,1,0,1,0.0018574484294582052
4152,H4,Oxidative Stress Induced Senescence,0.002328122068057073,0,0,1,0.0024717257702910373
4153,H4,Oxidative Stress Induced Senescence,0.001749533354742027,1,0,1,0.0018574484294582052
4154,H4,Senescence-Associated Secretory Phenotype (SASP),0.002328122068057073,0,0,1,0.0024717257702910373
4155,H4,Senescence-Associated Secretory Phenotype (SASP),0.001749533354742027,1,0,1,0.0018574484294582052
4156,H4,DNA Damage/Telomere Stress Induced Senescence,0.002328122068057073,0,0,1,0.0024717257702910373
4157,H4,DNA Damage/Telomere Stress Induced Senescence,0.001749533354742027,1,0,1,0.0018574484294582052
4158,H4,SUMO E3 ligases SUMOylate target proteins,0.002328122068057073,0,0,1,0.0024717257702910373
4159,H4,SUMO E3 ligases SUMOylate target proteins,0.001749533354742027,1,0,1,0.0018574484294582052
4160,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.002328122068057073,0,0,1,0.0024717257702910373
4161,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.001749533354742027,1,0,1,0.0018574484294582052
4162,H4,B-WICH complex positively regulates rRNA expression,0.002328122068057073,0,0,1,0.0024717257702910373
4163,H4,B-WICH complex positively regulates rRNA expression,0.001749533354742027,1,0,1,0.0018574484294582052
4164,H4,SIRT1 negatively regulates rRNA expression,0.002328122068057073,0,0,1,0.0024717257702910373
4165,H4,SIRT1 negatively regulates rRNA expression,0.001749533354742027,1,0,1,0.0018574484294582052
4166,H4,NoRC negatively regulates rRNA expression,0.002328122068057073,0,0,1,0.0024717257702910373
4167,H4,NoRC negatively regulates rRNA expression,0.001749533354742027,1,0,1,0.0018574484294582052
4168,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.002328122068057073,0,0,1,0.0024717257702910373
4169,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.001749533354742027,1,0,1,0.0018574484294582052
4170,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.002328122068057073,0,0,1,0.0024717257702910373
4171,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.001749533354742027,1,0,1,0.0018574484294582052
4172,H4,Assembly of the ORC complex at the origin of replication,0.002328122068057073,0,0,1,0.0024717257702910373
4173,H4,Assembly of the ORC complex at the origin of replication,0.001749533354742027,1,0,1,0.0018574484294582052
4174,H4,Mitotic Prophase,0.002328122068057073,0,0,1,0.0024717257702910373
4175,H4,Mitotic Prophase,0.001749533354742027,1,0,1,0.0018574484294582052
4176,H4,G2/M DNA damage checkpoint,0.002328122068057073,0,0,1,0.0024717257702910373
4177,H4,G2/M DNA damage checkpoint,0.001749533354742027,1,0,1,0.0018574484294582052
4178,H4,RNA Polymerase I Promoter Opening,0.002328122068057073,0,0,1,0.0024717257702910373
4179,H4,RNA Polymerase I Promoter Opening,0.001749533354742027,1,0,1,0.0018574484294582052
4180,H4,RNA Polymerase I Promoter Escape,0.002328122068057073,0,0,1,0.0024717257702910373
4181,H4,RNA Polymerase I Promoter Escape,0.001749533354742027,1,0,1,0.0018574484294582052
4182,H4,Depurination,0.002328122068057073,0,0,1,0.0024717257702910373
4183,H4,Depurination,0.001749533354742027,1,0,1,0.0018574484294582052
4184,H4,Depyrimidination,0.002328122068057073,0,0,1,0.0024717257702910373
4185,H4,Depyrimidination,0.001749533354742027,1,0,1,0.0018574484294582052
4186,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.002328122068057073,0,0,1,0.0024717257702910373
4187,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.001749533354742027,1,0,1,0.0018574484294582052
4188,H4,Estrogen-dependent gene expression,0.002328122068057073,0,0,1,0.0024717257702910373
4189,H4,Estrogen-dependent gene expression,0.001749533354742027,1,0,1,0.0018574484294582052
4190,H4,HCMV Early Events,0.002328122068057073,0,0,1,0.0024717257702910373
4191,H4,HCMV Early Events,0.001749533354742027,1,0,1,0.0018574484294582052
4192,H4,HCMV Late Events,0.002328122068057073,0,0,1,0.0024717257702910373
4193,H4,HCMV Late Events,0.001749533354742027,1,0,1,0.0018574484294582052
4194,H4,Transcriptional regulation of granulopoiesis,0.002328122068057073,0,0,1,0.0024717257702910373
4195,H4,Transcriptional regulation of granulopoiesis,0.001749533354742027,1,0,1,0.0018574484294582052
4196,H4,Meiotic synapsis,0.002328122068057073,0,0,1,0.0024717257702910373
4197,H4,Meiotic synapsis,0.001749533354742027,1,0,1,0.0018574484294582052
4198,H4,Meiotic recombination,0.002328122068057073,0,0,1,0.0024717257702910373
4199,H4,Meiotic recombination,0.001749533354742027,1,0,1,0.0018574484294582052
4200,H4,Transcriptional regulation by small RNAs,0.002328122068057073,0,0,1,0.0024717257702910373
4201,H4,Transcriptional regulation by small RNAs,0.001749533354742027,1,0,1,0.0018574484294582052
4202,H4,PRC2 methylates histones and DNA,0.002328122068057073,0,0,1,0.0024717257702910373
4203,H4,PRC2 methylates histones and DNA,0.001749533354742027,1,0,1,0.0018574484294582052
4204,H4,DNA methylation,0.002328122068057073,0,0,1,0.0024717257702910373
4205,H4,DNA methylation,0.001749533354742027,1,0,1,0.0018574484294582052
4206,H4,HDACs deacetylate histones,0.002328122068057073,0,0,1,0.0024717257702910373
4207,H4,HDACs deacetylate histones,0.001749533354742027,1,0,1,0.0018574484294582052
4208,H4,PKMTs methylate histone lysines,0.002328122068057073,0,0,1,0.0024717257702910373
4209,H4,PKMTs methylate histone lysines,0.001749533354742027,1,0,1,0.0018574484294582052
4210,H4,HDMs demethylate histones,0.002328122068057073,0,0,1,0.0024717257702910373
4211,H4,HDMs demethylate histones,0.001749533354742027,1,0,1,0.0018574484294582052
4212,H4,HATs acetylate histones,0.002328122068057073,0,0,1,0.0024717257702910373
4213,H4,HATs acetylate histones,0.001749533354742027,1,0,1,0.0018574484294582052
4214,H4,RMTs methylate histone arginines,0.002328122068057073,0,0,1,0.0024717257702910373
4215,H4,RMTs methylate histone arginines,0.001749533354742027,1,0,1,0.0018574484294582052
4216,H4,Amyloid fiber formation,0.002328122068057073,0,0,1,0.0024717257702910373
4217,H4,Amyloid fiber formation,0.001749533354742027,1,0,1,0.0018574484294582052
4218,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.002328122068057073,0,0,1,0.0024717257702910373
4219,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.001749533354742027,1,0,1,0.0018574484294582052
4220,H4,Nonhomologous End-Joining (NHEJ),0.002328122068057073,0,0,1,0.0024717257702910373
4221,H4,Nonhomologous End-Joining (NHEJ),0.001749533354742027,1,0,1,0.0018574484294582052
4222,H4,Defective pyroptosis,0.002328122068057073,0,0,1,0.0024717257702910373
4223,H4,Defective pyroptosis,0.001749533354742027,1,0,1,0.0018574484294582052
4224,RAP1A,Signaling by NTRK1 (TRKA),0.0005108833987842584,0,0,1,0.0005423958132241578
4225,RAP1A,Signaling by NTRK1 (TRKA),0.000520281266447081,1,0,1,0.0005523733620849739
4226,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.0005108833987842584,0,0,1,0.0005423958132241578
4227,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.000520281266447081,1,0,1,0.0005523733620849739
4228,RAP1A,RAF/MAP kinase cascade,0.0005108833987842584,0,0,1,0.0005423958132241578
4229,RAP1A,RAF/MAP kinase cascade,0.000520281266447081,1,0,1,0.0005523733620849739
4230,RAP1A,Signaling by RAS mutants,0.0005108833987842584,0,0,1,0.0005423958132241578
4231,RAP1A,Signaling by RAS mutants,0.000520281266447081,1,0,1,0.0005523733620849739
4232,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.0005108833987842584,0,0,1,0.0005423958132241578
4233,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.000520281266447081,1,0,1,0.0005523733620849739
4234,RAP1A,Signaling by high-kinase activity BRAF mutants,0.0005108833987842584,0,0,1,0.0005423958132241578
4235,RAP1A,Signaling by high-kinase activity BRAF mutants,0.000520281266447081,1,0,1,0.0005523733620849739
4236,RAP1A,Signaling by BRAF and RAF1 fusions,0.0005108833987842584,0,0,1,0.0005423958132241578
4237,RAP1A,Signaling by BRAF and RAF1 fusions,0.000520281266447081,1,0,1,0.0005523733620849739
4238,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005108833987842584,0,0,1,0.0005423958132241578
4239,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.000520281266447081,1,0,1,0.0005523733620849739
4240,RAP1A,Signaling by RAF1 mutants,0.0005108833987842584,0,0,1,0.0005423958132241578
4241,RAP1A,Signaling by RAF1 mutants,0.000520281266447081,1,0,1,0.0005523733620849739
4242,RAP1A,MET promotes cell motility,0.0005108833987842584,0,0,1,0.0005423958132241578
4243,RAP1A,MET promotes cell motility,0.000520281266447081,1,0,1,0.0005523733620849739
4244,RAP1A,Rap1 signalling,0.0005108833987842584,0,0,1,0.0005423958132241578
4245,RAP1A,Rap1 signalling,0.000520281266447081,1,0,1,0.0005523733620849739
4246,RAP1A,Neutrophil degranulation,0.0005108833987842584,0,0,1,0.0005423958132241578
4247,RAP1A,Neutrophil degranulation,0.000520281266447081,1,0,1,0.0005523733620849739
4248,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0005108833987842584,0,0,1,0.0005423958132241578
4249,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.000520281266447081,1,0,1,0.0005523733620849739
4250,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.0005108833987842584,0,0,1,0.0005423958132241578
4251,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.000520281266447081,1,0,1,0.0005523733620849739
4252,PPIA,Downstream signaling events of B Cell Receptor (BCR),4.202174119514145e-05,0,0,1,4.461373484218241e-05
4253,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.00015612234345071141,1,0,1,0.00016575231381548485
4254,PPIA,HIV Life Cycle,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4255,PPIA,HIV Life Cycle,0.00015612234345071141,1,0,1,0.00016575231381548485
4256,PPIA,Host Interactions of HIV factors,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4257,PPIA,Host Interactions of HIV factors,0.00015612234345071141,1,0,1,0.00016575231381548485
4258,PPIA,Interleukin-12 family signaling,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4259,PPIA,Interleukin-12 family signaling,0.00015612234345071141,1,0,1,0.00016575231381548485
4260,PPIA,Platelet degranulation ,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4261,PPIA,Platelet degranulation ,0.00015612234345071141,1,0,1,0.00016575231381548485
4262,PPIA,Neutrophil degranulation,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4263,PPIA,Neutrophil degranulation,0.00015612234345071141,1,0,1,0.00016575231381548485
4264,PPIA,Basigin interactions,4.202174119514145e-05,0,0,1,4.461373484218241e-05
4265,PPIA,Basigin interactions,0.00015612234345071141,1,0,1,0.00016575231381548485
4266,1433Z,Activation of BH3-only proteins,0.00015454379373431286,0,0,1,0.00016407639567217027
4267,1433Z,Activation of BH3-only proteins,0.0019567841101778114,1,0,1,0.0020774828684386425
4268,1433Z,RHO GTPase Effectors,0.00015454379373431286,0,0,1,0.00016407639567217027
4269,1433Z,RHO GTPase Effectors,0.0019567841101778114,1,0,1,0.0020774828684386425
4270,1433Z,Deactivation of the beta-catenin transactivating complex,0.00015454379373431286,0,0,1,0.00016407639567217027
4271,1433Z,Deactivation of the beta-catenin transactivating complex,0.0019567841101778114,1,0,1,0.0020774828684386425
4272,1433Z,Transcriptional Regulation by TP53,0.00015454379373431286,0,0,1,0.00016407639567217027
4273,1433Z,Transcriptional Regulation by TP53,0.0019567841101778114,1,0,1,0.0020774828684386425
4274,1433Z,FOXO-mediated transcription,0.00015454379373431286,0,0,1,0.00016407639567217027
4275,1433Z,FOXO-mediated transcription,0.0019567841101778114,1,0,1,0.0020774828684386425
4276,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.00015454379373431286,0,0,1,0.00016407639567217027
4277,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0019567841101778114,1,0,1,0.0020774828684386425
4278,1433Z,G2/M DNA damage checkpoint,0.00015454379373431286,0,0,1,0.00016407639567217027
4279,1433Z,G2/M DNA damage checkpoint,0.0019567841101778114,1,0,1,0.0020774828684386425
4280,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.00015454379373431286,0,0,1,0.00016407639567217027
4281,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0019567841101778114,1,0,1,0.0020774828684386425
4282,1433Z,Negative regulation of NOTCH4 signaling,0.00015454379373431286,0,0,1,0.00016407639567217027
4283,1433Z,Negative regulation of NOTCH4 signaling,0.0019567841101778114,1,0,1,0.0020774828684386425
4284,1433Z,SARS-CoV-2 Infection,0.00015454379373431286,0,0,1,0.00016407639567217027
4285,1433Z,SARS-CoV-2 Infection,0.0019567841101778114,1,0,1,0.0020774828684386425
4286,1433Z,Rap1 signalling,0.00015454379373431286,0,0,1,0.00016407639567217027
4287,1433Z,Rap1 signalling,0.0019567841101778114,1,0,1,0.0020774828684386425
4288,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00015454379373431286,0,0,1,0.00016407639567217027
4289,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0019567841101778114,1,0,1,0.0020774828684386425
4290,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.00015454379373431286,0,0,1,0.00016407639567217027
4291,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.0019567841101778114,1,0,1,0.0020774828684386425
4292,1433Z,GP1b-IX-V activation signalling,0.00015454379373431286,0,0,1,0.00016407639567217027
4293,1433Z,GP1b-IX-V activation signalling,0.0019567841101778114,1,0,1,0.0020774828684386425
4294,TPM4,RHO GTPase cycle,0.0008913507477645077,0,0,1,0.0009463312271492587
4295,TPM4,RHO GTPase cycle,0.002306374248771971,1,0,1,0.0024486364975625325
4296,TPM4,Signaling by ALK fusions and activated point mutants,0.0008913507477645077,0,0,1,0.0009463312271492587
4297,TPM4,Signaling by ALK fusions and activated point mutants,0.002306374248771971,1,0,1,0.0024486364975625325
4298,TPM4,Striated Muscle Contraction,0.0008913507477645077,0,0,1,0.0009463312271492587
4299,TPM4,Striated Muscle Contraction,0.002306374248771971,1,0,1,0.0024486364975625325
4300,TPM4,Smooth Muscle Contraction,0.0008913507477645077,0,0,1,0.0009463312271492587
4301,TPM4,Smooth Muscle Contraction,0.002306374248771971,1,0,1,0.0024486364975625325
4302,TBA1B,Activation of NMDA receptors and postsynaptic events,0.0034759318672338037,0,0,1,0.0036903350085881396
4303,TBA1B,Activation of NMDA receptors and postsynaptic events,0.0033534009264886075,1,0,1,0.0035602460892598426
4304,TBA1B,Gap junction trafficking,0.0034759318672338037,0,0,1,0.0036903350085881396
4305,TBA1B,Gap junction trafficking,0.0033534009264886075,1,0,1,0.0035602460892598426
4306,TBA1B,RHO GTPase Effectors,0.0034759318672338037,0,0,1,0.0036903350085881396
4307,TBA1B,RHO GTPase Effectors,0.0033534009264886075,1,0,1,0.0035602460892598426
4308,TBA1B,RHO GTPase cycle,0.0034759318672338037,0,0,1,0.0036903350085881396
4309,TBA1B,RHO GTPase cycle,0.0033534009264886075,1,0,1,0.0035602460892598426
4310,TBA1B,COPI-mediated anterograde transport,0.0034759318672338037,0,0,1,0.0036903350085881396
4311,TBA1B,COPI-mediated anterograde transport,0.0033534009264886075,1,0,1,0.0035602460892598426
4312,TBA1B,Mitotic Metaphase and Anaphase,0.0034759318672338037,0,0,1,0.0036903350085881396
4313,TBA1B,Mitotic Metaphase and Anaphase,0.0033534009264886075,1,0,1,0.0035602460892598426
4314,TBA1B,L1CAM interactions,0.0034759318672338037,0,0,1,0.0036903350085881396
4315,TBA1B,L1CAM interactions,0.0033534009264886075,1,0,1,0.0035602460892598426
4316,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0034759318672338037,0,0,1,0.0036903350085881396
4317,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0033534009264886075,1,0,1,0.0035602460892598426
4318,TBA1B,G2/M Transition,0.0034759318672338037,0,0,1,0.0036903350085881396
4319,TBA1B,G2/M Transition,0.0033534009264886075,1,0,1,0.0035602460892598426
4320,TBA1B,Golgi-to-ER retrograde transport,0.0034759318672338037,0,0,1,0.0036903350085881396
4321,TBA1B,Golgi-to-ER retrograde transport,0.0033534009264886075,1,0,1,0.0035602460892598426
4322,TBA1B,Mitotic Prometaphase,0.0034759318672338037,0,0,1,0.0036903350085881396
4323,TBA1B,Mitotic Prometaphase,0.0033534009264886075,1,0,1,0.0035602460892598426
4324,TBA1B,HCMV Early Events,0.0034759318672338037,0,0,1,0.0036903350085881396
4325,TBA1B,HCMV Early Events,0.0033534009264886075,1,0,1,0.0035602460892598426
4326,TBA1B,Aggrephagy,0.0034759318672338037,0,0,1,0.0036903350085881396
4327,TBA1B,Aggrephagy,0.0033534009264886075,1,0,1,0.0035602460892598426
4328,TBA1B,MHC class II antigen presentation,0.0034759318672338037,0,0,1,0.0036903350085881396
4329,TBA1B,MHC class II antigen presentation,0.0033534009264886075,1,0,1,0.0035602460892598426
4330,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0034759318672338037,0,0,1,0.0036903350085881396
4331,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0033534009264886075,1,0,1,0.0035602460892598426
4332,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0034759318672338037,0,0,1,0.0036903350085881396
4333,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0033534009264886075,1,0,1,0.0035602460892598426
4334,TBA1B,Post-chaperonin tubulin folding pathway,0.0034759318672338037,0,0,1,0.0036903350085881396
4335,TBA1B,Post-chaperonin tubulin folding pathway,0.0033534009264886075,1,0,1,0.0035602460892598426
4336,TBA1B,Intraflagellar transport,0.0034759318672338037,0,0,1,0.0036903350085881396
4337,TBA1B,Intraflagellar transport,0.0033534009264886075,1,0,1,0.0035602460892598426
4338,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.0034759318672338037,0,0,1,0.0036903350085881396
4339,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.0033534009264886075,1,0,1,0.0035602460892598426
4340,TBA1B,Kinesins,0.0034759318672338037,0,0,1,0.0036903350085881396
4341,TBA1B,Kinesins,0.0033534009264886075,1,0,1,0.0035602460892598426
4342,TBA4A,Activation of NMDA receptors and postsynaptic events,0.0010869804053829728,0,0,1,0.0011540277533766449
4343,TBA4A,Activation of NMDA receptors and postsynaptic events,0.00021399060598259017,1,0,1,0.00022719001836908712
4344,TBA4A,Gap junction trafficking,0.0010869804053829728,0,0,1,0.0011540277533766449
4345,TBA4A,Gap junction trafficking,0.00021399060598259017,1,0,1,0.00022719001836908712
4346,TBA4A,RHO GTPase Effectors,0.0010869804053829728,0,0,1,0.0011540277533766449
4347,TBA4A,RHO GTPase Effectors,0.00021399060598259017,1,0,1,0.00022719001836908712
4348,TBA4A,COPI-mediated anterograde transport,0.0010869804053829728,0,0,1,0.0011540277533766449
4349,TBA4A,COPI-mediated anterograde transport,0.00021399060598259017,1,0,1,0.00022719001836908712
4350,TBA4A,Mitotic Metaphase and Anaphase,0.0010869804053829728,0,0,1,0.0011540277533766449
4351,TBA4A,Mitotic Metaphase and Anaphase,0.00021399060598259017,1,0,1,0.00022719001836908712
4352,TBA4A,L1CAM interactions,0.0010869804053829728,0,0,1,0.0011540277533766449
4353,TBA4A,L1CAM interactions,0.00021399060598259017,1,0,1,0.00022719001836908712
4354,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0010869804053829728,0,0,1,0.0011540277533766449
4355,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00021399060598259017,1,0,1,0.00022719001836908712
4356,TBA4A,G2/M Transition,0.0010869804053829728,0,0,1,0.0011540277533766449
4357,TBA4A,G2/M Transition,0.00021399060598259017,1,0,1,0.00022719001836908712
4358,TBA4A,Golgi-to-ER retrograde transport,0.0010869804053829728,0,0,1,0.0011540277533766449
4359,TBA4A,Golgi-to-ER retrograde transport,0.00021399060598259017,1,0,1,0.00022719001836908712
4360,TBA4A,Mitotic Prometaphase,0.0010869804053829728,0,0,1,0.0011540277533766449
4361,TBA4A,Mitotic Prometaphase,0.00021399060598259017,1,0,1,0.00022719001836908712
4362,TBA4A,Platelet degranulation ,0.0010869804053829728,0,0,1,0.0011540277533766449
4363,TBA4A,Platelet degranulation ,0.00021399060598259017,1,0,1,0.00022719001836908712
4364,TBA4A,HCMV Early Events,0.0010869804053829728,0,0,1,0.0011540277533766449
4365,TBA4A,HCMV Early Events,0.00021399060598259017,1,0,1,0.00022719001836908712
4366,TBA4A,Aggrephagy,0.0010869804053829728,0,0,1,0.0011540277533766449
4367,TBA4A,Aggrephagy,0.00021399060598259017,1,0,1,0.00022719001836908712
4368,TBA4A,MHC class II antigen presentation,0.0010869804053829728,0,0,1,0.0011540277533766449
4369,TBA4A,MHC class II antigen presentation,0.00021399060598259017,1,0,1,0.00022719001836908712
4370,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0010869804053829728,0,0,1,0.0011540277533766449
4371,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00021399060598259017,1,0,1,0.00022719001836908712
4372,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0010869804053829728,0,0,1,0.0011540277533766449
4373,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00021399060598259017,1,0,1,0.00022719001836908712
4374,TBA4A,Post-chaperonin tubulin folding pathway,0.0010869804053829728,0,0,1,0.0011540277533766449
4375,TBA4A,Post-chaperonin tubulin folding pathway,0.00021399060598259017,1,0,1,0.00022719001836908712
4376,TBA4A,Anchoring of the basal body to the plasma membrane,0.0010869804053829728,0,0,1,0.0011540277533766449
4377,TBA4A,Anchoring of the basal body to the plasma membrane,0.00021399060598259017,1,0,1,0.00022719001836908712
4378,TBA4A,Intraflagellar transport,0.0010869804053829728,0,0,1,0.0011540277533766449
4379,TBA4A,Intraflagellar transport,0.00021399060598259017,1,0,1,0.00022719001836908712
4380,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.0010869804053829728,0,0,1,0.0011540277533766449
4381,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.00021399060598259017,1,0,1,0.00022719001836908712
4382,TBA4A,Kinesins,0.0010869804053829728,0,0,1,0.0011540277533766449
4383,TBA4A,Kinesins,0.00021399060598259017,1,0,1,0.00022719001836908712
4384,HBB,Cytoprotection by HMOX1,0.001236596101503652,0,0,1,0.0013128720755088336
4385,HBB,Cytoprotection by HMOX1,0.0021745400986796556,1,0,1,0.0023086705264227397
4386,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.001236596101503652,0,0,1,0.0013128720755088336
4387,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.0021745400986796556,1,0,1,0.0023086705264227397
4388,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.001236596101503652,0,0,1,0.0013128720755088336
4389,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.0021745400986796556,1,0,1,0.0023086705264227397
4390,HBB,Neutrophil degranulation,0.001236596101503652,0,0,1,0.0013128720755088336
4391,HBB,Neutrophil degranulation,0.0021745400986796556,1,0,1,0.0023086705264227397
4392,HBB,Scavenging of heme from plasma,0.001236596101503652,0,0,1,0.0013128720755088336
4393,HBB,Scavenging of heme from plasma,0.0021745400986796556,1,0,1,0.0023086705264227397
4394,HBB,Heme signaling,0.001236596101503652,0,0,1,0.0013128720755088336
4395,HBB,Heme signaling,0.0021745400986796556,1,0,1,0.0023086705264227397
4396,HBB,Chaperone Mediated Autophagy,0.001236596101503652,0,0,1,0.0013128720755088336
4397,HBB,Chaperone Mediated Autophagy,0.0021745400986796556,1,0,1,0.0023086705264227397
4398,HBB,Late endosomal microautophagy,0.001236596101503652,0,0,1,0.0013128720755088336
4399,HBB,Late endosomal microautophagy,0.0021745400986796556,1,0,1,0.0023086705264227397
4400,HBA,Cytoprotection by HMOX1,0.00013193797299370695,0,0,1,0.00014007619806665302
4401,HBA,Cytoprotection by HMOX1,0.0007307535903320395,1,0,1,0.0007758280829594898
4402,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.00013193797299370695,0,0,1,0.00014007619806665302
4403,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0007307535903320395,1,0,1,0.0007758280829594898
4404,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.00013193797299370695,0,0,1,0.00014007619806665302
4405,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0007307535903320395,1,0,1,0.0007758280829594898
4406,HBA,Scavenging of heme from plasma,0.00013193797299370695,0,0,1,0.00014007619806665302
4407,HBA,Scavenging of heme from plasma,0.0007307535903320395,1,0,1,0.0007758280829594898
4408,HBA,Heme signaling,0.00013193797299370695,0,0,1,0.00014007619806665302
4409,HBA,Heme signaling,0.0007307535903320395,1,0,1,0.0007758280829594898
4410,GSTO1,Methylation,0.0005231145116368186,0,0,1,0.0005553813680847932
4411,GSTO1,Methylation,0.0011943321975555535,1,0,1,0.0012680012407811682
4412,GSTO1,Glutathione conjugation,0.0005231145116368186,0,0,1,0.0005553813680847932
4413,GSTO1,Glutathione conjugation,0.0011943321975555535,1,0,1,0.0012680012407811682
4414,GSTO1,Vitamin C (ascorbate) metabolism,0.0005231145116368186,0,0,1,0.0005553813680847932
4415,GSTO1,Vitamin C (ascorbate) metabolism,0.0011943321975555535,1,0,1,0.0012680012407811682
4416,GSTO1,Interleukin-12 family signaling,0.0005231145116368186,0,0,1,0.0005553813680847932
4417,GSTO1,Interleukin-12 family signaling,0.0011943321975555535,1,0,1,0.0012680012407811682
4418,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0009348307543229663,0,0,1,0.0009924931763775715
4419,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0005116207371371773,1,0,1,0.0005431786322323787
4420,NGAL,Interleukin-4 and Interleukin-13 signaling,0.0003953878170245774,0,0,1,0.00041977620933526046
4421,NGAL,Interleukin-4 and Interleukin-13 signaling,0.0006716715546700392,1,0,1,0.0007131017370729559
4422,NGAL,Metal sequestration by antimicrobial proteins,0.0003953878170245774,0,0,1,0.00041977620933526046
4423,NGAL,Metal sequestration by antimicrobial proteins,0.0006716715546700392,1,0,1,0.0007131017370729559
4424,NGAL,Neutrophil degranulation,0.0003953878170245774,0,0,1,0.00041977620933526046
4425,NGAL,Neutrophil degranulation,0.0006716715546700392,1,0,1,0.0007131017370729559
4426,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4427,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4428,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4429,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4430,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4431,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4432,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4433,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4434,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4435,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4436,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4437,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4438,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0014949956439615129,0,0,1,0.0015872102714684327
4439,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0008692579895853618,1,0,1,0.0009228757389351999
4440,S10AC,TRAF6 mediated NF-kB activation,0.0014949956439615129,0,0,1,0.0015872102714684327
4441,S10AC,TRAF6 mediated NF-kB activation,0.0008692579895853618,1,0,1,0.0009228757389351999
4442,S10AC,Interleukin-1 family signaling,0.0014949956439615129,0,0,1,0.0015872102714684327
4443,S10AC,Interleukin-1 family signaling,0.0008692579895853618,1,0,1,0.0009228757389351999
4444,S10AC,Neutrophil degranulation,0.0014949956439615129,0,0,1,0.0015872102714684327
4445,S10AC,Neutrophil degranulation,0.0008692579895853618,1,0,1,0.0009228757389351999
4446,S10AC,Advanced glycosylation endproduct receptor signaling,0.0014949956439615129,0,0,1,0.0015872102714684327
4447,S10AC,Advanced glycosylation endproduct receptor signaling,0.0008692579895853618,1,0,1,0.0009228757389351999
4448,BASP1,RHO GTPase cycle,0.00018116491194489426,0,0,1,0.0001923395631485953
4449,BASP1,RHO GTPase cycle,2.8688549979203812e-06,1,0,1,3.0458122994838654e-06
4450,LV321,Initial triggering of complement,0.00046818385626183124,0,0,1,0.0004970624687743968
4451,LV321,Initial triggering of complement,0.001267507470566234,1,0,1,0.001345690125969016
4452,LV321,Regulation of Complement cascade,0.00046818385626183124,0,0,1,0.0004970624687743968
4453,LV321,Regulation of Complement cascade,0.001267507470566234,1,0,1,0.001345690125969016
4454,LV321,FCGR activation,0.00046818385626183124,0,0,1,0.0004970624687743968
4455,LV321,FCGR activation,0.001267507470566234,1,0,1,0.001345690125969016
4456,LV321,Regulation of actin dynamics for phagocytic cup formation,0.00046818385626183124,0,0,1,0.0004970624687743968
4457,LV321,Regulation of actin dynamics for phagocytic cup formation,0.001267507470566234,1,0,1,0.001345690125969016
4458,LV321,Role of phospholipids in phagocytosis,0.00046818385626183124,0,0,1,0.0004970624687743968
4459,LV321,Role of phospholipids in phagocytosis,0.001267507470566234,1,0,1,0.001345690125969016
4460,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.00046818385626183124,0,0,1,0.0004970624687743968
4461,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.001267507470566234,1,0,1,0.001345690125969016
4462,LV321,FCERI mediated MAPK activation,0.00046818385626183124,0,0,1,0.0004970624687743968
4463,LV321,FCERI mediated MAPK activation,0.001267507470566234,1,0,1,0.001345690125969016
4464,LV321,FCERI mediated Ca+2 mobilization,0.00046818385626183124,0,0,1,0.0004970624687743968
4465,LV321,FCERI mediated Ca+2 mobilization,0.001267507470566234,1,0,1,0.001345690125969016
4466,LV321,FCERI mediated NF-kB activation,0.00046818385626183124,0,0,1,0.0004970624687743968
4467,LV321,FCERI mediated NF-kB activation,0.001267507470566234,1,0,1,0.001345690125969016
4468,LV321,Parasite infection,0.00046818385626183124,0,0,1,0.0004970624687743968
4469,LV321,Parasite infection,0.001267507470566234,1,0,1,0.001345690125969016
4470,LV321,Leishmania parasite growth and survival,0.00046818385626183124,0,0,1,0.0004970624687743968
4471,LV321,Leishmania parasite growth and survival,0.001267507470566234,1,0,1,0.001345690125969016
4472,LV321,Potential therapeutics for SARS,0.00046818385626183124,0,0,1,0.0004970624687743968
4473,LV321,Potential therapeutics for SARS,0.001267507470566234,1,0,1,0.001345690125969016
4474,LV321,CD22 mediated BCR regulation,0.00046818385626183124,0,0,1,0.0004970624687743968
4475,LV321,CD22 mediated BCR regulation,0.001267507470566234,1,0,1,0.001345690125969016
4476,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00046818385626183124,0,0,1,0.0004970624687743968
4477,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001267507470566234,1,0,1,0.001345690125969016
4478,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00046818385626183124,0,0,1,0.0004970624687743968
4479,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001267507470566234,1,0,1,0.001345690125969016
4480,LV321,Scavenging of heme from plasma,0.00046818385626183124,0,0,1,0.0004970624687743968
4481,LV321,Scavenging of heme from plasma,0.001267507470566234,1,0,1,0.001345690125969016
4482,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.0006675891683680398,0,0,1,0.0007087675401829466
4483,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.00020805427283711962,1,0,1,0.00022088751910669333
4484,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.0006675891683680398,0,0,1,0.0007087675401829466
4485,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.00020805427283711962,1,0,1,0.00022088751910669333
4486,PGBM,Diseases associated with glycosaminoglycan metabolism,0.0006675891683680398,0,0,1,0.0007087675401829466
4487,PGBM,Diseases associated with glycosaminoglycan metabolism,0.00020805427283711962,1,0,1,0.00022088751910669333
4488,PGBM,SARS-CoV-2 Infection,0.0006675891683680398,0,0,1,0.0007087675401829466
4489,PGBM,SARS-CoV-2 Infection,0.00020805427283711962,1,0,1,0.00022088751910669333
4490,PGBM,Integrin cell surface interactions,0.0006675891683680398,0,0,1,0.0007087675401829466
4491,PGBM,Integrin cell surface interactions,0.00020805427283711962,1,0,1,0.00022088751910669333
4492,PGBM,Laminin interactions,0.0006675891683680398,0,0,1,0.0007087675401829466
4493,PGBM,Laminin interactions,0.00020805427283711962,1,0,1,0.00022088751910669333
4494,PGBM,ECM proteoglycans,0.0006675891683680398,0,0,1,0.0007087675401829466
4495,PGBM,ECM proteoglycans,0.00020805427283711962,1,0,1,0.00022088751910669333
4496,PGBM,Retinoid metabolism and transport,0.0006675891683680398,0,0,1,0.0007087675401829466
4497,PGBM,Retinoid metabolism and transport,0.00020805427283711962,1,0,1,0.00022088751910669333
4498,PGBM,Amyloid fiber formation,0.0006675891683680398,0,0,1,0.0007087675401829466
4499,PGBM,Amyloid fiber formation,0.00020805427283711962,1,0,1,0.00022088751910669333
4500,DHSO,Fructose biosynthesis,0.000231869406958269,0,0,1,0.0002461716232083771
4501,DHSO,Fructose biosynthesis,4.963243552049104e-05,1,0,1,5.269387357368521e-05
4502,DHSO,Formation of xylulose-5-phosphate,0.000231869406958269,0,0,1,0.0002461716232083771
4503,DHSO,Formation of xylulose-5-phosphate,4.963243552049104e-05,1,0,1,5.269387357368521e-05
4504,CAP1,Signaling by ROBO receptors,2.4051646981063312e-05,0,0,1,2.5535205596264055e-05
4505,CAP1,Signaling by ROBO receptors,3.826567819798011e-06,1,0,1,4.062598959793576e-06
4506,CAP1,Platelet degranulation ,2.4051646981063312e-05,0,0,1,2.5535205596264055e-05
4507,CAP1,Platelet degranulation ,3.826567819798011e-06,1,0,1,4.062598959793576e-06
4508,CAP1,Neutrophil degranulation,2.4051646981063312e-05,0,0,1,2.5535205596264055e-05
4509,CAP1,Neutrophil degranulation,3.826567819798011e-06,1,0,1,4.062598959793576e-06
4510,DSC2,Formation of the cornified envelope,6.583828494305247e-05,0,0,1,6.989933551951444e-05
4511,DSC2,Formation of the cornified envelope,3.737526385024392e-06,1,0,1,3.9680652530033155e-06
4512,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00018474863522873982,0,0,1,0.00019614433838603185
4513,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00020356224710210393,1,0,1,0.0002161184153202605
4514,NUCB1,Post-translational protein phosphorylation,0.00018474863522873982,0,0,1,0.00019614433838603185
4515,NUCB1,Post-translational protein phosphorylation,0.00020356224710210393,1,0,1,0.0002161184153202605
4516,FHR3,Regulation of Complement cascade,7.814517511672554e-05,0,0,1,8.29653418135038e-05
4517,FHR3,Regulation of Complement cascade,9.084213964429236e-06,1,0,1,9.64454831075765e-06
4518,ACY1,Defective ACY1 causes encephalopathy,0.00041496405466034215,0,0,1,0.00044055995247036254
4519,ACY1,Defective ACY1 causes encephalopathy,0.001681308896720485,1,0,1,0.0017850157364436524
4520,ACY1,Aflatoxin activation and detoxification,0.00041496405466034215,0,0,1,0.00044055995247036254
4521,ACY1,Aflatoxin activation and detoxification,0.001681308896720485,1,0,1,0.0017850157364436524
4522,ACY1,Paracetamol ADME,0.00041496405466034215,0,0,1,0.00044055995247036254
4523,ACY1,Paracetamol ADME,0.001681308896720485,1,0,1,0.0017850157364436524
4524,FHR1,Regulation of Complement cascade,3.717169385031192e-05,0,0,1,3.946452588367136e-05
4525,FHR1,Regulation of Complement cascade,4.392142443935936e-06,1,0,1,4.663059473735195e-06
4526,HGFA,MET Receptor Activation,0.00023307878368736281,0,0,1,0.00024745559696057217
4527,HGFA,MET Receptor Activation,0.00017859955520574668,1,0,1,0.00018961596954964258
4528,AK1C1,Bile acid and bile salt metabolism,0.0009905483947740632,0,0,1,0.0010516476037387278
4529,AK1C1,Bile acid and bile salt metabolism,8.348333998176986e-05,1,0,1,8.863277645708485e-05
4530,AK1C1,Retinoid metabolism and transport,0.0009905483947740632,0,0,1,0.0010516476037387278
4531,AK1C1,Retinoid metabolism and transport,8.348333998176986e-05,1,0,1,8.863277645708485e-05
4532,1433F,Activation of BH3-only proteins,0.0002538740356363531,0,0,1,0.0002695335458994395
4533,1433F,Activation of BH3-only proteins,0.00016018663666215205,1,0,1,0.00017006730159321786
4534,1433F,RHO GTPase Effectors,0.0002538740356363531,0,0,1,0.0002695335458994395
4535,1433F,RHO GTPase Effectors,0.00016018663666215205,1,0,1,0.00017006730159321786
4536,1433F,Transcriptional Regulation by TP53,0.0002538740356363531,0,0,1,0.0002695335458994395
4537,1433F,Transcriptional Regulation by TP53,0.00016018663666215205,1,0,1,0.00017006730159321786
4538,1433F,G2/M DNA damage checkpoint,0.0002538740356363531,0,0,1,0.0002695335458994395
4539,1433F,G2/M DNA damage checkpoint,0.00016018663666215205,1,0,1,0.00017006730159321786
4540,1433F,SARS-CoV-2 Infection,0.0002538740356363531,0,0,1,0.0002695335458994395
4541,1433F,SARS-CoV-2 Infection,0.00016018663666215205,1,0,1,0.00017006730159321786
4542,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0002538740356363531,0,0,1,0.0002695335458994395
4543,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00016018663666215205,1,0,1,0.00017006730159321786
4544,EF1A2,Eukaryotic Translation Elongation,6.602474515740516e-06,0,0,1,7.009729701099849e-06
4545,EF1A2,Eukaryotic Translation Elongation,5.408162575393565e-05,1,0,1,5.741749967036575e-05
4546,ITIH3,Platelet degranulation ,1.5526941672157958e-05,0,0,1,1.6484677668515535e-05
4547,ITIH3,Platelet degranulation ,3.002891696538213e-05,1,0,1,3.1881166771984394e-05
4548,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0002886333659354498,0,0,1,0.0003064369083292437
4549,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0003698492587203051,1,0,1,0.00039266237644700893
4550,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0002886333659354498,0,0,1,0.0003064369083292437
4551,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0003698492587203051,1,0,1,0.00039266237644700893
4552,PSME1,Antigen processing-Cross presentation,0.0002886333659354498,0,0,1,0.0003064369083292437
4553,PSME1,Antigen processing-Cross presentation,0.0003698492587203051,1,0,1,0.00039266237644700893
4554,PSME1,PTEN Regulation,0.0002886333659354498,0,0,1,0.0003064369083292437
4555,PSME1,PTEN Regulation,0.0003698492587203051,1,0,1,0.00039266237644700893
4556,PSME1,Host Interactions of HIV factors,0.0002886333659354498,0,0,1,0.0003064369083292437
4557,PSME1,Host Interactions of HIV factors,0.0003698492587203051,1,0,1,0.00039266237644700893
4558,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0002886333659354498,0,0,1,0.0003064369083292437
4559,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0003698492587203051,1,0,1,0.00039266237644700893
4560,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0002886333659354498,0,0,1,0.0003064369083292437
4561,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0003698492587203051,1,0,1,0.00039266237644700893
4562,PSME1,Degradation of AXIN,0.0002886333659354498,0,0,1,0.0003064369083292437
4563,PSME1,Degradation of AXIN,0.0003698492587203051,1,0,1,0.00039266237644700893
4564,PSME1,Degradation of DVL,0.0002886333659354498,0,0,1,0.0003064369083292437
4565,PSME1,Degradation of DVL,0.0003698492587203051,1,0,1,0.00039266237644700893
4566,PSME1,Downstream TCR signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4567,PSME1,Downstream TCR signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4568,PSME1,Transcriptional regulation by RUNX3,0.0002886333659354498,0,0,1,0.0003064369083292437
4569,PSME1,Transcriptional regulation by RUNX3,0.0003698492587203051,1,0,1,0.00039266237644700893
4570,PSME1,Transcriptional regulation by RUNX2,0.0002886333659354498,0,0,1,0.0003064369083292437
4571,PSME1,Transcriptional regulation by RUNX2,0.0003698492587203051,1,0,1,0.00039266237644700893
4572,PSME1,Transcriptional regulation by RUNX1,0.0002886333659354498,0,0,1,0.0003064369083292437
4573,PSME1,Transcriptional regulation by RUNX1,0.0003698492587203051,1,0,1,0.00039266237644700893
4574,PSME1,FCERI mediated NF-kB activation,0.0002886333659354498,0,0,1,0.0003064369083292437
4575,PSME1,FCERI mediated NF-kB activation,0.0003698492587203051,1,0,1,0.00039266237644700893
4576,PSME1,Mitotic Metaphase and Anaphase,0.0002886333659354498,0,0,1,0.0003064369083292437
4577,PSME1,Mitotic Metaphase and Anaphase,0.0003698492587203051,1,0,1,0.00039266237644700893
4578,PSME1,Regulation of ornithine decarboxylase (ODC),0.0002886333659354498,0,0,1,0.0003064369083292437
4579,PSME1,Regulation of ornithine decarboxylase (ODC),0.0003698492587203051,1,0,1,0.00039266237644700893
4580,PSME1,Signaling by ROBO receptors,0.0002886333659354498,0,0,1,0.0003064369083292437
4581,PSME1,Signaling by ROBO receptors,0.0003698492587203051,1,0,1,0.00039266237644700893
4582,PSME1,PCP/CE pathway,0.0002886333659354498,0,0,1,0.0003064369083292437
4583,PSME1,PCP/CE pathway,0.0003698492587203051,1,0,1,0.00039266237644700893
4584,PSME1,Interleukin-1 family signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4585,PSME1,Interleukin-1 family signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4586,PSME1,G2/M Transition,0.0002886333659354498,0,0,1,0.0003064369083292437
4587,PSME1,G2/M Transition,0.0003698492587203051,1,0,1,0.00039266237644700893
4588,PSME1,G1/S Transition,0.0002886333659354498,0,0,1,0.0003064369083292437
4589,PSME1,G1/S Transition,0.0003698492587203051,1,0,1,0.00039266237644700893
4590,PSME1,Hh mutants are degraded by ERAD,0.0002886333659354498,0,0,1,0.0003064369083292437
4591,PSME1,Hh mutants are degraded by ERAD,0.0003698492587203051,1,0,1,0.00039266237644700893
4592,PSME1,CLEC7A (Dectin-1) signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4593,PSME1,CLEC7A (Dectin-1) signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4594,PSME1,Degradation of GLI1 by the proteasome,0.0002886333659354498,0,0,1,0.0003064369083292437
4595,PSME1,Degradation of GLI1 by the proteasome,0.0003698492587203051,1,0,1,0.00039266237644700893
4596,PSME1,Degradation of GLI2 by the proteasome,0.0002886333659354498,0,0,1,0.0003064369083292437
4597,PSME1,Degradation of GLI2 by the proteasome,0.0003698492587203051,1,0,1,0.00039266237644700893
4598,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0002886333659354498,0,0,1,0.0003064369083292437
4599,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0003698492587203051,1,0,1,0.00039266237644700893
4600,PSME1,Defective CFTR causes cystic fibrosis,0.0002886333659354498,0,0,1,0.0003064369083292437
4601,PSME1,Defective CFTR causes cystic fibrosis,0.0003698492587203051,1,0,1,0.00039266237644700893
4602,PSME1,NIK-->noncanonical NF-kB signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4603,PSME1,NIK-->noncanonical NF-kB signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4604,PSME1,RAF/MAP kinase cascade,0.0002886333659354498,0,0,1,0.0003064369083292437
4605,PSME1,RAF/MAP kinase cascade,0.0003698492587203051,1,0,1,0.00039266237644700893
4606,PSME1,UCH proteinases,0.0002886333659354498,0,0,1,0.0003064369083292437
4607,PSME1,UCH proteinases,0.0003698492587203051,1,0,1,0.00039266237644700893
4608,PSME1,Ub-specific processing proteases,0.0002886333659354498,0,0,1,0.0003064369083292437
4609,PSME1,Ub-specific processing proteases,0.0003698492587203051,1,0,1,0.00039266237644700893
4610,PSME1,Orc1 removal from chromatin,0.0002886333659354498,0,0,1,0.0003064369083292437
4611,PSME1,Orc1 removal from chromatin,0.0003698492587203051,1,0,1,0.00039266237644700893
4612,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0002886333659354498,0,0,1,0.0003064369083292437
4613,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0003698492587203051,1,0,1,0.00039266237644700893
4614,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0002886333659354498,0,0,1,0.0003064369083292437
4615,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0003698492587203051,1,0,1,0.00039266237644700893
4616,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0002886333659354498,0,0,1,0.0003064369083292437
4617,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0003698492587203051,1,0,1,0.00039266237644700893
4618,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0002886333659354498,0,0,1,0.0003064369083292437
4619,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0003698492587203051,1,0,1,0.00039266237644700893
4620,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0002886333659354498,0,0,1,0.0003064369083292437
4621,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0003698492587203051,1,0,1,0.00039266237644700893
4622,PSME1,Negative regulation of NOTCH4 signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4623,PSME1,Negative regulation of NOTCH4 signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4624,PSME1,KEAP1-NFE2L2 pathway,0.0002886333659354498,0,0,1,0.0003064369083292437
4625,PSME1,KEAP1-NFE2L2 pathway,0.0003698492587203051,1,0,1,0.00039266237644700893
4626,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0002886333659354498,0,0,1,0.0003064369083292437
4627,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0003698492587203051,1,0,1,0.00039266237644700893
4628,PSME1,Degradation of beta-catenin by the destruction complex,0.0002886333659354498,0,0,1,0.0003064369083292437
4629,PSME1,Degradation of beta-catenin by the destruction complex,0.0003698492587203051,1,0,1,0.00039266237644700893
4630,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0002886333659354498,0,0,1,0.0003064369083292437
4631,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0003698492587203051,1,0,1,0.00039266237644700893
4632,PSME1,Hedgehog ligand biogenesis,0.0002886333659354498,0,0,1,0.0003064369083292437
4633,PSME1,Hedgehog ligand biogenesis,0.0003698492587203051,1,0,1,0.00039266237644700893
4634,PSME1,Hedgehog 'on' state,0.0002886333659354498,0,0,1,0.0003064369083292437
4635,PSME1,Hedgehog 'on' state,0.0003698492587203051,1,0,1,0.00039266237644700893
4636,PSME1,MAPK6/MAPK4 signaling,0.0002886333659354498,0,0,1,0.0003064369083292437
4637,PSME1,MAPK6/MAPK4 signaling,0.0003698492587203051,1,0,1,0.00039266237644700893
4638,PSME1,Neddylation,0.0002886333659354498,0,0,1,0.0003064369083292437
4639,PSME1,Neddylation,0.0003698492587203051,1,0,1,0.00039266237644700893
4640,LRP1,Scavenging of heme from plasma,0.00015347498828799096,0,0,1,0.000162941663949402
4641,LRP1,Scavenging of heme from plasma,6.642482371230853e-05,1,0,1,7.052205329326711e-05
4642,LRP1,Retinoid metabolism and transport,0.00015347498828799096,0,0,1,0.000162941663949402
4643,LRP1,Retinoid metabolism and transport,6.642482371230853e-05,1,0,1,7.052205329326711e-05
4644,LG3BP,Platelet degranulation ,0.00011496112661572467,0,0,1,0.00012205218237328767
4645,LG3BP,Platelet degranulation ,0.00022394848186536943,1,0,1,0.00023776211799158068
4646,BST1,Nicotinate metabolism,9.867968999849855e-05,0,0,1,0.00010476647084797113
4647,BST1,Nicotinate metabolism,0.0011385564738411816,1,0,1,0.0012087851474529953
4648,BST1,Neutrophil degranulation,9.867968999849855e-05,0,0,1,0.00010476647084797113
4649,BST1,Neutrophil degranulation,0.0011385564738411816,1,0,1,0.0012087851474529953
4650,BST1,Post-translational modification: synthesis of GPI-anchored proteins,9.867968999849855e-05,0,0,1,0.00010476647084797113
4651,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0011385564738411816,1,0,1,0.0012087851474529953
4652,FBLN3,Molecules associated with elastic fibres,0.00019421448269173395,0,0,1,0.00020619406019097678
4653,FBLN3,Molecules associated with elastic fibres,0.00014050778890386338,1,0,1,0.00014917461911699827
4654,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005687144632229043,0,0,1,0.0006037940252241218
4655,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018589477235602622,1,0,1,0.001973611717783485
4656,FSTL1,Post-translational protein phosphorylation,0.0005687144632229043,0,0,1,0.0006037940252241218
4657,FSTL1,Post-translational protein phosphorylation,0.0018589477235602622,1,0,1,0.001973611717783485
4658,FSTL1,Signaling by BMP,0.0005687144632229043,0,0,1,0.0006037940252241218
4659,FSTL1,Signaling by BMP,0.0018589477235602622,1,0,1,0.001973611717783485
4660,LMAN2,COPII-mediated vesicle transport,0.0010532435995342238,0,0,1,0.0011182099869597622
4661,LMAN2,COPII-mediated vesicle transport,0.000916438004968754,1,0,1,0.0009729659216905996
4662,LMAN2,Cargo concentration in the ER,0.0010532435995342238,0,0,1,0.0011182099869597622
4663,LMAN2,Cargo concentration in the ER,0.000916438004968754,1,0,1,0.0009729659216905996
4664,TRAP1,Respiratory electron transport,0.0003694635007807011,0,0,1,0.0003922528241071656
4665,TRAP1,Respiratory electron transport,7.706613571360603e-05,1,0,1,8.181974488091868e-05
4666,SPP24,Platelet degranulation ,1.7622726111047196e-05,0,0,1,1.87097347124104e-05
4667,SPP24,Platelet degranulation ,0.0001938039519705013,1,0,1,0.00020575820702971458
4668,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1.7622726111047196e-05,0,0,1,1.87097347124104e-05
4669,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001938039519705013,1,0,1,0.00020575820702971458
4670,SPP24,Post-translational protein phosphorylation,1.7622726111047196e-05,0,0,1,1.87097347124104e-05
4671,SPP24,Post-translational protein phosphorylation,0.0001938039519705013,1,0,1,0.00020575820702971458
4672,MMRN1,Platelet degranulation ,8.982119280890598e-06,0,0,1,9.536156202038557e-06
4673,MMRN1,Platelet degranulation ,1.8490646260513966e-05,1,0,1,1.9631190090298803e-05
4674,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,3.5599291716372245e-05,0,0,1,3.779513451925599e-05
4675,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,2.1414249120998138e-05,1,0,1,2.273512722121825e-05
4676,APOF,LDL remodeling,0.0005349954101394143,0,0,1,0.0005679951066022008
4677,APOF,LDL remodeling,0.0002769126042032791,1,0,1,0.00029399318417133274
4678,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,4.4716504323198745e-05,0,0,1,4.747471690142984e-05
4679,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,1.6501460336970586e-05,1,0,1,1.7519306793206233e-05
4680,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0016571697040323905,0,0,1,0.0017593875851281253
4681,TBB2A,Activation of NMDA receptors and postsynaptic events,0.00021913646081062732,1,0,1,0.00023265328086857054
4682,TBB2A,Gap junction trafficking,0.0016571697040323905,0,0,1,0.0017593875851281253
4683,TBB2A,Gap junction trafficking,0.00021913646081062732,1,0,1,0.00023265328086857054
4684,TBB2A,RHO GTPase Effectors,0.0016571697040323905,0,0,1,0.0017593875851281253
4685,TBB2A,RHO GTPase Effectors,0.00021913646081062732,1,0,1,0.00023265328086857054
4686,TBB2A,COPI-mediated anterograde transport,0.0016571697040323905,0,0,1,0.0017593875851281253
4687,TBB2A,COPI-mediated anterograde transport,0.00021913646081062732,1,0,1,0.00023265328086857054
4688,TBB2A,Mitotic Metaphase and Anaphase,0.0016571697040323905,0,0,1,0.0017593875851281253
4689,TBB2A,Mitotic Metaphase and Anaphase,0.00021913646081062732,1,0,1,0.00023265328086857054
4690,TBB2A,L1CAM interactions,0.0016571697040323905,0,0,1,0.0017593875851281253
4691,TBB2A,L1CAM interactions,0.00021913646081062732,1,0,1,0.00023265328086857054
4692,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0016571697040323905,0,0,1,0.0017593875851281253
4693,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00021913646081062732,1,0,1,0.00023265328086857054
4694,TBB2A,G2/M Transition,0.0016571697040323905,0,0,1,0.0017593875851281253
4695,TBB2A,G2/M Transition,0.00021913646081062732,1,0,1,0.00023265328086857054
4696,TBB2A,Golgi-to-ER retrograde transport,0.0016571697040323905,0,0,1,0.0017593875851281253
4697,TBB2A,Golgi-to-ER retrograde transport,0.00021913646081062732,1,0,1,0.00023265328086857054
4698,TBB2A,Mitotic Prometaphase,0.0016571697040323905,0,0,1,0.0017593875851281253
4699,TBB2A,Mitotic Prometaphase,0.00021913646081062732,1,0,1,0.00023265328086857054
4700,TBB2A,HCMV Early Events,0.0016571697040323905,0,0,1,0.0017593875851281253
4701,TBB2A,HCMV Early Events,0.00021913646081062732,1,0,1,0.00023265328086857054
4702,TBB2A,Aggrephagy,0.0016571697040323905,0,0,1,0.0017593875851281253
4703,TBB2A,Aggrephagy,0.00021913646081062732,1,0,1,0.00023265328086857054
4704,TBB2A,MHC class II antigen presentation,0.0016571697040323905,0,0,1,0.0017593875851281253
4705,TBB2A,MHC class II antigen presentation,0.00021913646081062732,1,0,1,0.00023265328086857054
4706,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0016571697040323905,0,0,1,0.0017593875851281253
4707,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00021913646081062732,1,0,1,0.00023265328086857054
4708,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0016571697040323905,0,0,1,0.0017593875851281253
4709,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00021913646081062732,1,0,1,0.00023265328086857054
4710,TBB2A,Post-chaperonin tubulin folding pathway,0.0016571697040323905,0,0,1,0.0017593875851281253
4711,TBB2A,Post-chaperonin tubulin folding pathway,0.00021913646081062732,1,0,1,0.00023265328086857054
4712,TBB2A,Intraflagellar transport,0.0016571697040323905,0,0,1,0.0017593875851281253
4713,TBB2A,Intraflagellar transport,0.00021913646081062732,1,0,1,0.00023265328086857054
4714,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0016571697040323905,0,0,1,0.0017593875851281253
4715,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.00021913646081062732,1,0,1,0.00023265328086857054
4716,TBB2A,Kinesins,0.0016571697040323905,0,0,1,0.0017593875851281253
4717,TBB2A,Kinesins,0.00021913646081062732,1,0,1,0.00023265328086857054
4718,DAG1,Signaling by ROBO receptors,0.0005597900845959007,0,0,1,0.0005943191712468094
4719,DAG1,Signaling by ROBO receptors,0.0006902929913101311,1,0,1,0.0007328717849818134
4720,DAG1,Diseases associated with O-glycosylation of proteins,0.0005597900845959007,0,0,1,0.0005943191712468094
4721,DAG1,Diseases associated with O-glycosylation of proteins,0.0006902929913101311,1,0,1,0.0007328717849818134
4722,DAG1,ECM proteoglycans,0.0005597900845959007,0,0,1,0.0005943191712468094
4723,DAG1,ECM proteoglycans,0.0006902929913101311,1,0,1,0.0007328717849818134
4724,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0005597900845959007,0,0,1,0.0005943191712468094
4725,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0006902929913101311,1,0,1,0.0007328717849818134
4726,KRT81,Formation of the cornified envelope,2.0964569486131766e-05,0,0,1,2.225771035501335e-05
4727,KRT81,Formation of the cornified envelope,5.79225931126756e-06,1,0,1,6.149538636441149e-06
4728,ITIH4,Platelet degranulation ,5.695228464348883e-05,0,0,1,6.046522712949556e-05
4729,ITIH4,Platelet degranulation ,0.00010634963170821388,1,0,1,0.0001129095114731368
4730,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0015899080754763584,0,0,1,0.0016879771110233745
4731,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0005701895753574099,1,0,1,0.0006053601255274316
4732,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0015899080754763584,0,0,1,0.0016879771110233745
4733,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0005701895753574099,1,0,1,0.0006053601255274316
4734,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.00030151474940221814,0,0,1,0.00032011284392929727
4735,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0003564933158024711,1,0,1,0.00037848260952263253
4736,GANAB,SARS-CoV-1 Infection,0.00030151474940221814,0,0,1,0.00032011284392929727
4737,GANAB,SARS-CoV-1 Infection,0.0003564933158024711,1,0,1,0.00037848260952263253
4738,GANAB,SARS-CoV-2 Infection,0.00030151474940221814,0,0,1,0.00032011284392929727
4739,GANAB,SARS-CoV-2 Infection,0.0003564933158024711,1,0,1,0.00037848260952263253
4740,PCOC1,Crosslinking of collagen fibrils,0.0011696474222456894,0,0,1,0.0012417938541048525
4741,PCOC1,Crosslinking of collagen fibrils,0.0007834621988175446,1,0,1,0.0008317878746290603
4742,PON3,Arachidonic acid metabolism,0.00023022804233107475,0,0,1,0.00024442901559207375
4743,PON3,Arachidonic acid metabolism,0.00013574996326146186,1,0,1,0.00014412332029885267
4744,PON3,Atorvastatin ADME,0.00023022804233107475,0,0,1,0.00024442901559207375
4745,PON3,Atorvastatin ADME,0.00013574996326146186,1,0,1,0.00014412332029885267
4746,FCN2,Initial triggering of complement,5.814820514420292e-05,0,0,1,6.173491464347599e-05
4747,FCN2,Initial triggering of complement,4.917235645305408e-05,1,0,1,5.2205415814979954e-05
4748,BGH3,Amyloid fiber formation,3.346598067814347e-05,0,0,1,3.553023615263515e-05
4749,BGH3,Amyloid fiber formation,9.869205933197706e-05,1,0,1,0.00010477960314921068
4750,ADIPO,Transcriptional regulation of white adipocyte differentiation,5.7787375884714e-06,0,0,1,6.1351828639700386e-06
4751,ADIPO,Transcriptional regulation of white adipocyte differentiation,2.3527730896663332e-05,1,0,1,2.497897321264075e-05
4752,ADIPO,AMPK inhibits chREBP transcriptional activation activity,5.7787375884714e-06,0,0,1,6.1351828639700386e-06
4753,ADIPO,AMPK inhibits chREBP transcriptional activation activity,2.3527730896663332e-05,1,0,1,2.497897321264075e-05
4754,ECM1,Platelet degranulation ,3.555077493203601e-05,0,0,1,3.774362511269141e-05
4755,ECM1,Platelet degranulation ,6.99490920475845e-05,1,0,1,7.426370626981919e-05
4756,UGPA,Glucuronidation,0.0011470651453204907,0,0,1,0.0012178186525491866
4757,UGPA,Glucuronidation,0.0014214045187898056,1,0,1,0.001509079883441389
4758,UGPA,Glycogen synthesis,0.0011470651453204907,0,0,1,0.0012178186525491866
4759,UGPA,Glycogen synthesis,0.0014214045187898056,1,0,1,0.001509079883441389
4760,TKFC,Fructose catabolism,4.619429754651728e-05,0,0,1,4.90436636690219e-05
4761,TKFC,Fructose catabolism,4.359985325144347e-05,1,0,1,4.6289188329560744e-05
4762,TKFC,SARS-CoV-2 Infection,4.619429754651728e-05,0,0,1,4.90436636690219e-05
4763,TKFC,SARS-CoV-2 Infection,4.359985325144347e-05,1,0,1,4.6289188329560744e-05
4764,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0004971520965629338,0,0,1,0.0005278175340068541
4765,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0003827542937029777,1,0,1,0.00040636342244061496
4766,CTRB2,Activation of Matrix Metalloproteinases,0.0004971520965629338,0,0,1,0.0005278175340068541
4767,CTRB2,Activation of Matrix Metalloproteinases,0.0003827542937029777,1,0,1,0.00040636342244061496
4768,OLFM4,Neutrophil degranulation,8.20718552194226e-05,0,0,1,8.713422820253461e-05
4769,OLFM4,Neutrophil degranulation,6.980602197726682e-05,1,0,1,7.411181132212142e-05
4770,LDH6A,Pyruvate metabolism,0.00040722560319418475,0,0,1,0.0004323441762559262
4771,LDH6A,Pyruvate metabolism,0.0005538306803191056,1,0,1,0.0005879921777748434
4772,TBA1A,Activation of NMDA receptors and postsynaptic events,0.0005300502830715661,0,0,1,0.0005627449531937221
4773,TBA1A,Activation of NMDA receptors and postsynaptic events,0.001469224633774271,1,0,1,0.0015598496485525568
4774,TBA1A,Gap junction trafficking,0.0005300502830715661,0,0,1,0.0005627449531937221
4775,TBA1A,Gap junction trafficking,0.001469224633774271,1,0,1,0.0015598496485525568
4776,TBA1A,RHO GTPase Effectors,0.0005300502830715661,0,0,1,0.0005627449531937221
4777,TBA1A,RHO GTPase Effectors,0.001469224633774271,1,0,1,0.0015598496485525568
4778,TBA1A,COPI-mediated anterograde transport,0.0005300502830715661,0,0,1,0.0005627449531937221
4779,TBA1A,COPI-mediated anterograde transport,0.001469224633774271,1,0,1,0.0015598496485525568
4780,TBA1A,Mitotic Metaphase and Anaphase,0.0005300502830715661,0,0,1,0.0005627449531937221
4781,TBA1A,Mitotic Metaphase and Anaphase,0.001469224633774271,1,0,1,0.0015598496485525568
4782,TBA1A,L1CAM interactions,0.0005300502830715661,0,0,1,0.0005627449531937221
4783,TBA1A,L1CAM interactions,0.001469224633774271,1,0,1,0.0015598496485525568
4784,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0005300502830715661,0,0,1,0.0005627449531937221
4785,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.001469224633774271,1,0,1,0.0015598496485525568
4786,TBA1A,G2/M Transition,0.0005300502830715661,0,0,1,0.0005627449531937221
4787,TBA1A,G2/M Transition,0.001469224633774271,1,0,1,0.0015598496485525568
4788,TBA1A,Golgi-to-ER retrograde transport,0.0005300502830715661,0,0,1,0.0005627449531937221
4789,TBA1A,Golgi-to-ER retrograde transport,0.001469224633774271,1,0,1,0.0015598496485525568
4790,TBA1A,Mitotic Prometaphase,0.0005300502830715661,0,0,1,0.0005627449531937221
4791,TBA1A,Mitotic Prometaphase,0.001469224633774271,1,0,1,0.0015598496485525568
4792,TBA1A,HCMV Early Events,0.0005300502830715661,0,0,1,0.0005627449531937221
4793,TBA1A,HCMV Early Events,0.001469224633774271,1,0,1,0.0015598496485525568
4794,TBA1A,Aggrephagy,0.0005300502830715661,0,0,1,0.0005627449531937221
4795,TBA1A,Aggrephagy,0.001469224633774271,1,0,1,0.0015598496485525568
4796,TBA1A,MHC class II antigen presentation,0.0005300502830715661,0,0,1,0.0005627449531937221
4797,TBA1A,MHC class II antigen presentation,0.001469224633774271,1,0,1,0.0015598496485525568
4798,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005300502830715661,0,0,1,0.0005627449531937221
4799,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.001469224633774271,1,0,1,0.0015598496485525568
4800,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0005300502830715661,0,0,1,0.0005627449531937221
4801,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001469224633774271,1,0,1,0.0015598496485525568
4802,TBA1A,Post-chaperonin tubulin folding pathway,0.0005300502830715661,0,0,1,0.0005627449531937221
4803,TBA1A,Post-chaperonin tubulin folding pathway,0.001469224633774271,1,0,1,0.0015598496485525568
4804,TBA1A,Anchoring of the basal body to the plasma membrane,0.0005300502830715661,0,0,1,0.0005627449531937221
4805,TBA1A,Anchoring of the basal body to the plasma membrane,0.001469224633774271,1,0,1,0.0015598496485525568
4806,TBA1A,Intraflagellar transport,0.0005300502830715661,0,0,1,0.0005627449531937221
4807,TBA1A,Intraflagellar transport,0.001469224633774271,1,0,1,0.0015598496485525568
4808,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.0005300502830715661,0,0,1,0.0005627449531937221
4809,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.001469224633774271,1,0,1,0.0015598496485525568
4810,TBA1A,Kinesins,0.0005300502830715661,0,0,1,0.0005627449531937221
4811,TBA1A,Kinesins,0.001469224633774271,1,0,1,0.0015598496485525568
4812,DCXR,Essential pentosuria,0.000444479620478324,0,0,1,0.0004718961034643312
4813,DCXR,Essential pentosuria,0.0003383442830648344,1,0,1,0.0003592141044304963
4814,DCXR,Formation of xylulose-5-phosphate,0.000444479620478324,0,0,1,0.0004718961034643312
4815,DCXR,Formation of xylulose-5-phosphate,0.0003383442830648344,1,0,1,0.0003592141044304963
4816,K2C1B,Formation of the cornified envelope,1.4311074032383228e-05,0,0,1,1.5193812631957466e-05
4817,K2C1B,Formation of the cornified envelope,5.585623680801024e-07,1,0,1,5.930157264694301e-07
4818,URP2,Platelet degranulation ,3.6196618857317805e-05,0,0,1,3.8429306115250336e-05
4819,URP2,Platelet degranulation ,7.117836839409526e-05,1,0,1,7.556880709170847e-05
4820,C163A,Leishmania parasite growth and survival,3.675442277865144e-05,0,0,1,3.902151661230574e-05
4821,C163A,Leishmania parasite growth and survival,0.00031678771875008144,1,0,1,0.0003363278837005939
4822,C163A,Scavenging of heme from plasma,3.675442277865144e-05,0,0,1,3.902151661230574e-05
4823,C163A,Scavenging of heme from plasma,0.00031678771875008144,1,0,1,0.0003363278837005939
4824,K2C78,Formation of the cornified envelope,0.00013795954153576374,0,0,1,0.0001464691902328227
4825,K2C78,Formation of the cornified envelope,5.247663426290599e-06,1,0,1,5.571350876546161e-06
4826,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005233553019564996,0,0,1,0.00055563701088229
4827,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000427282897981243,1,0,1,0.0004536386492080552
4828,LIRA3,Neutrophil degranulation,0.0005233553019564996,0,0,1,0.00055563701088229
4829,LIRA3,Neutrophil degranulation,0.000427282897981243,1,0,1,0.0004536386492080552
4830,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00030300310555240377,0,0,1,0.0003216930051683749
4831,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0007226811507704956,1,0,1,0.0007672577175275616
4832,GOLM1,Post-translational protein phosphorylation,0.00030300310555240377,0,0,1,0.0003216930051683749
4833,GOLM1,Post-translational protein phosphorylation,0.0007226811507704956,1,0,1,0.0007672577175275616
4834,TXND5,Lysosome Vesicle Biogenesis,0.0004360967039173176,0,0,1,0.00046299611012706987
4835,TXND5,Lysosome Vesicle Biogenesis,0.0004833261471337445,1,0,1,0.0005131387695332251
4836,TXND5,Golgi Associated Vesicle Biogenesis,0.0004360967039173176,0,0,1,0.00046299611012706987
4837,TXND5,Golgi Associated Vesicle Biogenesis,0.0004833261471337445,1,0,1,0.0005131387695332251
4838,TXND5,Neutrophil degranulation,0.0004360967039173176,0,0,1,0.00046299611012706987
4839,TXND5,Neutrophil degranulation,0.0004833261471337445,1,0,1,0.0005131387695332251
4840,BHMT1,Choline catabolism,0.00043275037393042447,0,0,1,0.0004594433711285499
4841,BHMT1,Choline catabolism,0.0016222776996378367,1,0,1,0.0017223433649721344
4842,H2B1A,Packaging Of Telomere Ends,0.007582137760644788,0,0,1,0.008049820734925087
4843,H2B1A,Packaging Of Telomere Ends,0.004023437681347888,1,0,1,0.004271612188465283
4844,H2B1A,Inhibition of DNA recombination at telomere,0.007582137760644788,0,0,1,0.008049820734925087
4845,H2B1A,Inhibition of DNA recombination at telomere,0.004023437681347888,1,0,1,0.004271612188465283
4846,H2B1A,Pre-NOTCH Transcription and Translation,0.007582137760644788,0,0,1,0.008049820734925087
4847,H2B1A,Pre-NOTCH Transcription and Translation,0.004023437681347888,1,0,1,0.004271612188465283
4848,H2B1A,RHO GTPase Effectors,0.007582137760644788,0,0,1,0.008049820734925087
4849,H2B1A,RHO GTPase Effectors,0.004023437681347888,1,0,1,0.004271612188465283
4850,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.007582137760644788,0,0,1,0.008049820734925087
4851,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.004023437681347888,1,0,1,0.004271612188465283
4852,H2B1A,Transcriptional regulation by RUNX1,0.007582137760644788,0,0,1,0.008049820734925087
4853,H2B1A,Transcriptional regulation by RUNX1,0.004023437681347888,1,0,1,0.004271612188465283
4854,H2B1A,Oxidative Stress Induced Senescence,0.007582137760644788,0,0,1,0.008049820734925087
4855,H2B1A,Oxidative Stress Induced Senescence,0.004023437681347888,1,0,1,0.004271612188465283
4856,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.007582137760644788,0,0,1,0.008049820734925087
4857,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.004023437681347888,1,0,1,0.004271612188465283
4858,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.007582137760644788,0,0,1,0.008049820734925087
4859,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.004023437681347888,1,0,1,0.004271612188465283
4860,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.007582137760644788,0,0,1,0.008049820734925087
4861,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.004023437681347888,1,0,1,0.004271612188465283
4862,H2B1A,B-WICH complex positively regulates rRNA expression,0.007582137760644788,0,0,1,0.008049820734925087
4863,H2B1A,B-WICH complex positively regulates rRNA expression,0.004023437681347888,1,0,1,0.004271612188465283
4864,H2B1A,SIRT1 negatively regulates rRNA expression,0.007582137760644788,0,0,1,0.008049820734925087
4865,H2B1A,SIRT1 negatively regulates rRNA expression,0.004023437681347888,1,0,1,0.004271612188465283
4866,H2B1A,NoRC negatively regulates rRNA expression,0.007582137760644788,0,0,1,0.008049820734925087
4867,H2B1A,NoRC negatively regulates rRNA expression,0.004023437681347888,1,0,1,0.004271612188465283
4868,H2B1A,Ub-specific processing proteases,0.007582137760644788,0,0,1,0.008049820734925087
4869,H2B1A,Ub-specific processing proteases,0.004023437681347888,1,0,1,0.004271612188465283
4870,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.007582137760644788,0,0,1,0.008049820734925087
4871,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.004023437681347888,1,0,1,0.004271612188465283
4872,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.007582137760644788,0,0,1,0.008049820734925087
4873,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.004023437681347888,1,0,1,0.004271612188465283
4874,H2B1A,Assembly of the ORC complex at the origin of replication,0.007582137760644788,0,0,1,0.008049820734925087
4875,H2B1A,Assembly of the ORC complex at the origin of replication,0.004023437681347888,1,0,1,0.004271612188465283
4876,H2B1A,Mitotic Prophase,0.007582137760644788,0,0,1,0.008049820734925087
4877,H2B1A,Mitotic Prophase,0.004023437681347888,1,0,1,0.004271612188465283
4878,H2B1A,G2/M DNA damage checkpoint,0.007582137760644788,0,0,1,0.008049820734925087
4879,H2B1A,G2/M DNA damage checkpoint,0.004023437681347888,1,0,1,0.004271612188465283
4880,H2B1A,RNA Polymerase I Promoter Opening,0.007582137760644788,0,0,1,0.008049820734925087
4881,H2B1A,RNA Polymerase I Promoter Opening,0.004023437681347888,1,0,1,0.004271612188465283
4882,H2B1A,RNA Polymerase I Promoter Escape,0.007582137760644788,0,0,1,0.008049820734925087
4883,H2B1A,RNA Polymerase I Promoter Escape,0.004023437681347888,1,0,1,0.004271612188465283
4884,H2B1A,Depurination,0.007582137760644788,0,0,1,0.008049820734925087
4885,H2B1A,Depurination,0.004023437681347888,1,0,1,0.004271612188465283
4886,H2B1A,Depyrimidination,0.007582137760644788,0,0,1,0.008049820734925087
4887,H2B1A,Depyrimidination,0.004023437681347888,1,0,1,0.004271612188465283
4888,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.007582137760644788,0,0,1,0.008049820734925087
4889,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.004023437681347888,1,0,1,0.004271612188465283
4890,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.007582137760644788,0,0,1,0.008049820734925087
4891,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.004023437681347888,1,0,1,0.004271612188465283
4892,H2B1A,Estrogen-dependent gene expression,0.007582137760644788,0,0,1,0.008049820734925087
4893,H2B1A,Estrogen-dependent gene expression,0.004023437681347888,1,0,1,0.004271612188465283
4894,H2B1A,HCMV Early Events,0.007582137760644788,0,0,1,0.008049820734925087
4895,H2B1A,HCMV Early Events,0.004023437681347888,1,0,1,0.004271612188465283
4896,H2B1A,HCMV Late Events,0.007582137760644788,0,0,1,0.008049820734925087
4897,H2B1A,HCMV Late Events,0.004023437681347888,1,0,1,0.004271612188465283
4898,H2B1A,Transcriptional regulation of granulopoiesis,0.007582137760644788,0,0,1,0.008049820734925087
4899,H2B1A,Transcriptional regulation of granulopoiesis,0.004023437681347888,1,0,1,0.004271612188465283
4900,H2B1A,Meiotic synapsis,0.007582137760644788,0,0,1,0.008049820734925087
4901,H2B1A,Meiotic synapsis,0.004023437681347888,1,0,1,0.004271612188465283
4902,H2B1A,Meiotic recombination,0.007582137760644788,0,0,1,0.008049820734925087
4903,H2B1A,Meiotic recombination,0.004023437681347888,1,0,1,0.004271612188465283
4904,H2B1A,Transcriptional regulation by small RNAs,0.007582137760644788,0,0,1,0.008049820734925087
4905,H2B1A,Transcriptional regulation by small RNAs,0.004023437681347888,1,0,1,0.004271612188465283
4906,H2B1A,PRC2 methylates histones and DNA,0.007582137760644788,0,0,1,0.008049820734925087
4907,H2B1A,PRC2 methylates histones and DNA,0.004023437681347888,1,0,1,0.004271612188465283
4908,H2B1A,DNA methylation,0.007582137760644788,0,0,1,0.008049820734925087
4909,H2B1A,DNA methylation,0.004023437681347888,1,0,1,0.004271612188465283
4910,H2B1A,HDACs deacetylate histones,0.007582137760644788,0,0,1,0.008049820734925087
4911,H2B1A,HDACs deacetylate histones,0.004023437681347888,1,0,1,0.004271612188465283
4912,H2B1A,HATs acetylate histones,0.007582137760644788,0,0,1,0.008049820734925087
4913,H2B1A,HATs acetylate histones,0.004023437681347888,1,0,1,0.004271612188465283
4914,H2B1A,Amyloid fiber formation,0.007582137760644788,0,0,1,0.008049820734925087
4915,H2B1A,Amyloid fiber formation,0.004023437681347888,1,0,1,0.004271612188465283
4916,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.007582137760644788,0,0,1,0.008049820734925087
4917,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.004023437681347888,1,0,1,0.004271612188465283
4918,H2B1A,Nonhomologous End-Joining (NHEJ),0.007582137760644788,0,0,1,0.008049820734925087
4919,H2B1A,Nonhomologous End-Joining (NHEJ),0.004023437681347888,1,0,1,0.004271612188465283
4920,H2B1A,Defective pyroptosis,0.007582137760644788,0,0,1,0.008049820734925087
4921,H2B1A,Defective pyroptosis,0.004023437681347888,1,0,1,0.004271612188465283
4922,CBPB2,Regulation of Complement cascade,2.0689869542635715e-05,0,0,1,2.1966066313340174e-05
4923,CBPB2,Regulation of Complement cascade,2.672334882151799e-05,1,0,1,2.8371703896843685e-05
4924,CBPB2,Metabolism of Angiotensinogen to Angiotensins,2.0689869542635715e-05,0,0,1,2.1966066313340174e-05
4925,CBPB2,Metabolism of Angiotensinogen to Angiotensins,2.672334882151799e-05,1,0,1,2.8371703896843685e-05
4926,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.00036404566961366607,0,0,1,0.0003865008091684376
4927,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.001663249919987591,1,0,1,0.001765842842209188
4928,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00036404566961366607,0,0,1,0.0003865008091684376
4929,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.001663249919987591,1,0,1,0.001765842842209188
4930,PSB7,Antigen processing-Cross presentation,0.00036404566961366607,0,0,1,0.0003865008091684376
4931,PSB7,Antigen processing-Cross presentation,0.001663249919987591,1,0,1,0.001765842842209188
4932,PSB7,PTEN Regulation,0.00036404566961366607,0,0,1,0.0003865008091684376
4933,PSB7,PTEN Regulation,0.001663249919987591,1,0,1,0.001765842842209188
4934,PSB7,Host Interactions of HIV factors,0.00036404566961366607,0,0,1,0.0003865008091684376
4935,PSB7,Host Interactions of HIV factors,0.001663249919987591,1,0,1,0.001765842842209188
4936,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00036404566961366607,0,0,1,0.0003865008091684376
4937,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.001663249919987591,1,0,1,0.001765842842209188
4938,PSB7,APC/C-mediated degradation of cell cycle proteins,0.00036404566961366607,0,0,1,0.0003865008091684376
4939,PSB7,APC/C-mediated degradation of cell cycle proteins,0.001663249919987591,1,0,1,0.001765842842209188
4940,PSB7,Degradation of AXIN,0.00036404566961366607,0,0,1,0.0003865008091684376
4941,PSB7,Degradation of AXIN,0.001663249919987591,1,0,1,0.001765842842209188
4942,PSB7,Degradation of DVL,0.00036404566961366607,0,0,1,0.0003865008091684376
4943,PSB7,Degradation of DVL,0.001663249919987591,1,0,1,0.001765842842209188
4944,PSB7,Downstream TCR signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
4945,PSB7,Downstream TCR signaling,0.001663249919987591,1,0,1,0.001765842842209188
4946,PSB7,Transcriptional regulation by RUNX3,0.00036404566961366607,0,0,1,0.0003865008091684376
4947,PSB7,Transcriptional regulation by RUNX3,0.001663249919987591,1,0,1,0.001765842842209188
4948,PSB7,Transcriptional regulation by RUNX2,0.00036404566961366607,0,0,1,0.0003865008091684376
4949,PSB7,Transcriptional regulation by RUNX2,0.001663249919987591,1,0,1,0.001765842842209188
4950,PSB7,Transcriptional regulation by RUNX1,0.00036404566961366607,0,0,1,0.0003865008091684376
4951,PSB7,Transcriptional regulation by RUNX1,0.001663249919987591,1,0,1,0.001765842842209188
4952,PSB7,FCERI mediated NF-kB activation,0.00036404566961366607,0,0,1,0.0003865008091684376
4953,PSB7,FCERI mediated NF-kB activation,0.001663249919987591,1,0,1,0.001765842842209188
4954,PSB7,Mitotic Metaphase and Anaphase,0.00036404566961366607,0,0,1,0.0003865008091684376
4955,PSB7,Mitotic Metaphase and Anaphase,0.001663249919987591,1,0,1,0.001765842842209188
4956,PSB7,Regulation of ornithine decarboxylase (ODC),0.00036404566961366607,0,0,1,0.0003865008091684376
4957,PSB7,Regulation of ornithine decarboxylase (ODC),0.001663249919987591,1,0,1,0.001765842842209188
4958,PSB7,Signaling by ROBO receptors,0.00036404566961366607,0,0,1,0.0003865008091684376
4959,PSB7,Signaling by ROBO receptors,0.001663249919987591,1,0,1,0.001765842842209188
4960,PSB7,PCP/CE pathway,0.00036404566961366607,0,0,1,0.0003865008091684376
4961,PSB7,PCP/CE pathway,0.001663249919987591,1,0,1,0.001765842842209188
4962,PSB7,Interleukin-1 family signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
4963,PSB7,Interleukin-1 family signaling,0.001663249919987591,1,0,1,0.001765842842209188
4964,PSB7,G2/M Transition,0.00036404566961366607,0,0,1,0.0003865008091684376
4965,PSB7,G2/M Transition,0.001663249919987591,1,0,1,0.001765842842209188
4966,PSB7,G1/S Transition,0.00036404566961366607,0,0,1,0.0003865008091684376
4967,PSB7,G1/S Transition,0.001663249919987591,1,0,1,0.001765842842209188
4968,PSB7,Hh mutants are degraded by ERAD,0.00036404566961366607,0,0,1,0.0003865008091684376
4969,PSB7,Hh mutants are degraded by ERAD,0.001663249919987591,1,0,1,0.001765842842209188
4970,PSB7,CLEC7A (Dectin-1) signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
4971,PSB7,CLEC7A (Dectin-1) signaling,0.001663249919987591,1,0,1,0.001765842842209188
4972,PSB7,Degradation of GLI1 by the proteasome,0.00036404566961366607,0,0,1,0.0003865008091684376
4973,PSB7,Degradation of GLI1 by the proteasome,0.001663249919987591,1,0,1,0.001765842842209188
4974,PSB7,Degradation of GLI2 by the proteasome,0.00036404566961366607,0,0,1,0.0003865008091684376
4975,PSB7,Degradation of GLI2 by the proteasome,0.001663249919987591,1,0,1,0.001765842842209188
4976,PSB7,GLI3 is processed to GLI3R by the proteasome,0.00036404566961366607,0,0,1,0.0003865008091684376
4977,PSB7,GLI3 is processed to GLI3R by the proteasome,0.001663249919987591,1,0,1,0.001765842842209188
4978,PSB7,Defective CFTR causes cystic fibrosis,0.00036404566961366607,0,0,1,0.0003865008091684376
4979,PSB7,Defective CFTR causes cystic fibrosis,0.001663249919987591,1,0,1,0.001765842842209188
4980,PSB7,NIK-->noncanonical NF-kB signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
4981,PSB7,NIK-->noncanonical NF-kB signaling,0.001663249919987591,1,0,1,0.001765842842209188
4982,PSB7,RAF/MAP kinase cascade,0.00036404566961366607,0,0,1,0.0003865008091684376
4983,PSB7,RAF/MAP kinase cascade,0.001663249919987591,1,0,1,0.001765842842209188
4984,PSB7,UCH proteinases,0.00036404566961366607,0,0,1,0.0003865008091684376
4985,PSB7,UCH proteinases,0.001663249919987591,1,0,1,0.001765842842209188
4986,PSB7,Ub-specific processing proteases,0.00036404566961366607,0,0,1,0.0003865008091684376
4987,PSB7,Ub-specific processing proteases,0.001663249919987591,1,0,1,0.001765842842209188
4988,PSB7,Orc1 removal from chromatin,0.00036404566961366607,0,0,1,0.0003865008091684376
4989,PSB7,Orc1 removal from chromatin,0.001663249919987591,1,0,1,0.001765842842209188
4990,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.00036404566961366607,0,0,1,0.0003865008091684376
4991,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.001663249919987591,1,0,1,0.001765842842209188
4992,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.00036404566961366607,0,0,1,0.0003865008091684376
4993,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.001663249919987591,1,0,1,0.001765842842209188
4994,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.00036404566961366607,0,0,1,0.0003865008091684376
4995,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.001663249919987591,1,0,1,0.001765842842209188
4996,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.00036404566961366607,0,0,1,0.0003865008091684376
4997,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.001663249919987591,1,0,1,0.001765842842209188
4998,PSB7,p53-Independent G1/S DNA damage checkpoint,0.00036404566961366607,0,0,1,0.0003865008091684376
4999,PSB7,p53-Independent G1/S DNA damage checkpoint,0.001663249919987591,1,0,1,0.001765842842209188
5000,PSB7,Negative regulation of NOTCH4 signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
5001,PSB7,Negative regulation of NOTCH4 signaling,0.001663249919987591,1,0,1,0.001765842842209188
5002,PSB7,KEAP1-NFE2L2 pathway,0.00036404566961366607,0,0,1,0.0003865008091684376
5003,PSB7,KEAP1-NFE2L2 pathway,0.001663249919987591,1,0,1,0.001765842842209188
5004,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.00036404566961366607,0,0,1,0.0003865008091684376
5005,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.001663249919987591,1,0,1,0.001765842842209188
5006,PSB7,Neutrophil degranulation,0.00036404566961366607,0,0,1,0.0003865008091684376
5007,PSB7,Neutrophil degranulation,0.001663249919987591,1,0,1,0.001765842842209188
5008,PSB7,Degradation of beta-catenin by the destruction complex,0.00036404566961366607,0,0,1,0.0003865008091684376
5009,PSB7,Degradation of beta-catenin by the destruction complex,0.001663249919987591,1,0,1,0.001765842842209188
5010,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00036404566961366607,0,0,1,0.0003865008091684376
5011,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.001663249919987591,1,0,1,0.001765842842209188
5012,PSB7,Hedgehog ligand biogenesis,0.00036404566961366607,0,0,1,0.0003865008091684376
5013,PSB7,Hedgehog ligand biogenesis,0.001663249919987591,1,0,1,0.001765842842209188
5014,PSB7,Hedgehog 'on' state,0.00036404566961366607,0,0,1,0.0003865008091684376
5015,PSB7,Hedgehog 'on' state,0.001663249919987591,1,0,1,0.001765842842209188
5016,PSB7,MAPK6/MAPK4 signaling,0.00036404566961366607,0,0,1,0.0003865008091684376
5017,PSB7,MAPK6/MAPK4 signaling,0.001663249919987591,1,0,1,0.001765842842209188
5018,PSB7,Neddylation,0.00036404566961366607,0,0,1,0.0003865008091684376
5019,PSB7,Neddylation,0.001663249919987591,1,0,1,0.001765842842209188
5020,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0001307362655480865,0,0,1,0.00013880036665624525
5021,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0002525284949738561,1,0,1,0.00026810500932221274
5022,PARK7,Aggrephagy,0.0001307362655480865,0,0,1,0.00013880036665624525
5023,PARK7,Aggrephagy,0.0002525284949738561,1,0,1,0.00026810500932221274
5024,PARK7,Chaperone Mediated Autophagy,0.0001307362655480865,0,0,1,0.00013880036665624525
5025,PARK7,Chaperone Mediated Autophagy,0.0002525284949738561,1,0,1,0.00026810500932221274
5026,PARK7,Late endosomal microautophagy,0.0001307362655480865,0,0,1,0.00013880036665624525
5027,PARK7,Late endosomal microautophagy,0.0002525284949738561,1,0,1,0.00026810500932221274
5028,RARR2,Platelet degranulation ,3.857356076425765e-06,0,0,1,4.09528630397251e-06
5029,RARR2,Platelet degranulation ,7.205048358268015e-06,1,0,1,7.649471626797707e-06
5030,FUCO2,Neutrophil degranulation,0.0006891136194477662,0,0,1,0.0007316196668626823
5031,FUCO2,Neutrophil degranulation,0.001066255180648561,1,0,1,0.0011320241510853484
5032,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006891136194477662,0,0,1,0.0007316196668626823
5033,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001066255180648561,1,0,1,0.0011320241510853484
5034,FUCO2,Post-translational protein phosphorylation,0.0006891136194477662,0,0,1,0.0007316196668626823
5035,FUCO2,Post-translational protein phosphorylation,0.001066255180648561,1,0,1,0.0011320241510853484
5036,COL11,Initial triggering of complement,0.00020127771729556136,0,0,1,0.00021369297067828702
5037,COL11,Initial triggering of complement,0.00015148930274127973,1,0,1,0.00016083349694010225
5038,COL11,Scavenging by Class A Receptors,0.00020127771729556136,0,0,1,0.00021369297067828702
5039,COL11,Scavenging by Class A Receptors,0.00015148930274127973,1,0,1,0.00016083349694010225
5040,FHR5,Regulation of Complement cascade,2.1779885442596965e-05,0,0,1,2.3123316797293383e-05
5041,FHR5,Regulation of Complement cascade,3.042920020413123e-06,1,0,1,3.2306140363449636e-06
5042,CHM4A,HIV Life Cycle,0.0008268110293198878,0,0,1,0.0008778105565728977
5043,CHM4A,HIV Life Cycle,0.0015916181249581844,1,0,1,0.0016897926401275806
5044,CHM4A,Mitotic Metaphase and Anaphase,0.0008268110293198878,0,0,1,0.0008778105565728977
5045,CHM4A,Mitotic Metaphase and Anaphase,0.0015916181249581844,1,0,1,0.0016897926401275806
5046,CHM4A,HCMV Late Events,0.0008268110293198878,0,0,1,0.0008778105565728977
5047,CHM4A,HCMV Late Events,0.0015916181249581844,1,0,1,0.0016897926401275806
5048,CHM4A,SARS-CoV-1 Infection,0.0008268110293198878,0,0,1,0.0008778105565728977
5049,CHM4A,SARS-CoV-1 Infection,0.0015916181249581844,1,0,1,0.0016897926401275806
5050,CHM4A,SARS-CoV-2 Infection,0.0008268110293198878,0,0,1,0.0008778105565728977
5051,CHM4A,SARS-CoV-2 Infection,0.0015916181249581844,1,0,1,0.0016897926401275806
5052,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0008268110293198878,0,0,1,0.0008778105565728977
5053,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0015916181249581844,1,0,1,0.0016897926401275806
5054,CHM4A,Pyroptosis,0.0008268110293198878,0,0,1,0.0008778105565728977
5055,CHM4A,Pyroptosis,0.0015916181249581844,1,0,1,0.0016897926401275806
5056,CHM4A,Late endosomal microautophagy,0.0008268110293198878,0,0,1,0.0008778105565728977
5057,CHM4A,Late endosomal microautophagy,0.0015916181249581844,1,0,1,0.0016897926401275806
5058,TBB1,Activation of NMDA receptors and postsynaptic events,0.00027797560338734597,0,0,1,0.0002951217514887884
5059,TBB1,Activation of NMDA receptors and postsynaptic events,0.0005515516422193162,1,0,1,0.0005855725635802038
5060,TBB1,Gap junction trafficking,0.00027797560338734597,0,0,1,0.0002951217514887884
5061,TBB1,Gap junction trafficking,0.0005515516422193162,1,0,1,0.0005855725635802038
5062,TBB1,RHO GTPase Effectors,0.00027797560338734597,0,0,1,0.0002951217514887884
5063,TBB1,RHO GTPase Effectors,0.0005515516422193162,1,0,1,0.0005855725635802038
5064,TBB1,COPI-mediated anterograde transport,0.00027797560338734597,0,0,1,0.0002951217514887884
5065,TBB1,COPI-mediated anterograde transport,0.0005515516422193162,1,0,1,0.0005855725635802038
5066,TBB1,Mitotic Metaphase and Anaphase,0.00027797560338734597,0,0,1,0.0002951217514887884
5067,TBB1,Mitotic Metaphase and Anaphase,0.0005515516422193162,1,0,1,0.0005855725635802038
5068,TBB1,L1CAM interactions,0.00027797560338734597,0,0,1,0.0002951217514887884
5069,TBB1,L1CAM interactions,0.0005515516422193162,1,0,1,0.0005855725635802038
5070,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00027797560338734597,0,0,1,0.0002951217514887884
5071,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0005515516422193162,1,0,1,0.0005855725635802038
5072,TBB1,G2/M Transition,0.00027797560338734597,0,0,1,0.0002951217514887884
5073,TBB1,G2/M Transition,0.0005515516422193162,1,0,1,0.0005855725635802038
5074,TBB1,Golgi-to-ER retrograde transport,0.00027797560338734597,0,0,1,0.0002951217514887884
5075,TBB1,Golgi-to-ER retrograde transport,0.0005515516422193162,1,0,1,0.0005855725635802038
5076,TBB1,Mitotic Prometaphase,0.00027797560338734597,0,0,1,0.0002951217514887884
5077,TBB1,Mitotic Prometaphase,0.0005515516422193162,1,0,1,0.0005855725635802038
5078,TBB1,HCMV Early Events,0.00027797560338734597,0,0,1,0.0002951217514887884
5079,TBB1,HCMV Early Events,0.0005515516422193162,1,0,1,0.0005855725635802038
5080,TBB1,Aggrephagy,0.00027797560338734597,0,0,1,0.0002951217514887884
5081,TBB1,Aggrephagy,0.0005515516422193162,1,0,1,0.0005855725635802038
5082,TBB1,MHC class II antigen presentation,0.00027797560338734597,0,0,1,0.0002951217514887884
5083,TBB1,MHC class II antigen presentation,0.0005515516422193162,1,0,1,0.0005855725635802038
5084,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00027797560338734597,0,0,1,0.0002951217514887884
5085,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005515516422193162,1,0,1,0.0005855725635802038
5086,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00027797560338734597,0,0,1,0.0002951217514887884
5087,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0005515516422193162,1,0,1,0.0005855725635802038
5088,TBB1,Post-chaperonin tubulin folding pathway,0.00027797560338734597,0,0,1,0.0002951217514887884
5089,TBB1,Post-chaperonin tubulin folding pathway,0.0005515516422193162,1,0,1,0.0005855725635802038
5090,TBB1,Intraflagellar transport,0.00027797560338734597,0,0,1,0.0002951217514887884
5091,TBB1,Intraflagellar transport,0.0005515516422193162,1,0,1,0.0005855725635802038
5092,TBB1,Carboxyterminal post-translational modifications of tubulin,0.00027797560338734597,0,0,1,0.0002951217514887884
5093,TBB1,Carboxyterminal post-translational modifications of tubulin,0.0005515516422193162,1,0,1,0.0005855725635802038
5094,TBB1,Kinesins,0.00027797560338734597,0,0,1,0.0002951217514887884
5095,TBB1,Kinesins,0.0005515516422193162,1,0,1,0.0005855725635802038
5096,RETN,FOXO-mediated transcription,0.0014754845288010117,0,0,1,0.001566495667706451
5097,RETN,FOXO-mediated transcription,0.0020512634448631465,1,0,1,0.002177789896796732
5098,RETN,Neutrophil degranulation,0.0014754845288010117,0,0,1,0.001566495667706451
5099,RETN,Neutrophil degranulation,0.0020512634448631465,1,0,1,0.002177789896796732
5100,SAE1,Processing and activation of SUMO,3.566918281547555e-05,0,0,1,3.786933665544886e-05
5101,SAE1,Processing and activation of SUMO,0.0003056677562042215,1,0,1,0.0003245220173474559
5102,GRHPR,Glyoxylate metabolism and glycine degradation,8.95960453499125e-05,0,0,1,9.512252696971311e-05
5103,GRHPR,Glyoxylate metabolism and glycine degradation,5.168200755525241e-05,1,0,1,5.4869867730475845e-05
5104,CATZ,COPII-mediated vesicle transport,0.0030656416450159122,0,0,1,0.00325473718085021
5105,CATZ,COPII-mediated vesicle transport,0.0018115807401470198,1,0,1,0.001923323034397924
5106,CATZ,Cargo concentration in the ER,0.0030656416450159122,0,0,1,0.00325473718085021
5107,CATZ,Cargo concentration in the ER,0.0018115807401470198,1,0,1,0.001923323034397924
5108,CATZ,Lysosome Vesicle Biogenesis,0.0030656416450159122,0,0,1,0.00325473718085021
5109,CATZ,Lysosome Vesicle Biogenesis,0.0018115807401470198,1,0,1,0.001923323034397924
5110,CATZ,Neutrophil degranulation,0.0030656416450159122,0,0,1,0.00325473718085021
5111,CATZ,Neutrophil degranulation,0.0018115807401470198,1,0,1,0.001923323034397924
5112,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.0030656416450159122,0,0,1,0.00325473718085021
5113,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.0018115807401470198,1,0,1,0.001923323034397924
5114,FBLN5,Molecules associated with elastic fibres,0.00027030908832632134,0,0,1,0.00028698234887555976
5115,FBLN5,Molecules associated with elastic fibres,0.00023414970219325974,1,0,1,0.000248592572081089
5116,DMBT1,Surfactant metabolism,7.245731708257717e-05,0,0,1,7.692664415513996e-05
5117,DMBT1,Surfactant metabolism,0.0001466153545766362,1,0,1,0.00015565891290651422
5118,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003520360217587922,0,0,1,0.00037375037975483506
5119,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009825761338055747,1,0,1,0.00104318359613635
5120,ZPI,Post-translational protein phosphorylation,0.0003520360217587922,0,0,1,0.00037375037975483506
5121,ZPI,Post-translational protein phosphorylation,0.0009825761338055747,1,0,1,0.00104318359613635
5122,MINP1,Synthesis of IPs in the ER lumen,3.060462895611202e-05,0,0,1,3.2492389947640374e-05
5123,MINP1,Synthesis of IPs in the ER lumen,0.0003256056869791367,1,0,1,0.0003456897636519974
5124,TLN1,Semaphorin interactions,0.0005911114997334476,0,0,1,0.0006275725603279358
5125,TLN1,Semaphorin interactions,0.0012135961149738828,1,0,1,0.0012884533990992152
5126,TLN1,IRE1alpha activates chaperones,0.0005911114997334476,0,0,1,0.0006275725603279358
5127,TLN1,IRE1alpha activates chaperones,0.0012135961149738828,1,0,1,0.0012884533990992152
5128,TLN1,RAF/MAP kinase cascade,0.0005911114997334476,0,0,1,0.0006275725603279358
5129,TLN1,RAF/MAP kinase cascade,0.0012135961149738828,1,0,1,0.0012884533990992152
5130,TLN1,Signaling by RAS mutants,0.0005911114997334476,0,0,1,0.0006275725603279358
5131,TLN1,Signaling by RAS mutants,0.0012135961149738828,1,0,1,0.0012884533990992152
5132,TLN1,Signaling by moderate kinase activity BRAF mutants,0.0005911114997334476,0,0,1,0.0006275725603279358
5133,TLN1,Signaling by moderate kinase activity BRAF mutants,0.0012135961149738828,1,0,1,0.0012884533990992152
5134,TLN1,Signaling by high-kinase activity BRAF mutants,0.0005911114997334476,0,0,1,0.0006275725603279358
5135,TLN1,Signaling by high-kinase activity BRAF mutants,0.0012135961149738828,1,0,1,0.0012884533990992152
5136,TLN1,Signaling by BRAF and RAF1 fusions,0.0005911114997334476,0,0,1,0.0006275725603279358
5137,TLN1,Signaling by BRAF and RAF1 fusions,0.0012135961149738828,1,0,1,0.0012884533990992152
5138,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005911114997334476,0,0,1,0.0006275725603279358
5139,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0012135961149738828,1,0,1,0.0012884533990992152
5140,TLN1,Signaling by RAF1 mutants,0.0005911114997334476,0,0,1,0.0006275725603279358
5141,TLN1,Signaling by RAF1 mutants,0.0012135961149738828,1,0,1,0.0012884533990992152
5142,TLN1,Platelet degranulation ,0.0005911114997334476,0,0,1,0.0006275725603279358
5143,TLN1,Platelet degranulation ,0.0012135961149738828,1,0,1,0.0012884533990992152
5144,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0005911114997334476,0,0,1,0.0006275725603279358
5145,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0012135961149738828,1,0,1,0.0012884533990992152
5146,TLN1,p130Cas linkage to MAPK signaling for integrins,0.0005911114997334476,0,0,1,0.0006275725603279358
5147,TLN1,p130Cas linkage to MAPK signaling for integrins,0.0012135961149738828,1,0,1,0.0012884533990992152
5148,TLN1,Smooth Muscle Contraction,0.0005911114997334476,0,0,1,0.0006275725603279358
5149,TLN1,Smooth Muscle Contraction,0.0012135961149738828,1,0,1,0.0012884533990992152
5150,HYOU1,IRE1alpha activates chaperones,0.0013823590553389286,0,0,1,0.0014676260097168763
5151,HYOU1,IRE1alpha activates chaperones,0.000637785134172814,1,0,1,0.0006771251274462065
5152,HYOU1,Scavenging by Class F Receptors,0.0013823590553389286,0,0,1,0.0014676260097168763
5153,HYOU1,Scavenging by Class F Receptors,0.000637785134172814,1,0,1,0.0006771251274462065
5154,COL10,Initial triggering of complement,0.00015780232370808024,0,0,1,0.00016753591895917223
5155,COL10,Initial triggering of complement,0.00012936351328425176,1,0,1,0.00013734294000611373
5156,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.00012631123345133998,0,1,2,0.004012961191773503
5157,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.00021692421070866163,1,1,2,0.006891773719123019
5158,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,2.199105979838801e-06,0,1,2,6.986652503151953e-05
5159,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,6.823004669711733e-06,1,1,2,0.0002167697377556731
5160,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.00011459312398461766,0,1,2,0.0036406719088173203
5161,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.00010596940733494147,1,1,2,0.0033666927915337146
5162,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,6.15616638039364e-06,0,1,2,0.00019558400388938925
5163,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,8.719993358109203e-06,1,1,2,0.0002770378689405769
5164,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.00015777992194638925,0,1,2,0.0050127347054672875
5165,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,2.5317509082723688e-05,1,1,2,0.0008043479478844842
5166,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),2.1700098696416934e-05,0,1,2,0.0006894212933161102
5167,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),2.9959180433904297e-05,1,1,2,0.0009518158055586828
5168,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,9.3319705446064e-05,0,1,2,0.002964806424181241
5169,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,3.1167231261556456e-05,1,1,2,0.0009901960901667463
5170,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.00022881900985325748,0,1,2,0.007269676507710644
5171,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0001400055640112954,1,1,2,0.004448035852853348
5172,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.001078889829633748,0,1,2,0.034276785193355475
5173,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.0007805932613992638,1,1,2,0.02479977733541738
5174,Downregulation of ERBB2 signaling,Signaling by ERBB2,7.676054630635382e-05,0,1,2,0.0024387149501267336
5175,Downregulation of ERBB2 signaling,Signaling by ERBB2,0.0001248824700070805,1,1,2,0.003967568774192158
5176,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,1.7470859236866625e-05,0,1,2,0.000555056570890763
5177,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,2.841647704736729e-05,1,1,2,0.0009028034679270065
5178,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,0.00014371532741620864,0,1,2,0.004565896601797056
5179,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,4.02731414392223e-05,1,1,2,0.00127949469932668
5180,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,0.0003635126912403795,0,1,2,0.011548951607908723
5181,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,0.00010189808809687737,1,1,2,0.003237345261189423
5182,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,7.313018762444495e-05,0,1,2,0.002323376922742727
5183,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,2.049793954772448e-05,1,1,2,0.0006512281898349637
5184,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,7.730516488220647e-05,0,1,2,0.002456017712117872
5185,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,2.1670344625273188e-05,1,1,2,0.0006884759939192587
5186,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,1.055127303133013e-05,0,1,2,0.0003352183969832415
5187,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,2.9574333297122056e-06,1,1,2,9.395890496124887e-05
5188,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,3.131441069872657e-05,0,1,2,0.0009948720429973253
5189,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,8.774918908872175e-06,1,1,2,0.0002787828768676312
5190,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.00046596775021771,0,1,2,0.014803992069019277
5191,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.00021121547471579437,1,1,2,0.006710404767466932
5192,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0001657645791538143,0,1,2,0.00526641063457897
5193,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0003151119191706439,1,1,2,0.010011238653482156
5194,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,3.074150819511003e-05,0,1,2,0.0009766706886849335
5195,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,7.926303683644171e-05,1,1,2,0.0025182201303519916
5196,PTEN Regulation,PIP3 activates AKT signaling,3.5356317397949643e-05,0,1,2,0.001123285124570154
5197,PTEN Regulation,PIP3 activates AKT signaling,1.4355648079027574e-05,1,1,2,0.00045608499774557734
5198,Defensins,Antimicrobial peptides,0.00026889103262846715,0,1,2,0.008542781582206884
5199,Defensins,Antimicrobial peptides,9.575111968631792e-05,1,1,2,0.0030420534806833315
5200,Glycerophospholipid biosynthesis,Phospholipid metabolism,5.6396976867802964e-05,0,1,2,0.0017917557553661933
5201,Glycerophospholipid biosynthesis,Phospholipid metabolism,2.8992210498814197e-05,1,1,2,0.0009210947626466665
5202,Antagonism of Activin by Follistatin,Signaling by Activin,5.342032365457862e-06,0,1,2,0.0001697186226594717
5203,Antagonism of Activin by Follistatin,Signaling by Activin,2.6453402608868014e-06,1,1,2,8.404357645723006e-05
5204,Methylation,Phase II - Conjugation of compounds,3.6079894057989146e-05,0,1,2,0.001146273460418606
5205,Methylation,Phase II - Conjugation of compounds,3.1104049874206076e-05,1,1,2,0.000988188790827237
5206,Glucuronidation,Phase II - Conjugation of compounds,1.8765153889468962e-05,0,1,2,0.0005961768582135375
5207,Glucuronidation,Phase II - Conjugation of compounds,1.5954673933824064e-05,1,1,2,0.0005068867239626899
5208,Glutathione conjugation,Phase II - Conjugation of compounds,0.00012223246086264433,0,1,2,0.0038833768653342335
5209,Glutathione conjugation,Phase II - Conjugation of compounds,0.00010439599934913074,1,1,2,0.0033167049558253617
5210,Packaging Of Telomere Ends,Telomere Maintenance,5.031460743848838e-06,0,1,2,0.0001598516311755883
5211,Packaging Of Telomere Ends,Telomere Maintenance,1.3611661461947208e-05,1,1,2,0.00043244822894866324
5212,Inhibition of DNA recombination at telomere,Telomere Maintenance,4.483191151804728e-05,0,1,2,0.0014243287485926983
5213,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0001213117340294186,1,1,2,0.003854124985283654
5214,Gap junction trafficking,Gap junction trafficking and regulation,7.539140954783327e-05,0,1,2,0.002395216897514571
5215,Gap junction trafficking,Gap junction trafficking and regulation,0.00019133884897256317,1,1,2,0.006078915979403428
5216,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0005049834277246061,0,1,2,0.016043536608549413
5217,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0001798767033175662,1,1,2,0.0057147587747659
5218,Methionine salvage pathway,Sulfur amino acid metabolism,2.867711596705048e-05,0,1,2,0.0009110840763984401
5219,Methionine salvage pathway,Sulfur amino acid metabolism,2.5848969907834027e-05,1,1,2,0.000821232682581793
5220,Cysteine formation from homocysteine,Sulfur amino acid metabolism,4.991357825024421e-06,0,1,2,0.00015857754452057018
5221,Cysteine formation from homocysteine,Sulfur amino acid metabolism,4.3529071309204865e-06,1,1,2,0.0001382936965341838
5222,HIV Life Cycle,HIV Infection,6.999901237632833e-05,0,1,2,0.002223898163712364
5223,HIV Life Cycle,HIV Infection,0.0003667511343249819,1,1,2,0.011651838311372694
5224,Host Interactions of HIV factors,HIV Infection,1.7613238715262244e-05,0,1,2,0.0005595800270054297
5225,Host Interactions of HIV factors,HIV Infection,9.163681129376496e-05,1,1,2,0.0029113401667589327
5226,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,8.129157374858246e-05,0,1,2,0.0025826676041203235
5227,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,5.3833462638105516e-05,1,1,2,0.001710311826451525
5228,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0006104195302117115,0,1,2,0.01939328608000562
5229,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.00040237842420787375,1,1,2,0.012783732346143462
5230,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.0001747954788166902,0,1,2,0.00555332612802859
5231,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.00011524400371097284,1,1,2,0.003661350632403546
5232,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.0004143272961923831,0,1,2,0.013163353051674598
5233,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.00027365707469036827,1,1,2,0.008694200749846772
5234,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",1.41464331925836e-05,0,1,2,0.0004494381525117811
5235,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",3.257499739092179e-05,1,1,2,0.001034921414192757
5236,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,1.2224762716693574e-05,0,1,2,0.0003883858705221954
5237,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,2.1655990365865466e-05,1,1,2,0.0006880199530401866
5238,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,6.457368754542452e-06,0,1,2,0.00020515333042751436
5239,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,1.1438718449084595e-05,1,1,2,0.0003634129124190981
5240,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0010179246794531384,0,1,2,0.03233989664401137
5241,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0002879885787386663,1,1,2,0.009149518681546969
5242,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,9.652261341610658e-06,0,1,2,0.00030665641620593564
5243,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,8.050861537687552e-05,1,1,2,0.0025577926862323233
5244,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.00028377526942321437,0,1,2,0.00901566006652236
5245,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.00017907157207030784,1,1,2,0.005689179415264382
5246,Initial triggering of complement,Complement cascade,4.2087610184168294e-05,0,1,2,0.0013371411370836144
5247,Initial triggering of complement,Complement cascade,0.00026732861828682403,1,1,2,0.008493143019213202
5248,Terminal pathway of complement,Complement cascade,3.199866050907279e-05,0,1,2,0.0010166109482345669
5249,Terminal pathway of complement,Complement cascade,0.00020331477210254952,1,1,2,0.006459396111242311
5250,Activation of C3 and C5,Complement cascade,1.1202103491965762e-05,0,1,2,0.0003558955553767665
5251,Activation of C3 and C5,Complement cascade,7.144464194854737e-05,1,1,2,0.002269826425296715
5252,Regulation of Complement cascade,Complement cascade,6.0404996465161456e-05,0,1,2,0.0019190922294119756
5253,Regulation of Complement cascade,Complement cascade,0.00038054214548865643,1,1,2,0.0120899845560332
5254,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0001281230020224034,0,1,2,0.0040705218438666785
5255,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0010699706720557229,1,1,2,0.03399341979309821
5256,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,4.238243564389814e-05,0,1,2,0.001346507866359506
5257,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.00036526226123843685,1,1,2,0.011604536185088866
5258,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,7.518603417283919e-07,0,1,2,2.388692035179863e-05
5259,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,6.53653389350106e-06,1,1,2,0.00020766844030097338
5260,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,1.7422469728191358e-05,0,1,2,0.000553519215779132
5261,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.00014978810269267596,1,1,2,0.004758831235122549
5262,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,6.652698554635116e-05,0,1,2,0.00211359040608238
5263,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0005714957276614505,1,1,2,0.01815666044662024
5264,Virus Assembly and Release,Influenza Infection,0.000468649170234407,0,1,2,0.014889181914544735
5265,Virus Assembly and Release,Influenza Infection,0.0008403603501646274,1,1,2,0.026698602968001226
5266,Influenza Viral RNA Transcription and Replication,Influenza Infection,7.301023598408166e-05,0,1,2,0.002319566008507194
5267,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.0001303332502558369,1,1,2,0.0041407423629970805
5268,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",3.057331460109099e-05,0,1,2,0.0009713271072230098
5269,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",4.0927375751375554e-05,1,1,2,0.0013002799995193908
5270,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.00013562197009054825,0,1,2,0.004308767224056137
5271,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.001137305150366374,1,1,2,0.036132664585075115
5272,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.00010102050791693626,0,1,2,0.003209464168522158
5273,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0008437619921695793,1,1,2,0.026806674570036822
5274,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,4.574915214778468e-06,0,1,2,0.00014534698704872292
5275,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,3.809355077954088e-05,1,1,2,0.001210248184252286
5276,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.00022908075624317124,0,1,2,0.00727799230097867
5277,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,6.682800715857227e-05,1,1,2,0.002123153989737778
5278,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,3.7333985579813274e-05,0,1,2,0.0011861164773102994
5279,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,8.135924448278987e-06,1,1,2,0.0002584817531904045
5280,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0005147947316255354,0,1,2,0.01635524587398298
5281,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0015696029652732656,1,1,2,0.04986694860010812
5282,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0002129320211476306,0,1,2,0.006764940172011846
5283,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0006575428503730954,1,1,2,0.020890413848202116
5284,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0002129320211476306,0,1,2,0.006764940172011846
5285,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0006575428503730954,1,1,2,0.020890413848202116
5286,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,6.46506317812421e-05,0,1,2,0.0020539778551185613
5287,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.00016183721990600258,1,1,2,0.005141636773878031
5288,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,3.731966615167934e-05,0,1,2,0.001185661543035495
5289,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,7.443198833436839e-06,1,1,2,0.00023647356806742492
5290,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0003427984228239189,0,1,2,0.010890850558620343
5291,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,6.913939815459735e-05,1,1,2,0.0021965878571193094
5292,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,4.609292643047222e-05,0,1,2,0.0014643917245255429
5293,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,2.4185889922564042e-05,1,1,2,0.0007683959296078406
5294,Bile acid and bile salt metabolism,Metabolism of steroids,0.00020986697989100863,0,1,2,0.006667562517800695
5295,Bile acid and bile salt metabolism,Metabolism of steroids,8.305619442045251e-05,1,1,2,0.0026387303475590837
5296,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,5.7290973222063596e-05,0,1,2,0.0018201583968194335
5297,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,1.8774846225386463e-05,1,1,2,0.0005964847878159314
5298,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0005369403757812585,0,1,2,0.017058822334567368
5299,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.00017591567516227294,1,1,2,0.0055889152386655455
5300,RHO GTPase Effectors,Signaling by Rho GTPases,0.0010925074945403763,0,1,2,0.034709424154275186
5301,RHO GTPase Effectors,Signaling by Rho GTPases,0.00023421301671741908,1,1,2,0.007441046382127864
5302,RHO GTPase cycle,Signaling by Rho GTPases,1.5091427092915252e-05,0,1,2,0.00047946100752534177
5303,RHO GTPase cycle,Signaling by Rho GTPases,3.2576081779094956e-06,1,1,2,0.00010349558656626448
5304,Metabolism of steroid hormones,Metabolism of steroids,0.0003290642517654513,0,1,2,0.010454510148089544
5305,Metabolism of steroid hormones,Metabolism of steroids,0.0001318948780115229,1,1,2,0.004190355935822957
5306,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,9.185541890263054e-05,0,1,2,0.0029182854227479175
5307,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.00013909001892804744,1,1,2,0.00441894859918633
5308,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,8.289398302913285e-05,0,1,2,0.002633576823201488
5309,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,0.00012375736508050432,1,1,2,0.003931823715865554
5310,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,5.298344702828772e-07,0,1,2,1.6833064718096946e-05
5311,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,8.029407542959257e-07,1,1,2,2.5509766615684256e-05
5312,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,6.329312173842906e-05,0,1,2,0.0020108491881710554
5313,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,9.597556770136248e-05,1,1,2,0.003049184288841352
5314,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,3.0181211546308074e-05,0,1,2,0.0009588698276998401
5315,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,4.591813391237933e-05,1,1,2,0.001458838492460959
5316,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,6.55132822375059e-05,0,1,2,0.002081384624164056
5317,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,9.906837263299379e-05,1,1,2,0.003147444006724191
5318,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.0007411987458896579,0,1,2,0.02354819695266647
5319,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.0013578837494333592,1,1,2,0.04314053976454268
5320,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.00042124686958634717,0,1,2,0.013383190818553058
5321,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.0007696103162457147,1,1,2,0.024450844532939855
5322,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.00029445309715080565,0,1,2,0.009354899159613588
5323,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.0005384426830827172,1,1,2,0.017106551271528422
5324,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,8.616133466598444e-05,0,1,2,0.002737381963570212
5325,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.00029320325585718024,1,1,2,0.00931519117426542
5326,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0001608798519403069,0,1,2,0.005111220789585835
5327,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0005477363051680274,1,1,2,0.017401813567211145
5328,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,5.789691778523673e-05,0,1,2,0.0018394095113081275
5329,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,3.1610215756639026e-05,1,1,2,0.001004269894520882
5330,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,0.00011473932412509893,0,1,2,0.003645316748978818
5331,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,6.262406067052034e-05,1,1,2,0.0019895928356909055
5332,Degradation of AXIN,TCF dependent signaling in response to WNT,0.0002714962554514363,0,1,2,0.008625550610731378
5333,Degradation of AXIN,TCF dependent signaling in response to WNT,0.00014697243414001822,1,1,2,0.004669376256954945
5334,Degradation of DVL,TCF dependent signaling in response to WNT,0.00011608086077194111,0,1,2,0.003687937934395344
5335,Degradation of DVL,TCF dependent signaling in response to WNT,6.322366757304564e-05,1,1,2,0.0020086426000262407
5336,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,6.90115452787464e-05,0,1,2,0.0021925259172979068
5337,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,4.950921057284431e-05,1,1,2,0.0015729285134461562
5338,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0006830278059889568,0,1,2,0.021700081643109055
5339,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0004893217792772158,1,1,2,0.015545959427951382
5340,Downstream TCR signaling,TCR signaling,3.963692768427117e-05,0,1,2,0.0012592819198411966
5341,Downstream TCR signaling,TCR signaling,1.1558444710774473e-05,1,1,2,0.0003672166662790641
5342,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0003636337233465983,0,1,2,0.011552796849000454
5343,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.00048609778845700027,1,1,2,0.015443531879026029
5344,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.00024077598821697373,0,1,2,0.007649554756330183
5345,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.00032015133285594535,1,1,2,0.010171342952963939
5346,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,3.446850605400453e-05,0,1,2,0.0010950789835047947
5347,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,4.5917000682125195e-05,1,1,2,0.0014588024892575467
5348,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,1.92642592867691e-05,0,1,2,0.0006120336473148943
5349,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,5.518548592996649e-06,1,1,2,0.0001753266177005802
5350,Catecholamine biosynthesis,Metabolism of amine-derived hormones,8.15362294455609e-05,0,1,2,0.0025904404188612945
5351,Catecholamine biosynthesis,Metabolism of amine-derived hormones,1.8423287608434318e-05,1,1,2,0.0005853156221929387
5352,Ethanol oxidation,Phase I - Functionalization of compounds,6.77913015081727e-05,0,1,2,0.0021537582577476413
5353,Ethanol oxidation,Phase I - Functionalization of compounds,7.054663903896459e-05,1,1,2,0.0022412964938900706
5354,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,1.2882958706975076e-05,0,1,2,0.0004092970349009213
5355,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,1.332551600803919e-05,1,1,2,0.0004233572671208092
5356,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.00040230987995962237,0,1,2,0.01278155466644993
5357,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0008276459194547236,1,1,2,0.02629466013868832
5358,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0002802804543433308,0,1,2,0.008904628316575904
5359,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0005791579905267583,1,1,2,0.018400093771428146
5360,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0009921400992171413,0,1,2,0.03152070964847714
5361,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0020841610326010943,1,1,2,0.06621467554947746
5362,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0010859717855276954,0,1,2,0.034501781920785984
5363,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0022758571786343873,1,1,2,0.0723049430072844
5364,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.00012183027368782721,0,1,2,0.003870599209061944
5365,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0002521762067682189,1,1,2,0.008011744510747452
5366,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0002451710245779931,0,1,2,0.007789186916283704
5367,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0005068439174654597,1,1,2,0.016102645152767804
5368,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0008561455154814225,0,1,2,0.02720010433166601
5369,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.001793731891869675,1,1,2,0.05698761918347104
5370,FOXO-mediated transcription,Generic Transcription Pathway,0.0006900491590676936,0,1,2,0.021923152993525125
5371,FOXO-mediated transcription,Generic Transcription Pathway,0.001449246713052859,1,1,2,0.046043179675122836
5372,Arachidonic acid metabolism,Fatty acid metabolism,0.0005818414364302076,0,1,2,0.018485347980230674
5373,Arachidonic acid metabolism,Fatty acid metabolism,0.00016849378841856248,1,1,2,0.005353118764682714
5374,DAP12 signaling,DAP12 interactions,8.67808090703914e-05,0,1,2,0.002757062926824679
5375,DAP12 signaling,DAP12 interactions,0.0007909046797108827,1,1,2,0.025127375446733508
5376,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.00012490349028556168,0,1,2,0.0039682365973103435
5377,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.00013648351281526767,1,1,2,0.004336138800002989
5378,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,4.6371336655025275e-05,0,1,2,0.0014732369348524198
5379,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.00010146828470465037,1,1,2,0.0032236902260356095
5380,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0012551648006398684,0,1,2,0.039877115412607696
5381,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0016556718642069949,1,1,2,0.05260139384145547
5382,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0008996958252278022,0,1,2,0.028583716051119794
5383,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0011660523386712767,1,1,2,0.037045974889218576
5384,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.001127270462359493,0,1,2,0.03581385831232439
5385,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.001486070916809907,1,1,2,0.04721310016878916
5386,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0002796926103671587,0,1,2,0.00888595226537492
5387,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00036716824293245255,1,1,2,0.011665090027857431
5388,Retinoid cycle disease events,Diseases associated with visual transduction,3.662785799030291e-05,0,1,2,0.0011636825057962988
5389,Retinoid cycle disease events,Diseases associated with visual transduction,5.590246734228749e-05,1,1,2,0.0017760449790509543
5390,Retinoid metabolism disease events,Diseases associated with visual transduction,3.736171465535886e-06,0,1,2,0.00011869974417424224
5391,Retinoid metabolism disease events,Diseases associated with visual transduction,5.6922698653735966e-06,1,1,2,0.0001808458158366887
5392,Mitotic Metaphase and Anaphase,M Phase,2.8825701570819437e-05,0,1,2,0.0009158047037352855
5393,Mitotic Metaphase and Anaphase,M Phase,1.2647605597287074e-05,1,1,2,0.0004018197672839836
5394,Oxidative Stress Induced Senescence,Cellular Senescence,0.0003674283360375882,0,1,2,0.011673353295570349
5395,Oxidative Stress Induced Senescence,Cellular Senescence,0.00021249641667733332,1,1,2,0.006751100834159608
5396,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.000247611092204975,0,1,2,0.007866708894533989
5397,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.00014324280835418054,1,1,2,0.00455088447178708
5398,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.0007181106892613538,0,1,2,0.022814679650117554
5399,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.00041469391115168746,1,1,2,0.0131750005636481
5400,EPH-Ephrin signaling,Axon guidance,0.0006702248406950529,0,1,2,0.02129332603269969
5401,EPH-Ephrin signaling,Axon guidance,0.0003124430629154885,1,1,2,0.009926447963962947
5402,SUMO E3 ligases SUMOylate target proteins,SUMOylation,8.304212691849169e-05,0,1,2,0.002638283417085115
5403,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.000129000749993008,1,1,2,0.004098408267314132
5404,Processing and activation of SUMO,SUMOylation,4.4873763871355044e-07,0,1,2,1.4256584155195368e-05
5405,Processing and activation of SUMO,SUMOylation,6.971189426688947e-07,1,1,2,2.2147763002078216e-05
5406,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.00013089925297961064,0,1,2,0.004158724508392068
5407,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,2.6457151629418305e-05,1,1,2,0.00084055487253732
5408,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.00047925525213571665,0,1,2,0.015226141612457299
5409,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0005441035847626767,1,1,2,0.017286400506876715
5410,HSF1 activation,Cellular response to heat stress,5.4844040435081145e-05,0,1,2,0.0017424183095387437
5411,HSF1 activation,Cellular response to heat stress,6.190127246808686e-05,1,1,2,0.0019666295494733363
5412,HSF1-dependent transactivation,Cellular response to heat stress,1.739816245005183e-05,0,1,2,0.0005527469632946437
5413,HSF1-dependent transactivation,Cellular response to heat stress,1.9714915192458257e-05,1,1,2,0.000626351175621439
5414,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,1.7629465628516962e-05,0,1,2,0.000560095562887506
5415,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,4.3148672237323804e-06,1,1,2,0.0001370851526294697
5416,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0018026685927741036,0,1,2,0.05727154194261166
5417,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0008685483707761839,1,1,2,0.02759414827855086
5418,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,4.7001503087802645e-05,0,1,2,0.0014932575883603925
5419,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.00045880955032106646,1,1,2,0.014576573037447126
5420,Semaphorin interactions,Axon guidance,0.000254660948412539,0,1,2,0.008090685801381602
5421,Semaphorin interactions,Axon guidance,0.00011740336572536411,1,1,2,0.003729954474880314
5422,L1CAM interactions,Axon guidance,1.1429336673673907e-05,0,1,2,0.00036311484945506623
5423,L1CAM interactions,Axon guidance,5.369321547025462e-06,1,1,2,0.00017058561147427275
5424,NCAM signaling for neurite out-growth,Axon guidance,0.0004160939298081448,0,1,2,0.013219479747190285
5425,NCAM signaling for neurite out-growth,Axon guidance,0.00019452409978747235,1,1,2,0.0061801127420114
5426,Signaling by ROBO receptors,Axon guidance,0.00038951314595324956,0,1,2,0.012374997026675116
5427,Signaling by ROBO receptors,Axon guidance,0.00017655239813615166,1,1,2,0.0056091441962512565
5428,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0004862396286599335,0,1,2,0.015448038202131673
5429,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0002372553610804537,1,1,2,0.007537702946451354
5430,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0008432783301652981,0,1,2,0.026791308424048997
5431,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00040719166323645274,1,1,2,0.012936650981332455
5432,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.00044086894653040236,0,1,2,0.014006592483843753
5433,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.00020943517098794242,1,1,2,0.006653843766721168
5434,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),5.313326222004817e-05,0,1,2,0.0016880661636759322
5435,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),1.086227561384402e-05,1,1,2,0.0003450990802769437
5436,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0005136493866076552,0,1,2,0.016318857779414057
5437,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.00010641950607171838,1,1,2,0.0033809926183487847
5438,PERK regulates gene expression,Unfolded Protein Response (UPR),0.000149574965832799,0,1,2,0.00475205978713766
5439,PERK regulates gene expression,Unfolded Protein Response (UPR),3.098177681754275e-05,1,1,2,0.0009843041242161832
5440,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0003236876892433914,0,1,2,0.01028369448778264
5441,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0005026347004975944,1,1,2,0.015968916553353044
5442,G alpha (q) signalling events,GPCR downstream signalling,0.001017054578424826,0,1,2,0.032312253167147656
5443,G alpha (q) signalling events,GPCR downstream signalling,0.00027877744027330844,1,1,2,0.00885687692527932
5444,G alpha (s) signalling events,GPCR downstream signalling,8.173688076592302e-05,0,1,2,0.002596815195986731
5445,G alpha (s) signalling events,GPCR downstream signalling,2.2304801849438856e-05,1,1,2,0.000708632967680409
5446,G alpha (i) signalling events,GPCR downstream signalling,3.7014527255067767e-05,0,1,2,0.0011759671515174628
5447,G alpha (i) signalling events,GPCR downstream signalling,1.0127569777866107e-05,1,1,2,0.00032175716581226793
5448,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.00020213822366809228,0,1,2,0.006422016670960481
5449,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.00023330828642881697,1,1,2,0.007412302719050731
5450,Peroxisomal lipid metabolism,Fatty acid metabolism,7.587500167481701e-05,0,1,2,0.0024105808234711687
5451,Peroxisomal lipid metabolism,Fatty acid metabolism,2.1738781807069588e-05,1,1,2,0.0006906502720663334
5452,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0005036119589488126,0,1,2,0.015999964466764344
5453,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.00031741200150740557,1,1,2,0.010084313239986483
5454,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,1.0457172734683392e-06,0,1,2,3.3222879084719496e-05
5455,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,2.5422873657561963e-05,1,1,2,0.0008076954248923515
5456,Adherens junctions interactions,Cell-cell junction organization,0.0004773114693413619,0,1,2,0.015164386812778395
5457,Adherens junctions interactions,Cell-cell junction organization,2.5832938094628232e-06,1,1,2,8.207233451106061e-05
5458,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,1.2964121626356444e-05,0,1,2,0.00041187561510150144
5459,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,0.00017587463802842395,1,1,2,0.005587611471604945
5460,Netrin-1 signaling,Axon guidance,0.00018970056012660493,0,1,2,0.006026866851387601
5461,Netrin-1 signaling,Axon guidance,8.713408860231413e-05,1,1,2,0.0027682867666425364
5462,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",7.687310537814742e-05,0,1,2,0.002442290999339045
5463,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.00023821692944615011,1,1,2,0.007568252379224198
5464,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,2.1750606586276153e-05,0,1,2,0.0006910259502919406
5465,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,4.661311864710193e-05,1,1,2,0.001480918450775919
5466,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,2.4411843147335354e-05,0,1,2,0.0007755745589140982
5467,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,5.1149175559828855e-05,1,1,2,0.001625030893169743
5468,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",3.2999529944601453e-05,0,1,2,0.0010484089925815571
5469,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",9.415096870365576e-06,1,1,2,0.0002991216008679108
5470,Glycosphingolipid metabolism,Sphingolipid metabolism,3.861037019739485e-05,0,1,2,0.001226667755262191
5471,Glycosphingolipid metabolism,Sphingolipid metabolism,1.4629117653809777e-05,1,1,2,0.00046477324154421424
5472,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.00020107111832695055,0,1,2,0.006388114283939728
5473,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.0003021122370513773,1,1,2,0.009598233266513894
5474,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,8.064153155316079e-06,0,1,2,0.00025620154892453046
5475,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,1.2121977932521784e-06,1,1,2,3.851203545525085e-05
5476,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.0001313776689859906,0,1,2,0.004173923986812692
5477,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,1.920362856576803e-05,1,1,2,0.0006101073837217177
5478,Interleukin-1 family signaling,Signaling by Interleukins,8.962009336539896e-05,0,1,2,0.0028472681870928937
5479,Interleukin-1 family signaling,Signaling by Interleukins,0.00014078753110418244,1,1,2,0.004472879277394907
5480,Interleukin-12 family signaling,Signaling by Interleukins,5.148742666174973e-06,0,1,2,0.00016357772734242436
5481,Interleukin-12 family signaling,Signaling by Interleukins,8.133246238029814e-06,1,1,2,0.0002583966653205478
5482,Other interleukin signaling,Signaling by Interleukins,8.487283680944049e-05,0,1,2,0.0026964458429045383
5483,Other interleukin signaling,Signaling by Interleukins,0.00013441103388677083,1,1,2,0.004270295269830907
5484,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00016169380300311208,0,1,2,0.005137080358349355
5485,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00025805162554749084,1,1,2,0.008198409044869974
5486,Interleukin-10 signaling,Signaling by Interleukins,3.135093347418141e-05,0,1,2,0.0009960323869866237
5487,Interleukin-10 signaling,Signaling by Interleukins,4.958766305605011e-05,1,1,2,0.0015754209819455985
5488,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.00016773449443130192,0,1,2,0.00532899567427526
5489,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0002659630315070059,1,1,2,0.008449757750922554
5490,G2/M Transition,Mitotic G2-G2/M phases,0.0004626732665389548,0,1,2,0.014699324932229191
5491,G2/M Transition,Mitotic G2-G2/M phases,0.00042557806081932367,1,1,2,0.013520794591845162
5492,G1/S Transition,Mitotic G1 phase and G1/S transition,0.0001670568626275384,0,1,2,0.005307467025900038
5493,G1/S Transition,Mitotic G1 phase and G1/S transition,0.0002098762414382963,1,1,2,0.00666785676106652
5494,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,4.607754513629142e-05,0,1,2,0.0014639030543183076
5495,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.00015280743153008988,1,1,2,0.00485475658648421
5496,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,1.1050185465132858e-06,0,1,2,3.510690555528525e-05
5497,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,9.53828539468997e-06,1,1,2,0.00030303535227289635
5498,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.00010617751475476168,0,1,2,0.0033733044520855085
5499,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.00019022393550543998,1,1,2,0.006043494708044577
5500,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.00019218241954528133,0,1,2,0.006105716572496711
5501,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0003440624639708939,1,1,2,0.010931009679301955
5502,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,8.085333521282987e-05,0,1,2,0.002568744580896959
5503,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.00017386956309314535,1,1,2,0.005523909394742792
5504,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.00014689855552990543,0,1,2,0.004667029102333904
5505,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.0003155470093112997,1,1,2,0.010025061650864628
5506,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,2.2292683853879797e-05,0,1,2,0.0007082479738475418
5507,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,2.680561671607896e-05,1,1,2,0.0008516257553974413
5508,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,2.361376377251212e-05,0,1,2,0.0007502192403758284
5509,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.0005395972888399584,1,1,2,0.017143233583695
5510,RA biosynthesis pathway,Signaling by Retinoic Acid,4.149046403631127e-05,0,1,2,0.0013181695519625617
5511,RA biosynthesis pathway,Signaling by Retinoic Acid,8.362117218640208e-05,1,1,2,0.00265667992961145
5512,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.00022021321972503298,0,1,2,0.006996266923578789
5513,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0001380091335360546,1,1,2,0.004384608414134673
5514,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,0.00018505595162331226,0,1,2,0.005879305679151284
5515,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,5.678217898149263e-05,1,1,2,0.0018039937890785413
5516,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,9.516239533972628e-05,0,1,2,0.0030233494597425928
5517,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,2.914191812811937e-05,1,1,2,0.0009258510372083073
5518,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,5.8742619473705786e-05,0,1,2,0.0018662778108481765
5519,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,1.806873181147996e-05,1,1,2,0.0005740512348964257
5520,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0010795506806445083,0,1,2,0.034297780708855266
5521,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0009916842281139915,1,1,2,0.03150622643114639
5522,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0012071036860942315,0,1,2,0.03835019352106174
5523,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.001109615204251415,1,1,2,0.03525294331147646
5524,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.0003224258821988806,0,1,2,0.010243606345479139
5525,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.0005140536394059483,1,1,2,0.0163317010614159
5526,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,1.420050231923953e-06,0,1,2,4.5115595148353225e-05
5527,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,1.2257794441965124e-06,1,1,2,3.8943530237390104e-05
5528,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,9.107554496476673e-06,0,1,2,0.00028935084986247853
5529,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,7.85071422049425e-06,1,1,2,0.000249420503891165
5530,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,0.00010826212603787639,0,1,2,0.003439533432283815
5531,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,9.345290561726371e-05,1,1,2,0.002969038249832504
5532,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.00018999062839159285,0,1,2,0.006036082442578942
5533,Defective CFTR causes cystic fibrosis,ABC transporter disorders,2.1689506764906834e-05,1,1,2,0.0006890847831820981
5534,Defective ABCA1 causes TGD,ABC transporter disorders,0.0014066383330223313,0,1,2,0.044689493460248565
5535,Defective ABCA1 causes TGD,ABC transporter disorders,0.000160850044798059,1,1,2,0.005110273804097608
5536,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0001714683377229698,0,1,2,0.005447621451383195
5537,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,3.89187179277962e-05,1,1,2,0.0012364640927838948
5538,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,0.00020773518559591476,0,1,2,0.00659983451339995
5539,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,4.670101033145772e-05,1,1,2,0.001483710806679365
5540,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.00021156965237474504,0,1,2,0.0067216571411594876
5541,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,4.80222277009394e-05,1,1,2,0.0015256864400791416
5542,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,1.5287790669445635e-05,0,1,2,0.0004856995612197591
5543,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,3.468950526185665e-06,1,1,2,0.00011021002216028685
5544,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),6.461143179715086e-05,0,1,2,0.002052732455081067
5545,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.00010412664929842741,1,1,2,0.0033081475910452045
5546,Fructose biosynthesis,Fructose metabolism,1.7797992680746847e-05,0,1,2,0.0005654497384575121
5547,Fructose biosynthesis,Fructose metabolism,0.0001187629412403472,1,1,2,0.0037731487627503195
5548,Fructose catabolism,Fructose metabolism,5.854834804634336e-07,0,1,2,1.86010572561574e-05
5549,Fructose catabolism,Fructose metabolism,3.947718766705967e-06,1,1,2,0.00012542069120819704
5550,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.000601378430391041,0,1,2,0.01910604652323826
5551,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.00011714726839979129,1,1,2,0.00372181815477038
5552,Essential pentosuria,Diseases of carbohydrate metabolism,0.0001071566510263022,0,1,2,0.0034044120246409103
5553,Essential pentosuria,Diseases of carbohydrate metabolism,2.083404416424195e-05,1,1,2,0.0006619063753423527
5554,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,0.00010381551378325034,0,1,2,0.0032982626844246937
5555,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,2.0176546649732877e-05,1,1,2,0.0006410174018336829
5556,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,8.459023784932936e-05,0,1,2,0.0026874675546812786
5557,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0003533710708874479,1,1,2,0.011226748049397092
5558,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,6.601236549122861e-05,0,1,2,0.0020972407097546125
5559,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0010142748883793173,1,1,2,0.03222394124133559
5560,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.00017095415793574382,0,1,2,0.005431285742552302
5561,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,2.4027245875322708e-05,1,1,2,0.0007633557412770805
5562,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.0005364448387887291,0,1,2,0.017043078915191495
5563,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,7.539756408390863e-05,1,1,2,0.0023954124297229816
5564,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,5.5448784726922435e-05,0,1,2,0.0017616312909006949
5565,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,7.793153191197618e-06,1,1,2,0.00024759176569888924
5566,UCH proteinases,Deubiquitination,0.00019030302777885418,0,1,2,0.00604600750294894
5567,UCH proteinases,Deubiquitination,0.0003569429045842414,1,1,2,0.011340226713305661
5568,Ub-specific processing proteases,Deubiquitination,2.4777932747589622e-05,0,1,2,0.0007872053800088683
5569,Ub-specific processing proteases,Deubiquitination,4.707521518467795e-05,1,1,2,0.0014955994527856085
5570,Metalloprotease DUBs,Deubiquitination,0.0001668666428038354,0,1,2,0.005301423661825693
5571,Metalloprotease DUBs,Deubiquitination,0.00031533771812641603,1,1,2,0.010018412381597204
5572,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,4.929942381780161e-06,0,1,2,0.00015662634997056423
5573,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.00026327815853596456,1,1,2,0.008364458203580382
5574,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,9.476387056589964e-05,0,1,2,0.0030106881594953528
5575,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.00016901669830779467,1,1,2,0.005369731832538565
5576,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),9.050501999615155e-05,0,1,2,0.0028753826796027383
5577,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.00010468191432634745,1,1,2,0.0033257885953114686
5578,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0004207428134077302,0,1,2,0.013367176741039969
5579,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0004242674938199214,1,1,2,0.013479157325197406
5580,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00021633778160875532,0,1,2,0.006873142619138098
5581,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00021817490689527818,1,1,2,0.006931508864782292
5582,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00017203529476983898,0,1,2,0.005465633916025661
5583,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00017350205689350506,1,1,2,0.005512233567687703
5584,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00010964341601377582,0,1,2,0.0034834175977409244
5585,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00011067100825004377,1,1,2,0.0035160646367447803
5586,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,5.66387654447713e-05,0,1,2,0.0017994374804944804
5587,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,5.724605269101238e-05,1,1,2,0.0018187312525908734
5588,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0003098650155068172,0,1,2,0.009844542309819083
5589,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0003130324034709632,1,1,2,0.00994517156211995
5590,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00016536610533405324,0,1,2,0.0052537509531638965
5591,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.0001636901377303748,1,1,2,0.005200504755114361
5592,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.00041355765694193157,0,1,2,0.013138901287889729
5593,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.00014714111219679032,1,1,2,0.004674735230002984
5594,MET Receptor Activation,Signaling by MET,0.00013113169614678157,0,1,2,0.0041661093259072034
5595,MET Receptor Activation,Signaling by MET,0.00021125532217748113,1,1,2,0.00671167073814088
5596,MET promotes cell motility,Signaling by MET,0.00012921381715462992,0,1,2,0.004105177500956043
5597,MET promotes cell motility,Signaling by MET,0.00020883163437359666,1,1,2,0.006634669153782905
5598,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,8.298927401151121e-05,0,1,2,0.0026366042579257136
5599,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,3.0221351665615455e-05,1,1,2,0.0009601450962299011
5600,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0004365984897617059,0,1,2,0.01387091827011258
5601,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.00015888903783376507,1,1,2,0.005047971785270907
5602,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,6.905374698593557e-05,0,1,2,0.0021938666833449896
5603,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.0001519573314663798,1,1,2,0.00482774854870658
5604,Mitotic Prophase,M Phase,2.7689034131842814e-05,0,1,2,0.0008796922995101855
5605,Mitotic Prophase,M Phase,1.2173812664223262e-05,1,1,2,0.00038676716585361225
5606,Mitotic Prometaphase,M Phase,0.000729009770033104,0,1,2,0.023160948045793446
5607,Mitotic Prometaphase,M Phase,0.0003212653243285855,1,1,2,0.010206734932168969
5608,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.000546873030257556,0,1,2,0.017374386958991947
5609,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.00031952312761561723,1,1,2,0.010151384607367728
5610,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,1.6725268984849067e-05,0,1,2,0.000531368853935139
5611,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,9.928673173916774e-06,1,1,2,0.00031543813676777915
5612,Cyclin A:Cdk2-associated events at S phase entry,S Phase,0.00047066808007155045,0,1,2,0.014953323532077649
5613,Cyclin A:Cdk2-associated events at S phase entry,S Phase,6.294815188686807e-05,1,1,2,0.0019998893504050864
5614,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.00011592403341150754,0,1,2,0.0036829554629711327
5615,Ubiquitin-dependent degradation of Cyclin D,S Phase,1.5471193258894908e-05,1,1,2,0.0004915263388849003
5616,G2/M DNA damage checkpoint,G2/M Checkpoints,1.19370886525049e-06,0,1,2,3.792463441006311e-05
5617,G2/M DNA damage checkpoint,G2/M Checkpoints,3.7462760473433754e-06,1,1,2,0.00011902077100253441
5618,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00034895815415115675,0,1,2,0.01108654782237543
5619,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00016777991441203948,1,1,2,0.00533043868623113
5620,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.000317038288088084,0,1,2,0.01007244020694259
5621,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0001532814212646718,1,1,2,0.004869815440381865
5622,Glycolysis,Glucose metabolism,0.00022064758024549372,0,1,2,0.007010066740619757
5623,Glycolysis,Glucose metabolism,0.0002560262345333761,1,1,2,0.008134061517609538
5624,Gluconeogenesis,Glucose metabolism,0.0002394346755018947,0,1,2,0.007606940685320274
5625,Gluconeogenesis,Glucose metabolism,0.0002779649666621398,1,1,2,0.008831064295777796
5626,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0011277728492667695,0,1,2,0.03582981935638253
5627,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.00035932542401303,1,1,2,0.011415920361013234
5628,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.00012242968519499554,0,1,2,0.003889642765604329
5629,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,3.767104807672053e-05,1,1,2,0.0011968250950819101
5630,mRNA Splicing - Major Pathway,mRNA Splicing,0.00030314672025048226,0,1,2,0.009631099234315162
5631,mRNA Splicing - Major Pathway,mRNA Splicing,0.00024238925036882065,1,1,2,0.007700808775712494
5632,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.00017965797072753363,0,1,2,0.0057078095480724966
5633,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.00013076915574810518,1,1,2,0.004154591264444373
5634,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.00031783395597059967,0,1,2,0.010097718911352567
5635,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.00022989198559374014,1,1,2,0.007303765399795844
5636,Depurination,"Base-Excision Repair, AP Site Formation",0.0005987347968898737,0,1,2,0.019022057171257593
5637,Depurination,"Base-Excision Repair, AP Site Formation",0.0001201636999522394,1,1,2,0.003817651458165985
5638,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.0004863664139266632,0,1,2,0.01545206622356075
5639,Depyrimidination,"Base-Excision Repair, AP Site Formation",9.95784486370069e-05,1,1,2,0.0031636493366305617
5640,Utilization of Ketone Bodies,Ketone body metabolism,9.502319530122985e-05,0,1,2,0.003018927015775289
5641,Utilization of Ketone Bodies,Ketone body metabolism,8.787838961154359e-05,1,1,2,0.002791933523810705
5642,Synthesis of Ketone Bodies,Ketone body metabolism,1.1608865909965509e-05,0,1,2,0.00036881856905578153
5643,Synthesis of Ketone Bodies,Ketone body metabolism,1.0734003129807304e-05,1,1,2,0.0003410238093263989
5644,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.0002912248313875149,0,1,2,0.00925233579394265
5645,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,1.7739095291980433e-05,1,1,2,0.0005635785435609199
5646,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,1.3606605109200665e-05,0,1,2,0.00043228758648805734
5647,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.00028331773964872334,1,1,2,0.009001124152503117
5648,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,2.000610892615709e-05,0,1,2,0.0006356025234286886
5649,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,1.0313243679027133e-05,1,1,2,0.0003276561040090153
5650,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,1.1979165086032357e-05,0,1,2,0.0003805831301506143
5651,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0004149986324289341,1,1,2,0.013184681687222666
5652,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,1.8384232997022577e-05,0,1,2,0.000584074840706821
5653,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.00018550271500612209,1,1,2,0.005893499540363256
5654,Extra-nuclear estrogen signaling,ESR-mediated signaling,5.8390663156304645e-05,0,1,2,0.0018550960101140844
5655,Extra-nuclear estrogen signaling,ESR-mediated signaling,6.848967931717032e-05,1,1,2,0.0021759460154642416
5656,Estrogen-dependent gene expression,ESR-mediated signaling,2.222702229900403e-05,0,1,2,0.0007061618785390871
5657,Estrogen-dependent gene expression,ESR-mediated signaling,2.6093735608658323e-05,1,1,2,0.0008290089921913699
5658,Pyrimidine catabolism,Nucleotide catabolism,0.00017800594565959714,0,1,2,0.0056553240144875516
5659,Pyrimidine catabolism,Nucleotide catabolism,7.0978740434892075e-06,1,1,2,0.00022550245375912363
5660,Pyrimidine salvage,Nucleotide salvage,2.069466291008036e-05,0,1,2,0.0006574781740768915
5661,Pyrimidine salvage,Nucleotide salvage,1.5004525442139676e-05,1,1,2,0.00047670010540654654
5662,Vitamin D (calciferol) metabolism,Metabolism of steroids,3.615813113727916e-05,0,1,2,0.00114875908544474
5663,Vitamin D (calciferol) metabolism,Metabolism of steroids,1.449671952070759e-05,1,1,2,0.00046056689698178055
5664,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.0003511846115898937,0,1,2,0.011157283314798823
5665,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,9.635623146419065e-05,1,1,2,0.0030612781372315856
5666,VLDL assembly,Plasma lipoprotein assembly,3.702463525626299e-05,0,1,2,0.0011762882869811463
5667,VLDL assembly,Plasma lipoprotein assembly,7.730989017484193e-05,1,1,2,0.0024561678366590367
5668,Chylomicron assembly,Plasma lipoprotein assembly,9.075548882777595e-05,0,1,2,0.002883340180084632
5669,Chylomicron assembly,Plasma lipoprotein assembly,0.00019144115404689962,1,1,2,0.006082166254789202
5670,HDL assembly,Plasma lipoprotein assembly,0.0001246144533282695,0,1,2,0.003959053771199721
5671,HDL assembly,Plasma lipoprotein assembly,0.0002632698284669938,1,1,2,0.008364193553773781
5672,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.00024371061000944474,0,1,2,0.007742788929126506
5673,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0002723382012651785,1,1,2,0.008652299584546327
5674,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0008856151490653971,0,1,2,0.02813636702720713
5675,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0009976753959600145,1,1,2,0.03169656836196724
5676,LDL remodeling,Plasma lipoprotein remodeling,0.000327659321203959,0,1,2,0.010409874911251508
5677,LDL remodeling,Plasma lipoprotein remodeling,0.00036738170435483386,1,1,2,0.01167187178733005
5678,HDL remodeling,Plasma lipoprotein remodeling,0.0003020934811760766,0,1,2,0.009597637384440362
5679,HDL remodeling,Plasma lipoprotein remodeling,0.00033660416052666987,1,1,2,0.010694056231375473
5680,HDL clearance,Plasma lipoprotein clearance,0.00023492335732634953,0,1,2,0.0074636142030467915
5681,HDL clearance,Plasma lipoprotein clearance,0.00018609409236343966,1,1,2,0.005912287848574365
5682,Chylomicron clearance,Plasma lipoprotein clearance,5.821954909093974e-05,0,1,2,0.0018496596440450246
5683,Chylomicron clearance,Plasma lipoprotein clearance,4.6184740650635736e-05,1,1,2,0.0014673087010469625
5684,LDL clearance,Plasma lipoprotein clearance,0.00020896534221008801,0,1,2,0.0066389171081747255
5685,LDL clearance,Plasma lipoprotein clearance,0.00016594933655363688,1,1,2,0.005272280455141418
5686,VLDL clearance,Plasma lipoprotein clearance,0.00047522224774650286,0,1,2,0.015098011361030358
5687,VLDL clearance,Plasma lipoprotein clearance,0.00037766708262933007,1,1,2,0.011998642595677546
5688,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,6.055922509625502e-05,0,1,2,0.0019239921381083564
5689,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,1.73498931405729e-05,1,1,2,0.000551213426962206
5690,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,3.601565518222045e-05,0,1,2,0.0011442325642257725
5691,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,1.9738712977912857e-05,1,1,2,0.0006271072413083143
5692,NADPH regeneration,Metabolism of cofactors,3.131643561250412e-05,0,1,2,0.0009949363753625788
5693,NADPH regeneration,Metabolism of cofactors,1.7215973466729596e-05,1,1,2,0.0005469587424083166
5694,Triglyceride catabolism,Triglyceride metabolism,0.00014376935265724298,0,1,2,0.004567613006504089
5695,Triglyceride catabolism,Triglyceride metabolism,5.359198398141162e-05,1,1,2,0.0017026399476211475
5696,Glycogen synthesis,Glycogen metabolism,0.00017449704788065028,0,1,2,0.0055438448512487686
5697,Glycogen synthesis,Glycogen metabolism,1.1006538475642623e-05,1,1,2,0.0003496823722771363
5698,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.00032039127875250047,0,1,2,0.010178966135357863
5699,Glycogen breakdown (glycogenolysis),Glycogen metabolism,2.3385434187407254e-05,1,1,2,0.0007429651130989179
5700,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,2.795945827963039e-05,0,1,2,0.0008882837888079925
5701,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.00020972584159811367,1,1,2,0.00666307849467318
5702,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,3.6146033665801123e-06,0,1,2,0.00011483747436705886
5703,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,6.520833727785332e-07,1,1,2,2.071696394105055e-05
5704,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.0004562127728119781,0,1,2,0.01449407232010866
5705,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,8.062347503975505e-05,1,1,2,0.002561441826194315
5706,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.000496181338639687,0,1,2,0.015763890523722592
5707,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,8.884218505506955e-05,1,1,2,0.0028225537117860505
5708,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),6.350919712591339e-05,0,1,2,0.002017713994418127
5709,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),4.050165876962758e-05,1,1,2,0.001286754791351016
5710,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00012272930680271854,0,1,2,0.0038991618705260015
5711,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),7.826209441403536e-05,1,1,2,0.0024864197671810953
5712,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0002595014840187502,0,1,2,0.008244471660361487
5713,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0003116900681058451,1,1,2,0.00990252500108673
5714,Interferon gamma signaling,Interferon Signaling,0.0006199291241925498,0,1,2,0.019695409893952288
5715,Interferon gamma signaling,Interferon Signaling,0.00020730241140445564,1,1,2,0.006586085094700815
5716,Interferon alpha/beta signaling,Interferon Signaling,0.0006254215509516097,0,1,2,0.019869906609964932
5717,Interferon alpha/beta signaling,Interferon Signaling,0.0002069498585456708,1,1,2,0.006574884341595215
5718,HCMV Early Events,HCMV Infection,0.00027679577113742663,0,1,2,0.00879391846054156
5719,HCMV Early Events,HCMV Infection,7.431616429706308e-05,1,1,2,0.002361055902129772
5720,HCMV Late Events,HCMV Infection,0.0003609952143543745,0,1,2,0.011468970304831533
5721,HCMV Late Events,HCMV Infection,9.721670280126594e-05,1,1,2,0.0030886156747408433
5722,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.00028009677319501574,0,1,2,0.008898792688978042
5723,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0001716270319016341,1,1,2,0.00545266323241042
5724,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,4.862939218342982e-06,0,1,2,0.00015449763119193682
5725,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,2.937213187274187e-06,1,1,2,9.331650250282334e-05
5726,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),8.534093092351624e-05,0,1,2,0.0027113173904506813
5727,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1.0116657698576313e-05,1,1,2,0.00032141048444818827
5728,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),3.0406365809036782e-05,0,1,2,0.0009660230736448318
5729,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),3.6326586884201085e-06,1,1,2,0.00011541109956150207
5730,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),3.7516800372567984e-05,0,1,2,0.0011919245804263964
5731,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),4.075049001310229e-06,1,1,2,0.00012946602649663096
5732,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5.313510846341843e-05,0,1,2,0.0016881248196069444
5733,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5.705073672633375e-06,1,1,2,0.00018125259819670923
5734,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1.1373897879894883e-05,0,1,2,0.0003613535355807966
5735,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1.2523678497403257e-06,1,1,2,3.9788255102178645e-05
5736,Parasite infection,Leishmania infection,0.0003736524465686733,0,1,2,0.011871095913800542
5737,Parasite infection,Leishmania infection,0.0007129823597014028,1,1,2,0.02265175045577447
5738,Cell recruitment (pro-inflammatory response),Leishmania infection,5.7886003690115556e-05,0,1,2,0.0018390627659002343
5739,Cell recruitment (pro-inflammatory response),Leishmania infection,0.00010829623059395126,1,1,2,0.003440616948422891
5740,Leishmania parasite growth and survival,Leishmania infection,0.00029588689591235627,0,1,2,0.009400451551350242
5741,Leishmania parasite growth and survival,Leishmania infection,0.0005642262055267464,1,1,2,0.017925704660565433
5742,Lipophagy,Selective autophagy,0.00017143651640082847,0,1,2,0.005446610474549743
5743,Lipophagy,Selective autophagy,0.0004652407749255807,1,1,2,0.014780895757195062
5744,Aggrephagy,Selective autophagy,9.027882619675854e-05,0,1,2,0.0028681964071392238
5745,Aggrephagy,Selective autophagy,0.0002454918559322572,1,1,2,0.007799379863803784
5746,SARS-CoV-1 Infection,SARS-CoV Infections,0.00020646326880422133,0,1,2,0.0065594251801620075
5747,SARS-CoV-1 Infection,SARS-CoV Infections,7.334096005980787e-05,1,1,2,0.0023300732519629845
5748,Potential therapeutics for SARS,SARS-CoV Infections,0.0004723206870487398,0,1,2,0.015005827553165131
5749,Potential therapeutics for SARS,SARS-CoV Infections,0.00016959616722220366,1,1,2,0.005388141804492945
5750,SARS-CoV-2 Infection,SARS-CoV Infections,0.0003536340209762867,0,1,2,0.011235102084687943
5751,SARS-CoV-2 Infection,SARS-CoV Infections,0.00012709747207496585,1,1,2,0.004037940324649278
5752,ALK mutants bind TKIs,Signaling by ALK in cancer,0.0003869282664988629,0,1,2,0.012292874315555662
5753,ALK mutants bind TKIs,Signaling by ALK in cancer,0.00012383853431498755,1,1,2,0.003934402496699586
5754,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,8.385752479923587e-05,0,1,2,0.0026641889518651336
5755,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,2.6802753396498652e-05,1,1,2,0.0008515347865260158
5756,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0005966854183586944,0,1,2,0.018956947550456967
5757,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.00022501616699120518,1,1,2,0.007148858585132856
5758,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0005959187205617174,0,1,2,0.018932589237890315
5759,Cytoprotection by HMOX1,Cellular response to chemical stress,0.00022414760794580395,1,1,2,0.007121264097716963
5760,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0004497969135710601,0,1,2,0.014290237764446562
5761,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.00016837242336745486,1,1,2,0.0053492629457913545
5762,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0002092396839243566,0,1,2,0.006647633060212899
5763,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0005373351600864397,1,1,2,0.017071364798547217
5764,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.00014124519739348192,0,1,2,0.004487419528547228
5765,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.00036438361312344006,1,1,2,0.0115766211636742
5766,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.00020181993137169453,0,1,2,0.006411904390380332
5767,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.00028015685115834866,1,1,2,0.008900701391226831
5768,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0002352245645065084,0,1,2,0.0074731836822738845
5769,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.00032656651026553645,1,1,2,0.010375155846557038
5770,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,3.575147660062681e-05,0,1,2,0.0011358394992016592
5771,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00047042485807582,1,1,2,0.014945596266630367
5772,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0004282108089812147,0,1,2,0.013604438112003264
5773,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0002053468506808362,1,1,2,0.00652395610523873
5774,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,6.224501491781061e-05,0,1,2,0.0019775503921649566
5775,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,3.8885371631044675e-05,1,1,2,0.001235404666863517
5776,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,1.3598405929631872e-05,0,1,2,0.0004320270950929937
5777,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,1.0755438400928838e-05,1,1,2,0.0003417048169359003
5778,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,8.174811752636336e-05,0,1,2,0.002597172192607983
5779,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0002833133928157474,1,1,2,0.009000986051785051
5780,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.00011005169026988881,0,1,2,0.0034963886431548133
5781,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,3.813792486272376e-05,1,1,2,0.0012116579676014606
5782,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007972630652080985,0,1,2,0.0253293840373035
5783,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0014879728996513527,1,1,2,0.047273526966324
5784,MHC class II antigen presentation,MHC class II antigen presentation,0.0002779812082615554,0,1,2,0.008831580298245403
5785,MHC class II antigen presentation,MHC class II antigen presentation,0.00033346875117444476,1,1,2,0.010594442953070738
5786,Rap1 signalling,Rap1 signalling,8.59439366723762e-05,0,1,2,0.002730475137568427
5787,Rap1 signalling,Rap1 signalling,0.0002092769521941083,1,1,2,0.006648817088870618
5788,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.00010806415313223384,0,1,2,0.0034332437495243453
5789,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.00011687075622373833,1,1,2,0.003713033246245353
5790,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.0009127288308725487,0,1,2,0.028997780140555526
5791,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.00030039964440682176,1,1,2,0.009543823475459437
5792,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.0017943451800747794,0,1,2,0.057007103608563
5793,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.0004206373098775676,1,1,2,0.013363824849362806
5794,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,4.818838063357012e-05,0,1,2,0.0015309651888675722
5795,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.00013553398635188243,1,1,2,0.0043059719435484135
5796,Collagen degradation,Collagen degradation,3.925317974382806e-05,0,1,2,0.0012470900858265724
5797,Collagen degradation,Collagen degradation,0.00011093944330738232,1,1,2,0.0035245929317995984
5798,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.00012574401204419654,0,1,2,0.00399494032829356
5799,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0005255310647953593,1,1,2,0.01669634370966401
5800,Fibronectin matrix formation,Fibronectin matrix formation,2.987081457855613e-05,0,1,2,0.0009490083850427025
5801,Fibronectin matrix formation,Fibronectin matrix formation,1.063046577436456e-06,1,1,2,3.377343838498387e-05
5802,Integrin cell surface interactions,Integrin cell surface interactions,0.00014945709535883566,0,1,2,0.004748314992436934
5803,Integrin cell surface interactions,Integrin cell surface interactions,0.0007073785207601039,1,1,2,0.022473714127714664
5804,Laminin interactions,Laminin interactions,9.67916880724923e-05,0,1,2,0.003075112777445823
5805,Laminin interactions,Laminin interactions,7.970617019044384e-05,1,1,2,0.002532298664016822
5806,ECM proteoglycans,ECM proteoglycans,0.0007568992326563657,0,1,2,0.024047008043059506
5807,ECM proteoglycans,ECM proteoglycans,0.0005836397914320602,1,1,2,0.018542482477569316
5808,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,2.472499271804279e-05,0,1,2,0.000785523452928767
5809,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0004086655303050287,1,1,2,0.012983476360092665
5810,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.00017845272794212238,0,1,2,0.005669518476151459
5811,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.00020927711720737925,1,1,2,0.006648822331411874
5812,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,1.2069528625934116e-05,0,1,2,0.00038345401794791164
5813,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,5.392402265338921e-06,1,1,2,0.00017131889563546217
5814,Meiotic synapsis,Meiotic synapsis,0.0008701906979113488,0,1,2,0.027646325704718998
5815,Meiotic synapsis,Meiotic synapsis,0.0005539724519965759,1,1,2,0.01759993858369123
5816,Meiotic recombination,Meiotic recombination,0.0003831577846286393,0,1,2,0.012173084515345042
5817,Meiotic recombination,Meiotic recombination,3.9241585124778646e-06,1,1,2,0.00012467217198862884
5818,Nephrin family interactions,Nephrin family interactions,2.6359039545384223e-05,0,1,2,0.0008374378102229498
5819,Nephrin family interactions,Nephrin family interactions,1.1270897339457447e-05,1,1,2,0.000358081164943498
5820,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.00011423289289167156,0,1,2,0.0036292272149720988
5821,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.00010199095824442929,1,1,2,0.003240295784969588
5822,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.0001330157371975368,0,1,2,0.0042259661051801374
5823,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,7.08108513725645e-05,1,1,2,0.0022496906312296666
5824,Cristae formation,Cristae formation,2.5356736909882873e-06,0,1,2,8.055942325079976e-05
5825,Cristae formation,Cristae formation,1.7050141941396717e-05,1,1,2,0.0005416902048653766
5826,Signaling by Hippo,Signaling by Hippo,0.0006013955042796767,0,1,2,0.019106588967885627
5827,Signaling by Hippo,Signaling by Hippo,8.460390326114333e-05,1,1,2,0.002687901710581595
5828,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,4.081693232526654e-05,0,1,2,0.001296771165263309
5829,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.00011539131590616411,1,1,2,0.0036660308030124827
5830,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.00032710274074257347,0,1,2,0.010392192115108915
5831,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0001520675902569851,1,1,2,0.00483125151701479
5832,mTORC1-mediated signalling,mTORC1-mediated signalling,0.00010042746306759267,0,1,2,0.0031906228833856803
5833,mTORC1-mediated signalling,mTORC1-mediated signalling,0.0001436896777081275,1,1,2,0.004565081699746799
5834,Neutrophil degranulation,Neutrophil degranulation,0.00010652630495086425,0,1,2,0.0033843856638097994
5835,Neutrophil degranulation,Neutrophil degranulation,0.0008171497927805415,1,1,2,0.025961193764744168
5836,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,2.0184883868512863e-05,0,1,2,0.0006412822787927405
5837,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.00018867786674136737,1,1,2,0.005994375450948361
5838,Heme biosynthesis,Heme biosynthesis,1.8385316711392932e-05,0,1,2,0.000584109270769709
5839,Heme biosynthesis,Heme biosynthesis,4.547956369181516e-06,1,1,2,0.00014449049314711553
5840,Heme degradation,Heme degradation,0.0008241968479279389,0,1,2,0.026185081680728205
5841,Heme degradation,Heme degradation,0.00026099850103161824,1,1,2,0.008292032522621442
5842,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,4.5326952737858786e-05,0,1,2,0.0014400564170601042
5843,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,7.910339603292557e-05,1,1,2,0.0025131482746537366
5844,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0007721466473899939,0,1,2,0.02453142484375916
5845,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0011908590574703016,1,1,2,0.03783409481422964
5846,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),3.864118149104442e-05,0,1,2,0.0012276466430642145
5847,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.00012956001352031863,1,1,2,0.004116176305593455
5848,eNOS activation,eNOS activation,3.9343706421600774e-05,0,1,2,0.0012499661565828761
5849,eNOS activation,eNOS activation,1.7060979258660275e-05,1,1,2,0.000542034511008332
5850,PECAM1 interactions,PECAM1 interactions,1.172513921673396e-05,0,1,2,0.00037251262108070073
5851,PECAM1 interactions,PECAM1 interactions,1.1577658822226957e-05,1,1,2,0.0003678271067085207
5852,Basigin interactions,Basigin interactions,0.00012917871973158195,0,1,2,0.004104062441014229
5853,Basigin interactions,Basigin interactions,0.0002934181191698473,1,1,2,0.009322017472384037
5854,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,9.414549173283754e-05,0,1,2,0.0029910420030048583
5855,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,3.3903325381431716e-05,1,1,2,0.0010771229550233779
5856,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,3.554241080509279e-05,0,1,2,0.0011291973906489906
5857,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,7.611141676174212e-05,1,1,2,0.002418091830553098
5858,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",5.8913287299441124e-05,0,1,2,0.001871699999695886
5859,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",5.169196249645317e-05,1,1,2,0.001642275463209621
5860,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,7.019110789088945e-07,0,1,2,2.230001119276839e-05
5861,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,2.22155086659565e-06,1,1,2,7.057960855582606e-05
5862,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.0006965745314243628,0,1,2,0.022130466827090634
5863,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.0004983518342553995,1,1,2,0.015832848085411865
5864,DNA methylation,DNA methylation,0.0001697578326997162,0,1,2,0.005393277984938506
5865,DNA methylation,DNA methylation,0.0003180623126783831,1,1,2,0.010104973900328423
5866,Abacavir metabolism,Abacavir metabolism,1.7146917842386165e-05,0,1,2,0.0005447648160805317
5867,Abacavir metabolism,Abacavir metabolism,0.0008411790943955105,1,1,2,0.02672461481773736
5868,Scavenging of heme from plasma,Scavenging of heme from plasma,9.240734925149088e-05,0,1,2,0.002935820482853176
5869,Scavenging of heme from plasma,Scavenging of heme from plasma,0.001159250547449479,1,1,2,0.03682987911165549
5870,Scavenging by Class B Receptors,Scavenging by Class B Receptors,3.060170567105299e-05,0,1,2,0.0009722291034971126
5871,Scavenging by Class B Receptors,Scavenging by Class B Receptors,1.0872254323600994e-05,1,1,2,0.0003454161080970713
5872,Scavenging by Class A Receptors,Scavenging by Class A Receptors,6.075849931943973e-05,0,1,2,0.0019303231642753133
5873,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.00025299887901092193,1,1,2,0.008037881155076781
5874,Scavenging by Class F Receptors,Scavenging by Class F Receptors,6.103043367336906e-05,0,1,2,0.0019389626334595713
5875,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.00011597944576166769,1,1,2,0.003684715936720471
5876,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.00015581003902824414,0,1,2,0.004950150693840964
5877,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.000189611577042259,1,1,2,0.006024039821245883
5878,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.00024321740768866063,0,1,2,0.00772711968325724
5879,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.0001241242729056328,1,1,2,0.00394348053230988
5880,Retinoid metabolism and transport,Retinoid metabolism and transport,0.0008466656631130464,0,1,2,0.026898925421298618
5881,Retinoid metabolism and transport,Retinoid metabolism and transport,0.0005130611139204378,1,1,2,0.016300168107882245
5882,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.0008466656631130464,0,1,2,0.026898925421298618
5883,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.0005130611139204378,1,1,2,0.016300168107882245
5884,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00020488040606925104,0,1,2,0.006509136963082825
5885,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00041808314122646653,1,1,2,0.013282677833424104
5886,Heme signaling,Heme signaling,0.00017478674660686074,0,1,2,0.005553048702037199
5887,Heme signaling,Heme signaling,5.394127073045846e-05,1,1,2,0.0017137369350420306
5888,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.0007367308623732353,0,1,2,0.023406250407843318
5889,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.0005568680240445284,1,1,2,0.017691932129624686
5890,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",4.9856825432146616e-05,0,1,2,0.0015839723842242955
5891,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.00012218675507613629,1,1,2,0.003881924773208422
5892,Syndecan interactions,Syndecan interactions,0.00018926627944662133,0,1,2,0.0060130695709122856
5893,Syndecan interactions,Syndecan interactions,0.0002078002102751058,1,1,2,0.006601900374899131
5894,HDACs deacetylate histones,HDACs deacetylate histones,0.00013982947821712855,0,1,2,0.004442441532862115
5895,HDACs deacetylate histones,HDACs deacetylate histones,0.0002582075672285908,1,1,2,0.008203363377887988
5896,PKMTs methylate histone lysines,PKMTs methylate histone lysines,1.5445496684280563e-06,0,1,2,4.9070994786510554e-05
5897,PKMTs methylate histone lysines,PKMTs methylate histone lysines,1.5722355372621087e-05,1,1,2,0.0004995058652317413
5898,HDMs demethylate histones,HDMs demethylate histones,0.00032454867249527276,0,1,2,0.010311048289041322
5899,HDMs demethylate histones,HDMs demethylate histones,0.00023382102883288513,1,1,2,0.007428592761612108
5900,HATs acetylate histones,HATs acetylate histones,0.0001504526744521763,0,1,2,0.0047799449603800155
5901,HATs acetylate histones,HATs acetylate histones,0.0007358699031431086,1,1,2,0.02337889736976592
5902,RMTs methylate histone arginines,RMTs methylate histone arginines,6.365890450591546e-05,0,1,2,0.002022470261059303
5903,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0001295686372844467,1,1,2,0.004116450286219147
5904,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00018942979983280726,0,1,2,0.006018264682589195
5905,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0001336938516671377,1,1,2,0.004247510088052704
5906,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,1.3367494531013883e-05,0,1,2,0.0004246909425112116
5907,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,3.89442202644808e-05,1,1,2,0.0012372743127826906
5908,Miscellaneous transport and binding events,Miscellaneous transport and binding events,1.4646915265929316e-05,0,1,2,0.0004653386791920816
5909,Miscellaneous transport and binding events,Miscellaneous transport and binding events,1.0704042868701666e-05,1,1,2,0.0003400719591874432
5910,Intracellular oxygen transport,Intracellular oxygen transport,5.6738083289674987e-05,0,1,2,0.001802592850340525
5911,Intracellular oxygen transport,Intracellular oxygen transport,6.515033436962167e-05,1,1,2,0.0020698536172325346
5912,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,1.7019099008890158e-05,0,1,2,0.0005407039577991117
5913,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,4.663837328200641e-06,1,1,2,0.0001481720801184627
5914,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.00044547151469833546,0,1,2,0.014152818016884113
5915,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.00012765519713312518,1,1,2,0.004055659485114409
5916,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),8.260799069149462e-06,0,1,2,0.0002624490725942142
5917,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.000334059955336213,1,1,2,0.01061322575878615
5918,Surfactant metabolism,Surfactant metabolism,1.3732539743526606e-05,0,1,2,0.00043628858296668703
5919,Surfactant metabolism,Surfactant metabolism,2.7407495457884975e-05,1,1,2,0.0008707476970254713
5920,Amyloid fiber formation,Amyloid fiber formation,0.0007658218450093117,0,1,2,0.024330483202973964
5921,Amyloid fiber formation,Amyloid fiber formation,0.002350461989304483,1,1,2,0.07467516932649804
5922,Striated Muscle Contraction,Striated Muscle Contraction,3.7462956720919022e-06,0,1,2,0.00011902139448907701
5923,Striated Muscle Contraction,Striated Muscle Contraction,0.0004425876147579771,1,1,2,0.014061195298734706
5924,Smooth Muscle Contraction,Smooth Muscle Contraction,2.10755991209377e-05,0,1,2,0.0006695806782559886
5925,Smooth Muscle Contraction,Smooth Muscle Contraction,0.00012780105163792221,1,1,2,0.004060293344284357
5926,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00018337201577496625,0,1,2,0.005825806326605954
5927,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00040863784301026164,1,1,2,0.012982596723053508
5928,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0005402743121877268,0,1,2,0.01716474290116648
5929,Platelet sensitization by LDL,Platelet sensitization by LDL,0.00020221465160541577,1,1,2,0.006424444818782856
5930,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.0003057687978708152,0,1,2,0.00971440374686485
5931,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.00037578901681968666,1,1,2,0.011938975652336366
5932,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.00010811971998900567,0,1,2,0.0034350091320139407
5933,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.000126513125975309,1,1,2,0.004019375402461335
5934,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,7.741562495391521e-05,0,1,2,0.0024595270752116815
5935,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,9.19944272059668e-05,1,1,2,0.0029227017752082676
5936,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",6.512111927610751e-05,0,1,2,0.0020689254413824307
5937,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",2.9618634415861648e-05,1,1,2,0.0009409965148505082
5938,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,3.134056183169465e-06,0,1,2,9.957028755278482e-05
5939,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,5.121025536872595e-06,1,1,2,0.00016269714244748973
5940,Pyroptosis,Pyroptosis,0.00024259990631283007,0,1,2,0.00770750140395329
5941,Pyroptosis,Pyroptosis,0.00019274267979568405,1,1,2,0.006123516277089301
5942,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.00015913869020518602,0,1,2,0.00505590334646758
5943,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.000302010563430527,1,1,2,0.009595003052671858
5944,Hedgehog 'on' state,Hedgehog 'on' state,2.6082357725255822e-05,0,1,2,0.0008286475120340538
5945,Hedgehog 'on' state,Hedgehog 'on' state,0.00022903953504513819,1,1,2,0.007276682686121264
5946,Physiological factors,Physiological factors,0.0002766899494330167,0,1,2,0.008790556460334286
5947,Physiological factors,Physiological factors,0.000380300969620552,1,1,2,0.01208232229692409
5948,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.0003016497542048086,0,1,2,0.00958353999130448
5949,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.00011596284351990246,1,1,2,0.003684188476493222
5950,Intraflagellar transport,Intraflagellar transport,0.0003591027964502786,0,1,2,0.011408847389392823
5951,Intraflagellar transport,Intraflagellar transport,6.811762785283523e-05,1,1,2,0.0021641257834316375
5952,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0002519625246617958,0,1,2,0.008004955740049691
5953,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0001816024937651662,1,1,2,0.005769587865592728
5954,Metallothioneins bind metals,Metallothioneins bind metals,0.0005410688037798001,0,1,2,0.01718998423433269
5955,Metallothioneins bind metals,Metallothioneins bind metals,0.0003665563656747092,1,1,2,0.011645650429158563
5956,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00038592770911675175,0,1,2,0.012261086185277435
5957,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,3.7219577436725406e-05,1,1,2,0.0011824816823226363
5958,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.00031704988614919,0,1,2,0.010072808682238466
5959,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.00014710889613317316,1,1,2,0.004673711712066258
5960,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.00028811633479923276,0,1,2,0.009153577545505926
5961,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.00027185477717332827,1,1,2,0.00863694099713683
5962,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.00017167898454231202,0,1,2,0.005454313789729464
5963,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.00012113223957895492,1,1,2,0.003848422370843372
5964,RAB geranylgeranylation,RAB geranylgeranylation,4.148127345615649e-06,0,1,2,0.00013178775633524968
5965,RAB geranylgeranylation,RAB geranylgeranylation,0.0001347959800954284,1,1,2,0.00428252517333239
5966,Protein methylation,Protein methylation,0.00022508876130361875,0,1,2,0.007151164937074003
5967,Protein methylation,Protein methylation,2.2511452746568677e-06,1,1,2,7.151983538916568e-05
5968,Neddylation,Neddylation,0.00010677124845905692,0,1,2,0.0033921676224345065
5969,Neddylation,Neddylation,0.0003864257527782471,1,1,2,0.012276909242584209
5970,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,9.812752672088914e-05,0,1,2,0.003117552935047109
5971,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,5.741866723302489e-05,1,1,2,0.0018242152894362487
5972,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.0006439695305623919,0,1,2,0.02045918374969415
5973,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.001800445474358187,1,1,2,0.05720091253235238
5974,Formation of the cornified envelope,Formation of the cornified envelope,7.188425691508205e-05,0,1,2,0.0022837931783068984
5975,Formation of the cornified envelope,Formation of the cornified envelope,7.676572662024177e-05,1,1,2,0.0024388795308851155
5976,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,1.2262311715604311e-05,0,1,2,0.0003895788180637677
5977,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,1.6833931800961344e-05,1,1,2,0.0005348211174601831
5978,Choline catabolism,Choline catabolism,3.235678432155034e-05,0,1,2,0.0010279886928900017
5979,Choline catabolism,Choline catabolism,0.000802541879386296,1,1,2,0.025497094191474792
5980,Urea cycle,Urea cycle,0.0001374939828436134,0,1,2,0.004368241859235356
5981,Urea cycle,Urea cycle,0.00022703527111165211,1,1,2,0.007213006375128312
5982,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,4.962554334417688e-06,0,1,2,0.00015766244546853726
5983,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,1.519025876368133e-05,1,1,2,0.00048260093141386267
5984,Tryptophan catabolism,Tryptophan catabolism,9.84857381942864e-05,0,1,2,0.003128933464726957
5985,Tryptophan catabolism,Tryptophan catabolism,4.793885642440155e-05,1,1,2,0.001523037699439744
5986,Threonine catabolism,Threonine catabolism,2.721375747264551e-05,0,1,2,0.0008645925594744008
5987,Threonine catabolism,Threonine catabolism,2.257391855347137e-05,1,1,2,0.0007171829189383587
5988,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,2.9985602028724954e-06,0,1,2,9.526552307764003e-05
5989,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,4.119532555188445e-06,1,1,2,0.00013087928777599464
5990,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,7.317650919605216e-05,0,1,2,0.0023248485786210088
5991,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,7.161770210891542e-05,1,1,2,0.0022753246196253025
5992,Alanine metabolism,Alanine metabolism,6.399809011652785e-06,0,1,2,0.0002033246331049308
5993,Alanine metabolism,Alanine metabolism,0.00027322433547643935,1,1,2,0.008680452442398533
5994,Lactose synthesis,Lactose synthesis,1.4955585337342976e-05,0,1,2,0.0004751452576237787
5995,Lactose synthesis,Lactose synthesis,2.0143962106529347e-05,1,1,2,0.0006399821771449952
5996,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,9.187007976303216e-05,0,1,2,0.0029187512044699555
5997,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,2.3506718702643634e-05,1,1,2,0.0007468183733316601
5998,Galactose catabolism,Galactose catabolism,2.0670586263112072e-05,0,1,2,0.000656713248842043
5999,Galactose catabolism,Galactose catabolism,1.2003978538117282e-05,1,1,2,0.00038137146399495994
6000,Pentose phosphate pathway,Pentose phosphate pathway,0.00015885313416386218,0,1,2,0.005046831110526266
6001,Pentose phosphate pathway,Pentose phosphate pathway,0.0008000093393310253,1,1,2,0.025416634325153176
6002,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,8.75982130744121e-05,0,1,2,0.002783032196987803
6003,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,9.028647252820021e-05,1,1,2,0.00286843933431598
6004,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.00035283991950896493,0,1,2,0.011209873145949725
6005,GPVI-mediated activation cascade,GPVI-mediated activation cascade,6.127995023807163e-05,1,1,2,0.0019468898800194883
6006,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.00025459815894036356,0,1,2,0.008088690953352592
6007,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0002076911956312692,1,1,2,0.006598436933658808
6008,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0004266501094987569,0,1,2,0.01355485403080959
6009,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0001915252249063581,1,1,2,0.006084837221473222
6010,Signaling by SCF-KIT,Signaling by SCF-KIT,0.00017690667647662748,0,1,2,0.005620399768638356
6011,Signaling by SCF-KIT,Signaling by SCF-KIT,0.00032861091564102146,1,1,2,0.01044010746810252
6012,Signaling by PDGF,Signaling by PDGF,0.0008938254456926341,0,1,2,0.028397211615909083
6013,Signaling by PDGF,Signaling by PDGF,0.0006030862725292259,1,1,2,0.019160305388700546
6014,Signaling by MST1,Signaling by MST1,1.0102427511345829e-05,0,1,2,0.000320958385394547
6015,Signaling by MST1,Signaling by MST1,5.973829405158267e-06,1,1,2,0.0001897910812375271
6016,Signaling by BMP,Signaling by BMP,0.000104973493000613,0,1,2,0.003335052172842973
6017,Signaling by BMP,Signaling by BMP,0.0001896331779632793,1,1,2,0.0060247260916225735
6018,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,7.4095764218701486e-06,0,1,2,0.00023540536986284524
6019,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,1.1973834746636316e-05,1,1,2,0.00038041378301852775
6020,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.00046683803513477114,0,1,2,0.014831641388106147
6021,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,9.521908380746692e-05,1,1,2,0.003025150476286002
6022,Mitochondrial protein import,Mitochondrial protein import,1.1425000064975143e-05,0,1,2,0.00036297707356659987
6023,Mitochondrial protein import,Mitochondrial protein import,0.0003113390356780923,1,1,2,0.00989137255271666
6024,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0001410194608965082,0,1,2,0.004480247784774561
6025,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.00031099068862736805,1,1,2,0.009880305419908048
6026,Late endosomal microautophagy,Late endosomal microautophagy,2.89099081418485e-05,0,1,2,0.0009184799820331744
6027,Late endosomal microautophagy,Late endosomal microautophagy,0.0007961045068953764,1,1,2,0.025292576150781267
6028,Defective pyroptosis,Defective pyroptosis,0.0001997886729614361,0,1,2,0.006347370453468292
6029,Defective pyroptosis,Defective pyroptosis,1.8147171238444967e-05,1,1,2,0.0005765432885935878
6030,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.00017749686538903799,0,1,2,0.005639150319453226
6031,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,3.0845113498884445e-05,1,1,2,0.0009799622729086662
6032,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0016410681745569282,0,1,2,0.05213742845832113
6033,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0011828774045124408,1,1,2,0.037580514331394456
6034,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,7.927669391312051e-06,0,1,2,0.00025186540214415455
6035,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,1.802945048312182e-05,1,1,2,0.0005728032505172433
6036,Aspirin ADME,Aspirin ADME,0.00014892898948251336,0,1,2,0.004731536845878455
6037,Aspirin ADME,Aspirin ADME,6.7009118512799685e-06,1,1,2,0.00021289079738929888
6038,Paracetamol ADME,Paracetamol ADME,0.000150231343611595,0,1,2,0.004772913186170183
6039,Paracetamol ADME,Paracetamol ADME,0.0015007520397666483,1,1,2,0.047679525640754436
6040,Atorvastatin ADME,Atorvastatin ADME,6.619256615440948e-05,0,1,2,0.002102965760870951
6041,Atorvastatin ADME,Atorvastatin ADME,6.0859474554399406e-05,1,1,2,0.0019335311901028777
6042,Kinesins,Kinesins,3.782870396258511e-05,0,1,2,0.0012018338891087135
6043,Kinesins,Kinesins,2.2319298383487603e-05,1,1,2,0.0007090935286848683
6044,Stimuli-sensing channels,Stimuli-sensing channels,8.450438865923753e-05,0,1,2,0.0026847400896825584
6045,Stimuli-sensing channels,Stimuli-sensing channels,3.570624387790883e-06,1,1,2,0.0001134402436512097
6046,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0003724338360966451,0,2,3,0.025597321594109945
6047,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",3.3323242117941255e-05,1,2,3,0.0022903014237137826
6048,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,1.3474500843725835e-07,0,2,3,9.261004183504234e-06
6049,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,1.365215221196687e-06,1,2,3,9.38310370196258e-05
6050,Defects in vitamin and cofactor metabolism,Diseases of metabolism,7.993545122199205e-05,0,2,3,0.005493951551621793
6051,Defects in vitamin and cofactor metabolism,Diseases of metabolism,2.491375695996545e-05,1,2,3,0.0017123187723906037
6052,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,3.787746221130846e-05,0,2,3,0.002603312286427199
6053,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,9.553192588095885e-05,1,2,3,0.0065658949114521855
6054,Cellular response to chemical stress,Cellular responses to stress,0.0009442959478320024,0,2,3,0.06490131860736263
6055,Cellular response to chemical stress,Cellular responses to stress,0.0003330867456068444,1,2,3,0.022893001976924
6056,Asparagine N-linked glycosylation,Post-translational protein modification,5.890205617010606e-05,0,2,3,0.004048329470121726
6057,Asparagine N-linked glycosylation,Post-translational protein modification,0.00019487997893723362,1,2,3,0.013394071670263791
6058,Signaling by NOTCH4,Signaling by NOTCH,0.0002029908583853317,0,2,3,0.01395153119601469
6059,Signaling by NOTCH4,Signaling by NOTCH,7.655292888719182e-05,1,2,3,0.005261471299798827
6060,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,4.651392945020758e-06,0,2,3,0.0003196895382066577
6061,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,6.279566550151304e-06,1,2,3,0.0004315936654427045
6062,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,8.645322150541174e-05,0,2,3,0.005941916923860241
6063,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00021843374127475095,1,2,3,0.015012918216602326
6064,Heme biosynthesis,Metabolism of porphyrins,2.307102234128083e-05,0,2,3,0.001585667898932292
6065,Heme biosynthesis,Metabolism of porphyrins,3.901361728790921e-06,1,2,3,0.0002681400054126649
6066,Defective pyroptosis,Diseases of programmed cell death,1.5239754797673544e-05,0,2,3,0.001047426057363384
6067,Defective pyroptosis,Diseases of programmed cell death,3.9939842182773156e-06,1,2,3,0.000274505935197882
6068,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,1.2381694704792958e-05,0,2,3,0.0008509920166234019
6069,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,1.4574427350545669e-05,1,2,3,0.00100169820189243
6070,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.0001885457447383372,0,2,3,0.012958720705537035
6071,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.00037015516382724934,1,2,3,0.025440708791420966
6072,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,3.0483794059399664e-07,0,2,3,2.0951465852973303e-05
6073,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,7.80718498712359e-06,1,2,3,0.0005365866510803578
6074,Neurotransmitter clearance,Transmission across Chemical Synapses,1.3215561901621546e-06,0,2,3,9.083035837669992e-05
6075,Neurotransmitter clearance,Transmission across Chemical Synapses,4.791337473103931e-07,1,2,3,3.2930790459416114e-05
6076,HATs acetylate histones,Chromatin modifying enzymes,0.00030747817805600963,0,2,3,0.02113292897702314
6077,HATs acetylate histones,Chromatin modifying enzymes,0.0007531951856945774,1,2,3,0.05176699193989568
6078,Cellular Senescence,Cellular responses to stress,0.0003239792896383352,0,2,3,0.022267047896667898
6079,Cellular Senescence,Cellular responses to stress,0.00011463676703863892,1,2,3,0.007878967773582312
6080,Heme signaling,Cellular responses to stress,0.00010355907244996294,0,2,3,0.0071175994890044095
6081,Heme signaling,Cellular responses to stress,3.6674094740492315e-05,1,2,3,0.0025206050209724603
6082,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.00019490125642446655,0,2,3,0.013395534068764217
6083,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0002623258119793893,1,2,3,0.01802961364103871
6084,RAB geranylgeranylation,Post-translational protein modification,2.868005703746307e-05,0,2,3,0.0019711760108038464
6085,RAB geranylgeranylation,Post-translational protein modification,9.256860021611695e-05,1,2,3,0.006362225983768197
6086,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,3.683901259645041e-05,0,2,3,0.0025319398004323888
6087,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.00013989862542112505,1,2,3,0.009615211504438068
6088,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,9.446098222258396e-05,0,2,3,0.006492289114728923
6089,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,8.239525199277879e-06,1,2,3,0.0005663013288995538
6090,Choline catabolism,Metabolism of amino acids and derivatives,0.00027047199642387347,0,2,3,0.0185894996738864
6091,Choline catabolism,Metabolism of amino acids and derivatives,0.0003185046727114314,1,2,3,0.021890778297881636
6092,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.00013131060293901636,0,2,3,0.009024958009653727
6093,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,3.7837910595090546e-05,1,2,3,0.0026005939097874507
6094,C-type lectin receptors (CLRs),Innate Immune System,7.324358688640528e-05,0,2,3,0.0050340207213367604
6095,C-type lectin receptors (CLRs),Innate Immune System,0.00025147889807024325,1,2,3,0.017284106877888474
6096,Threonine catabolism,Metabolism of amino acids and derivatives,3.2823456791530925e-05,0,2,3,0.0022559512533258733
6097,Threonine catabolism,Metabolism of amino acids and derivatives,3.890366504603505e-05,1,2,3,0.0026738430530637383
6098,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.00026949297623467353,0,2,3,0.01852221176338738
6099,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.00024569628624076037,1,2,3,0.016886668835726357
6100,Cell-extracellular matrix interactions,Cell junction organization,3.407942986179044e-05,0,2,3,0.0023422740937259915
6101,Cell-extracellular matrix interactions,Cell junction organization,4.699180484527774e-05,1,2,3,0.0032297396861655984
6102,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0003614730532684764,0,2,3,0.024843988637264895
6103,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,4.8300906010164795e-05,1,2,3,0.003319714012526596
6104,Kinesins,Factors involved in megakaryocyte development and platelet production,4.6067756170371556e-05,0,2,3,0.0031662299595841313
6105,Kinesins,Factors involved in megakaryocyte development and platelet production,1.6445322424648472e-05,1,2,3,0.001130284539220326
6106,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00015933078565684425,0,2,3,0.010950780957619822
6107,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00018875905599425604,1,2,3,0.012973381556104814
6108,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0006269072678912892,0,2,3,0.04308724232492667
6109,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),1.4191585005042831e-05,1,2,3,0.0009753855050107842
6110,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,9.459043302041465e-07,0,2,3,6.50118624861293e-05
6111,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,3.4438727068292913e-07,1,2,3,2.366968536741965e-05
6112,Phospholipid metabolism,Metabolism of lipids,3.044396217880377e-05,0,2,3,0.002092408946128996
6113,Phospholipid metabolism,Metabolism of lipids,6.2585452384977135e-06,1,2,3,0.0004301488738513536
6114,PKMTs methylate histone lysines,Chromatin modifying enzymes,2.8976753646745196e-07,0,2,3,1.9915679241790473e-05
6115,PKMTs methylate histone lysines,Chromatin modifying enzymes,7.082156236124481e-07,1,2,3,4.867555339648761e-05
6116,Syndecan interactions,Non-integrin membrane-ECM interactions,4.388856969509859e-05,0,2,3,0.003016454800576769
6117,Syndecan interactions,Non-integrin membrane-ECM interactions,7.900739533305093e-05,1,2,3,0.005430166409821816
6118,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.00010392310496991754,0,2,3,0.007142619389402434
6119,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.000354282539086539,1,2,3,0.024349785677965845
6120,Integrin cell surface interactions,Integrin cell surface interactions,9.100904415612579e-05,0,2,3,0.006255037930099309
6121,Integrin cell surface interactions,Integrin cell surface interactions,0.00012231197963266308,1,2,3,0.00840648398191473
6122,Regulation of Apoptosis,Apoptosis,4.068024746308549e-06,0,2,3,0.00027959472956435677
6123,Regulation of Apoptosis,Apoptosis,1.678952588377321e-05,1,2,3,0.0011539415912469701
6124,M Phase,"Cell Cycle, Mitotic",8.580928851866877e-05,0,2,3,0.005897659506436872
6125,M Phase,"Cell Cycle, Mitotic",0.00018576599486412048,1,2,3,0.012767668914359157
6126,Laminin interactions,Laminin interactions,2.8281813811526905e-05,0,2,3,0.001943804813724109
6127,Laminin interactions,Laminin interactions,2.4479054458155674e-05,1,2,3,0.0016824417347583369
6128,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,5.362181134202687e-05,0,2,3,0.003685419036481896
6129,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0001771410227643473,1,2,3,0.012174875877904681
6130,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,6.489443031196152e-05,0,2,3,0.004460184444494944
6131,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.0002674821785345317,1,2,3,0.01838400993959318
6132,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.00018266336610204067,0,2,3,0.012554425705733282
6133,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.00040065056627241655,1,2,3,0.027536653219327863
6134,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",7.736821145226021e-05,0,2,3,0.0053175055479940175
6135,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.00016783857088319628,1,2,3,0.01153551975787222
6136,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,1.4256353509195546e-05,0,2,3,0.0009798370345692755
6137,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,5.5418128790664796e-05,1,2,3,0.0038088796648174062
6138,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,4.0457986262924634e-07,0,2,3,2.780671316752826e-05
6139,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,4.791378960143342e-07,1,2,3,3.293107559921461e-05
6140,Metabolism of steroids,Metabolism of lipids,0.00022694053918747222,0,2,3,0.015597589158937232
6141,Metabolism of steroids,Metabolism of lipids,4.617374843505578e-05,1,2,3,0.003173514792009792
6142,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.00013152452620753937,0,2,3,0.009039660923755834
6143,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.00028847137886037986,1,2,3,0.019826594524213235
6144,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.00018501066513977672,0,2,3,0.012715755215898633
6145,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,5.7648737657210096e-05,1,2,3,0.003962189077050339
6146,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,3.905954426025734e-05,0,2,3,0.0026845566080352843
6147,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,4.939163710819715e-05,1,2,3,0.003394679797004314
6148,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,4.695822031929968e-07,0,2,3,3.227431426741438e-05
6149,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,3.697526222743802e-06,1,2,3,0.00025413042170976984
6150,G2/M Checkpoints,Cell Cycle Checkpoints,3.128072728508227e-06,0,2,3,0.0002149919686153654
6151,G2/M Checkpoints,Cell Cycle Checkpoints,9.152854215153354e-08,1,2,3,6.290742949265444e-06
6152,Glycogen metabolism,Metabolism of carbohydrates,0.00010946618344237068,0,2,3,0.007523594339927475
6153,Glycogen metabolism,Metabolism of carbohydrates,9.94342692581367e-05,1,2,3,0.006834102385410983
6154,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,1.1250176808731377e-05,0,2,3,0.0007732229616456395
6155,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,1.522422124641158e-05,1,2,3,0.0010463584387191748
6156,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.00011506239991174806,0,2,3,0.00790822145699676
6157,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),2.305065971378916e-06,1,2,3,0.0001584268378604418
6158,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.000176495330486162,0,2,3,0.012130497544644825
6159,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0006056054908231783,1,2,3,0.04162317438777775
6160,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.0001771708869589209,0,2,3,0.012176928439510418
6161,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,5.529010398595577e-05,1,2,3,0.003800080539226385
6162,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0005951949546963383,0,2,3,0.04090765980403657
6163,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.002036873958408029,1,2,3,0.13999404110669555
6164,Signaling by MET,Signaling by Receptor Tyrosine Kinases,5.570143405586366e-05,0,2,3,0.0038283511931259083
6165,Signaling by MET,Signaling by Receptor Tyrosine Kinases,7.517182794934777e-05,1,2,3,0.005166548439860969
6166,Neurotransmitter release cycle,Transmission across Chemical Synapses,2.3641626262014404e-05,0,2,3,0.0016248854206670443
6167,Neurotransmitter release cycle,Transmission across Chemical Synapses,8.591163055031668e-06,1,2,3,0.0005904693458894421
6168,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.00018573476105478124,0,2,3,0.012765522219336372
6169,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.00017014732404582015,1,2,3,0.011694200015832901
6170,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0006067528499447759,0,2,3,0.04170203220780635
6171,Generic Transcription Pathway,RNA Polymerase II Transcription,0.002790380137176832,1,2,3,0.19178240755385387
6172,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",8.894823704559566e-06,0,2,3,0.0006113398967043387
6173,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",1.9190478980712685e-05,1,2,3,0.0013189587368394717
6174,Striated Muscle Contraction,Striated Muscle Contraction,0.00010084251939103529,0,2,3,0.006930891205445582
6175,Striated Muscle Contraction,Striated Muscle Contraction,0.00027979470425593095,1,2,3,0.01923024798238106
6176,Nucleosome assembly,Chromosome Maintenance,9.950878976375636e-05,0,2,3,0.006839224168564991
6177,Nucleosome assembly,Chromosome Maintenance,0.0003812027946781564,1,2,3,0.026200010799819307
6178,Fibronectin matrix formation,Fibronectin matrix formation,4.192637877786223e-05,0,2,3,0.0028815937136681485
6179,Fibronectin matrix formation,Fibronectin matrix formation,1.6253008013033466e-05,1,2,3,0.0011170667986066243
6180,Rap1 signalling,Adaptive Immune System,3.594813333989888e-05,0,2,3,0.0024707098029904976
6181,Rap1 signalling,Adaptive Immune System,4.2019749552942296e-05,1,2,3,0.0028880110730097833
6182,Lactose synthesis,Metabolism of carbohydrates,1.8919883935792227e-05,0,2,3,0.0013003607800609039
6183,Lactose synthesis,Metabolism of carbohydrates,1.729143937569876e-05,1,2,3,0.0011884380301309685
6184,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,1.3142483344523004e-05,0,2,3,0.0009032809055181854
6185,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,7.000375452080126e-06,1,2,3,0.00048113475296564755
6186,Physiological factors,Cardiac conduction,8.705448855493492e-05,0,2,3,0.005983241917829352
6187,Physiological factors,Cardiac conduction,0.00017327862259279464,1,2,3,0.01190941369446675
6188,Homology Directed Repair,DNA Double-Strand Break Repair,2.0496170375085298e-05,0,2,3,0.001408698710185354
6189,Homology Directed Repair,DNA Double-Strand Break Repair,0.00011319051749717981,1,2,3,0.007779567259907029
6190,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.00015106835804212568,0,2,3,0.01038290554914828
6191,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.00017700108746978953,1,2,3,0.012165258146135987
6192,Leishmania infection,Infectious disease,9.013687314665435e-05,0,2,3,0.006195093747668187
6193,Leishmania infection,Infectious disease,0.00016764665697008535,1,2,3,0.011522329543460526
6194,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,3.366305451307078e-05,0,2,3,0.0023136566785718245
6195,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,4.27185209215343e-05,1,2,3,0.0029360375241777818
6196,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,6.0112707078536086e-05,0,2,3,0.0041315373251492775
6197,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,9.082494995817339e-05,1,2,3,0.006242385163535493
6198,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,2.828711759380885e-05,0,2,3,0.001944169341883417
6199,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,3.8092198573288665e-05,1,2,3,0.002618071084320444
6200,Ketone body metabolism,Metabolism of lipids,0.00010503895154109385,0,2,3,0.007219311356575559
6201,Ketone body metabolism,Metabolism of lipids,2.190398393436849e-05,1,2,3,0.0015054575245809644
6202,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",6.952135261017617e-05,0,2,3,0.0047781921188235045
6203,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00019938567664969458,1,2,3,0.01370374759702835
6204,Collagen degradation,Degradation of the extracellular matrix,4.258917503854861e-05,0,2,3,0.0029271476010753073
6205,Collagen degradation,Degradation of the extracellular matrix,0.00012845771148212761,1,2,3,0.00882887920848884
6206,Protein methylation,Post-translational protein modification,4.079717174196039e-05,0,2,3,0.0028039834837619414
6207,Protein methylation,Post-translational protein modification,0.00013471455965516143,1,2,3,0.009258911443285858
6208,Telomere Maintenance,Chromosome Maintenance,1.3614535343005886e-05,0,2,3,0.0009357249684447694
6209,Telomere Maintenance,Chromosome Maintenance,5.2233625704474926e-05,1,2,3,0.0035900092461976403
6210,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0002769104594716538,0,2,3,0.019032014271735828
6211,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.00022209013150247214,1,2,3,0.015264221367555165
6212,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0007695387751939541,0,2,3,0.052890284390448176
6213,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0008846871158330309,1,2,3,0.06080441254072103
6214,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,9.672243953529115e-05,0,2,3,0.006647718736031365
6215,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,4.133055440901407e-05,1,2,3,0.0028406427943240306
6216,Cristae formation,Mitochondrial biogenesis,2.382336391825715e-06,0,2,3,0.00016373762224732426
6217,Cristae formation,Mitochondrial biogenesis,2.5096351929661358e-06,1,2,3,0.00017248684972216203
6218,TCF dependent signaling in response to WNT,Signaling by WNT,5.012433300831377e-05,0,2,3,0.0034450378761265994
6219,TCF dependent signaling in response to WNT,Signaling by WNT,0.0001625070027026817,1,2,3,0.0111690818779312
6220,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,3.182886062434586e-05,0,2,3,0.0021875928082003377
6221,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,6.98050685867497e-05,1,2,3,0.004797691875263075
6222,Signaling by Activin,Signaling by TGFB family members,4.7842309489857455e-06,0,2,3,0.00032881947425932365
6223,Signaling by Activin,Signaling by TGFB family members,5.503392759436132e-06,1,2,3,0.00037824735743244097
6224,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,2.9479309283863938e-05,0,2,3,0.002026108497605687
6225,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,7.543097648353742e-06,1,2,3,0.0005184359679676927
6226,Aspirin ADME,Aspirin ADME,0.00011150854595988039,0,2,3,0.007663965608876534
6227,Aspirin ADME,Aspirin ADME,0.0002538345819893348,1,2,3,0.0174460126796895
6228,S Phase,"Cell Cycle, Mitotic",3.6907761390695e-05,0,2,3,0.0025366648947308277
6229,S Phase,"Cell Cycle, Mitotic",7.943940580114912e-05,1,2,3,0.0054598584243815826
6230,Diseases of glycosylation,Diseases of metabolism,0.0019260593680675423,0,2,3,0.13237777096326822
6231,Diseases of glycosylation,Diseases of metabolism,0.0005999154268858067,1,2,3,0.041232097148334465
6232,Alanine metabolism,Metabolism of amino acids and derivatives,0.00012047233056752152,0,2,3,0.008280045178087806
6233,Alanine metabolism,Metabolism of amino acids and derivatives,0.000142191675706438,1,2,3,0.009772812506000636
6234,Galactose catabolism,Metabolism of carbohydrates,8.254737144506444e-06,0,2,3,0.0005673468436094109
6235,Galactose catabolism,Metabolism of carbohydrates,7.206404336961134e-06,1,2,3,0.0004952950872662252
6236,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.00014269765302525614,0,2,3,0.009807588251096344
6237,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.00038237640185839777,1,2,3,0.02628067264497453
6238,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,3.657894824521193e-05,0,2,3,0.002514065616648272
6239,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.00012536892140153113,1,2,3,0.008616587130361954
6240,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,3.167072751691614e-05,0,2,3,0.0021767243434873086
6241,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,2.7510899463531763e-06,1,2,3,0.0001890819986421725
6242,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0002943066815094213,0,2,3,0.020227653998486445
6243,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0005791377489696443,1,2,3,0.03980405046714938
6244,ER to Golgi Anterograde Transport,Membrane Trafficking,0.0007854298608419625,0,2,3,0.05398247631928802
6245,ER to Golgi Anterograde Transport,Membrane Trafficking,0.0017242771325631304,1,2,3,0.11850930823625504
6246,Diseases of carbohydrate metabolism,Diseases of metabolism,0.00035462884626169197,0,2,3,0.02437358731807901
6247,Diseases of carbohydrate metabolism,Diseases of metabolism,0.00011078732247850127,1,2,3,0.007614396027370265
6248,Hedgehog 'on' state,Signaling by Hedgehog,0.00011932934034741939,0,2,3,0.008201487632002536
6249,Hedgehog 'on' state,Signaling by Hedgehog,1.2138723924728909e-05,1,2,3,0.0008342926714176745
6250,Eukaryotic Translation Elongation,Translation,8.021739788627049e-05,0,2,3,0.0055133297034931725
6251,Eukaryotic Translation Elongation,Translation,4.0499208627834795e-05,1,2,3,0.0027835045236991505
6252,Cell-cell junction organization,Cell junction organization,9.794887304056819e-05,0,2,3,0.006732011326568765
6253,Cell-cell junction organization,Cell junction organization,0.00013716863837379177,1,2,3,0.009427579904874672
6254,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,4.833546622624123e-07,0,2,3,3.322089330984613e-05
6255,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,4.2231995908255766e-08,1,2,3,2.902598733118965e-06
6256,O-linked glycosylation,Post-translational protein modification,3.555912709062625e-05,0,2,3,0.0024439734619289247
6257,O-linked glycosylation,Post-translational protein modification,0.00011729022508191561,1,2,3,0.00806133954619592
6258,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.00013380525349348686,0,2,3,0.009196414967423632
6259,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,6.68856338885456e-05,1,2,3,0.004597039567121176
6260,Phase II - Conjugation of compounds,Biological oxidations,4.2314966866783625e-05,0,2,3,0.0029083013146316127
6261,Phase II - Conjugation of compounds,Biological oxidations,0.00020841809515876762,1,2,3,0.01432454436397231
6262,SUMOylation,Post-translational protein modification,5.823644740875753e-05,0,2,3,0.004002582279966656
6263,SUMOylation,Post-translational protein modification,0.00019214097174802833,1,2,3,0.013205820117704874
6264,ESR-mediated signaling,Signaling by Nuclear Receptors,2.0108447920649598e-05,0,2,3,0.0013820506041500237
6265,ESR-mediated signaling,Signaling by Nuclear Receptors,7.642862263195791e-05,1,2,3,0.005252927749554492
6266,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.0003455466522161818,0,2,3,0.02374936948599485
6267,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.000679105139220917,1,2,3,0.04667479417831341
6268,Atorvastatin ADME,Atorvastatin ADME,8.3474562546806e-07,0,2,3,5.7371941411998e-05
6269,Atorvastatin ADME,Atorvastatin ADME,4.938977172556931e-06,1,2,3,0.000339455158953659
6270,Triglyceride metabolism,Metabolism of lipids,3.589686096389128e-05,0,2,3,0.0024671858602915322
6271,Triglyceride metabolism,Metabolism of lipids,7.482330212102161e-06,1,2,3,0.0005142594312048577
6272,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0003127214114721457,0,2,3,0.021493295621881348
6273,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",2.8014374956562198e-05,1,2,3,0.0019254237814069605
6274,Rab regulation of trafficking,Membrane Trafficking,6.360771823643416e-05,0,2,3,0.004371748916881519
6275,Rab regulation of trafficking,Membrane Trafficking,0.00013932904329323469,1,2,3,0.009576064210371897
6276,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,4.6789869927082974e-05,0,2,3,0.003215860729580219
6277,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,1.2913766411218373e-06,1,2,3,8.875612250584915e-05
6278,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.00034997555428213525,0,2,3,0.02405376725951404
6279,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0002444511524833435,1,2,3,0.016801090979669232
6280,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,3.9809647605037345e-06,0,2,3,0.0002736111098213692
6281,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.00010158574329019073,1,2,3,0.0069819728723599
6282,Metallothioneins bind metals,Response to metal ions,8.28487773541799e-05,0,2,3,0.00569418401893925
6283,Metallothioneins bind metals,Response to metal ions,4.7819883089364456e-05,1,2,3,0.003286653379457078
6284,Cellular response to hypoxia,Cellular responses to stress,0.0005224265110642628,0,2,3,0.03590629560717627
6285,Cellular response to hypoxia,Cellular responses to stress,0.00018566735345330431,1,2,3,0.01276088930501533
6286,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.00070059484635652,0,2,3,0.048151778520763244
6287,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,4.88964367301311e-06,1,2,3,0.00033606447494271863
6288,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,5.252676596325363e-05,0,2,3,0.003610156732137108
6289,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,3.589574607747008e-05,1,2,3,0.0024671092343153227
6290,Switching of origins to a post-replicative state,Synthesis of DNA,0.0006079683602847997,0,2,3,0.04178557405083718
6291,Switching of origins to a post-replicative state,Synthesis of DNA,2.798926473158787e-05,1,2,3,0.0019236979594174633
6292,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,4.391824191790487e-06,0,2,3,0.00030184941679917837
6293,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,5.169588079439647e-06,1,2,3,0.0003553050119327916
6294,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0005663800393495659,0,2,3,0.03892721500189731
6295,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0014314447607322676,1,2,3,0.09838298332045048
6296,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0010374410495493749,0,2,3,0.0713031674526887
6297,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",7.521588509368097e-05,1,2,3,0.005169576480771092
6298,Signaling by Interleukins,Cytokine Signaling in Immune system,1.637074777758397e-05,0,2,3,0.00112515903493295
6299,Signaling by Interleukins,Cytokine Signaling in Immune system,7.177363942519104e-05,1,2,3,0.004932991453197486
6300,Type I hemidesmosome assembly,Cell junction organization,1.2421455899522218e-05,0,2,3,0.0008537247975627439
6301,Type I hemidesmosome assembly,Cell junction organization,1.727464695513245e-05,1,2,3,0.0011872838895886258
6302,MAPK6/MAPK4 signaling,MAPK family signaling cascades,9.014885962720922e-06,0,2,3,0.000619591757667567
6303,MAPK6/MAPK4 signaling,MAPK family signaling cascades,3.1461581347961845e-05,1,2,3,0.0021623497587207677
6304,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.00020964126141628412,0,2,3,0.014408612397062056
6305,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",1.8719462419080557e-05,1,2,3,0.0012865858393320585
6306,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,2.6870539951985313e-05,0,2,3,0.0018468081734116736
6307,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,9.257092458910431e-05,1,2,3,0.006362385737574364
6308,Molecules associated with elastic fibres,Elastic fibre formation,6.344035327648793e-05,0,2,3,0.004360245948332181
6309,Molecules associated with elastic fibres,Elastic fibre formation,1.2362410340807975e-06,1,2,3,8.49666605184326e-05
6310,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,8.907455960148561e-07,0,2,3,6.122081097328848e-05
6311,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,6.192381916294881e-07,1,2,3,4.2560147865785906e-05
6312,Intrinsic Pathway for Apoptosis,Apoptosis,5.650818548481415e-05,0,2,3,0.0038837990976175792
6313,Intrinsic Pathway for Apoptosis,Apoptosis,0.00023305313824572562,1,2,3,0.01601770717374984
6314,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,6.180962621575363e-05,0,2,3,0.004248166322476163
6315,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,2.0297386533618903e-05,1,2,3,0.0013950363266300439
6316,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,2.027443430238767e-05,0,2,3,0.0013934588232262558
6317,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,6.671282076217376e-05,1,2,3,0.004585162146912031
6318,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,1.240339756885835e-06,0,2,3,8.524836512096078e-05
6319,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,2.2314135043563907e-05,1,2,3,0.0015336471486878665
6320,Gap junction trafficking and regulation,Membrane Trafficking,2.0023025793540604e-05,0,2,3,0.0013761795541891
6321,Gap junction trafficking and regulation,Membrane Trafficking,4.393265468635904e-05,1,2,3,0.0030194847554020185
6322,Complement cascade,Innate Immune System,0.0003091463566694434,0,2,3,0.021247582642468833
6323,Complement cascade,Innate Immune System,0.001057374989937927,1,2,3,0.07267322418037865
6324,Retinoid metabolism and transport,Visual phototransduction,4.806671939503144e-05,0,2,3,0.003303618401656672
6325,Retinoid metabolism and transport,Visual phototransduction,2.0504922706619385e-05,1,2,3,0.0014093002566165922
6326,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,9.95372259327675e-06,0,2,3,0.0006841178582188391
6327,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,1.1796174540964776e-05,1,2,3,0.0008107493037420283
6328,Neutrophil degranulation,Innate Immune System,0.00010016683101817245,0,2,3,0.0068844512451056656
6329,Neutrophil degranulation,Innate Immune System,0.00034361732030812177,1,2,3,0.023616766793849622
6330,Transferrin endocytosis and recycling,Iron uptake and transport,8.952853633198562e-05,0,2,3,0.0061532828498029055
6331,Transferrin endocytosis and recycling,Iron uptake and transport,0.0001918600498574822,1,2,3,0.013186512398378133
6332,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0006110850529551171,0,2,3,0.041999783869763024
6333,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),1.3033580654232675e-05,1,2,3,0.0008957960399779289
6334,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,2.123416721832687e-05,0,2,3,0.001459421122332113
6335,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,1.9110421127258406e-05,1,2,3,0.001313456372600817
6336,Heme degradation,Metabolism of porphyrins,0.0004614810899682031,0,2,3,0.03171752597272375
6337,Heme degradation,Metabolism of porphyrins,7.77166846114077e-05,1,2,3,0.0053414560558616726
6338,DNA Double Strand Break Response,DNA Double-Strand Break Repair,6.328451389457004e-06,0,2,3,0.0004349535131028931
6339,DNA Double Strand Break Response,DNA Double-Strand Break Repair,3.494105721911085e-05,1,2,3,0.0024014936125290316
6340,Antimicrobial peptides,Innate Immune System,8.782823942433305e-05,0,2,3,0.0060364216988215555
6341,Antimicrobial peptides,Innate Immune System,0.0003010463983628142,1,2,3,0.020690873725130118
6342,Signaling by BMP,Signaling by TGFB family members,0.00027119300452588117,0,2,3,0.018639054452400834
6343,Signaling by BMP,Signaling by TGFB family members,0.00031253274723409965,1,2,3,0.021480328757148576
6344,Sphingolipid metabolism,Metabolism of lipids,1.303155004464357e-05,0,2,3,0.0008956564764859831
6345,Sphingolipid metabolism,Metabolism of lipids,2.6750422001051507e-06,1,2,3,0.00018385524846925629
6346,Deubiquitination,Post-translational protein modification,0.00020084068164878726,0,2,3,0.013803749871991221
6347,Deubiquitination,Post-translational protein modification,0.0006600319283796605,1,2,3,0.0453638952630784
6348,RMTs methylate histone arginines,Chromatin modifying enzymes,3.335146834038353e-05,0,2,3,0.002292241407741051
6349,RMTs methylate histone arginines,Chromatin modifying enzymes,8.149835471135356e-05,1,2,3,0.00560136967360833
6350,HIV Infection,Infectious disease,0.0001242108213505693,0,2,3,0.008536991087872054
6351,HIV Infection,Infectious disease,0.0002312609840142789,1,2,3,0.01589453268270633
6352,Infection with Mycobacterium tuberculosis,Infectious disease,8.736734813418005e-05,0,2,3,0.006004744709701509
6353,Infection with Mycobacterium tuberculosis,Infectious disease,0.00016259019114351695,1,2,3,0.011174799406970158
6354,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
6355,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
6356,Meiotic recombination,Meiosis,9.914111996096586e-06,0,2,3,0.0006813954278264183
6357,Meiotic recombination,Meiosis,3.0318247280576294e-06,1,2,3,0.00020837685800633723
6358,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,1.4285316849411294e-05,0,2,3,0.0009818276805903575
6359,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,0.00010904926211189151,1,2,3,0.007494939399529014
6360,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.0006060156326850747,0,2,3,0.04165136337631919
6361,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.0011963088051517177,1,2,3,0.08222212442423618
6362,Abacavir metabolism,Abacavir ADME,7.528962298127383e-05,0,2,3,0.005174644474705712
6363,Abacavir metabolism,Abacavir ADME,0.0006506499253168494,1,2,3,0.04471907160228357
6364,PECAM1 interactions,Cell surface interactions at the vascular wall,1.80509882762072e-05,0,2,3,0.0012406417119353306
6365,PECAM1 interactions,Cell surface interactions at the vascular wall,1.5283061315463312e-05,1,2,3,0.0010504025078239647
6366,ECM proteoglycans,ECM proteoglycans,0.00020726300015584697,0,2,3,0.014245154857982752
6367,ECM proteoglycans,ECM proteoglycans,8.760841049333491e-05,1,2,3,0.006021312889424902
6368,Regulation of insulin secretion,Integration of energy metabolism,0.0001722043189193538,0,2,3,0.011835576964412871
6369,Regulation of insulin secretion,Integration of energy metabolism,0.0002604459683046804,1,2,3,0.017900412267735748
6370,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,2.1153617805059998e-05,0,2,3,0.0014538849732613987
6371,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,2.48876280524856e-05,1,2,3,0.0017105229365055664
6372,Protein ubiquitination,Post-translational protein modification,1.4290137353547031e-05,0,2,3,0.000982158993115292
6373,Protein ubiquitination,Post-translational protein modification,4.7195215689858685e-05,1,2,3,0.0032437200829497316
6374,DNA methylation,Epigenetic regulation of gene expression,0.00012428862955026756,0,2,3,0.008542338833746084
6375,DNA methylation,Epigenetic regulation of gene expression,0.00024452984460570726,1,2,3,0.016806499477415245
6376,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,2.3599922038039468e-05,0,2,3,0.0016220190956196007
6377,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,2.463190479008014e-05,1,2,3,0.001692947115104664
6378,HDMs demethylate histones,Chromatin modifying enzymes,5.377847674718779e-05,0,2,3,0.0036961866262385235
6379,HDMs demethylate histones,Chromatin modifying enzymes,0.00013143435338639707,1,2,3,0.009033463359307825
6380,Unfolded Protein Response (UPR),Cellular responses to stress,0.00028894247368025115,0,2,3,0.019858972800397667
6381,Unfolded Protein Response (UPR),Cellular responses to stress,0.00010191675458171801,1,2,3,0.007004723228689786
6382,Pentose phosphate pathway,Metabolism of carbohydrates,0.0002095216315616097,0,2,3,0.014400390255125513
6383,Pentose phosphate pathway,Metabolism of carbohydrates,0.00019127337862134716,1,2,3,0.013146190572470068
6384,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,7.694397017846964e-06,0,2,3,0.0005288347508991638
6385,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,2.347477256620467e-05,1,2,3,0.0016134175912249867
6386,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,7.165293685700697e-05,0,2,3,0.004924695583822608
6387,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0003959086305830571,1,2,3,0.027210740691907494
6388,Nephrin family interactions,Nephrin family interactions,1.334625497565405e-05,0,2,3,0.0009172860991076965
6389,Nephrin family interactions,Nephrin family interactions,2.036989839288609e-06,1,2,3,0.00014000200558220591
6390,Meiotic synapsis,Meiosis,0.0005861705185937349,0,2,3,0.04028741166668986
6391,Meiotic synapsis,Meiosis,0.00017937995977230882,1,2,3,0.012328757682045785
6392,Selective autophagy,Macroautophagy,0.00012660883681237417,0,2,3,0.008701806330243155
6393,Selective autophagy,Macroautophagy,0.0001810396087778326,1,2,3,0.012442825108821458
6394,Smooth Muscle Contraction,Smooth Muscle Contraction,2.1438166271636017e-05,0,2,3,0.001473441946613753
6395,Smooth Muscle Contraction,Smooth Muscle Contraction,0.00011355937804314948,1,2,3,0.007804918989807624
6396,Tryptophan catabolism,Metabolism of amino acids and derivatives,3.305385069112615e-05,0,2,3,0.0022717861914267434
6397,Tryptophan catabolism,Metabolism of amino acids and derivatives,3.884456150975672e-05,1,2,3,0.0026697808758960515
6398,p75 NTR receptor-mediated signalling,Death Receptor Signalling,9.511091047782517e-07,0,2,3,6.536958586055343e-05
6399,p75 NTR receptor-mediated signalling,Death Receptor Signalling,3.377377476778383e-05,1,2,3,0.002321266465041752
6400,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0003061310428418364,0,2,3,0.021040340576169592
6401,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0003606223874127868,1,2,3,0.024785522500821895
6402,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,9.75720676286715e-05,0,2,3,0.0067061135472267774
6403,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.000743852090770095,1,2,3,0.05112484242960197
6404,Beta-catenin independent WNT signaling,Signaling by WNT,4.7965055620932914e-05,0,2,3,0.0032966310657385803
6405,Beta-catenin independent WNT signaling,Signaling by WNT,0.00015426318081555678,1,2,3,0.010602485238321527
6406,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,4.2490711556506265e-06,0,2,3,0.000292038022074937
6407,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,5.732480983409589e-06,1,2,3,0.00039399255664401405
6408,Stimuli-sensing channels,Ion channel transport,3.0109372147968213e-05,0,2,3,0.0020694126235841818
6409,Stimuli-sensing channels,Ion channel transport,6.914145048683495e-05,1,2,3,0.004752081502969238
6410,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0001543754700565463,0,2,3,0.01061020286098249
6411,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.00020795466434027346,1,2,3,0.014292692833450958
6412,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,7.918844784146349e-07,0,2,3,5.442610121520595e-05
6413,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,2.6852921722565103e-06,1,2,3,0.0001845597275150886
6414,Toll-like Receptor Cascades,Innate Immune System,0.0003409764804295781,0,2,3,0.023435262265802146
6415,Toll-like Receptor Cascades,Innate Immune System,0.0011705654291899964,1,2,3,0.08045278606251101
6416,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.00031201693842182796,0,2,3,0.02144487729498506
6417,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,8.6141638407499e-06,1,2,3,0.0005920501864358258
6418,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0008287532242403695,0,2,3,0.056960084576019414
6419,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0005418101619550283,1,2,3,0.037238531020368226
6420,RIPK1-mediated regulated necrosis,Regulated Necrosis,1.5249424928134167e-06,0,2,3,0.00010480906839769371
6421,RIPK1-mediated regulated necrosis,Regulated Necrosis,1.5020239349959305e-05,1,2,3,0.0010323387936257294
6422,Apoptotic execution phase,Apoptosis,8.712095411942985e-06,0,2,3,0.0005987810086090168
6423,Apoptotic execution phase,Apoptosis,3.5920703412367045e-05,1,2,3,0.002468824548192775
6424,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,6.312056561240715e-05,0,2,3,0.004338266990230263
6425,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.00016925807803400042,1,2,3,0.01163308227105602
6426,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.002412082843155187,0,2,3,0.16578209137758462
6427,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0007041528959033884,1,2,3,0.048396322731497445
6428,Post-translational protein phosphorylation,Post-translational protein modification,0.0003431994685280617,0,2,3,0.023588047903791272
6429,Post-translational protein phosphorylation,Post-translational protein modification,0.0011367064353041965,1,2,3,0.07812566250029278
6430,Nucleotide salvage,Metabolism of nucleotides,2.016785051383351e-05,0,2,3,0.0013861333354538952
6431,Nucleotide salvage,Metabolism of nucleotides,2.057850659110756e-05,1,2,3,0.0014143576659409664
6432,Surfactant metabolism,Surfactant metabolism,5.153806798751312e-05,0,2,3,0.003542203668823312
6433,Surfactant metabolism,Surfactant metabolism,8.449752369627733e-06,1,2,3,0.0005807502107295832
6434,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0002835757946674126,0,2,3,0.019490121758226675
6435,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0006217702690059115,1,2,3,0.042734177163404996
6436,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,1.1125022478425367e-05,0,2,3,0.000764621123329029
6437,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,1.3727744666180704e-05,1,2,3,0.0009435058282160749
6438,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.00011133617077151025,0,2,3,0.0076521182880804435
6439,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.00016814114618691884,1,2,3,0.011556315713032997
6440,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,6.77557273587033e-05,0,2,3,0.00465684096058743
6441,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0002242238309185993,1,2,3,0.015410870207822187
6442,Basigin interactions,Cell surface interactions at the vascular wall,0.0002647098526122228,0,2,3,0.018193468395514428
6443,Basigin interactions,Cell surface interactions at the vascular wall,0.00022574826891222014,1,2,3,0.01551564460206618
6444,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,4.870226457846519e-05,0,2,3,0.003347299326618925
6445,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,6.231514396923618e-05,1,2,3,0.004282910481715408
6446,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0003767615732386975,0,2,3,0.025894766317610157
6447,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,7.701294098886139e-05,1,2,3,0.005293087862426511
6448,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.000519132620547449,0,2,3,0.035679907006885954
6449,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",4.674545496388781e-05,1,2,3,0.003212808095833477
6450,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5.541705397010737e-06,0,2,3,0.0003808805792561993
6451,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002938278240610901,1,2,3,0.020194742198014357
6452,Late endosomal microautophagy,Late endosomal microautophagy,0.00034020210695321967,0,2,3,0.02338203969312711
6453,Late endosomal microautophagy,Late endosomal microautophagy,0.0002644532709781244,1,2,3,0.018175833578356042
6454,Phase I - Functionalization of compounds,Biological oxidations,1.8946419180796334e-06,0,2,3,0.00013021845434629285
6455,Phase I - Functionalization of compounds,Biological oxidations,9.164858238681504e-06,1,2,3,0.0006298993296599449
6456,GPCR downstream signalling,Signaling by GPCR,0.0005374055920555786,0,2,3,0.036935805592996765
6457,GPCR downstream signalling,Signaling by GPCR,0.00031465351038423945,1,2,3,0.021626088489798054
6458,Nucleotide catabolism,Metabolism of nucleotides,7.577847834096791e-05,0,2,3,0.005208243430123518
6459,Nucleotide catabolism,Metabolism of nucleotides,7.73221031637971e-05,1,2,3,0.005314336532256044
6460,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,6.914502146312119e-06,0,2,3,0.0004752326935632827
6461,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,1.2918616093099496e-05,1,2,3,0.0008878945429654823
6462,Interferon Signaling,Cytokine Signaling in Immune system,7.107807226753285e-06,0,2,3,0.0004885185226965514
6463,Interferon Signaling,Cytokine Signaling in Immune system,3.1557500540000476e-05,1,2,3,0.0021689422703770477
6464,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,3.887104946724907e-05,0,2,3,0.002671601389234499
6465,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,5.173308079116248e-06,1,2,3,0.00035556068695160827
6466,Urea cycle,Metabolism of amino acids and derivatives,7.873463733529502e-05,0,2,3,0.0054114197936198675
6467,Urea cycle,Metabolism of amino acids and derivatives,9.270021833974982e-05,1,2,3,0.006371272077628933
6468,Fatty acid metabolism,Metabolism of lipids,0.00020752258204373474,0,2,3,0.014262995882133265
6469,Fatty acid metabolism,Metabolism of lipids,4.232504463968746e-05,1,2,3,0.0029089939584490366
6470,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.00029580659445181375,0,2,3,0.020330742789644574
6471,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0005820367060841633,1,2,3,0.04000329535404151
6472,Metabolism of polyamines,Metabolism of amino acids and derivatives,2.7625832159239812e-05,0,2,3,0.0018987192933282904
6473,Metabolism of polyamines,Metabolism of amino acids and derivatives,3.2512324349505285e-05,1,2,3,0.0022345671673352965
6474,Fructose metabolism,Metabolism of carbohydrates,7.406967078108218e-06,0,2,3,0.0005090797343292969
6475,Fructose metabolism,Metabolism of carbohydrates,6.651803307692998e-06,1,2,3,0.0004571774418573451
6476,Influenza Infection,Infectious disease,0.00028073554417668153,0,2,3,0.01929491176876641
6477,Influenza Infection,Infectious disease,0.0005219976048908675,1,2,3,0.03587681695032499
6478,Chaperonin-mediated protein folding,Protein folding,2.5732714883420338e-05,0,2,3,0.00176860562741545
6479,Chaperonin-mediated protein folding,Protein folding,6.895766201807297e-05,1,2,3,0.004739449749126741
6480,Pyroptosis,Regulated Necrosis,1.4727860648720704e-06,0,2,3,0.00010122436494215639
6481,Pyroptosis,Regulated Necrosis,1.4494231264428623e-05,1,2,3,0.0009961863369436332
6482,Formation of the cornified envelope,Keratinization,3.337567600234312e-05,0,2,3,0.0022939051967101613
6483,Formation of the cornified envelope,Keratinization,3.0586138265531526e-05,1,2,3,0.002102180687206834
6484,Intracellular oxygen transport,Intracellular oxygen transport,9.065938905819005e-06,0,2,3,0.0006231006187756333
6485,Intracellular oxygen transport,Intracellular oxygen transport,3.691497081005769e-05,1,2,3,0.002537160397040359
6486,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,9.952925044961711e-06,0,2,3,0.0006840630428429838
6487,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,6.693212371043285e-06,1,2,3,0.00046002348055940634
6488,Paracetamol ADME,Paracetamol ADME,0.0004043558347724416,0,2,3,0.027791315766591843
6489,Paracetamol ADME,Paracetamol ADME,0.0012670549286912351,1,2,3,0.08708449486500282
6490,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,2.908305507153134e-06,0,2,3,0.00019988740051320598
6491,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,6.996558227116933e-05,1,2,3,0.004808723956674923
6492,DAP12 interactions,Innate Immune System,0.00013743908745044825,0,2,3,0.009446167829276389
6493,DAP12 interactions,Innate Immune System,0.00047076587533489414,1,2,3,0.032355667875871894
6494,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,2.222376228997875e-05,0,2,3,0.0015274358429131028
6495,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,8.586192647096238e-05,1,2,3,0.0059012773049887885
6496,mTORC1-mediated signalling,MTOR signalling,0.0001245791708275222,0,2,3,0.008562307692075917
6497,mTORC1-mediated signalling,MTOR signalling,4.914485141271513e-05,1,2,3,0.0033777182532351274
6498,Cellular response to heat stress,Cellular responses to stress,0.000312523221259487,0,2,3,0.021479674038344797
6499,Cellular response to heat stress,Cellular responses to stress,0.00011066580966041957,1,2,3,0.0076060444696416695
6500,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,9.41733529465369e-05,0,2,3,0.0064725203978045365
6501,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0003559108145654953,1,2,3,0.024461696806974628
6502,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,3.7329862676833175e-05,0,2,3,0.002565675852703407
6503,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,2.9388370050876196e-05,1,2,3,0.002019858257786701
6504,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",1.2377339139167926e-05,0,2,3,0.0008506926592524481
6505,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",2.659123024831726e-05,1,2,3,0.0018276112594468228
6506,Axon guidance,Nervous system development,0.0008337652034409994,0,2,3,0.05730455715339345
6507,Axon guidance,Nervous system development,0.0004433192069337579,1,2,3,0.030469262480717445
6508,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,6.234549481388026e-05,0,2,3,0.004284996490707367
6509,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,7.391274951532516e-05,1,2,3,0.005080012168276016
6510,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.00017340995271181582,0,2,3,0.0119184399938138
6511,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,1.0502358191492198e-06,1,2,3,7.218255004478161e-05
6512,Clathrin-mediated endocytosis,Membrane Trafficking,0.00016581968184612743,0,2,3,0.011396761817706805
6513,Clathrin-mediated endocytosis,Membrane Trafficking,0.00036353520108535904,1,2,3,0.024985719746866974
6514,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,6.747829320432586e-05,0,2,3,0.004637772952843508
6515,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,2.3361904471512435e-05,1,2,3,0.0016056601840360172
6516,Miscellaneous transport and binding events,Miscellaneous transport and binding events,1.024450600733719e-05,0,2,3,0.0007041033585749529
6517,Miscellaneous transport and binding events,Miscellaneous transport and binding events,3.6054146006176664e-06,1,2,3,0.0002477996037614619
6518,Mitochondrial protein import,Mitochondrial protein import,1.5922525957657992e-05,0,2,3,0.0010943528165979293
6519,Mitochondrial protein import,Mitochondrial protein import,0.00026206357995825843,1,2,3,0.0180115904736286
6520,Diseases associated with visual transduction,Diseases of the neuronal system,7.912537147214911e-05,0,2,3,0.0054382748921352865
6521,Diseases associated with visual transduction,Diseases of the neuronal system,6.905734536991102e-06,1,2,3,0.0004746300970920444
6522,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,8.56158077311442e-05,0,2,3,0.005884361600982164
6523,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,1.755738420922222e-05,1,2,3,0.0012067163785789477
6524,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.00035443204378245136,0,2,3,0.02436006111325176
6525,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.00012577484972386863,1,2,3,0.008644486522962616
6526,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,6.537693174920933e-05,0,2,3,0.004493346695777739
6527,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00016537342788018725,1,2,3,0.011366090849680545
6528,Hedgehog ligand biogenesis,Signaling by Hedgehog,8.932487509445296e-05,0,2,3,0.006139285243548825
6529,Hedgehog ligand biogenesis,Signaling by Hedgehog,9.28794607632299e-06,1,2,3,0.000638359138246228
6530,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,1.89287621157612e-05,0,2,3,0.0013009709760361625
6531,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,2.5560308029821382e-05,1,2,3,0.0017567561302729404
6532,Uptake and actions of bacterial toxins,Infectious disease,5.929129932428161e-06,0,2,3,0.000407508209362168
6533,Uptake and actions of bacterial toxins,Infectious disease,1.1074566301722187e-05,1,2,3,0.0007611532778856161
6534,GPCR ligand binding,Signaling by GPCR,3.696460357775604e-05,0,2,3,0.002540571649706593
6535,GPCR ligand binding,Signaling by GPCR,2.1763368398945384e-05,1,2,3,0.001495793039959811
6536,Degradation of beta-catenin by the destruction complex,Signaling by WNT,5.9449907895025855e-06,0,2,3,0.0004085983236856875
6537,Degradation of beta-catenin by the destruction complex,Signaling by WNT,1.9277784511314627e-05,1,2,3,0.001324959232839471
6538,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,8.958829090142253e-06,0,2,3,0.0006157389772381759
6539,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,4.084644272466986e-05,1,2,3,0.0028073698710002508
6540,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00010886439152383743,0,2,3,0.007482233271790168
6541,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00021343781558183774,1,2,3,0.014669548994401498
6542,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0001896816717833432,0,2,3,0.013036792800659242
6543,Pre-NOTCH Expression and Processing,Signaling by NOTCH,7.234962422669434e-05,1,2,3,0.004972578802059026
6544,Hedgehog 'off' state,Signaling by Hedgehog,6.23925771175897e-05,0,2,3,0.004288232450366869
6545,Hedgehog 'off' state,Signaling by Hedgehog,6.232980025128994e-06,1,2,3,0.00042839178057787537
6546,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0005617189546987925,0,2,3,0.038606859354210515
6547,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0001755484452144347,1,2,3,0.012065418262195203
6548,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.00015124715368268151,0,2,3,0.010395194146658373
6549,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.00020343138398141672,1,2,3,0.013981808454041532
6550,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.00016103265743090952,0,2,3,0.011067750348933082
6551,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.00018641298648215866,1,2,3,0.012812136551051866
6552,Advanced glycosylation endproduct receptor signaling,Innate Immune System,7.12596587528149e-05,0,2,3,0.004897665638814298
6553,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.00024433440832608954,1,2,3,0.0167930671712828
6554,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,1.62944905444738e-05,0,2,3,0.0011199178867594753
6555,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,1.42133385908227e-06,1,2,3,9.768806256928046e-05
6556,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.00014184233181561648,0,2,3,0.009748802152875859
6557,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,3.72167349065435e-05,1,2,3,0.0025579005980496438
6558,PIP3 activates AKT signaling,Intracellular signaling by second messengers,2.6520308165951287e-05,0,2,3,0.0018227367953823528
6559,PIP3 activates AKT signaling,Intracellular signaling by second messengers,3.151344670463233e-06,1,2,3,0.00021659144568915943
6560,SLC transporter disorders,Disorders of transmembrane transporters,0.0002942523936852631,0,2,3,0.020223922804489182
6561,SLC transporter disorders,Disorders of transmembrane transporters,2.842167373807505e-06,1,2,3,0.0001953417365460822
6562,ROS and RNS production in phagocytes,Innate Immune System,0.00026422412859200295,0,2,3,0.018160084656588176
6563,ROS and RNS production in phagocytes,Innate Immune System,0.0009067318993762401,1,2,3,0.06231954720126149
6564,HCMV Infection,Infectious disease,0.0002372676891005069,0,2,3,0.01630737262073294
6565,HCMV Infection,Infectious disease,0.00044152807689145073,1,2,3,0.030346158382039603
6566,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0005654550299562469,0,2,3,0.03886363924528368
6567,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0006666622784120642,1,2,3,0.04581959822454861
6568,Amyloid fiber formation,Amyloid fiber formation,0.00014553075697201022,0,2,3,0.010002307059662888
6569,Amyloid fiber formation,Amyloid fiber formation,0.0009818564496600827,1,2,3,0.0674828462542761
6570,Signaling by Hippo,Signaling by Hippo,0.00021859591918096873,0,2,3,0.0150240646797283
6571,Signaling by Hippo,Signaling by Hippo,0.00030022899964162467,1,2,3,0.020634694033842688
6572,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,4.050304177953045e-05,0,2,3,0.002783767975639235
6573,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,5.1541292238709665e-05,1,2,3,0.0035424252711235837
6574,Transcriptional regulation by small RNAs,Gene Silencing by RNA,1.041319466987935e-05,0,2,3,0.0007156973050048135
6575,Transcriptional regulation by small RNAs,Gene Silencing by RNA,4.0358775693094144e-05,1,2,3,0.002773852589195465
6576,Metabolism of cofactors,Metabolism of vitamins and cofactors,1.8463352938470476e-08,0,2,3,1.2689834732119847e-06
6577,Metabolism of cofactors,Metabolism of vitamins and cofactors,1.3029499209960444e-07,1,2,3,8.955155229263644e-06
6578,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,2.0171029534837087e-05,0,2,3,0.0013863518290898008
6579,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,2.5811333027266456e-05,1,2,3,0.0017740090406290628
6580,Intraflagellar transport,Cilium Assembly,0.0002426235528242051,0,2,3,0.016675480329706397
6581,Intraflagellar transport,Cilium Assembly,0.00022266748676187038,1,2,3,0.015303902907781905
6582,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,4.126922459128213e-06,0,2,3,0.00028364276051665526
6583,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,2.7782867345001684e-06,1,2,3,0.00019095122980500588
6584,Neddylation,Post-translational protein modification,9.401043488360485e-05,0,2,3,0.006461323063818806
6585,Neddylation,Post-translational protein modification,0.00030989220002471845,1,2,3,0.021298844344208662
6586,Assembly of collagen fibrils and other multimeric structures,Collagen formation,9.292405211061603e-05,0,2,3,0.006386656139067962
6587,Assembly of collagen fibrils and other multimeric structures,Collagen formation,6.091076463078399e-05,1,2,3,0.0041863877008014964
6588,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.00019639488939712354,0,2,3,0.013498191238546035
6589,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.0001994635077460374,1,2,3,0.013709096916585322
6590,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,4.214922942567678e-06,0,2,3,0.00028969102052075595
6591,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,4.980890155031356e-06,1,2,3,0.00034233583194140474
6592,SARS-CoV Infections,Infectious disease,9.173255035261603e-05,0,2,3,0.006304764402272172
6593,SARS-CoV Infections,Infectious disease,0.00017066050663789393,1,2,3,0.011729470978276825
6594,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,7.179895098547927e-05,0,2,3,0.004934731112932856
6595,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.00021422524839133958,1,2,3,0.014723669133081221
6596,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,1.966284827443472e-05,0,2,3,0.0013514246074201668
6597,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.00025748059366831024,1,2,3,0.017696602514546494
6598,ABC transporter disorders,Disorders of transmembrane transporters,0.0009609626216563714,0,2,3,0.06604681659502613
6599,ABC transporter disorders,Disorders of transmembrane transporters,1.0017675199492548e-05,1,2,3,0.0006885133112347206
6600,Platelet sensitization by LDL,Platelet homeostasis,0.0003007574141370265,0,2,3,0.020671011882713645
6601,Platelet sensitization by LDL,Platelet homeostasis,7.895453044682488e-05,1,2,3,0.005426533014134822
6602,HDACs deacetylate histones,Chromatin modifying enzymes,5.630394795470663e-05,0,2,3,0.003869761882861419
6603,HDACs deacetylate histones,Chromatin modifying enzymes,0.00013783092415457164,1,2,3,0.00947309870707456
6604,Post-chaperonin tubulin folding pathway,Protein folding,7.099641291733399e-05,0,2,3,0.00487957279209624
6605,Post-chaperonin tubulin folding pathway,Protein folding,0.00019123884827459378,1,2,3,0.013143817306926136
6606,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,7.156650547532072e-06,0,2,3,0.0004918755167946237
6607,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,1.8100274902759352e-05,1,2,3,0.0012440291743725965
6608,Glucose metabolism,Metabolism of carbohydrates,4.5919556323139295e-05,0,2,3,0.003156044206351931
6609,Glucose metabolism,Metabolism of carbohydrates,4.1395801550695716e-05,1,2,3,0.002845127220567967
6610,TCR signaling,Adaptive Immune System,5.834430530416894e-05,0,2,3,0.004009995336911872
6611,TCR signaling,Adaptive Immune System,6.80001607003857e-05,1,2,3,0.004673640827433426
6612,Aflatoxin activation and detoxification,Biological oxidations,4.5103018616717394e-07,0,2,3,3.099923692480107e-05
6613,Aflatoxin activation and detoxification,Biological oxidations,2.1969703474436763e-06,1,2,3,0.0001509974418695032
6614,MHC class II antigen presentation,Adaptive Immune System,2.4364008105562258e-05,0,2,3,0.0016745346162311179
6615,MHC class II antigen presentation,Adaptive Immune System,2.8599422346949e-05,1,2,3,0.0019656340006407457
6616,Biological oxidations,Metabolism,0.00029034815472491594,0,3,4,0.034816062199786404
6617,Biological oxidations,Metabolism,0.00018406661612121742,1,3,4,0.02207169100782502
6618,Late endosomal microautophagy,Autophagy,0.00018146939804447002,0,3,4,0.02176025487628797
6619,Late endosomal microautophagy,Autophagy,4.1553459943441637e-05,1,3,4,0.004982734770186048
6620,RNA Polymerase I Transcription,Gene expression (Transcription),6.180186954676349e-05,0,3,4,0.0074107505048268095
6621,RNA Polymerase I Transcription,Gene expression (Transcription),0.000225560586017226,1,3,4,0.027047292241399956
6622,Cell Cycle Checkpoints,Cell Cycle,0.0005506053198148735,0,3,4,0.06602387082628453
6623,Cell Cycle Checkpoints,Cell Cycle,0.0002205522857694092,1,3,4,0.026446739800801883
6624,Degradation of the extracellular matrix,Extracellular matrix organization,0.0001924389754893284,0,3,4,0.023075632585464058
6625,Degradation of the extracellular matrix,Extracellular matrix organization,6.697728475861313e-05,1,3,4,0.008031341939603422
6626,Metabolism of amino acids and derivatives,Metabolism,0.00041314170236551103,0,3,4,0.04954041199439016
6627,Metabolism of amino acids and derivatives,Metabolism,0.00026174576931521073,1,3,4,0.031386309286667226
6628,Transcriptional regulation of testis differentiation,Developmental Biology,3.4140748363502628e-06,0,3,4,0.0004093865930359092
6629,Transcriptional regulation of testis differentiation,Developmental Biology,4.100307015496895e-06,1,3,4,0.0004916736744031043
6630,Keratinization,Developmental Biology,2.8149487495844187e-05,0,3,4,0.0033754452769846335
6631,Keratinization,Developmental Biology,3.377729928092315e-05,1,3,4,0.004050284231424132
6632,Integration of energy metabolism,Metabolism,0.00019748155602421672,0,3,4,0.023680295624278397
6633,Integration of energy metabolism,Metabolism,0.0001251152913630391,1,3,4,0.01500275340260725
6634,Death Receptor Signalling,Signal Transduction,1.7821866071807824e-05,0,3,4,0.002137045431751379
6635,Death Receptor Signalling,Signal Transduction,7.979640633890584e-06,1,3,4,0.0009568501129435171
6636,Metabolism of nucleotides,Metabolism,6.81870048635209e-05,0,3,4,0.008176401206319633
6637,Metabolism of nucleotides,Metabolism,4.3195154687636746e-05,1,3,4,0.005179592733279052
6638,O2/CO2 exchange in erythrocytes,Transport of small molecules,2.48721447119605e-05,0,3,4,0.0029824544197779765
6639,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0003211563008210709,1,3,4,0.03851031102929962
6640,Chromosome Maintenance,Cell Cycle,0.0006044502556367403,0,3,4,0.07248049403607808
6641,Chromosome Maintenance,Cell Cycle,0.0002422919903169956,1,3,4,0.02905357884357399
6642,Integrin cell surface interactions,Extracellular matrix organization,3.402211214310179e-05,0,3,4,0.004079640091615476
6643,Integrin cell surface interactions,Extracellular matrix organization,1.1858355626919012e-05,1,3,4,0.0014219523712322398
6644,Cardiac conduction,Muscle contraction,5.933381054936884e-06,0,3,4,0.0007114802023089616
6645,Cardiac conduction,Muscle contraction,2.4282739612659165e-05,1,3,4,0.0029117780119406736
6646,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,5.052056757673663e-05,0,3,4,0.006057993462319857
6647,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,3.0580649432292507e-06,1,3,4,0.0003666969379410328
6648,Abacavir ADME,Drug ADME,0.00014260750266736335,0,3,4,0.017100269460045787
6649,Abacavir ADME,Drug ADME,0.0006312920755073239,1,3,4,0.07569913501919402
6650,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.0005110629190450967,0,3,4,0.06128228503582629
6651,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.00132630995741442,1,3,4,0.15903972256095722
6652,Metabolism of vitamins and cofactors,Metabolism,6.885128622355592e-05,0,3,4,0.008256056133594957
6653,Metabolism of vitamins and cofactors,Metabolism,4.358495360027918e-05,1,3,4,0.005226334077996142
6654,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.0012932269220941011,0,3,4,0.1550726885132939
6655,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.0006877890930839381,1,3,4,0.08247377314256499
6656,Intracellular signaling by second messengers,Signal Transduction,1.2631215034867074e-05,0,3,4,0.0015146270474129897
6657,Intracellular signaling by second messengers,Signal Transduction,5.6418949667612724e-06,1,3,4,0.0006765276888827632
6658,Activation of HOX genes during differentiation,Developmental Biology,5.317463070111079e-05,0,3,4,0.006376245964760992
6659,Activation of HOX genes during differentiation,Developmental Biology,6.381991923852618e-05,1,3,4,0.0076527377275706085
6660,Iron uptake and transport,Transport of small molecules,6.658067563559424e-06,0,3,4,0.0007983783972826912
6661,Iron uptake and transport,Transport of small molecules,8.597923774750414e-05,1,3,4,0.010309893280167098
6662,Signaling by Nuclear Receptors,Signal Transduction,0.0002984337067630061,0,3,4,0.035785612300576496
6663,Signaling by Nuclear Receptors,Signal Transduction,0.0001338488293487765,1,3,4,0.01605000442448377
6664,Signaling by Hippo,Signal Transduction,0.0002711287106926255,0,3,4,0.032511431197369656
6665,Signaling by Hippo,Signal Transduction,0.00012130734018318422,1,3,4,0.014546136534292086
6666,Response to metal ions,Cellular responses to stimuli,7.868265238778984e-05,0,3,4,0.009434949301375338
6667,Response to metal ions,Cellular responses to stimuli,2.0758522804822298e-07,1,3,4,2.489184137688468e-05
6668,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,8.029665273424314e-05,0,3,4,0.009628486389654177
6669,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,5.090036925624185e-05,1,3,4,0.006103536024523378
6670,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,1.271824095662307e-05,0,3,4,0.00152506245006854
6671,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,1.527362281973439e-05,1,3,4,0.0018314819414360015
6672,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,8.775894865642284e-05,0,3,4,0.010523300958825352
6673,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.0011218960015253172,1,3,4,0.13452815296106727
6674,Cell surface interactions at the vascular wall,Hemostasis,0.0003069531235153678,0,3,4,0.03680718773933603
6675,Cell surface interactions at the vascular wall,Hemostasis,0.00016357422005450163,1,3,4,0.019614418507652276
6676,Dissolution of Fibrin Clot,Hemostasis,0.00017857223549284302,0,3,4,0.021412851974086294
6677,Dissolution of Fibrin Clot,Hemostasis,9.499918697370303e-05,1,3,4,0.011391488283227426
6678,Adaptive Immune System,Immune System,9.349806780357474e-05,0,3,4,0.011211486938131936
6679,Adaptive Immune System,Immune System,0.0009686196310933045,1,3,4,0.1161485643193747
6680,Regulated Necrosis,Programmed Cell Death,2.3414065487328137e-06,0,3,4,0.00028076140560597625
6681,Regulated Necrosis,Programmed Cell Death,1.393171111454347e-05,1,3,4,0.0016705713910010853
6682,DNA Double-Strand Break Repair,DNA Repair,2.5725948094977728e-05,0,3,4,0.003084835203694717
6683,DNA Double-Strand Break Repair,DNA Repair,3.703586740156595e-05,1,3,4,0.004441023791928751
6684,Diseases of metabolism,Disease,0.001685891170368242,0,3,4,0.20215761972113017
6685,Diseases of metabolism,Disease,0.0005755599438578493,1,3,4,0.06901621546052433
6686,Metabolism of porphyrins,Metabolism,0.00033087587457585006,0,3,4,0.03967579900948812
6687,Metabolism of porphyrins,Metabolism,0.00020954876148789942,1,3,4,0.02512729147792598
6688,Chromatin modifying enzymes,Chromatin organization,0.00017632652092805555,0,3,4,0.02114356513103856
6689,Chromatin modifying enzymes,Chromatin organization,0.0007489064534320046,1,3,4,0.0898024431710728
6690,Diseases of programmed cell death,Disease,2.1815133478901692e-05,0,3,4,0.0026158838337294486
6691,Diseases of programmed cell death,Disease,7.441995944273492e-06,1,3,4,0.0008923803698076322
6692,Signaling by TGFB family members,Signal Transduction,0.00031940276602455676,0,3,4,0.03830004216569079
6693,Signaling by TGFB family members,Signal Transduction,0.00014316059322791355,1,3,4,0.017166591339640557
6694,DNA Replication Pre-Initiation,DNA Replication,3.0448724650858393e-05,0,3,4,0.0036511500903211483
6695,DNA Replication Pre-Initiation,DNA Replication,5.402675679209461e-05,1,3,4,0.006478425622192813
6696,Collagen formation,Extracellular matrix organization,0.0005847791581213941,0,3,4,0.07012170461900319
6697,Collagen formation,Extracellular matrix organization,0.00020307450540943872,1,3,4,0.024350954178525567
6698,Platelet homeostasis,Hemostasis,0.00016285417802976965,0,3,4,0.019528077239379778
6699,Platelet homeostasis,Hemostasis,8.664534299110334e-05,1,3,4,0.010389766911927306
6700,Signaling by Hedgehog,Signal Transduction,0.000394315325475471,0,3,4,0.04728291423477376
6701,Signaling by Hedgehog,Signal Transduction,0.00017692544720998994,1,3,4,0.021215383237493106
6702,Meiosis,Reproduction,0.0008157578704736197,0,3,4,0.09781869213284036
6703,Meiosis,Reproduction,0.00039490463730193563,1,3,4,0.04735357945813191
6704,Meiosis,Cell Cycle,0.0008157578704736197,0,3,4,0.09781869213284036
6705,Meiosis,Cell Cycle,0.00039490463730193563,1,3,4,0.04735357945813191
6706,Ion channel transport,Transport of small molecules,4.2946498598410724e-06,0,3,4,0.0005149776026239702
6707,Ion channel transport,Transport of small molecules,5.524431190646707e-05,1,3,4,0.006624424396091761
6708,Fertilization,Reproduction,1.8570688602658018e-05,0,3,4,0.0022268378116457248
6709,Fertilization,Reproduction,1.5678283516184943e-05,1,3,4,0.0018800053838900423
6710,Mitochondrial biogenesis,Organelle biogenesis and maintenance,8.6590261203751e-05,0,3,4,0.010383161976082779
6711,Mitochondrial biogenesis,Organelle biogenesis and maintenance,7.883694610806055e-05,1,3,4,0.009453450881890188
6712,Disorders of transmembrane transporters,Disease,0.0010400791077603026,0,3,4,0.12471737229667883
6713,Disorders of transmembrane transporters,Disease,0.00035481412223637836,1,3,4,0.04254626849909953
6714,Apoptosis,Programmed Cell Death,2.1259659068771283e-05,0,3,4,0.0025492761033245053
6715,Apoptosis,Programmed Cell Death,0.00012645750147325098,1,3,4,0.015163699735214711
6716,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,2.9898019781041724e-05,0,3,4,0.0035851142823118713
6717,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0003142177596841029,1,3,4,0.037678300644975564
6718,Base Excision Repair,DNA Repair,4.594646016583948e-05,0,3,4,0.005509505705346924
6719,Base Excision Repair,DNA Repair,6.624168399416772e-05,1,3,4,0.007943135000615276
6720,Aspirin ADME,Drug ADME,5.656458250437165e-05,0,3,4,0.0067827399304224165
6721,Aspirin ADME,Drug ADME,0.00025155017987792583,1,3,4,0.030163741585665975
6722,Cilium Assembly,Organelle biogenesis and maintenance,0.0003763969371316607,0,3,4,0.045134294679436554
6723,Cilium Assembly,Organelle biogenesis and maintenance,0.0003422977170991318,1,3,4,0.04104540847059697
6724,Post-translational protein modification,Metabolism of proteins,7.622630083612887e-05,0,3,4,0.009140404676188396
6725,Post-translational protein modification,Metabolism of proteins,0.000796707586302054,1,3,4,0.09553434533108704
6726,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.00022694203287338717,0,3,4,0.027212943508291506
6727,Diseases of signal transduction by growth factor receptors and second messengers,Disease,7.740411813710053e-05,1,3,4,0.009281638432089014
6728,ABC-family proteins mediated transport,Transport of small molecules,2.192574573891413e-07,0,3,4,2.6291475079150156e-05
6729,ABC-family proteins mediated transport,Transport of small molecules,2.818884808265887e-06,1,3,4,0.00033801650612038867
6730,MAPK family signaling cascades,Signal Transduction,0.0006415509839830589,0,3,4,0.07692929539659164
6731,MAPK family signaling cascades,Signal Transduction,0.00028702670014063374,1,3,4,0.03441778183354921
6732,Miscellaneous transport and binding events,Transport of small molecules,1.9696318107011922e-07,0,3,4,2.3618136542669047e-05
6733,Miscellaneous transport and binding events,Transport of small molecules,2.5184952990452914e-06,1,3,4,0.00030199637075188206
6734,Metabolism of carbohydrates,Metabolism,0.00024228444309176616,0,3,4,0.029052673845010202
6735,Metabolism of carbohydrates,Metabolism,0.0001534707643452928,1,3,4,0.01840289869366251
6736,Cytokine Signaling in Immune system,Immune System,3.042556428156989e-05,0,3,4,0.0036483728973388733
6737,Cytokine Signaling in Immune system,Immune System,0.0003224854837596841,1,3,4,0.03866969525514219
6738,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.00017550339776642034,0,3,4,0.02104486325631603
6739,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,1.0436996552496492e-05,1,3,4,0.0012515151732062706
6740,Intracellular oxygen transport,Transport of small molecules,4.147686751987513e-06,0,3,4,0.0004973550463209997
6741,Intracellular oxygen transport,Transport of small molecules,5.3555195668634254e-05,1,3,4,0.006421880053921675
6742,Striated Muscle Contraction,Muscle contraction,1.51850464301408e-05,0,3,4,0.0018208606199661107
6743,Striated Muscle Contraction,Muscle contraction,6.214114267460004e-05,1,3,4,0.007451433230476175
6744,Laminin interactions,Extracellular matrix organization,1.5388135228471954e-05,0,3,4,0.0018452132880293066
6745,Laminin interactions,Extracellular matrix organization,5.358450247150482e-06,1,3,4,0.0006425394274539282
6746,Synthesis of DNA,DNA Replication,3.8126378495152735e-05,0,3,4,0.004571788535723476
6747,Synthesis of DNA,DNA Replication,6.815105916642184e-05,1,3,4,0.008172090906406753
6748,Non-integrin membrane-ECM interactions,Extracellular matrix organization,7.814542815073214e-05,0,3,4,0.00937052997530676
6749,Non-integrin membrane-ECM interactions,Extracellular matrix organization,2.723439378393136e-05,1,3,4,0.003265715082133643
6750,SLC-mediated transmembrane transport,Transport of small molecules,9.033068326373972e-06,0,3,4,0.0010831681331121908
6751,SLC-mediated transmembrane transport,Transport of small molecules,0.00011685110889178294,1,3,4,0.014011783471276917
6752,Membrane Trafficking,Vesicle-mediated transport,0.0005598617682213435,0,3,4,0.06713382478405672
6753,Membrane Trafficking,Vesicle-mediated transport,0.0014547711224701101,1,3,4,0.17444368445998606
6754,Cellular responses to stress,Cellular responses to stimuli,0.0009723951386644709,0,3,4,0.11660129082820349
6755,Cellular responses to stress,Cellular responses to stimuli,2.688860559200591e-06,1,3,4,0.0003224251125838022
6756,Reversible hydration of carbon dioxide,Metabolism,3.707054954015733e-05,0,3,4,0.004445182576735093
6757,Reversible hydration of carbon dioxide,Metabolism,2.345591049960682e-05,1,3,4,0.0028126317512871548
6758,"Platelet activation, signaling and aggregation",Hemostasis,0.0006082128521509657,0,3,4,0.07293167236161656
6759,"Platelet activation, signaling and aggregation",Hemostasis,0.0003236437099417921,1,3,4,0.03880857981198016
6760,Innate Immune System,Immune System,0.0002342766622341699,0,3,4,0.028092449397624022
6761,Innate Immune System,Immune System,0.0024227480150715436,1,3,4,0.2905151770881961
6762,Atorvastatin ADME,Drug ADME,1.0334974059973569e-06,0,3,4,0.00012392815103169
6763,Atorvastatin ADME,Drug ADME,4.587228257389923e-06,1,3,4,0.0005500610964282465
6764,RNA Polymerase II Transcription,Gene expression (Transcription),0.0006375480113985972,0,3,4,0.07644929323292471
6765,RNA Polymerase II Transcription,Gene expression (Transcription),0.0023147929101921785,1,3,4,0.2775701261722521
6766,Nervous system development,Developmental Biology,0.0004144231977730429,0,3,4,0.049694077940225574
6767,Nervous system development,Developmental Biology,0.0004973807896508817,1,3,4,0.05964164134561298
6768,Diseases of hemostasis,Disease,0.0002992727799519436,0,3,4,0.03588622676586868
6769,Diseases of hemostasis,Disease,0.00010224755948142794,1,3,4,0.012260650990031142
6770,Macroautophagy,Autophagy,3.142815295315495e-05,0,3,4,0.0037685947378522998
6771,Macroautophagy,Autophagy,7.181844846772277e-06,1,3,4,0.0008611852798972924
6772,Signaling by WNT,Signal Transduction,0.00014299106004789117,0,3,4,0.01714626237372659
6773,Signaling by WNT,Signal Transduction,6.425356695477756e-05,1,3,4,0.0077047370449973285
6774,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0006699073948863405,0,3,4,0.08032955315509784
6775,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.00030034557964085586,1,3,4,0.03601486770981568
6776,Nephrin family interactions,Cell-Cell communication,1.673383412523394e-05,0,3,4,0.0020065779660181785
6777,Nephrin family interactions,Cell-Cell communication,4.296801638896066e-06,1,3,4,0.0005152356255257855
6778,Peroxisomal protein import,Protein localization,7.1199362553458284e-06,0,3,4,0.0008537617322193452
6779,Peroxisomal protein import,Protein localization,2.065712694187417e-05,1,3,4,0.0024770256148469927
6780,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,6.935090414809948e-06,0,3,4,0.0008315966032982874
6781,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,4.385966872062542e-06,1,3,4,0.0005259275560700786
6782,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00010845520378074634,0,3,4,0.013005018489951996
6783,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00013011295793845872,1,3,4,0.01560203074435049
6784,Transmission across Chemical Synapses,Neuronal System,8.760943564809126e-05,0,3,4,0.010505372640311735
6785,Transmission across Chemical Synapses,Neuronal System,7.90776868302716e-06,1,3,4,0.00094823184459581
6786,"Cell Cycle, Mitotic",Cell Cycle,0.00048545628635507956,0,3,4,0.05821175711286645
6787,"Cell Cycle, Mitotic",Cell Cycle,0.00019453567616959484,1,3,4,0.023327050960647643
6788,ECM proteoglycans,Extracellular matrix organization,4.801652090979823e-05,0,3,4,0.005757729647693954
6789,ECM proteoglycans,Extracellular matrix organization,1.6688853246706125e-05,1,3,4,0.0020011842445870603
6790,Diseases of Immune System,Disease,0.001464041109808613,0,3,4,0.1755552618904482
6791,Diseases of Immune System,Disease,0.0004986361380350517,1,3,4,0.05979217196450763
6792,Signaling by NOTCH,Signal Transduction,0.00044216179630542443,0,3,4,0.05302025293435728
6793,Signaling by NOTCH,Signal Transduction,0.00019826665832474381,1,3,4,0.023774438363205887
6794,MTOR signalling,Signal Transduction,3.7723178584062875e-06,0,3,4,0.0004523440258129796
6795,MTOR signalling,Signal Transduction,1.6718351327173952e-06,1,3,4,0.00020047214015747296
6796,Chaperone Mediated Autophagy,Autophagy,7.39235974346077e-05,0,3,4,0.008864284220279258
6797,Chaperone Mediated Autophagy,Autophagy,1.6913972027085682e-05,1,3,4,0.0020281785592830173
6798,Metabolism of lipids,Metabolism,0.000529465858539533,0,3,4,0.06348900781215747
6799,Metabolism of lipids,Metabolism,0.0003355045538830779,1,3,4,0.040230830560544426
6800,Surfactant metabolism,Metabolism of proteins,8.946688957930838e-06,0,3,4,0.0010728102595884425
6801,Surfactant metabolism,Metabolism of proteins,9.44065970063167e-05,1,3,4,0.011320429973306224
6802,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.000679806601429998,0,3,4,0.08151658115973262
6803,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.00030511674910963286,1,3,4,0.03658698545979085
6804,Gene Silencing by RNA,Gene expression (Transcription),9.376129539264282e-06,0,3,4,0.0011243050934542991
6805,Gene Silencing by RNA,Gene expression (Transcription),3.4385072675165945e-05,1,3,4,0.004123163207759905
6806,Protein folding,Metabolism of proteins,2.6433855502319846e-05,0,3,4,0.003169721392653154
6807,Protein folding,Metabolism of proteins,0.00028283065908902264,1,3,4,0.03391462855405219
6808,Peptide hormone metabolism,Metabolism of proteins,5.378517862031982e-05,0,3,4,0.006449457638350828
6809,Peptide hormone metabolism,Metabolism of proteins,0.0005677901480452752,1,3,4,0.06808452814001592
6810,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.00022977149061714465,0,3,4,0.027552227830217577
6811,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.00038370178773973213,1,3,4,0.04601022975597154
6812,Smooth Muscle Contraction,Muscle contraction,1.3418478543435233e-05,0,3,4,0.0016090289398854923
6813,Smooth Muscle Contraction,Muscle contraction,5.4896130938804346e-05,1,3,4,0.006582673518637719
6814,Fibronectin matrix formation,Extracellular matrix organization,2.344330771617632e-05,0,3,4,0.002811120533514056
6815,Fibronectin matrix formation,Extracellular matrix organization,8.174135203808773e-06,1,3,4,0.0009801722347948095
6816,Factors involved in megakaryocyte development and platelet production,Hemostasis,3.3388519065465976e-05,0,3,4,0.004003665040142453
6817,Factors involved in megakaryocyte development and platelet production,Hemostasis,1.7768737436446438e-05,1,3,4,0.0021306747011535414
6818,Platelet Adhesion to exposed collagen,Hemostasis,0.00034044710944006624,0,3,4,0.04082349946130269
6819,Platelet Adhesion to exposed collagen,Hemostasis,0.00018118626227300096,1,3,4,0.02172630366127236
6820,Visual phototransduction,Sensory Perception,0.00018879962938968343,0,3,4,0.022639233393287904
6821,Visual phototransduction,Sensory Perception,3.572513730454477e-05,1,3,4,0.004283852272694345
6822,Signaling by GPCR,Signal Transduction,0.0003544498982675005,0,3,4,0.04250259388244106
6823,Signaling by GPCR,Signal Transduction,0.0001592705700566946,1,3,4,0.01909836168562178
6824,Elastic fibre formation,Extracellular matrix organization,3.734772007207082e-05,0,3,4,0.00447841849135005
6825,Elastic fibre formation,Extracellular matrix organization,1.3022705503345689e-05,1,3,4,0.0015615712290079737
6826,Translation,Metabolism of proteins,7.264268761730075e-06,0,3,4,0.0008710688493404645
6827,Translation,Metabolism of proteins,7.71016914163761e-05,1,3,4,0.009245374011777493
6828,Nucleotide Excision Repair,DNA Repair,4.6868497127986516e-07,0,3,4,5.620068475256819e-05
6829,Nucleotide Excision Repair,DNA Repair,6.750024699727974e-07,1,3,4,8.09405108906162e-05
6830,Epigenetic regulation of gene expression,Gene expression (Transcription),0.0002095152536532605,0,3,4,0.02512327350558489
6831,Epigenetic regulation of gene expression,Gene expression (Transcription),0.0007746367088846566,1,3,4,0.09288779487618234
6832,Amyloid fiber formation,Metabolism of proteins,6.829958262742159e-05,0,3,4,0.008189900566885545
6833,Amyloid fiber formation,Metabolism of proteins,0.0007127954957856123,1,3,4,0.08547232662977157
6834,Integrin signaling,Signal Transduction,1.6786711636758427e-05,0,3,4,0.002012918583997827
6835,Integrin signaling,Signal Transduction,7.535504085771852e-06,1,3,4,0.0009035930646969033
6836,Infectious disease,Disease,3.504140625704961e-05,0,3,4,0.004201865105598106
6837,Infectious disease,Disease,1.1982145794486245e-05,1,3,4,0.00143679622714662
6838,Mitochondrial protein import,Protein localization,9.308049055587543e-05,0,3,4,0.01116141465355727
6839,Mitochondrial protein import,Protein localization,0.0002697534045307344,1,3,4,0.03234651626990433
6840,Inositol phosphate metabolism,Metabolism,7.424015854071675e-06,0,3,4,0.0008902243514943167
6841,Inositol phosphate metabolism,Metabolism,4.702605960128633e-06,1,3,4,0.0005638962016619105
6842,Sensory processing of sound,Sensory Perception,0.0006452245532129964,0,3,4,0.07736979833323299
6843,Sensory processing of sound,Sensory Perception,0.00012256296432372387,1,3,4,0.014696700219527143
6844,Paracetamol ADME,Drug ADME,0.00017269202236938267,0,3,4,0.020707747214428498
6845,Paracetamol ADME,Drug ADME,0.0008113065865694493,1,3,4,0.09728493231809886
6846,Diseases of the neuronal system,Disease,0.00023439101903881385,0,3,4,0.02810616208550807
6847,Diseases of the neuronal system,Disease,8.010141300358642e-05,1,3,4,0.009605074914513742
6848,Cell junction organization,Cell-Cell communication,0.00022099656760862123,0,3,4,0.026500014271111146
6849,Cell junction organization,Cell-Cell communication,5.668753100378915e-05,1,3,4,0.006797482860706048
6850,Hemostasis,root,0.0009188737089347997,0,4,5,0.24611374164644248
6851,Hemostasis,root,0.0002193987128415073,1,4,5,0.058764373825030414
6852,Signal Transduction,root,0.000659224622171133,0,4,5,0.17656859345347994
6853,Signal Transduction,root,0.000866459464652489,1,4,5,0.23207496172439612
6854,Cell Cycle,root,0.0004666705901265952,0,4,5,0.12499437510901662
6855,Cell Cycle,root,0.0001686876553222233,1,4,5,0.04518178027864727
6856,Programmed Cell Death,root,1.93793519570984e-05,0,4,5,0.005190620620078298
6857,Programmed Cell Death,root,8.250225634703365e-05,1,4,5,0.0220976384528194
6858,Cellular responses to stimuli,root,0.0008613927594884389,0,4,5,0.2307178810357025
6859,Cellular responses to stimuli,root,0.00010165696842181076,1,4,5,0.02722809088936658
6860,Disease,root,0.0015587582409832901,0,4,5,0.4175022304809963
6861,Disease,root,6.949841396556802e-05,1,4,5,0.018614652408966682
6862,Autophagy,root,0.00020732732234949618,0,4,5,0.05553113834122471
6863,Autophagy,root,0.00011929130252958761,1,4,5,0.0319513209769263
6864,Neuronal System,root,7.785178682096728e-05,0,4,5,0.0208520434985359
6865,Neuronal System,root,1.4802031617521233e-05,1,4,5,0.003964618151476122
6866,Metabolism,root,0.0002076106313967301,0,4,5,0.05560702064036879
6867,Metabolism,root,0.0005040830476549866,1,4,5,0.13501503389701813
6868,Muscle contraction,root,2.596095183551058e-05,0,4,5,0.006953455007813217
6869,Muscle contraction,root,4.201320289125238e-05,1,4,5,0.011252935481312107
6870,Metabolism of RNA,root,8.389555370491405e-05,0,4,5,0.02247082317084944
6871,Metabolism of RNA,root,0.00011780538981727816,1,4,5,0.03155332989955569
6872,Vesicle-mediated transport,root,0.00011520695205331206,0,4,5,0.03085735695538857
6873,Vesicle-mediated transport,root,0.0013332237826690118,1,4,5,0.35709444117741823
6874,Extracellular matrix organization,root,0.0003012377731137889,0,4,5,0.08068437995926744
6875,Extracellular matrix organization,root,0.00029891705744006605,1,4,5,0.08006279288783019
6876,Transport of small molecules,root,0.00026959031785694893,0,4,5,0.07220783573875811
6877,Transport of small molecules,root,0.0008964534316675532,1,4,5,0.2401086309622013
6878,Gene expression (Transcription),root,0.0014371224099469252,0,4,5,0.3849229443358549
6879,Gene expression (Transcription),root,0.001170647796866687,1,4,5,0.313549627805782
6880,Protein localization,root,7.306523241772231e-05,0,4,5,0.01956999918458713
6881,Protein localization,root,0.00016229682095108912,1,4,5,0.043470041065708134
6882,Circadian Clock,root,4.23418917256788e-05,0,4,5,0.011340972431429952
6883,Circadian Clock,root,0.00020001256126505064,1,4,5,0.05357193197560822
6884,Reproduction,root,0.00011217724012645971,0,4,5,0.03004587031562729
6885,Reproduction,root,7.254336659580215e-05,1,4,5,0.019430221161969574
6886,Cell-Cell communication,root,0.00012431091560934356,0,4,5,0.033295788388131575
6887,Cell-Cell communication,root,4.946946897062765e-06,1,4,5,0.0013250042946312728
6888,Drug ADME,root,0.00047344950101561027,0,4,5,0.12681005783773175
6889,Drug ADME,root,0.00026087407400544454,1,4,5,0.06987325225188988
6890,Sensory Perception,root,0.0004555563924008557,0,4,5,0.12201751685191066
6891,Sensory Perception,root,0.0005073485712903001,1,4,5,0.1358896810139256
6892,Immune System,root,0.001460020177136228,0,4,5,0.39105594727577064
6893,Immune System,root,0.002284417268683475,1,4,5,0.6118648036292117
6894,DNA Replication,root,0.00021146893477450208,0,4,5,0.05664043956559995
6895,DNA Replication,root,0.00024039935153250276,1,4,5,0.06438924448456593
6896,Metabolism of proteins,root,0.000857808434936261,0,4,5,0.22975784537657545
6897,Metabolism of proteins,root,0.00125672719559704,1,4,5,0.3366053782252409
6898,Organelle biogenesis and maintenance,root,0.00015164797913790875,0,4,5,0.04061782505674093
6899,Organelle biogenesis and maintenance,root,0.000317744629660064,1,4,5,0.0851056232573637
6900,DNA Repair,root,0.00012022797311728567,0,4,5,0.03220220148508207
6901,DNA Repair,root,3.719032310567079e-05,1,4,5,0.009961161673879443
6902,Chromatin organization,root,0.000353930172718604,0,4,5,0.09479766179220186
6903,Chromatin organization,root,0.00046444007329675863,1,4,5,0.12439694715187895
6904,Developmental Biology,root,0.00046641247031102513,0,4,5,0.1249252395651597
6905,Developmental Biology,root,0.00042696710620637225,1,4,5,0.11436008131108753
